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Eukaryotic TFIIH consists of a core of seven subunits, including the DNA helicase
Xeroderma Pigmentosum B (XPB), and a cyclin-dependent kinase (CDK)-activating complex
(CAK) that contains CDK7. XPB is crucial for DNA unwinding during transcription and nucleotide
excision repair (NER) while the CAK complex phosphorylates RNA polymerase II (RNAPII)
carboxy terminal domain (CTD), enabling the enzyme’s promoter clearance.
Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are lethal human
parasites, belonging to the early-diverged order Kinetoplastida. They transcribe genes
polycistronically and require spliced leader (SL) trans splicing for the maturation of mRNAs from
polycistronic precursors. SL RNA gene (SLRNA) transcription by RNAPII depends on
trypanosome TFIIH complex which contains orthologs of all core subunits but lacks the CAK
complex. Despite this, the trypanosome CTD is phosphorylated and essential for SLRNA
transcription. Gene silencing of CDC2-related kinase 9 (CRK9) revealed its importance for
parasite survival and CTD phosphorylation. Interestingly, this loss of phosphorylation did not
cause a specific RNAPII transcription defect. Instead, CRK9 silencing blocked trans splicing and
caused hypomethylation of SL RNA’s extensively modified cap. Sedimentation analysis of
tandem affinity purified CRK9 revealed a putative tripartite complex including a novel L-type
cyclin (CYC12), and a CRK9-associated protein (CRK9AP). Silencing CYC12 or CRK9AP
recapitulated the defects observed upon CRK9 silencing, confirming that they functionally
partner with CRK9 in vivo. CRK9AP depletion caused a rapid co-loss of CRK9 and CYC12,
suggesting its role in complex assembly. This project identified CRK9 as crucial for parasitei	
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specific gene expression. As a CDK, CRK9 is a promising drug target against trypanosomes
which was validated in a mouse model.
Another feature related to trypanosome TFIIH is the presence of two divergent paralogs
of XPB in kinetoplastid genomes while only the larger XPB paralog consistently co-purified with
TFIIH. Gene knockout of the second paralog, termed XPB-R showed that XPB-R is specialized
in NER but dispensable for transcription. While XPB-R does not assemble into a TFIIH complex,
reciprocal co-immunoprecipitations revealed an interaction with the p52 ortholog, a TFIIH
component and known regulator of XPB in other systems, indicating that trypanosomes possess
a TFIIH whose function is restricted to transcription and a XPB-R/p52 repair complex.
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Chapter I
Introduction

1. Trypanosomatids and human diseases
Trypanosomatids are eukaryotic unicellular flagellates that are obligate parasites of
vertebrates, invertebrates and plants. They belong to the phylogenetic order Kinetoplastida and
family Trypanosomatidae. Kinetoplastids are thought to have diverged early from the main
eukaryotic lineage during evolution and they are characterized by the presence of the
kinetoplast, a structure that refers to a network of catenated DNA in a single large
mitochondrion located near the origin of flagellum. (Shlomai, 2004; Stechmann and CavalierSmith, 2002). The Trypanosomatidae include several species of Trypanosoma and Leishmania
that cause severe vector-borne diseases in humans and livestock. Trypanosoma brucei and
Trypanosoma cruzi cause Human African Trypanosomiasis (HAT), also known as (a.k.a.)
Sleeping sickness, and Chagas disease, respectively, while several species of Leishmania
cause a group of diseases called Leishmaniasis. These diseases, often lethal if untreated,
collectively affect millions of people in tropical and sub-tropical regions of the world.
Infection with Trypanosoma brucei causes HAT in humans and Nagana in livestock. The
parasite is transmitted to its vertebrate hosts by sanguivorous tsetse flies of the Glossina genus.
Tsetse flies as well as the disease are prevalent in 36 countries in the sub-Saharan region of
Africa. Currently just under 10,000 cases are reported each year although the exact number of
infected individuals is not known as the disease is mainly prevalent in remote rural areas in
Africa. T. brucei is classified in three subspecies: human-pathogenic, T brucei gambiense and
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T. brucei rhodesiense; and human non-pathogenic, T. brucei brucei. T. brucei gambiense is
found in west and central Africa, causes chronic infections and currently accounts for 97% of
reported cases of sleeping sickness. On the other hand, T. brucei rhodesiense infection,
prevalent in east and southern Africa, is usually acute, and accounts for fewer than 3% of
reported cases. (Kennedy, 2013) T. brucei brucei typically doesn’t infect humans but causes
animal trypanosomiasis in cattle and wild animals along with other Trypanosoma species such
as T. vivax. Wild animals can also host human pathogenic species and while they do not
develop the disease, they serve as important reservoirs from which tsetse flies can gain an
infection (Franco et al., 2014). The species of Trypanosoma including T. brucei brucei that are
non-pathogenic in humans are highly susceptible to trypanosome lytic factors (TLFs) which are
present in human serum. The two types of TLFs are TLF-1, which is high-density lipoprotein
particle consisting of apolipoprotein L1 (APOL1) and haptoglobin-related protein (HPR), and
TLF-2 which contains IgMs as a major component along with several other proteins including
HPR and APOL1. APOL1 is considered as the trypanolytic component of both complexes.
Human infective T brucei gambiense and T. brucei rhodesiense use distinct proteins to
neutralize APOL1 trypanolytic action, which makes them resistant to human serum (Pays et al.,
2014).
The disease progression in HAT can be divided into two major stages, the
haemolymphatic stage and the meningoencephalitic or neurological stage. In the first stage, the
parasites multiply in subcutaneous tissue, lymph and blood. The early stage symptoms that are
typically observed 1-3 weeks after the insect bite are intermittent fever, headache, itching,
malaise, fatigue etc. The recurrent intermittent fever in the first stage is associated with the
waves of parasitemia caused due to antigenic variation which is a primary mechanism that
enables parasites to evade the immune system in their hosts (Horn, 2014). As the disease
develops, other clinical features such as lymphadenopathy; enlargement of the spleen and liver;
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cardiac malfunction, ophthalmological features can become evident. The onset of the second
stage of the disease correlates with the parasites crossing the blood-brain barrier to infect the
central nervous system. The typical symptoms are mental disturbances, poor coordination,
sensory and motor disturbances and abnormal reflexes. Sleep abnormalities that give the
disease its name are also observed during late stage. This includes reversal of the sleep cycle
and irrepressible episodes of sleep. Eventually the patient succumbs to coma and death if left
untreated (Kennedy, 2013).
Trypanosoma cruzi infection causes Chagas disease in humans, also known as
American trypanosomiasis. This disease is mainly endemic in Latin America but widespread
emigration in last few decades of infected individuals from endemic areas to other nations,
including the United States, Canada, and Western Europe, has caused the disease to spread
elsewhere. According to the WHO, between 6-7 million people are estimated to be infected
worldwide, mostly in Latin American nations. Transmission in humans is mainly through contact
with the feces of an infected Triatomine bug also known as the kissing bug. Other ways of
transmission are consumption of contaminated food, congenital transmission, blood transfusion,
and organ transplants. Unlike T. brucei, T. cruzi is predominantly an intracellular parasite that
can invade many different cell types and establish a chronic infection. Infection is manifested in
two stages: acute and chronic stages. The acute Chagas phase, typically lasting for about two
months after infection, can be mild or asymptomatic. However, 10-30% of infected individuals
will display symptoms such as swelling or lesion at the site of infection, fever, headache,
enlarged

lymph

glands,

abdominal

pain,

anorexia

etc.

Rarely,

myocarditis

or

meningoencephalitis during acute phase can result in death. The majority of infected people
enter a prolonged asymptomatic phase with low or undetectable parasitemia in blood. About 3040% of infected asymptomatic carriers develop chronic disease. Clinical manifestations of the
chronic stage are dilated cardiomyopathy which can cause sudden death due to cardiac arrest
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and/or digestive disorders typically due to megacolon and megaesophagus (Bonney, 2014;
Nunes et al., 2013).
Leishmaniasis is caused by infection from over 20 different species of Leishmania. It is
transmitted through the bite of females of certain species of sandfly. The disease affects over
80 countries worldwide but it is primarily endemic in tropical and sub-tropical countries.
According to a recent World Health Organization (WHO) report, about 1.3 million new cases and
20,000-30,000 deaths are reported annually due to this disease. There are two major forms of
this disease, namely cutaneous leishmaniasis, which is caused by most Leishmania species
and visceral leishmaniasis, which is primarily caused by Leishmania donovani and Leishmania
infantum. Cutaneous Leishmaniasis, the less severe and more common form of the disease,
causes skin lesions such as ulcers which can produce lifelong scars. Muco-cutaneous
leishmaniasis is a more serious form of the cutaneous disease, affecting mucous membranes of
nose, mouth and throat. Visceral leishmaniasis, fatal if untreated, is characterized by prolonged
oscillating fever, weight loss, anemia, and the enlargement of lymphatic organs (Chappuis et al.,
2007; Murray et al., 2005).
Diseases caused by trypanosomatids are amongst the most important neglected tropical
diseases, collectively affecting over 21 million people worldwide (McCall and McKerrow, 2014)
and causing approximately 150,000 deaths annually (Nussbaum et al., 2010). Over 2 million
new cases are reported each year (McCall and McKerrow, 2014). In the absence of vaccines,
chemotherapeutic drugs are the only means of treatment.

However, some of the current

medications are unsatisfactory due to high toxicity, poor efficacy and increasing drug resistance.
Pentamidine and Suramin are the main drugs for first stage HAT treatment while
Melarsoprol and Eflornithine are typically administered in the second stage. In 2009, a
combination therapy of Eflornithine and Nifurtimox was also introduced for second stage of the
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disease (Barrett and Croft, 2012). Most of these compounds cannot be administered orally, and
have undesirable, sometimes fatal, side-affects. Moreover, poor efficacy and increasing
resistance further limits the treatment with these drugs. Benznidazole and nifurtimox are the two
main drugs for treatment of Chagas disease (Barrett and Croft, 2012). Although both are
effective in curing the disease during the acute phase, their efficacy is reduced the longer a
person has been infected. Additionally, both drugs are not suitable for individuals with kidney or
liver malfunction and for pregnant women. This is significant since Chagas disease can be
transmitted congenitally; an infected mother would invariably pass the disease to the infant
unless treated. Pentavalent antimonials can be used for treatment of Leishmaniasis but
resistance is on the rise in some areas (Barrett and Croft, 2012). Some other drugs are
allopurinol and amphotericin B. Thus there is a pressing need for the development of new and
more effective drugs for all three trypanosomatid diseases (Castillo et al., 2010; Nussbaum et
al., 2010; Patterson and Wyllie, 2014).

Since trypanosome parasites share several unique

biological features that are distinct from their hosts, it is possible to envision a potential drug
target common in all three parasites. One such shared feature is the mechanism of protein
coding gene expression in trypanosomes and factors crucial for this process can be potentially
suitable therapeutic targets for the treatment of trypanosomatid diseases.

2. Gene expression in trypanosomatids
Trypanosomatid genomes are organized into large gene clusters containing functionally
unrelated, tandemly linked protein coding genes that are transcribed polycistronically by RNA
polymerase (pol) II. This is highly unusual as transcription is typically monocistronic in
eukaryotic organisms with specific initiation and termination sites. For each gene the binding of
basal transcription factors to the core promoter recruits RNA pols to the transcription initiation
site, and allows precise transcription initiation. On the other hand, polycistronic transcription is
not initiated at a concrete transcription initiation site and, so far, no transcription factors or
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promoter elements have been identified for transcription initiation at these gene arrays (Siegel
et al., 2011). Instead, open chromatin formation in divergent strand switch regions appears to be
sufficient to allow bidirectional RNA polymerase II transcription initiation to occur at multiple
sites in these regions (Kolev et al., 2010; Siegel et al., 2009).
The polycistronic primary transcripts in trypanosomes are resolved into individual
mRNAs by the coupled processes of spliced leader (SL) trans splicing and polyadenylation
(LeBowitz et al., 1993; Matthews et al., 1994). The process of SL trans splicing was first
discovered in Trypanosoma brucei (Boothroyd and Cross, 1982; Campbell et al., 1984; Kooter
et al., 1984; Milhausen et al., 1984; Van der Ploeg et al., 1982) but later on it was also identified
in other members of Euglenozoa as well as in some multicellular organisms such as Nematoda,
Platyhelminthes, Hydra etc. Some instances of trans splicing have been observed in Drosophila,
C. elegans and mosquitoes where exons from two different pre-mRNA molecules are joined
together through trans splicing (Lasda and Blumenthal, 2011). Similar to cis splicing, SL trans
splicing requires two transesterification reactions with a Y-structure intermediate which is
analogous to the cis splicing specific lariat structure (Murphy et al., 1986; Sutton and Boothroyd,
1986).
During SL trans splicing, the 39-nucleotide long SL, also known as mini-exon, is fused to
the 5' ends of all mRNAs in the cell. The SL is derived from a small nuclear RNA called SL
RNA, also known as SL donor. Since maturation of each and every mRNA crucially depends on
SL trans splicing, this RNA processing step is an absolutely essential process for the survival of
trypanosomatid parasites. Whereas in most eukaryotes the mRNA capping enzymes associate
with RNA pol II and co-transcriptionally cap pre-mRNA, in trypanosomes, the 5' cap is obtained
as part of the SL post-transcriptionally during trans splicing (Figure 1.1). Thus, SL trans splicing
uncouples capping from RNA pol II in trypanosomatids (Gunzl, 2010; Michaeli, 2011; Preußer et
al., 2012). The SL harbors an extensively modified cap structure called cap4, consisting of a 7-
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methylguanosine followed by four methylated nucleotides (Bangs et al., 1992). Cap4 appears to
be essential for SL trans splicing (McNally and Agabian, 1992; Ullu and Tschudi, 1991) and it
was also shown to be important for efficient translation (Zamudio et al., 2009a).
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Figure 1.1 Protein coding gene transcription and mRNA processing in trypanosomes.
RNA pol II transcription of protein coding genes produces polycistronic transcripts that are processed
spliced leader (SL) trans splicing and polyadenylation to generate mature individual mRNAs. During
trans splicing, the capped SL, derived from the small nuclear SL RNA, is added to the 5’ end of each
mRNA. SL RNA genes (SLRNA) are transcribed monocistronically from a RNA pol II promoter. SL RNA
7
6,6
3
acquires the complex cap4 structure m G pppm AmpAmpCmpm Um that is implicated in trans splicing.
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In SL trans splicing, the conserved 5’ splice site (SS) dinucleotide GU is located on the
SL RNA while the 3’ SS dinucleotide AG is present on the pre-mRNA. The region upstream of
the 3’ SS on the pre mRNA also contains the branchpoint (BP) adenosine and a large
polypyrimidine tract (Y~20), typically just downstream of the BP. During the first step of trans
splicing, the 2’ hydroxyl (OH) group of the BP adenosine performs a nucleophilic attack at the 5’
SS or donor SS which results in the release of the SL with a free 3’ OH and the formation of a
Y-structure intermediate. In the second step, the free 3’ OH end of the SL does a nucleophilic
attack on the 3’ SS or acceptor SS which results in joining of the SL to the mRNA. Upon
completion of the splicing process, the Y-structure intermediate is rapidly degraded (Figure 1.2).
Interestingly, while all mRNAs in trypanosomes are trans spliced, two trypanosomatid
genes also harbor introns which are removed by cis splicing (Kolev et al., 2010; Mair et al.,
2000a). Both cis and trans splicing are catalyzed by the spliceosome, consisting of five U-rich
small nuclear RNAs (U snRNAs) and associated proteins. While trypanosomes possess all five
U snRNAs, due to highly divergent amino acid sequences only a few splicing proteins were
identified by standard genome annotation and most of the knowledge of splicing complexes
comes from biochemical and functional characterizations.
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Figure 1.2 Putative model for spliced leader (SL) trans splicing in trypanosomes.
Analogous to cis splicing, SL trans splicing is achieved through two transesterification steps. Presumably,
a pre-catalytic spliceosome is assembled on pre-mRNA that includes U1, U2, U5 andU4/U6 small nuclear
ribo-nucleoproteins (snRNPs) as well as the SL snRNP. Subsequently, the spliceosome undergoes major
structural and compositional changes to become activated during which U1 and U4 snRNAs leave the
spliceosome. The activated spliceosome performs the first transesterification step which results in the
release of the SL and the formation of a Y-structure intermediate. Thereafter, during the second catalytic
step, mature spliced mRNA is generated that contains SL at its 5’ end. The intronic structure is rapidly
degraded whereas the snRNPs are released and recycled for a new round of splicing.
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3. Splicing machinery in trypanosomes and other eukaryotes.
3.1 Eukaryotic Spliceosome
The process of pre-mRNA splicing is catalyzed by a macromolecular, dynamic complex
called the spliceosome, which is composed of five small nuclear ribo-nucleoproteins (snRNPs)
U1, U2, U4, U5, and U6, as well as various non-snRNP proteins. Uridine-rich (U-rich) snRNPs,
composed of U-rich snRNAs and stably interacting proteins, are the most important component
of the spliceosome. In humans, there are ~45 snRNA associated proteins amongst a total of
~170 proteins that are estimated to be associated with the spliceosome (Wahl et al., 2009). A
large repertoire of spliceosome-associated proteins has regulatory roles while others serve to
couple splicing to other processes of gene expression such as transcription and
polyadenylation. Some are thought to provide flexibility and specificity to the spliceosome in
order to rapidly respond to changes in cellular milieu. In accordance, several non-snRNP
proteins are redundant and/or are loosely associated and most likely not needed for every
splicing event (Hoskins and Moore, 2012; Matera and Wang, 2014; Wahl et al., 2009; Will and
Luhrmann, 2001).
U snRNPs are the main building blocks of the spliceosome. Biogenesis of snRNPs
occurs in a sequential manner in several distinct steps. In higher eukaryotes, all U snRNAs
except U6 are transcribed by RNA pol II and acquire an m7G cap cotranscriptionally. These are
then exported to cytoplasm, where they associate with seven common (Sm) proteins (B/B', D3,
D2, D1, E, F and G) to form the core snRNP structure. These proteins form a heteromeric ring
around the highly conserved Sm binding site in a process that is assisted by the survival of
motor neurons (SMN) complex. Subsequently, the m7G cap is hypermethylated to 2,2,7-trimethylated guanosine (m3G) cap (Mouaikel et al., 2003) and the U snRNAs undergo 3′ end
maturation (Seipelt et al., 1999). Thereafter, the core snRNPs are reimported into the nucleus
where they bind to various snRNP-specific proteins in a special nuclear substructure called the
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Cajal body. In contrast to other U snRNPs, the U6 snRNP lacks a cytoplasmic phase. It is
transcribed by RNA pol III and acquires a γ-monomethyl cap. The U6 snRNA lacks the Sm
binding site and, instead, binds to seven Sm-like proteins (LSm2-8) (Achsel et al., 1999; Vidal et
al., 1999).
In addition to the seven common Sm or Lsm proteins, there are additional snRNPspecific proteins. Human U1 snRNP contains three U1 snRNP specific proteins namely, U170K, U1-C and U1-A (Will and Luhrmann, 2001). U2 snRNP in humans consists of at least 14
U2 snRNP-specific proteins including U2A' and U2B'' that directly bind to the U2 snRNA. U4
snRNA and U6 snRNA extensively base pair with each other resulting in formation of stable
U4/U6 di-snRNP. Five proteins in addition to the Sm and LSm proteins are stably associated
with the U4/U6 di-snRNP. These are: Snu13 (aka 15.5K), CypH, Prp4 , Prp31, and Prp3 (Liu et
al., 2006; Will and Luhrmann, 2001). The U5 snRNP contains at least eight specific proteins of
which three are especially important for the RNA/RNP rearrangements that are crucial for
activating the splicing reaction (Sander et al., 2006; van der Feltz et al., 2012). These proteins
are helicase Brr2, GTPase Snu114 and the highly conserved and crucially important Prp8.
In addition to snRNP-specific proteins, there are several non-snRNP proteins that are
essential for splicing reaction such as SF1 that binds to the BP (Berglund et al., 1997; Kramer
and Utans, 1991), U2 auxiliary factor (U2AF) subunits U2A65 and U2A35 that bind
polypyrimidine tract and the 3' SS respectively (Berglund et al., 1998; Wu et al., 1999), and the
heteromeric PRP19 complex (orthologous to the nineteen complex (NTC) in yeast) that is an
integral part of the active spliceosome (Chan et al., 2003).
The spliceosome is assembled in a step-wise manner during RNA splicing. Firstly, the
“early complex” or complex E is formed by the association of the U1 snRNP with the 5' SS via
U1 snRNA base pairing. In addition, protein factor SF1 binds to the BP, and the U2AF
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associates at both the BP and 3' SS. Next, in an ATP-dependent step, the U2 snRNA
recognizes the BP adenosine and interacts with U1 snRNP to form the pre-spliceosome or
complex A. SF1 gets displaced during this process with the help of SF3a and SF3b complexes
that are associated with the U2 snRNP. Subsequently, the preassembled tri-snRNP, consisting
of the U4/U6 di-snRNP and the U5 snRNP, is recruited with the help of the helicase Prp28, to
form the precatalytic complex B. Thereafter, complex B undergoes extensive rearrangements,
both in composition as well as conformation to form the active complex B*. This activation
requires the U5 snRNP-specific proteins Brr2 and Snu114, and the protein factor Prp2. During
this process, U4/U6 base pairing is disrupted, U1 and U4 are released and U2-U6 base pairing
is established. Complex B* catalyzes the first transesterification step of splicing, which results in
the formation of complex C containing the lariat intermediate. Complex C undergoes further
ATP dependent remodeling with the help of Prp8 and Prp16 to perform the second step of
splicing. The resulting post-spliceosomal complex contains spliced exons and the lariat intron.
Both the release of the spliced product and the disassembly of the post-spliceosomal complex is
ATP driven and require additional RNA helicases. U2, U5 and U6 snRNPs are discharged and
recycled for new rounds of splicing (reviewed in (Matera and Wang, 2014; Wahl et al., 2009)).
Most of our current knowledge for RNA splicing comes from biochemical and structural
characterizations of snRNPs and different spliceosomal complexes in yeast and human
systems, and is related to cis-splicing, e.g. intron removal.

In contrast to our detailed

understanding of cis splicing, little is known about the particulars of the trypanosome trans
splicing machinery. Previously, it was shown that U2, U4, U5 and U6 snRNAs are needed for
trans splicing in T. brucei which indicated that the splicing machinery is similar for both forms of
splicing (Tschudi and Ullu, 1990). On the other hand, it was shown in the nematode Ascaris that
the U1 snRNP is dispensable for trans splicing in vitro (Hannon et al., 1991) and that the SL
RNA, which is the SL donor, binds the Sm proteins and is assembled in a core snRNP itself

	
  

13

(Bruzik et al., 1988; Palfi et al., 1991). This suggests that there are some important differences
between cis and trans spliceosomes. Thus, the detailed understanding of the trans splicing
machinery may reveal trans splicing-specific factors that can be potential antiparasitic drug
targets.
3.2 Splicing machinery of Trypanosomes
With the exception of two genes, trypanosomatid genes lack introns (Kolev et al., 2010).
SL trans splicing is crucial for the maturation of each and every pre-mRNA in the cells. While
trypanosomes harbor all five U-rich snRNAs, there are a few important differences between U
snRNAs of humans and trypanosomatids. First, while in yeast and metazoans all U snRNAs
with the exception of U6 snRNA, are synthesized by RNA pol II, in trypanosomatids all U
snRNAs are transcribed by RNA pol III (Fantoni et al., 1994; Nakaar et al., 1994; Nakaar et al.,
1997). Unlike human and yeast U5, trypanosomatid U5 snRNA lacks the m3G cap (Dungan et
al., 1996; Xu et al., 1997). U1, U2 and U5 snRNAs in trypanosomatids are distinctively smaller
than their counterparts in humans and yeasts, and lack the key stem-loop structures that are
known to be important for RNA-protein interactions (Dungan et al., 1996; Hartshorne and
Agabian, 1990; Tschudi et al., 1990; Xu et al., 1997). Lastly, the consensus Sm binding site that
is typically well conserved in higher eukaryotes is relatively degenerate in trypanosomes
(Preußer et al., 2012).
Since antibodies raised against the Sm core proteins that typically cross-react with Sm
proteins in other organisms, did not recognize trypanosome Sm core, classical biochemistry and
bioinformatics tools were used to identify the Sm and LSm core proteins in trypanosomes
(Michaeli et al., 1990; Palfi and Bindereif, 1992; Palfi et al., 1991). Interestingly, while U1, U5
and U6 are assembled in a canonical core snRNP with trypanosomatid orthologs of the seven
Sm and Lsm proteins, U2 and U4 snRNP exhibit core variations. In U2 snRNP, paralogs of SmB
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and SmD3 called specific spliceosomal Sm2-1 (SSm2-1 a.k.a. Sm15k) and SSm2-2 (a.k.a.
Sm16.5K) replace the canonical SmB and SmD3 respectively. Similarly paralogs SSm4
replaces SmD3 in trypanosomatid U4 snRNP (Tkacz et al., 2007; Wang et al., 2006). While
orthologs of U2 snRNP specific U2A' (Cross et al., 1993) and U5 snRNP specific PRP8 (Lucke
et al., 1997) were characterized almost two decades ago, most of the other snRNP specific
proteins have been identified only in recent years. One method that has significantly contributed
in increasing the repertoire of identified splicing proteins in trypanosomes is tandem affinity
purification (TAP) using the modified TAP tag called the PTP (protein C epitope-TEV protease
cleavage site-protein A domains) tag (Schimanski et al., 2005a). With the help of TAP and
bioinformatic approaches, trypanosome orthologs of almost all known snRNP proteins have
been identified (Gunzl, 2010; Preußer et al., 2012).
However a majority of non snRNP spliceosomal proteins have not been identified yet
and remain under represented in the current repertoire of known spliceosomal proteins in
trypanosomes. In humans, only ~45 proteins of the estimated 170 spliceosomal proteins are
snRNP proteins. Since orthologs of almost all snRNP proteins are present in trypanosomes, it is
likely that a comparable number of non-snRNP proteins exist in trypanosomes and are yet to be
discovered (Gunzl, 2010).
3.3 The SL RNA and its assembly into the SL snRNP complex
One of the unique features of SL trans splicing is that the SL RNA, which is a splicing
substrate itself, is assembled into a core snRNP and binds the common Sm proteins (Bruzik et
al., 1988). Apart from the Sm proteins two other SL snRNP proteins, termed as SL175 and
SL30 according to their molecular masses, were identified in the nematode Ascaris (Denker et
al., 2002). These proteins are indispensable for trans splicing but are not required for cis
splicing or non-SL trans splicing. SL RNA has the most extensively modified cap structure
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known in any system. This complex cap structure that is composed of a m7G residue (cap0)
followed by four 2'-O-methylated nucleotides (AACU) and additional base methylations on the
first and the fourth position (m7G pppm6,6AmpAmpCmpm3Um) is termed cap4 (Bangs et al.,
1992). The base methylations occurring on the first adenosine and the third uracil are unique to
trypanosomes. The m7G cap is formed on nascent SL RNA cotranscriptionally by concerted
action of two enzymes: the RNA triphosphatase TbCet1 (Ho and Shuman, 2001) and the
bifunctional guanylytransferase/guanine N-7 methytransferase TbCgm1 (Ruan et al., 2007;
Takagi et al., 2007). However it is not clear yet whether the remaining cap4 modifications occur
cotranscriptionally.

While

it

was

thought

initially

that

these

modifications

occur

cotranscriptionally in a 5' to 3' direction and are independent of Sm binding (Hury et al., 2009;
Mair et al., 2000b), it was shown subsequently that complete cap4 formation requires Sm core
assembly (Zeiner et al., 2004a). In addition to cap4 methylations, SL RNA transcripts are also
modified by pseudouridylation at nucleotide 28 (Liang et al., 2002) and 3' end trimming (Sturm
et al., 1999). Pseudouridylation refers to the rotation of a uridine base relative to its ribose sugar
ring. Ψ28 formation on the SL RNA is directed by the SLA1 snoRNA (Hury et al., 2009; Liang et
al., 2002; Watkins et al., 1994) and requires pseudouridine synthase TbCBF5 (Barth et al.,
2005). Ψ28 is not essential for parasite survival since mutation of the base U at position 28 of
the SL RNA was not lethal. (Liang et al., 2002; Sturm et al., 1998), Surprisingly, silencing of
TbCBF5 resulted in elimination of Ψ28 as well as incomplete cap4 formation (Barth et al., 2005).
TbMTR1, the enzyme responsible for the cap1 ribose methylation and TbCBF5 are part of a
single RNP complex called the SLA1 small nucleolar RNP (snoRNP) complex (Zamudio et al.,
2009b). A knockout of TbMTR1 resulted in the specific loss of cap1 modification and
accumulation of SL RNA intermediates with cap 0 and 3' end extension indicating a delay in
downstream processing events (Zamudio et al., 2007). However, mRNAs from TbMTR1−/− cells
had the remaining cap4 methylations, which clearly demonstrated that SL RNA lacking cap1
can be trans spliced and methylations at the remaining cap4 positions are independent of cap1
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modification (Zamudio et al., 2009a). Two nuclear enzymes, TbMTR2 (a.k.a. TbMT48) and
TbMTR3 (a.k.a. TbMT57) are responsible for ribose methylations at position 2 and 3
respectively (Arhin et al., 2006a; Arhin et al., 2006b; Hall and Ho, 2006; Zamudio et al., 2006). It
has been speculated that TbMTR3 also catalyzes the methylation at position 4 since cap3
intermediates have not been detected yet. It appears that modification at positions 2, 3 and 4
requires binding of the Sm proteins to SL RNA. Knockout of either or both MTR2 and MTR3 did
not affect culture growth and trans splicing (Zamudio et al., 2009a). However, neither MTR2 nor
MTR3 could be deleted in TbMTR1−/− cells, indicating that at least a partly modified cap4 is
essential for cell survival. Additionally cap4 also appears to be important for translation, but the
mechanism for this remains to be determined (Zamudio et al., 2009a).
As mentioned above, assembly of the heptameric Sm proteins on SL RNA appears to
occur after cap1 modification and prior to remaining cap modifications. It is not known if Sm
assembly happens in the nucleus or cytoplasm and there are studies in support for both
scenarios. Knockdown of Sm subunits or mutation of the Sm binding site results in an
accumulation of immature SL RNA in the cytosol (Mandelboim et al., 2003; Zeiner et al., 2004a).
These studies support the notion that the assembly of the SL RNP occurs in the cytoplasm in a
manner that is similar to the association of Sm protein complex on U snRNAs in humans. On
the contrary, nuclear colocalization of the SLA1 snoRNA with the SL RNA, SmE as well as the
SL RNA transcription factor tSNAP42 suggests that SL RNA processing and Sm assembly
occurs in a distinct site within the nucleus presumably at the site of SL RNA transcription (Hury
et al., 2009; Tkacz et al., 2007). Nuclear localization of the Sm assembly factor SMN further
supports this hypothesis (Jae et al., 2011; Palfi et al., 2009).
Finally, maturation of the SL RNA requires 3' end trimming of SL RNA, which involves
removal of the last 4-6 nucleotides. Two nucleases are responsible for this, of which only one
called SNIP is currently known (Zeiner et al., 2004b). The 3' end processing is dependent on the
Sm-binding and is defined by the secondary structure of the SL RNA. SL RNA folds in a
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secondary structure containing three stem loops, with the second and the third loop flanking a
single stranded Sm-binding site (Bruzik et al., 1988).

4. SL RNA gene (SLRNA) transcription
Unlike other spilceosomal U snRNAs that are typically recycled, SL RNA is consumed in
the trans splicing event. Consequently, it has a high turnover rate with a half life of ~4 minutes
(Laird et al., 1987; Ullu and Tschudi, 1991). Most likely, to meet the constant high demand of SL
RNA, there are ~100 SLRNA copies organized in a 1.4 kb long tandem array on chromosome 9
(Gilinger and Bellofatto, 2001). These genes are transcribed in a monocistronic fashion by RNA
pol II, and SL RNA constitutes ~6% of total RNA synthesis in T. brucei (Campbell et al., 2000).
Since a strong continuous supply of SL RNA is crucial for the survival of all trypanosomatid
parasites, the processes of SL RNA synthesis and SL trans splicing are attractive targets for
parasite control. Accordingly, proteins that are involved in SL RNA biosynthesis are typically
encoded by essential genes.
SLRNA is the best-characterized transcription unit in trypanosomes. Unlike the protein
coding genes, SLRNA units are transcribed in a monocistronic fashion from a definite
transcription initiation site (TIS) (Hartree and Bellofatto, 1995) and transcription termination
occurs at a poly T tract downstream of the SLRNA coding region (Sturm et al., 1999).
Identification of the RNA pol that transcribes SLRNA has been controversial issue in the past.
SL RNA has a m7G cap that is characteristic of RNA pol II transcripts (Laird et al., 1985) but
termination of SLRNA transcription requires poly T tract (Sturm et al., 1999), which is a hallmark
of RNA pol III transcription. While Tagetitoxin, a potent inhibitor of RNA pol III transcription, had
no effect on SL RNA transcription (Grondal et al., 1989; Saito et al., 1994), α-amanitin that
typically inhibits RNA pol II at low doses, did not affect SLRNA transcription in this manner
(Crenshaw-Williams and Bellofatto, 1999; Gunzl et al., 1997; Saito et al., 1994). However, an in
vitro transcription study unambiguously demonstrated that SLRNA is transcribed by RNA pol II
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and not by RNA pol III (Gilinger and Bellofatto, 2001).
4.1 The SLRNA promoter
Mutational analyses in Trypanosoma brucei, Leptomonas seymouri and Leishmania
tarentolae led to the identification of the tripartite SLRNA promoter elements that consist of two
upstream sequence elements (USEs) and an initiator element (Inr) at the TIS (Gunzl et al.,
1997; Hartree and Bellofatto, 1995; Yu et al., 1998). The relative spacing between these three
promoter elements is important for efficient transcription. Also, mutations within the Inr
abolished correct transcription initiation (Luo et al., 1999). Thus, the SLRNA promoter has three
important sequence elements called USE1, USE2 and Inr that are essential for accurate and
efficient SLRNA transcription.
4.2 Trans-acting factors binding to the SLRNA promoter
After characterization of the SLRNA promoter, the next obvious step was to identify a
trans-acting factor that associates with it. Initial studies using conventional chromatography led
to the purification of a tripartite complex that interacted specifically with USE1 of the SLRNA
promoter (Luo et al., 1999). Of the two proteins that were identified in this study, one was a
clear ortholog of the human snRNA-activating protein (SNAP)50 (Das and Bellofatto, 2003).
SNAP50 is an essential subunit of the SNAP complex (SNAPc) which interacts with the
proximal sequence element of the snRNA gene promoters to nucleate transcription pre-initiation
complex formation in humans. Hence, this was the first evidence of a transcription factor in
trypanosomes and suggested that a transcription pre-initiation complex (PIC), consisting of
basal transcription factors (BTFs) and RNA pol II, is assembled at the SLRNA promoter. This
was surprising since annotation of completed trypanosomatid genomes revealed only the
trypanosome homolog of the TATA-binding protein (TBP), termed TBP-related factor 4 (TRF4)
(Ruan et al., 2004), and the TFIIH helicases XPB and XPD as potential BTFs (Ivens et al.,
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2005).
4.3 Basal factors for RNA pol II mediated transcription in humans
Promoter-dependent transcription initiation by RNA pol II in eukaryotes invariably
depends upon the formation of the PIC at the core promoter. PIC assembly for protein coding
genes is typically initiated by binding of the basal transcription factor TFIID to the TATA box.
This interaction is mediated by TBP, which is a part of the TFIID complex. This is followed by
the binding of the bipartite TFIIA to TBP that serves to counteract repressors that might
associate with TBP and to strengthen the DNA-protein interaction of the complex. DNA is
severely bent upon TBP binding, allowing the single subunit TFIIB to enter the PIC. TFIIB
directly interacts with RNA pol II and aids the recruitment of TFIIF-bound RNA pol II to the
promoter, positioning it at the correct TIS and, thus, directing accurate start site selection. The
bipartite, multi-functional TFIIF complex tightly associates with RNA pol II and facilitates the
recruitment of the enzyme to the TFIID-TFIIB complex (Flores et al., 1991). It also aids the
polymerase in start site selection (Ghazy et al., 2004) and promoter escape (Yan et al., 1999),
and enhances the enzyme’s elongation efficiency (Price et al., 1989). TFIIF is also thought to
recruit TFIIE to the PIC (Maxon et al., 1994). The two-subunit TFIIE complex brings TFIIH into
the PIC and stimulates its helicase and kinase activity. TFIIH is a large complex consisting of a
core of seven subunits, including the two helicases Xeroderma pigmentosum (XP)B and XPD,
and a CDK-activating kinase (CAK) sub-complex of three subunits. The ATPase/helicase
activity of XPB and XPD is needed for promoter opening and clearance and the kinase activity
of CAK is required for CTD phosphorylation, facilitating promoter escape of RNA pol II
[Reviewed in (Sikorski and Buratowski, 2009; Thomas and Chiang, 2006)].
Transcription initiation by RNA pol II at the snRNA genes is less well characterized
(Hernandez, 2001; Jawdekar and Henry, 2008). In the human system, PIC formation is initiated
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by SNAPc (Henry et al., 1995; Yoon et al., 1995). While human SNAPc consists of five subunits
namely SNAP190, SNAP50, SNAP45, SNAP43 and SNAP19, only three of these factors:
SNAP190, SNAP50 and SNAP43 are essential and conserved in other eukaryotes (Li et al.,
2004a). An in vitro study showed that TBP, TFIIA, TFIIB and TFIIF are also essential for snRNA
gene transcription (Kuhlman et al., 1999), but the role of TFIIH although suggested, has not
been conclusively established (Jawdekar and Henry, 2008; Kuhlman et al., 1999). Nevertheless,
these findings indicate that, except for the DNA-protein contact by SNAPc, an RNA pol II PIC is
formed at snRNA promoters that is largely congruent to that studied in much more detail at
protein coding genes.
4.4 Transcription factors essential for SLRNA transcription in trypanosomes
As mentioned above, genomic annotation of the completed genome of the Trypanosoma
brucei, Trypanosoma cruzi, and Leishmania major (also referred as Tritryp) did not identify
orthologs of BTFs for RNA pol II other than the multifunctional TBP and TFIIH helicases XPB
and XPD (Ivens et al., 2005). This was surprising since BTFs are typically highly conserved, and
the apparent lack of the genes encoding for BTFs in the genome suggested that RNA pol II
recruitment to DNA and transcription initiation does not require PIC formation in
trypanosomatids. However, since these organisms diverged very early from the main eukaryotic
lineage, it was possible that, due to sequence divergence, in silico identification of the
corresponding BTF genes failed. Accordingly, BTF identification in trypanosomes relied on
biochemical analysis. Since previous studies had identified SNAP50 (Das and Bellofatto, 2003)
and TRF4 (Ruan et al., 2004) as transcription factors that bind to the SLRNA promoter and
since both were needed for SLRNA transcription, these factors were tagged and tandem affinitypurified to further characterize the transcription machinery. In both purifications, a complex
consisting of tripartite SNAPc, TRF4, a clear ortholog of the smaller TFIIA subunit, and a sixth
protein that is most likely a highly divergent ortholog of the larger TFIIA subunit, were identified
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(Das et al., 2005; Schimanski et al., 2005b). This complex bound to the SLRNA USE and its
depletion from extract completely abolished SLRNA transcription activity while control
transcription by RNA pol I remained unaffected (Schimanski et al., 2005b). Next, a highly
divergent putative TFIIB ortholog was identified by a more thorough in silico search. Functional
analysis showed that this protein was recruited to the PIC and interacted with both RNA pol II
and TRF4. Expression silencing of TFIIB was lethal for the cells and clearly affected SLRNA
transcription (Schimanski et al., 2006). Subsequent biochemical characterization of the TFIIH
complex by tagging and TAP of the XPD helicase revealed a full core complex of seven
subunits (Lee et al., 2007) and two additional bona fide subunits termed as trypanosomatidspecific protein 1 (TSP1) and TSP2 that most likely represent divergent trypanosome orthologs
of the two TFIIE subunits (Lee et al., 2009). Gene silencing of both TSP1 and 2 affected
trypanosome culture growth and SL RNA abundance in the cells. Moreover, depletion of TSP2
from extract completely abolished transcription from the SLRNA promoter (Lee et al., 2009).
Interestingly, trypanosome TFIIH lacked the CAK complex, which consists of CDK7, cyclin H
and MAT1. Potential homologs of these proteins did not co-purify with TFIIH subunits and the
electron microscopic structure of TFIIH in T. brucei lacked the characteristic knob-like structure
that corresponds to the CAK complex in the human TFIIH. This suggested that, unlike in the
model organisms, trypanosomatid TFIIH does not have kinase activity to phosphorylate the
polymerase’s CTD (Lee et al., 2009). Nonetheless, the TFIIH complex was indispensable for
SLRNA transcription, and localized to the putative sites of SLRNA synthesis (Lee et al., 2009;
Lee et al., 2007). Finally, the trypanosome TFIIH complex associated with another protein
complex of at least nine subunits termed Med-T that is essential for cell-survival, SLRNA
transcription and PIC assembly. Molecular structure analysis by electron microscopy revealed
that Med-T is similar to the head module of the mediator complex of higher eukaryotes. This
was the first evidence that the mediator complex plays a role in the transcription of an snRNA
gene (Lee et al., 2010).
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Taken together, the current repertoire of BTFs for SLRNA transcription in trypanosomes
includes 25 unique proteins with orthologs of all known BTFs except TFIIF. Thus, the
transcription machinery in trypanosomes is not as simplified as it was initially speculated. Since
gene sequences in trypanosomes are highly divergent from those of the model organisms,
standard

genome

annotations

failed

to

identify

these

factors.

However,

functional

characterizations have clearly demonstrated that a PIC is assembled at the SLRNA promoter
that, albeit extremely divergent in amino acid sequence, closely resembles the PIC in other
eukaryotes.
While a PIC is formed for SLRNA transcription in trypanosomes, there are some
important distinctions between BTFs of trypanosomes and humans. For example, highresolution crystal structure of the C-terminal domain of trypanosome TFIIB revealed
trypanosome specific structural attributes that are absent in human TFIIB (Ibrahim et al., 2009).
Additionally, trypanosome TFIIH has unique features that distinguish it from human TFIIH.
Firstly, while two divergent paralogs of the TFIIH helicase Xeroderma pigmentosum B (XPB) are
present in the genome, only the larger of the two was identified as a TFIIH subunit. Secondly,
trypanosome TFIIH lacks the CAK complex (Lee et al., 2009; Lee et al., 2007), which has
essential function in RNA pol II CTD phosphorylation and promoter escape (Compe and Egly,
2012). Despite the apparent lack of CAK complex, the CTD of trypanosome RPB1 is
phosphorylated and important for SLRNA transcription (Chapman and Agabian, 1994; Das and
Bellofatto, 2009).

5. The TFIIH complex is essential for transcription and DNA repair
5.1 The multifunctional TFIIH complex of eukaryotes
The multisubunit TFIIH is an essential component of the RNA pol II PIC amongst all
eukaryotes. Apart from its essential role in transcription initiation by RNA pol II, it has also been
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shown to function as an elongation factor in RNA pol I transcription (Assfalg et al., 2012) and as
a DNA repair factor for nucleotide excision repair of helix-distorting lesions that are generated
after exposure to UV light or certain chemical agents (Compe and Egly, 2012). Conserved from
yeast to mammals, TFIIH is composed of ten subunits that are present in two subcomplexes.
The core complex consists of the two DNA helicases XPB & XPD, p62, p52, p44, p34 and the
repair specific subunit TTDA. XPD connects the core to the tripartite CAK subcomplex of CDK7,
cyclin H and MAT1.
Mutations in TFIIH subunits XPB, XPD and TTD-A are responsible for autosomal
recessive disorders of Xeroderma pigmentosum (XP), Trichothiodystrophy (TTD) and Cockayne
Syndrome. Patients with XP have a 1000-fold increase risk of developing skin cancer in addition
to neurological and sexual developmental defects. Cockayne syndrome is associated with
dwarfism, mental retardation, microcephaly etc. Lastly, patients with TTD experience
neurological problems including retardation, tremors and ataxia, have short stature and develop
sterility. For a long time clinical symptoms of these diseases were attributed to impairment of
nucleotide excision repair (NER) of damaged DNA in patients, but it is now becoming clear that
at least some of the symptoms are due to transcriptional defects of specific genes (Compe and
Egly, 2012).
TFIIH was initially identified as a factor that is indispensable for basal transcription by
RNA pol II (Flores et al., 1992). The enzymatic activities of the ATP dependent DNA helicase
XPB and the cyclin dependent kinase CDK7 are essential for basal RNA pol II transcription. The
ATPase activity of XPB facilitates melting of promoter DNA that allows RNA pol II to read the
coding strand and initiate transcription. Subsequently, CDK7 of the CAK complex
phosphorylates the CTD of RPB1, the largest subunit of RNA pol II (Compe and Egly, 2012). In
most eukaryotes, the CTD is composed of 5-52 repeats of the heptad sequence motif
‘YSPTSPS’. Post-translational modifications of the CTD regulate different stages of RNA pol II
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transcription (Buratowski, 2009). Specific post-translational modifications also facilitate
association of the CTD with various mRNA processing factors. RNA pol II that is recruited to a
promoter is typically hypo-phosphorylated at the CTD. Phosphorylation of the CTD at Serine 5
of the heptad repeat by CDK7 enables promoter clearance of RNA pol II and allows the enzyme
to dissociate from most BTFs (Egloff et al., 2010; Phatnani and Greenleaf, 2006). Additionally,
CDK7 is implicated in the phosphorylation of the serine at position 7 of the CTD heptad repeat.
The exact role of serine 7 phosphorylation for transcription of protein coding genes is not clear,
although it is suggested that the bivalent marks might play a role in recruiting specific RNA
processing factors (Akhtar et al., 2009; Glover-Cutter et al., 2009). On the other hand, serine 7
phosphorylation by CDK7 at U snRNA genes is important for recruitment of the Integrator
complex, which plays a role in 3′ processing of snRNAs (Egloff et al., 2007; Kim et al., 2009). In
summary, TFIIH is a BTF that plays an essential role in transcription initiation, promoter
clearance and recruitment of various processing factors during RNA pol II transcription.
Even before XPB and XPD helicases were identified as subunits of TFIIH, they
were known to be important for NER of damaged DNA. Both of these helicases belong to the
SF2 family of helicases and contain seven conserved helicase motifs. But while XPB is a 3/ - 5/
helicase, XPD is a 5/ - 3/ one. Interestingly, while ATPase activity of XPB is essential for both
transcription and repair, its helicase activity is not required for DNA repair (Coin et al., 2007; Lin
et al., 2005). Conversely, the helicase activity of XPD is essential for NER (Coin et al., 2007;
Tirode et al., 1999). It is proposed that XPB is involved in anchoring of TFIIH complex to the
sites of DNA damage (Oksenych et al., 2009) while XPD opens the damaged DNA that allows
subsequent NER factors to repair the damage (Coin et al., 1998a; Coin et al., 1998b). Another
subunit of TFIIH that is especially important for DNA repair is TTD-A (a.k.a. Tfb5). While
recombinant TFIIH complex containing all nine subunits except for TTD-A, was competent in
transcription assays, its repair activity was much reduced. Addition of TTD-A restored the invitro repair activity of the recombinant TFIIH, clearly demonstrating the importance of TTD-A in
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NER (Coin et al., 2006). In addition to the XPB, XPD and TTD-A subunits that appear to have a
direct role in DNA repair, other subunits of TFIIH perform regulatory functions. p52 and TTD-A
stimulate the ATPase activity of XPB while p44 and p34 are known to stimulate the helicase
activity of XPD.
The main function of TFIIH in NER is to unwind the DNA at the site of damage, allowing
subsequent repair factors to access the damaged DNA and repair the defect (Compe and Egly,
2012). NER is triggered when XPC-RAD23B recognizes the DNA lesions that are generated
due to exposure to UV light or certain genotoxic chemicals such as cisplatin (Mocquet et al.,
2007; Sugasawa et al., 2001). These lesions include covalently linked bulky DNA adducts that
distort the double helical structure. UV-induced lesions are also recognized by UV-damaged
DNA binding (UV-DDB) proteins, which in turn, recruit XPC to the damage site (Fei et al., 2011;
Fitch et al., 2003; Wang et al., 2004). In the transcription-coupled NER (TC-NER) pathway,
which involves repair of DNA lesions on genes that are being transcribed, damage detection is
mediated by stalled RNA pol II along with the Cockayne syndrome type B (CSB) protein
(Hanawalt and Spivak, 2008). Subsequent to damage recognition, TFIIH enters the site of
lesion, and unwinds the DNA with the help of XPB and XPD helicases (Compe and Egly, 2012;
Oksenych and Coin, 2010). XPA and Replication Protein A (RPA) are then recruited to stabilize
the TFIIH-XPC complex and protect the single-stranded DNA respectively (Aboussekhra et al.,
1995; Krasikova et al., 2010). Next, the NER endonucleases XPF and XPG incise the damaged
DNA at 5′ and 3′ sides, respectively (Evans et al., 1997). This results in removal of an
oligonucleotide that is about 27 nucleotides long, encompassing the DNA lesion. After XPF
generates the 5′ incision, XPC, TFIIH and XPA are released from the reaction and recycled
(Coin et al., 2008). Prior to the 3′ incision, RPC and Proliferating Cell Nuclear Antigen (PCNA)
and DNA polymerases are recruited to the site of damage (Staresincic et al., 2009).
Subsequently, DNA polymerases fill the gap and DNA ligases seal the newly synthesized DNA
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(Lehmann, 2011). It appears that in non-dividing cells, DNA polymerase δ (Pol δ) and Pol κ
synthesize DNA (Ogi et al., 2010), and DNA ligase III–X-ray repair cross-complementing protein
1 (XRCC1) performs ligation while in diving cells synthesis also needs Pol ɛ (Ogi et al., 2010)
and ligation is mediated by both DNA ligase III–XRCC1 and DNA ligase I–flap endonuclease 1
(FEN1) (Moser et al., 2007). In a final step, chromatin assembly factor 1 (CAF1) repositions the
nucleosomes on the repaired DNA (Gaillard et al., 1996) (Reviewed in (Compe and Egly,
2012)).
5.2 Unique features of trypanosome TFIIH
As mentioned earlier, trypanosome TFIIH is composed of the orthologs of XPD, XPB,
p52, p62, p34, p44 and TTD-A, and two trypanosomatid specific subunits which are
indispensable for SLRNA transcription (Lee et al., 2009; Lee et al., 2007). Surprisingly,
annotation of completely sequenced genomes showed that trypanosomatids have two divergent
XPB genes. The sequences of the XPB paralogs from T. brucei exhibit only 24.2% identity and
37.1% similarity, indicating that this XPB dualism is not the result of a recent gene duplication
event. Moreover, two divergent XPB genes are present in all kinetoplastids whose genome has
been completed, suggesting that the XPB dualism is not restricted to trypanosomatid
organisms. Interestingly, only the larger of the two XPB proteins co-purified with T. brucei TFIIH
leaving the functional role of the smaller XPB paralog undetermined.
The study described in Chapter II is the functional characterization of the smaller
XPB paralog termed XPB-R (R for repair). This study identified that while XPB-R was
dispensable for SLRNA and protein coding gene transcription, it was essential for NER in
T. brucei. Our results also suggest that although XPB-R is not assembled in a TFIIH
complex, it interacts with the p52 subunit of TFIIH. In other eukaryotes, it has been
shown that p52 regulates XPB activity and interacts directly with XPB. Consistent with
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this, a knockdown of p52 also impaired NER in T. brucei. To our knowledge, this is the
first study that demonstrates a TFIIH independent function of XPB for NER in any
eukaryotic organism.
Another interesting feature of trypanosome TFIIH is the apparent lack of the CAK subcomplex that is typically associated with TFIIH in all eukaryotes (Lee et al., 2009). As introduced
above, the CAK enzyme CDK7 plays a crucial role in RNA pol II transcription by
phosphorylating the CTD of RPB1. Interestingly, a comparative genomics study indicated that
organisms that lack the heptad repeat motif in the CTD do not possess orthologs of CDK7 (Guo
and Stiller, 2004). Accordingly, the finding that trypanosome TFIIH is not associated with a CAK
complex was consistent with the fact that there are no heptad repeats in trypanosomatid
RPB1s. Despite the absence of heptad repeats, the trypanosome CTD of RPB1 is
phosphorylated (Chapman and Agabian, 1994; Das and Bellofatto, 2009). Moreover, it was
shown that deletion of a major part of T. brucei CTD is lethal for cells and abolishes RNA pol II
transcription (Das and Bellofatto, 2009). However, the kinase that phosphorylates the CTD and
the functional significance of CTD phosphorylations in trypanosomes is not yet known although
a recent study suggests that chromatin-associated RNA pol II is phosphorylated at the CTD
(Rocha et al., 2014). In summary, these results indicated that trypanosomes possess a socalled transcriptional CDK that controls RNA pol II phosphorylation and function. This prospect
was exciting since CDKs, in contrast to almost all other transcription factors, are promising
targets of chemotherapy.
5.3 CDKs are essential regulators of the cell cycle and of gene expression
CDKs form a special class of serine-threonine kinases that require association with their
regulatory partners called cyclins for kinase activity. CDK/cyclin complexes were first identified
in yeast as key regulators of cell cycle progression (Beach et al., 1982; Nasmyth and Reed,
1980). Although now it is well established that several CDK/cyclin complexes have crucial
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functions in transcription and RNA splicing (Lim and Kaldis, 2013; Loyer et al., 2005). CDKs
share a conserved catalytic domain that consists of the ATP binding pocket, PSTAIRE-like helix
domain responsible for cyclin binding and an activating T-loop motif. Association of cyclin to the
PSTAIRE domain confers spatial reorientation of the T loop that enables substrate binding (Cao
et al., 2014; Malumbres et al., 2009). While Saccharomyces cerevisiae encodes for six
members of the CDK family and about 23 cyclins, the human CDK family is composed of 13
established members that associate with 29 cyclins or cyclin-related proteins (Malumbres and
Barbacid, 2009).
Pioneering studies in yeast showed that a single CDK − Cdc28p in Saccharomyces
cerevisiae and cdc2 in S. pombe − controls the progression through the cell cycle by binding to
specific cyclins at different stages (Beach et al., 1982; Evans et al., 1983; Nurse and Thuriaux,
1980; Reed et al., 1982). In contrast to yeasts, many more CDKs and cyclins are involved in cell
cycle regulation in mammals. These include CDK2, CDK4 and CDK6 also referred as
interphase CDKs, CDK1 (a.k.a. cell division control protein 2 (CDC2)), and ten cyclins belonging
to the classes of A-, B-, D- and E-type cyclins (Malumbres and Barbacid, 2009). According to
the classical model, specific CDK-cyclin pairs control distinct events during the mammalian cell
cycle. In response to mitogenic stimulus, D-type cyclins are expressed that preferentially bind to
CDK4 and CDK6 during G1 phase. Activation of CDK4 and CDK6 stimulates the expression of
E-type cyclins which bind and activate CDK2. The expression and availability of E-type cyclin is
tightly restricted to the early stage of DNA replication. During the late stages, CDK2 interacts
with cyclin A2 to drive the transition from S to G2 phase of cell cycle. Next, CDK1 activation by
A-type cyclins drives initiation of mitosis. Subsequent to the breakdown of nuclear envelope, Atype cyclins are rapidly degraded and CDK1 interacts with cyclin B to drive mitosis (reviewed in
(Malumbres and Barbacid, 2009)). However, in recent years the classical model has been
challenged by the studies that show that CDK2, CDK4 and CDK6 are not essential for the cell
cycle (Berthet et al., 2003; Malumbres et al., 2004; Martin et al., 2003; Mettus and Rane, 2003;
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Ortega et al., 2003; Rane et al., 1999). Instead, they regulate specific functions in specialized
cell types. For instance CDK4 is important for development of pancreatic β cells (Rane et al.,
1999) while CDK2 is essential for meiotic division in germ cells (Berthet et al., 2003; Ortega et
al., 2003).
While CDKs that are important for the cell cycle are regulated by their sequential binding
to different cyclins, each of which are transcribed and degraded at definite stages during the cell
cycle, the CDKs and cyclins that are involved in gene expression appear to be constitutively
expressed throughout the cell cycle. CDK7 is a unique CDK that has roles in both cell cycle and
transcription regulation (Fisher, 2005). It associates stoichiometrically with Cyclin H and a RING
finger domain containing protein, MAT1 forming a trimeric complex of CDK7/Cyclin H/MAT1
called the CDK activating kinase (CAK) complex because of its ability to phosphorylate and
activate key cell cycle CDKs at the T loop (Fisher, 2005; Roy et al., 1994; Serizawa et al., 1995;
Shiekhattar et al., 1995). MAT1 functions as an assembly factor (Fisher et al., 1995; Tassan et
al., 1995) and interacts directly with both Cyclin H and CDK7 (Busso et al., 2000).
Another CDK/cyclin complex that appears to function both in gene expression and cell
cycle is the CDK11/cyclin L complex. As a result of alternative splicing and exon skipping,
different isoforms of CDK11 are produced which are grouped as CDK11p110 and CDK11p58
proteins based on their size. While CDK11p58 isoforms are only expressed during G2/M phase
and are implicated in mitosis, CDK11p110 forms are constitutively expressed and have a role in
transcription and pre-mRNA splicing (Hu et al., 2003; Loyer et al., 1998; Trembley et al., 2004).
CDK11p110 associates with RNA pol II as well as the splicing factors RNPS1 and 9G8, and it was
shown to phosphorylate the SR protein 9G8 (Hu et al., 2003). Phosphorylation of 9G8 is critical
for its role in pre-mRNA splicing and export of mRNA from nucleus to cytoplasm. Thus,
CDK11p110 might regulate splicing by controlling the phosphorylation status of 9G8 (Dickinson et
al., 2002; Hu et al., 2003; Loyer et al., 2008; Loyer et al., 1998).
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Two other CDK/cyclin complexes known to function in transcription are CDK8/cyclin C
and CDK9/cyclin T. CDK8/cyclin C associates with the Mediator complex and functions as a
transcriptional repressor by phosphorylating cyclin H, which deceases the activity of TFIIH on
the CTD (Akoulitchev et al., 2000). Conversely, CDK9/cyclin T, a.k.a. positive transcription
elongation factor b (P-TEFb), promotes transcription elongation by RNA pol II by
phosphorylating the CTD at Serine 2 of the heptad repeats (Ramanathan et al., 2001; Zhou et
al., 2000).
In summary, CDKs are crucial regulators of the cell cycle and gene expression. CDKs as
well as other kinases that control the cell cycle are often dysregulated during cancer leading to
unrestricted cell proliferation (Malumbres and Barbacid, 2001). Since, kinases can be effectively
inactivated by small molecule inhibitors, they are considered as relevant drug targets (Shapiro,
2006). Pan-CDK inhibitor flavopiridol was the first CDK inhibitor to enter clinical trials. It showed
anti-tumor effects in leukemia cell and non-small cell lung cancer cell lines (Konig et al., 1997;
Shapiro et al., 1999) as well as in patients with renal, prostate and colon cancer, metastatic
gastric cancer and non-Hodgkin’s lymphoma during phase I clinical trials (Senderowicz et al.,
1998; Tan et al., 2002; Thomas et al., 2002). However it exhibited several adverse effects in
patients and did not show significant advantages in phase II and III clinical trials (Aklilu et al.,
2003; Burdette-Radoux et al., 2004; Schwartz et al., 2001; Shapiro et al., 2001). As of 2013,
there were at least 40 ongoing clinical studies with several first and second-generation CDK
inhibitors (Pitts et al., 2014). Currently, more attention is focused on the development of
selective ATP-noncompetitive CDK inhibitors that do not exhibit toxicity that pan CDK showed in
previous clinical trials (Abate et al., 2013).
5.4 T. brucei CRK9 is a transcriptional CDK
T. brucei contains eleven CDKs, termed cdc2-related kinases (CRK)1-4 and CRK6-12
and 10 cyclins (CYC2-11) (Hammarton, 2007; Naula et al., 2005). Due to high sequence
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divergence of trypanosome CDKs, it has been impossible to identify their putative orthologs in
other eukaryotes without functional validation. Due to their potential druggability, trypanosomatid
kinases have constantly been a subject of interest. A number of studies have been performed to
identify essential CDKs in T. brucei (Jones et al., 2014; Mackey et al., 2011; Merritt and Stuart,
2013). RNAi mediated gene knockdowns identified CRK1-4, CRK6, CRK9, and CRK12 as
crucial for cell survival in T. brucei (Jones et al., 2014). CRK3 appears to be the functional
homolog of CDK1 in trypanosomes. It partners with CYC6 (a.k.a. cyclin B2) and regulates
mitosis (Hammarton et al., 2003; Li and Wang, 2003; Tu and Wang, 2004). CRK1 is important
for G1/S progression and interacts with CYC2 in a yeast two-hybrid screen although interaction
was not observed in vivo (Gourguechon et al., 2007; Tu and Wang, 2004; Van Hellemond et al.,
2000). In addition, CRK2, CRK4 and CRK6 appear to have accessory functions in the cell cycle
although their cyclin partners are unknown (Tu and Wang, 2005). Recently CRK12 was shown
to associate with CYC9 during TAP. Both CYC9 and CRK12 were essential in the humaninfective bloodstream stage of T. brucei, but gene silencing resulted in distinct phenotypes
suggesting that while CYC9 is important for cytokinesis, CRK12 has a role in endocytosis
(Monnerat et al., 2013).
In an attempt to identify the trypanosome CDK that is involved in CTD
phosphorylation, we performed RNAi-mediated gene knockdowns of CRK1, CRK3, CRK7
and CRK9 since CRK1, CRK3 and CRK9 were shown to be most important for
trypanosome survival (Gourguechon and Wang, 2009; Tu and Wang, 2004) and CRK7 was
speculated to be the ortholog of CDK7 based on sequence similarity (Parsons et al.,
2005). In a study described in chapter III, we identified that CRK9 is required for RPB1
phosphorylation in T. brucei. Interestingly, CRK9 silencing did not lead to a specific
defect in RNA pol II transcription; instead it caused SL RNA cap4 hypomethylation and a
block at the first step of SL trans splicing. This study is the first identification of a
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trypanosome CDK that is essential for phosphorylation of RNA pol II and parasite
specific process of trans splicing.
In a next step, I characterized the enzyme complex of this crucial CDK by TAP of
CRK9. This led to identification of a putative tripartite complex comprised of CRK9, a
previously unannotated cyclin termed CYC12, and a third protein termed CRK9AP with
no obvious conserved sequence motifs. Gene silencing analysis identified CYC12 and
CRK9AP as functional partners of CRK9 in vivo. A phylogenetic analysis suggested that
CYC12 is an L-type cyclin, which, in other eukaryotes, associates with CDK11, a CDK that
is involved in transcription and RNA splicing. However, the presence of CRK9AP in the
enzyme complex distinguishes CRK9 from CDK11. CRK9AP appears to be important for
enzyme complex assembly or stability, since its ablation led to rapid co-depletion of the
other two proteins. Moreover, we validated in the mouse host that this unusual key
enzyme is a suitable target for chemotherapy. This work is discussed in Chapter IV.
Lastly, due to CRK9’s putative role in the trans splicing process we renewed our
interest in the trypanosome spliceosome, focusing on the non-snRNP PRP19 complex,
which is important for the activation of the spliceosome. Most interestingly, we
discovered that ablation of the PRP19 complex, in contrast to that of an essential U6
snRNP protein, led to similar defects in trans splicing, cap4 formation and RPB1
phosphorylation as we observed upon CRK9 depletion, indicating that CRK9 acts
upstream of spliceosome activation. The functional and biochemical characterization of
the trypanosome PRP19 complex was a collaborative study with Dr. Daniela Ambrósio
and is described in Chapter V.
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Chapter II

Trypanosoma brucei harbors a divergent XPB helicase
paralog that is specialized in nucleotide excision repair and
conserved among kinetoplastid organisms

1. Abstract
Conserved from yeast to humans, TFIIH is essential for RNA polymerase II transcription
and nucleotide excision repair (NER). TFIIH consists of a core that includes the DNA helicase
Xeroderma pigmentosum B (XPB) and a kinase subcomplex. Trypanosoma brucei TFIIH
harbors all core complex components and is indispensable for RNA polymerase II transcription
of spliced leader RNA genes (SLRNAs). Kinetoplastid organisms, however, possess two highly
divergent XPB paralogs with only the larger being identified as a TFIIH subunit in T. brucei.
Here we show that a knockout of the gene for the smaller paralog, termed XPB-R (R for repair)
resulted in viable cultured trypanosomes that grew slower than normal. XPB-R depletion did not
affect transcription in vivo or in vitro and XPB-R was not found to occupy the SLRNA promoter
which assembles a RNA polymerase II transcription pre-initiation complex including TFIIH.
However, XPB-R-/- cells were much less tolerant than wild-type cells to UV light- and cisplatininduced DNA damage, which require NER. Since XPB-R-/- cells were not impaired in DNA base
excision repair, XPB-R appears to function specifically in NER. Interestingly, several other
protists possess highly divergent XPB paralogs suggesting that XPBs specialized in
transcription or NER exist beyond the Kinetoplastida.
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2. Introduction
The multi-subunit transcription factor TFIIH is of central importance to transcription
initiation by RNA polymerase II and DNA nucleotide excision repair (NER) in yeast and
mammalian systems (Compe and Egly, 2012; Feaver et al., 1993; Schaeffer et al., 1993). It
consists of two sub-complexes: the core and the cyclin activating kinase (CAK) complex. The
core complex includes the two ATP-dependent DNA helicases Xeroderma pigmentosum B
(XPB, also known as ERCC3, RAD25, SSL2), and XPD (also known as ERCC2, RAD3), their
respective regulators p52 and p44 along with p62, p34 and p8 (also known as TTDA, TFB5).
XPD connects the core complex to the CAK complex which consists of cyclin-dependent kinase
7 (CDK7), cyclin H and MAT1. Both XPB and XPD belong to the SF2 superfamily of helicases
and contain seven characteristic helicase motifs, namely Walker motifs I, Ia, II, III, IV, V, and VI.
While XPB is a 3/ - 5/ helicase, XPD exhibits 5/ - 3/ activity. Recent studies in human cells have
demonstrated that these helicases have distinct roles in NER and transcription. The ATPase
activity of XPB is essential for DNA opening in both repair and transcription while its helicase
activity is specifically important for transcription: by unwinding DNA it facilitates RNA pol II
escape from the promoter (Coin et al., 2007; Lin et al., 2005). The TFIIH subunit p52 directly
interacts with an N-terminal region of XPB, termed XPB domain, and regulates its ATPase
activity (Coin et al., 2007; Jawhari et al., 2002). In contrast, XPD helicase activity is essential for
NER whereas it appears to be dispensable for transcription initiation (Coin et al., 2007; Tirode et
al., 1999). Given the importance of these helicases in NER, it is not surprising that mutations in
XPB and XPD cause deficiency in NER leading to the human diseases Xeroderma
pigmentosum, Cockayne Syndrome and Trichothiodystrophy (Compe and Egly, 2012).
XPB homologs have been identified in both bacteria and archaea (Balasingham et al.,
2012; Biswas et al., 2009; Richards et al., 2008). Recent data suggest that archaeal XPB
functions in NER. Crystal structure data of XPB from the archaeon Archaeoglobus fulgidus
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revealed a DNA damage recognition domain (Fan et al., 2006), and a functional analysis of the
association between Sulfolobus solfataricus XPB and BAX1 endonuclease showed that this
complex can recognize, unwind and cleave model NER substrates in vitro (Rouillon and White,
2010). Moreover, homologs of other eukaryotic NER proteins have been identified in archaeal
organisms as well (Rouillon and White, 2011). Conversely, the bacterial NER pathway is
controlled by so-called Uvr proteins whose amino acid sequences are different from those of
eukaryotic NER proteins (Truglio et al., 2006). Interestingly, bacterial and archaeal XPB appears
to function independently of a TFIIH complex since, except for XPD, TFIIH subunit homologs
have remained elusive in these organisms (Rouillon and White, 2011).
In eukaryotes, XPB exerts its dual function in transcription and DNA repair exclusively
within a TFIIH complex (Compe and Egly, 2012). Notably, the completed genomes of members
of the protistan family Trypanosomatidae, which include the human parasites Trypanosoma
brucei, Trypanosoma cruzi and Leishmania major, harbor two distinct XPB genes that encode
two divergent XPB paralogs (Ivens et al., 2005). The T. brucei TFIIH complex has been
functionally, biochemically and structurally characterized, and has been shown to have a basal
function in RNA polymerase II transcription as in other eukaryotes (Lecordier et al., 2007; Lee et
al., 2010). This function, however, may be restricted to a single gene, namely the spliced leader
(SL) RNA gene (SLRNA). In trypanosomatids, protein coding genes are arranged in long
tandem arrays that are transcribed polycistronically. Individual mRNAs are then processed from
precursor RNA by polyadenylation and SL trans splicing (Gunzl, 2010). Transcription of the
gene arrays initiates predominantly in divergent strand-switch regions (dSSRs) in which the
arrays are arranged head-to-head (Martinez-Calvillo et al., 2010; Martinez-Calvillo et al., 2003).
While dSSRs typically harbor two peaks of open chromatin marks, it remains unclear whether
basal transcription factors such as TFIIB or TFIIH are required for RNA pol II transcription
initiation in these regions (see reviews by (Alsford et al., 2012) and Günzl, 2012) In contrast,
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SLRNA genes, which are tandemly linked on chromosome 9 and encode the SL donor in the
trans splicing process, are transcribed monocistronically by RNA pol II from a concrete
transcription initiation site. Accordingly, the SLRNA promoter assembles a conventional, albeit
highly divergent, transcription pre-initiation complex which includes TFIIH (Preußer et al., 2012).
The T. brucei TFIIH was characterized biochemically by tandem affinity purification revealing a
full core of seven subunits and two additional subunits, termed TSP1 and TSP2, which most
likely represent divergent subunit orthologs of the factor TFIIE (Lecordier et al., 2007; Lee et al.,
2009; Lee et al., 2007). Importantly, only the larger of the two XPB paralogs was identified in the
TFIIH complex regardless of whether the complex was purified through tagging XPD or TSP2
(Lecordier et al., 2007; Lee et al., 2009).
Here, we functionally characterized the smaller T. brucei XPB paralog which has
previously been named XPBz (Lecordier et al., 2007). Our results showed that this helicase was
neither important for transcription nor essential for the viability of the insect stage, procyclic form
of the parasite in culture although the gene knockout did retard trypanosome proliferation.
Instead, we found that the helicase specifically functioned in NER and, correspondingly, was
localized throughout the nucleus. We therefore renamed this helicase XPB-R (R for repair).
Furthermore, our results strongly indicate that XPB-R does not assemble into a TFIIH complex
yet forms a repair complex with the trypanosome p52 ortholog. Interestingly, comparative
genomics showed that the two divergent XPB orthologs are present in all kinetoplastids
including the bodonid Bodo saltans and a phylogenetic analysis revealed that highly divergent
XPB paralogs are present in distantly related protistan organisms suggesting that a bifunctional
TFIIH complex is not the norm among deep branching eukaryotes.
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3. Materials and Methods
3.1 DNAs
For XPB-R and p52 silencing, the coding region from position 8 to position 487 and from
position 1 to 500, respectively, were integrated in a stem-loop arrangement (sense-stufferantisense) into the pT7-stl construct (Brandenburg et al., 2007). For C-terminal PTP tagging of
XPB-R, 499 bp of the 3/ terminal XPB-R coding sequence including an internal Bsgl linearization
site were cloned into the pC-PTP-NEO vector using the vector’s ApaI and NotI restriction sites
(Schimanski et al., 2005a). DNA oligonucleotides used for semi-quantitative RT-PCR or PCR
are specified in Table S1 of the supplemental material. Plasmids used in dot blots were
described previously and contained the complete coding regions of GPEET procyclin, α tubulin,
actin, HSP70 and 18S rRNA or the threonine tRNA/U6 snRNA gene association (Schimanski et
al., 2006). The template plasmids for in vitro transcription, GPEET-trm and SLins19, have been
described previously (Gunzl et al., 1997; Laufer et al., 1999).
3.2 Cells
T. brucei brucei 427 cell culture, stable transfection by electroporation, and the
generation of clonal cell lines by selection and limiting dilution was carried out as described (Lee
et al., 2007). In RNAi experiments, dsRNA synthesis was induced with 2 µg/ml of doxycycline.
For measurement of procyclic and bloodstream form culture growth, cells were counted and
diluted daily to 2 × 106 cells/ml and 2 × 105 cells/ml, respectively. The procyclic clonal XPB-R+/cell line was generated by knocking out one of the XPB-R alleles with a PCR product in which
101 bp of XPB-R 5/ and 3/ gene flanks were fused to the hygromycin phosphotransferase coding
region. The clonal cell line that exclusively expressed XPB-R-PTP was obtained by targeted
integration of the linearized plasmid XPB-R-PTP-NEO into the remaining XPB-R allele of the
XPB-R+/- cell line. For HA tagging of p52, the construct p52-HA-BLA (Lee et al., 2007) was
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linearized with StuI and transfected into a clonal cell line that exclusively expressed XPB-RPTP. Immunoblotting was performed to confirm correct tagging of the protein in each clonal cell
line. The XPB-R-/- KO-1 and KO-2 knockout cell lines were created by removing the remaining
XPB-R allele in XPB-R+/- cells with a PCR product of the blasticidin-S deaminase coding region
surrounded by 101 bp of XPB-R 5/ and 3/ gene flanks, and by limiting dilution of the cells
immediately after transfection. Correct DNA integrations were ensured in clonal cell lines by
PCR amplification of genomic DNA using oligonucleotides that hybridize outside of the
transfected DNA constructs.

3.3 RNA analysis
The relative abundance of RNAs in cells was determined by preparing total RNA from 8
x 107 cells using Trizol reagent (Invitrogen), reverse transcription and semi-quantitative PCR.
Reverse transcription was carried out with SuperScript II reverse transcriptase (Invitrogen)
according to the manufacturer’s protocol using oligo-dT as primer. For semi-quantitative PCR,
the number of cycles for the linear amplification range was determined empirically for each
oligonucleotide pair. Labeling and analysis of nascent RNA using a permeabilized cell system
was carried out as described previously (Schimanski et al., 2006). Quantification was performed
by densitometry using ImageJ for SL RNA signals and by scintillation counting for dot blot
signals.

3.4 Protein Analysis
Immunoprecipitations (IPs) were performed as described previously (Lee et al., 2007).
Briefly, for reciprocal co-IPs, 100 µl of crude extract was incubated with either 40 µl settled
volume of IgG beads (Amersham, Piscataway, NJ) which interact with the PTP tag, or 25 µl
settled volume of anti-HA antibody (Bedez et al., 2013) immobilized on protein G-Sepharose
(Amersham). Once bound to protein G, the anti-HA antibody is unable to interact with the
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protein A domains of the PTP tag, ensuring that these beads precipitate HA-tagged protein only.
After washing the beads six times with 700 µl of TET100 buffer (100 mM NaCl, 20 mM Tris-HCl,
pH 8.0, 3 mM MgCl2, 0.05% Tween 20), PTP-tagged protein was released by AcTEV protease
(Invitrogen) digestion, whereas HA-tagged protein was directly eluted into SDS loading buffer at
100°C for 5 min. Precipitated complexes were analyzed by immunoblotting; PTP- and HAtagged proteins were detected on blots with the anti-protein C antibody HPC4 (Bedez et al.) or a
monoclonal rat anti-HA antibody (Bedez et al.), and TSP2 with a polyclonal rat immune serum
(Lee et al., 2009) in combination with the BM chemiluminescence blotting substrate (Bedez et
al.) according to the manufacturer's specifications.
XPB-R-PTP was tandem affinity purified according to the standard PTP purification
protocol (Schimanski et al., 2005a). Purified proteins were separated on a 10 to 20% SDSpolyacrylamide gradient gel and stained with SYPRO Ruby (Invitrogen) according to the
manufacturer's protocol. Proteins were trypsin digested, eluted from the gel and subjected to
liquid chromatography-tandem mass spectrometry.
For sedimentation analysis, 200 µl of crude extract prepared from a clonal cell line
expressing XPB-R-PTP and p52-HA was subjected to ultracentrifugation in 4 ml 10-40% linear
sucrose gradients at 41,000 rpm for 16 h at 4°C as described previously (Lee et al., 2010).
Twenty fractions were collected from top to bottom and protein in each fraction was collected
with hydrophobic StrataClean resin (Stratagene, La Jolla, CA) as previously described
(Schimanski et al., 2005a). Proteins were separated by denaturing PAGE and detected by
immunoblotting.
3.4 In vitro transcription
Preparation of extract active in transcription and the carrying out of in vitro transcription
assays were performed as described previously (Laufer and Gunzl, 2001; Laufer et al., 1999).
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Newly synthesized RNAs of the GPEET-trm and SLins19 templates were detected by primer
extension of

32

P-end-labeled oligonucleotides Tag-PE and SLtag, which hybridize to unrelated

oligonucleotide tags of the GPEET-trm and SLins19 RNAs. Primer extension products were
resolved on 6% polyacrylamide-50% urea gels and visualized by autoradiography.
3.5 Chromatin Immunoprecipitation
ChIP assays were performed as described previously (Lee et al., 2010). XPD-PTP- and
XPB-R-PTP-bound chromatin fragments were immunoprecipitated overnight at 4°C with a
polyclonal rabbit antibody directed against the protein A domains of the PTP tag (Kartalou and
Essigmann). Immunoprecipitated DNA was analyzed by semiquantitative and quantitative realtime PCR of the SLRNA promoter region (positions −90 to +63 relative to the transcription
initiation site), the SLRNA intergenic region (+407 to +540), and the α-tubulin-coding region
(+737 to +860 relative to the translation initiation codon) using the primer pairs listed in Table
S1. For quantification of immunoprecipitated DNA, qPCR was performed using the SsoFast
EvaGreen Supermix (BioRad) on a CFX96 cycler (BioRad) according to the manufacturer's
recommendations. Two independent ChIP experiments were performed for both XPD-PTP and
XPB-R-PTP cell lines. For each amplification and ChIP experiment, triplicate qPCR samples
were analyzed using the Bio-Rad CFX Manager software package. The specificity of each
amplification product was ensured by agarose gel electrophoresis and melting curve analysis.
Standard curves for oligonucleotide pairs were obtained from serial dilution of input DNA. Their
coefficient of determination (R2) value was above 0.98. Samples were standardized according to
the starting quantities of tubulin DNA in each experiment and the fold enrichment values were
calculated as the ratio between starting quantities of positive and control precipitations.
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3.6 Survival assays
Sensitivity of cells towards DNA damaging agents were tested at a cell density of 2 × 106
cells/ml. For assessing UV irradiation effects, the wildtype (427) and knockout cells were
exposed to doses of 300, 500 or 1000 J/m2 using the Stratalinker® UV Crosslinker (Stratagene).
For Cisplatin (Kartalou and Essigmann) and MMS (Kartalou and Essigmann) sensitivity assays,
cells were cultured with Cisplatin ranging from 0.5 to 10 µM and with MMS from 0.0001 to
0.0004% for two days. In each case, treated and untreated control cell cultures were diluted
daily to a concentration of 2 × 106 cells/ml. Total cell count was determined after two days and
the survival was calculated as a percentage of untreated controls. In order to assess the
sensitivity of RNAi cell lines towards UV irradiation, procyclic cell culture at the density of 2 ×
106 cells/ml was induced for dsRNA synthesis with 2 µg/ml of doxycycline. After 24 hours,
induced and non-induced cells were diluted to a concentration 2 × 106 cells/ml and exposed to
500 and 1000 J/m2 of UV light. The cells were counted 24 hours after exposure and the survival
was determined as a percentage of untreated controls.
3.7 Light Microscopy
Immunolocalizations were carried out as described previously (Luz Ambrósio et al.,
2009). XPB-R-PTP and XPD-PTP were detected with a rabbit polyclonal anti-protein A immune
serum (Kartalou and Essigmann) followed by an Alexa 594-conjugated anti-rabbit secondary
antibody (Invitrogen) whereas Tbp52-HA was visualized with a mouse monoclonal anti-HA
antibody conjugated with fluorescein isothiocyanate (FITC; Sigma). Images were acquired on a
Zeiss Axiovert 200 microscope equipped with DAPI (4′,6′-diamidino-2-phenylindole), EGFP, and
Texas-Red filters using a 100× (1.3-numerical-aperture) oil immersion objective.
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4. Results
4.1 XPB-specific domains are conserved in both trypanosome XPB and XPB-R.
Genome

annotation

of

T.

brucei

identified

two

genes,

Tb927.3.5100

and

Tb927.11.16270 (accession numbers are from www.genedb.org; (Logan-Klumpler et al., 2012)),
that encode XPB proteins with calculated masses of 105 kDa and 89 kDa, respectively
(Berriman et al., 2005). The sequences of these two XPB paralogs are divergent, exhibiting only
24.2% identity and 37.1% similarity between them according to a pair-wise alignment using the
EMBOSS

Needle

server

(http://www.ebi.ac.uk/Tools/psa/emboss_needle/).

Despite

this

divergence both proteins are clearly XPB helicases: they harbor all seven Walker motifs of the
SF2 superfamily of helicases and they possess an N-terminal XPB domain that interacts with
the regulatory TFIIH subunit p52 (Coin et al., 2007; Jawhari et al., 2002), an XPB-specific R-E-D
residue loop implicated in recognition of damaged DNA sites (Fan et al., 2006; Oksenych et al.,
2009), and an XPB signature sequence motif that was recently identified by a comparative
genomics analysis (Figure. 2.1A and 2.1B) (Bedez et al., 2013). Both XPB paralogs are present
in all sequenced kinetoplastid genomes, including that of the bodonid B. saltans, and a multiple
sequence alignment showed that XPB domains are equally well conserved among the paralogs
sequences (Attachment 1, Fig.S1). Moreover, the archaeal XPB structure revealed the
presence of a Thumb-like domain (ThM) between Walker motifs III and IV that is structurally
conserved in human XPB and thought to cooperate with the R-E-D loop in anchoring XPB to
sites of DNA damage (Fan et al., 2006; Oksenych et al., 2009). While sequence conservation
between human and archaeal ThM domains is very limited, there is clear sequence
conservation between the human ThM sequence and the aligned kinetoplastid XPB sequences
further supporting the notion that kinetoplastid organisms harbor two functional XPB paralogs
(Attachment 1, Fig.S1).
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To further verify the nature of XPB-R, we tested whether this protein interacts with its
functional partner p52. We created an insect-stage, procyclic T. brucei cell line in which XPB-R
and p52 (accession number Tb927.10.5210) were C-terminally tagged with the composite PTP
tag and the HA tag, respectively. Previously, we have shown that p52-HA interacted with XPD
as part of the TFIIH complex and correctly localized to the nucleus, indicating that the tag does
not interfere with p52 function (Lee et al., 2007). Similarly, cell proliferation assays (see below)
indicated that XPB-R-PTP was functional as well. In whole cell lysates XPB-R-PTP was
expressed as a single protein of correct size in two independently derived cell lines. However, in
the extract sample, the appearance of a second band, which was 15 kDa smaller than the full
length protein, suggested that some of XPB-R-PTP was cleaved at the N-terminus during
extract preparation (Attachment 1, Fig.S4). Both bands were precipitated with IgG beads which
bind to the protein A domains of the PTP tag (Figure 2.1C). p52-HA was co-precipitated but
TSP2, a trypanosome TFIIH subunit partner of p52, was not. In the reciprocal anti-HA
immunoprecipitation experiment, full length XPB-R-PTP was efficiently co-precipitated
confirming the XPB-R/p52 interaction. The smaller, N-terminally degraded XPB-R-PTP form,
however, did not interact with p52-HA which indicated that trypanosome XPB-R does possess a
functional N-terminal p52 interaction domain. This negative co-precipitation result confirmed our
previous finding (Nguyen et al., 2006) that protein G-bound anti-HA antibody does not coprecipitate PTP-tagged protein non-specifically. As expected, TSP2 did co-precipitate with p52,
verifying that both proteins are part of the same TFIIH complex. Together, these results showed
that kinetoplastid organisms harbor two highly divergent XPB paralogs with conserved
functional domains. Although T. brucei XPB-R was not detected in TFIIH complexes that were
purified via tagged XPD or TSP2 (Lee et al., 2009), its interaction with p52 suggested that it is a
functional enzyme in this parasite.
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Figure 2.1 Trypanosomatids possess two different XPB helicases.
A. Schematic (to scale) of human XPB (Hs XPB) and of T. brucei (Egloff et al.) XPB-R and XPB showing
the XPB and RED domains, Walker motifs I, Ia, II-VI, and an XBP-specific sequence signature motif
(Hegele et al.).
B. Alignment of XPB and RED domain sequences from humans (Ivens et al.), Drosophila melanogaster
(Ivens et al.), Caenorhabditis elegans (Ce), Saccharomyces cerevisiae (Sc), and T. brucei. Positions that
are identical and similar across the model organisms are shaded in black and gray, respectively. Specific
conservations in either TbXPB-R or TbXPB are shaded in pink and positions that are identical in
trypanosome XPBs and different from those of the model organisms are shaded in cyan. Stars in the
upper panel identify the phenylalanine and threonine residues found mutated in many Xeroderma
pigmentosum patients. Stars in the lower panel identify Walker motif III and the R-E-D residue loop.
C. Immunoprecipitation (IP) of either XPB-R-PTP (left panels) or p52-HA (right panels).Equivalent
amounts of the input extract (Inp) and the supernatant (S) were analyzed whereas four times of the
precipitate (4xP) were loaded. XPB-R-PTP was detected with the monoclonal anti-protein C epitope
HPC4 antibody, p52-HA with a monoclonal anti-HA antibody, and the TFIIH subunit TSP2 with a
polyclonal immune serum. Precipitated XPB-R-PTP was released from beads by TEV protease digest
which removed the protein A domains, resulting in the smaller XPB-R-P protein. Asterisks identify the Nterminally shortened XPB-R species seen in extract.
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4.2 Knockout of XPB-R retards trypanosome proliferation in culture.
Previously, XPB-R silencing in procyclic trypanosomes did not affect cell proliferation
(Lecordier et al., 2007). We confirmed this result (data not shown) and, in addition, analyzed
XPB-R silencing in bloodstream form trypanosomes by inducing synthesis of XPB-R dsRNA
from a tetracycline operator-controlled stem-loop construct that had been integrated in
tetracycline repressor-expressing single marker cells (Wirtz et al., 1999). Although semiquantitative reverse transcription (RT)-PCR showed that XPB-R mRNA was reduced after one
and two days of induction, XPB-R silencing did not affect trypanosome proliferation suggesting
that XPB-R is not an essential gene in either procyclic or bloodstream form trypanosomes
(Attachment 1, Fig. S2). Accordingly, we succeeded in generating a procyclic XPB-R-/- knockout
cell line in which the two XPB-R alleles were replaced by the hygromycin (HYGR) and blasticidin
(BLAR) resistance markers (Figure 2.2A). After the second transfection of a single allele
knockout XPB-R+/- cell line, we obtained two independently derived, double resistant XPB-R-/cell lines which we termed KO-1 and KO-2. The gene knockouts were confirmed by a PCR of
genomic DNA prepared from wild-type, XPB-R+/- and KO cell lines using primers that annealed
to the 5/ and 3/ XPB-R gene flanks outside of the transfected, linear DNA constructs. While the
KO cells gained HYGR- and BLAR-specific amplification products, they completely lost the wildtype product (Figure 2.2B). Correspondingly, an RT-PCR analysis with oligonucleotides specific
to the XPB-R coding region showed that the KO cells did not express XPB-R mRNA any longer
(Figure 2.2C). The successful XPB-R knockout demonstrated that this gene was dispensable for
cultured procyclics. However, the KO cell lines clearly grew slower than wild-type cells. While
our wild-type strain had a doubling time of 8.5 hours, KO-1 and KO-2 cells doubled every 13.8
and 15.6 hours, respectively (Figure 2.2D). This slow growth phenotype remained constant over
a period of three months and was not affected by the presence or absence of antibiotics (data
not shown). To determine whether the knockout delayed the cell cycle in a particular stage, we
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determined the number of kinetoplasts and nuclei in DAPI-stained wild-type and XPB-R-/- cells
(n=100 for each cell line). Compared to the wild-type cell line, we found a strong accumulation
of 2K2N cells (25% versus 6%) and a concomitant decrease of 1K1N trypanosomes (44%
versus 68%) indicating a cell cycle-relevant function of XPB-R in late mitosis/cytokinesis
(Attachment 1, Fig. S3)
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Figure 2.2 A knockout of XPB-R increases the doubling time of trypanosomes in culture.
-/-

A. Schematic (not to scale) of the XPB-R locus in wild-type and XPB-R (KO) cells. In the latter, the XPBR
R coding regions of the two alleles were replaced with those of hygromycin phosphotransferase (HYG )
R
and blasticidin-S deaminase (BLA ). Oligonucleotides used for competitive PCR analysis of XPB-R,
R
R
HYG and BLA alleles are indicated by arrows.
B. Corresponding competitive PCR analysis of total DNA prepared from wild-type cells, cells in which one
+/-/XPB-R allele was knocked out (XPB-R ), and two independently obtained XPB-R knockout cell lines
(KO-1, KO-2)
/

C. RT-PCR of XPB-R and, as a control, of U2A mRNA. A control reaction with wild-type RNA in the
absence of reverse transcriptase (-RT) demonstrated effective removal of genomic DNA from the RNA
preparation.
D. KO-1 and KO-2 cells have a prolonged doubling time versus wild-type cells.
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4.3 XPB-R does not function in transcription
To our knowledge eukaryotic XPB helicases function exclusively in transcription and
NER. It was therefore possible that XPB-R had an important, albeit non-essential, function in
transcription, possibly in a regulatory role. Since the SLRNA promoter is the only trypanosome
promoter known to assemble an RNA pol II transcription pre-initiation complex including TFIIH
(Lee et al., 2009), we first tested whether XPB-R occupies the SLRNA promoter by chromatin
immunoprecipitation (ChIP). We previously showed that chromatin bound by PTP-tagged
proteins can be highly enriched by a ChIP-grade, anti-protein A antibody (Lee et al., 2010).
Accordingly, when we used a cell line that exclusively expressed functional XPD-PTP (Lee et
al., 2007), we observed a 21 fold enrichment of the SLRNA promoter over a precipitation with a
comparable non-specific immune serum (Figure 2.3A). This occupancy was strongly reduced in
the SLRNA intergenic spacer approximately 500 bp downstream of the promoter, revealing the
specificity of the ChIP assay. To analyze XPB-R in an equivalent way, we generated a cell line
that exclusively expressed XPB-R-PTP. This was achieved by targeted integration of plasmid
XPB-R-PTP-NEO into the remaining XPB-R allele of the single knockout XPB-R+/- cell line
(Attachment 1, Fig. S4). To assess whether the PTP tag interferes with XPB-R function, we
determined the doubling time of the XPB-R-PTP-expressing cells which, with 11.1 hours, was
intermediate between wild-type and XPB-R-/- cells. Interestingly, single knockout XPB-R+/- cells
exhibited a similarly prolonged doubling time (12 h) suggesting that maximal trypanosome
proliferation requires a sufficiently high level of XPB-R and that the slower proliferation rate of
XPB-R-PTP-expressing cells is due to haplo-insufficiency rather than a functionally deleterious
PTP tag. Nevertheless, XPB-R-PTP did not occupy the SLRNA promoter, indicating that this
helicase has no function in pre-initiation complex formation and RNA pol II transcription initiation
(Figure 2.3A).
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To further validate this notion, we prepared transcriptionally active extract from XPB-R-PTPexpressing cells and depleted the helicase by IgG affinity chromatography. Although the extract
was almost fully depleted of XPB-R, it supported transcription of the SLRNA promoter template
SLins19 equally well as mock-depleted extract did (Figure 2.3B). Accordingly, adding back
tandem affinity-purified XPB-R (see below) to the extract had no impact on transcription
efficiency.
Finally, we employed permeabilization of wild-type and XPB-R-/- cells to label nascent RNA
which, in this system, increases linearly for up to 20 minutes (Ullu and Tschudi, 1990). Due to a
very strong synthesis rate, newly synthesized SL RNA can be directly visualized after
separating labeled RNA by denaturing PAGE (Figure 2.3C). To assess protein coding gene
transcription in these experiments, we hybridized the labeled RNA to dot blots of plasmids that
contained whole coding regions (Figure 2.3D). Quantification of SL RNA bands by densitometry
and of dots by scintillation counting in three independent experiments did not reveal any
nascent RNA synthesis defect in XPB-R-/- cells in either KO cell line (Figure 2.3E). This was true
for the RNA pol I transcripts 18S rRNA and GPEET procyclin mRNA, for the RNA pol IIsynthesized heat shock protein 70, actin and α tubulin mRNAs, and for the RNA pol III-derived
threonine tRNA and U6 snRNA. Therefore, we concluded that XPB-R does not function in
transcription.
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Figure 2.3 XPB-R does not function in transcription.
A. Anti-XPD-PTP and anti-XPB-R-PTP ChIP with a ChIP-grade, polyclonal anti-protein A antibody (α
ProtA) and a comparable non-specific immune serum (nonsp. IS). Top panels, semiquantitative PCR of
the SLRNA promoter (SL prom), the SLRNA intergenic region (SL intgen), and the α tubulin coding region
(α tub cod). Lower panel, corresponding qPCR analysis showing the corrected fold difference of
precipitated DNA over the nonspecific immunoprecipitation control. B. Co-transcription of the RNA pol Irecruiting GPEET-trm template DNA and the SLRNA promoter template SLins19 in extract prepared from
cells that exclusively express XPB-R-PTP. The extract was either mock-treated or depleted of XPB-RPTP by IgG affinity chromatography (depl). In a third reaction, tandem affinity-purified XPB-R was added
to the XPB-R-PTP-depleted extract (depl + XPB-R elu). Main panel, transcription signals were obtained
by primer extension of newly synthesized RNA with radiolabeled oligonucleotides specific for GPEET-trm
or for SLins19 RNA. Left panel, detection of XPB-R-PTP including its partially degraded product (degrad
/
prod) and, as a loading control, of U2A in mock-treated and XPB-R-PTP-depleted extract by
immunoblotting. C. Nascent RNA was radiolabeled in permeabilized wild-type (Logan-Klumpler et al.),
KO-1 and KO-2 cells, separated by denaturing PAGE, and visualized by autoradiography. Signals that
correspond to tRNAs, the SL RNA, and pre-mRNA/pre-rRNA are indicated on the right. D. Labeled
nascent RNA was hybridized to dot blots of plasmids containing the complete coding regions of GPEET
procyclin, 18S rRNA, heat shock protein 70 (HSP70), actin and a tubulin. In addition, a plasmid harboring
THR
the coupled genes of threonine tRNA and U6 snRNA (tRNA /U6 snRNA) and a control plasmid without
insert (ctrl) were analyzed. E. Quantification of RNA signals from three independent experiments. In each
case the wild-type signal was set to 100. Error bars represent standard deviations.
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4.4 XPB-R is important for Nucleotide Excision Repair
NER is essential for the removal of covalently cross-linked bulky DNA adducts that
cause a severe distortion of the DNA double helix. Formation of such DNA adducts can be
induced by exposure to UV light or by treatment with cisplatin, strategies that have been
employed in various systems (Kamileri et al., 2012) including trypanosomes (Sheader et al.,
2004). Ultraviolet (Van Hellemond et al.) radiation causes two major types of DNA lesions,
namely cis-syn cyclobutane-pyrimidine dimers and 6,4 pyrimidine-pyrimidine photoproducts,
both of which distort the helical structure of DNA (Thoma, 1999). To determine the role of XPBR in the repair of UV-induced DNA lesions, wild-type and XPB-R-/- cells were treated with
increasing doses of UV radiation. (Figure 2.4A) Two days after the exposure, cell densities were
determined and compared to those of untreated control cells. Even at the lowermost dose of
300 J/m2, XPB-R-/- cells showed only 17.4% survival as compared to untreated XPB-R-/- cells
while 75.3% of wild-type cells that had received the same dose survived relative to the
untreated wild-type control. This indicated that the repair of DNA lesions that require NER is
strongly impaired in XPB-R-/- cells. To validate this result, wild-type and XPB-R-/- cells were
exposed to increasing concentrations of cisplatin, a chemical that induces the formation of bulky
DNA lesions. The majority of cisplatin-induced lesions are 1,2-intrastrand crosslinks between
adjacent guanines or between guanine and adenine both of which are efficiently removed by
NER (Kartalou and Essigmann, 2001). As shown in figure 2.4B, XPB-R-/- cells were more
sensitive towards cisplatin treatment than wild-type cells. For example, while treatment with 1
µM of cisplatin reduced wild-type cell survival to 65.5%, only 33.5% of XPB-R-/- cells survived
the same treatment. Taken together, the increased sensitivity of XPB-R-/- cells towards UV
radiation and cisplatin strongly indicated direct involvement of XPB-R in NER.
To assess whether XPB-R’s role in DNA repair is specific to NER, cells were treated with
methylmethane sulfonate (MMS), an alkylating agent that methylates DNA on N7-deoxyguanine
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and N3-deoxyadenine. MMS causes formation of DNA base lesions that are repaired by the
base excision repair (BER) pathway. If left unrepaired, these MMS-induced lesions can cause
stalling of replication forks and lead to single or double strand DNA breaks (Brem et al., 2008).
Despite using a range of different MMS concentrations, we did not detect a significant difference
between XPB-R-/- cells and wild-type cells in their sensitivity towards MMS (Figure 2.4C). We
therefore concluded that XPB-R is specifically important for NER and not required for BER.

	
  

53

-/-

Figure 2.4 XPB-R cells are specifically sensitive to DNA lesions requiring NER.
Wild-type (Logan-Klumpler et al.) and KO-1 cell survival after treatment with (A) UV light, (B) cisplatin or
(C) methyl methanesulfonate (MMS) was determined relative to untreated wild-type and KO-1 cells,
respectively. The results were obtained from three independent experiments. Error bars represent
standard deviations.
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4.5 An XPB-R/p52 complex functions independently of a TFIIH complex
Previously, the T. brucei TFIIH complex was isolated and mass spectrometrically
analyzed in four independent experiments: it was purified using XPD as bait by two different
research groups (Lee et al., 2009; Lee et al., 2007) or through tagging TSP2 (Lee et al., 2009),
and it was co-purified as an associated complex of the multi-subunit mediator complex (Lee et
al., 2010). In each case, XPB was identified as a TFIIH subunit whereas XPB-R was never
found. Although unlikely, it is possible that XPB-R is part of a distinct TFIIH complex of minor
abundance that was not detected in these biochemical protein complex characterizations. To
facilitate XPB-R detection in isolated TFIIH complexes, we tried unsuccessfully to raise a
specific polyclonal immune serum in rats against two partial, recombinant XPB-R proteins that
were fused to the GST tag and purified from Escherichia coli (data not shown). Next, we carried
out a tandem affinity purification of XPB-R-PTP(Attachment 1, Fig. S4). Although the purification
was efficient and the final eluate revealed several distinct protein bands, mass spectrometry
identified only proteins that typically co-purify as contaminants such as α/β tubulin and HSP70
but no other proteins (Attachment 1, Figs. S4C to S4E). Since p52, which did interact with XPBR-PTP in reciprocal co-IPs (Figure 2.1C), was not detected in this analysis, it was possible that
tagging XPB-R at the C-terminus had a deleterious effect on the XPB-R/p52 interaction. It
therefore appeared that either XPB-R tagging partially interfered with the XPB-R/p52 interaction,
or that this interaction is weak and does not withstand purification. To obviate the latter concern,
we sedimented crude extract, freshly prepared from cells expressing XPB-R-PTP and p52-HA,
through a linear sucrose gradient by ultracentrifugation, a process which is much less stringent
than tandem affinity purification. An immunoblot analysis of proteins collected from gradient
fractions that were taken from top to bottom showed that p52-HA sedimentation peaked in
fractions 6/7 and in fractions 14-16, between the 17S apoferritin and the 19S thyroglobulin
markers (Figure 2.5A). The latter sedimentation peak corresponded to the previously
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determined ~17.5 S sedimentation coefficient of the TFIIH complex (Lee et al., 2009) and,
accordingly, the TFIIH subunit TSP2 did co-peak with p52-HA in these fractions. The additional
peak of TSP2 in fraction 11 likely corresponds to a XPB/TSP1/TSP2 subcomplex that we
previously found missing from a partial TFIIH complex (Lee et al., 2009). Importantly though,
neither band of XPB-R-PTP showed a peak in fractions 14-16 and they were, in fact, hardly
detectable in these fractions, further supporting the notion that XPB-R does not function within a
TFIIH complex. Its sedimentation in fractions 5 and 6 suggested that it peaks there by itself
and/or in a complex with p52-HA. Together, these data strongly indicated that XPB-R is not part
of a TFIIH complex comprising XPD and the other trypanosome TFIIH orthologs of p62, p44,
and p34.
To corroborate these findings at the functional level, we generated procyclic cell lines for
conditional p52 silencing by RNAi analogously to the XPB-R RNAi cell lines described above.
Examination of three independently derived cell lines demonstrated that cultures stopped
growing 3 days after induction of p52 dsRNA synthesis (Figure 2.5B). These growth defects
closely resembled those observed previously upon silencing of XPD (Lee et al., 2007),
indicating that p52 is an essential component of TFIIH. To assess whether RNAi-mediated
depletion of either XPD, XPB-R or p52 in cells led to increased UV susceptibility, we silenced
the expression of the respective genes in procyclic cell lines, exposed induced and non-induced
cells to 500 or 1000 J/m2 UV light, and recorded cell survival one day after the treatment. While
XPD silencing was as efficient as previously published (data not shown), UV exposure did not
affect the survival rate of XPD-silenced cells (Figure 2.5C, top panel), strongly indicating that
trypanosome TFIIH is specialized in transcription and, unlike its bifunctional counterparts in
yeast and mammals, not involved in DNA repair. Conversely and as expected, XPB-R silencing
significantly increased the UV susceptibility of trypanosomes (Figure 2.5C, middle panel). Since
UV treatment was similarly lethal to p52-silenced cells (Figure 2.5C, bottom panel), these
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results identify p52 as a functional partner of XPB-R in DNA repair and as the only trypanosome
protein so far that is likely involved in both RNA pol II transcription and NER. They also confirm
our co-IP results (Figure 2.1C).
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Figure 2.5 XPB-R and p52 but not XPD function together in NER.
A. Crude extract from XPB-R-PTP-expressing trypanosomes was sedimented through a linear 10-40%
sucrose gradient by ultracentrifugation. Fractions were taken from top to bottom and analyzed by
immunoblotting as described above. As sedimentation markers IgG (6.6S), apoferritin (17S) and
thyroglobulin (19S) were co-analyzed.
B. Upper panel, growth curve of a representative, procyclic cell line (one out of three) in which
doxycycline induces p52 silencing. Lower panel, semi-quantitative RT-PCR analysis of p52 mRNA and,
/
as a control, of U2A mRNA in total RNA prepared from non-induced cells and from cells that were
induced for one or two days.
C. Diagrams showing the survival of cells treated with UV relative to untreated cells. Three cell lines were
investigated in which XPD (upper panel), XPB-R (middle panel) or p52 (lower panel) were silenced (+
dox) or not (- dox). Each experiment was conducted three times, and the results were statistically
analyzed by an unpaired, two-tailed student’s t test assuming unequal variances. One and two asterisks
indicate p values that are smaller than 0.05 and 0.01, respectively.
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4.6 XPB-R-PTP is localized in the nucleus and partially co-localizes with p52-HA
NER factors including various TFIIH subunits typically exhibit a diffuse nuclear staining
pattern (Hoogstraten et al., 2008; Vermeulen et al., 2000). We have previously shown that in T.
brucei p52-HA localizes to the nucleus with the strongest accumulation in one or two
perinucleolar foci. These foci most likely represent the ~100 tandemly linked SLRNA copies on
chromosomes 9 that are transcribed monocistronically, thereby requiring the independent
formation of transcription pre-initiation complexes on each and every SLRNA promoter (Lee et
al., 2010). Accordingly, when we used a cell line in which the TFIIH helicase XPD and p52 were
PTP- and HA-tagged, respectively (Lee et al., 2007), we observed that XPD-PTP predominantly
localized to one or two perinucleolar foci in the nucleus with additional faint staining of other
nuclear regions (Figure 2.6 and Attachment1 Fig.S5, left panels). p52-HA invariably co-localized
with XPD-PTP in these foci presumably as part of the TFIIH complex, yet it also appeared to be
more widely distributed than XPD within the nucleus. When we co-localized XPB-R-PTP with
p52-HA in the cell line described above (Figure 2.6 and Attachment 1, Fig. S5, right panels), we
detected a partial overlap of the two proteins which supports our finding that XPB-R and p52 do
interact. On the other hand, the clearest difference from the XPD analysis was that XPB-R-PTP
most often did not co-localize with the brightest p52-HA spots, supporting our finding that XPBR does not occupy the SLRNA promoter and is not required for RNA pol II transcription initiation
at SLRNA genes. These results support a model in which trypanosomes possess a TFIIH
complex with a basal function in RNA pol II transcription initiation, and an XPB-R/p52 complex
specifically functioning in NER.
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Figure 2.6 XPB-R-PTP co-localizes with p52-HA outside putative SLRNA expression foci in the
nucleus. p52-HA (green) was co-localized with XPD-PTP (red; left panels) or with XPB-R-PTP (red, right
panels). White bars represent 10 µm.
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4.7 Highly divergent XPB paralogs are present in other protistan lineages
We have shown that T. brucei possesses two highly divergent XPB paralogs. One
participates in the transcriptionally active TFIIH complex while the other is important for DNA
repair and, likely, functions independently of TFIIH. Since TFIIH analyses have mainly been
restricted to yeast and higher eukaryotes, we wanted to know whether divergent XPB paralogs
could be found in other eukaryotes. We carried out a phylogenetic analysis of XPB sequences
of 33 species whose genomes were completely sequenced (Attachment 1, Fig. S6). Each XPB
sequence that was retrieved gave an E value smaller than e-95 during a protein-protein BLAST
analysis against the human XPB sequence and they all harbored the R-E-D motif, except for
one of the two sequences found in the ciliate Paramecium tetraurelia that contained an R-Q-D
motif instead (Attachment 1, Fig. S1). Despite the small E-values, multiple sequence alignment
revealed several blocks of ambiguous alignment due to poorly conserved regions. To restrict
our analysis to appropriately aligned sequences we applied the Gblock algorithm (Talavera and
Castresana, 2007) in combination with maximum likelihood calculations. As expected, metazoa,
yeasts and fungi have only a single XPB sequence which correlates with the dual function of
TFIIH described in these organisms. The two plant species investigated, Oryza sativa and
Arabidopsis thaliana, do possess two XPBs but their encoded sequences are nearly identical
and more closely conserved within each species. This strongly suggests that these XPB genes
stem from recent gene duplications that have not functionally diverged. In contrast, all
kinetoplastid organisms possess two highly divergent XPBs that clearly segregate into two
separate branches, one with T. brucei XPB and one with T. brucei XPB-R. Even the only
bodonid species investigated, B. saltans, encoded unambiguously identifiable orthologs of these
two helicases. The root of the two clusters is very deep, raising the possibility that the presence
of two functionally distinct XPB helicases is an ancient eukaryotic trait. This hypothesis is
supported by the presence of similarly divergent XPB paralogs in the ciliates Tetrahymena
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thermophila and P. tetraurelia although the ciliate XPB sequences do not form two separate
clusters. Ciliates are grouped together with Apicomplexa in the supergroup Chromalveolata.
However, all apicomplexan species investigated have only a single XPB gene. On the other
hand, Entamoeba histolytica and Entamoeba dispar again have two highly divergent XPB genes
that form two deeply rooted branches, while other members of the supergroup Amoebozoa,
Dictyostelium discoideum and Acanthamoeba castellanii, have only a single XPB gene. Finally,
among early diverged protists, the Giardia lamblia genome revealed only a single XPB gene
whereas Trichomonas vaginalis and Naegleria gruberi encode two divergent XPB paralogs,
although their roots are not as deep as those of ciliates and Entamoeba.
If distinct XPBs for transcription and DNA repair were a plesiomorphic trait in eukaryotes,
we would expect a phylogenetic tree with separate XPB-R and XPB branches. This was never
observed despite applying several different phylogenetic approaches (data not shown). On the
other hand, the bootstrap values at the base of the tree in Attachment 1, fig. S6 are not high and
it is possible that specific XPB-R and XPB branches do exist. Accordingly, when we carried out
the same phylogenetic analysis with an archaeal sequence as an outgroup, the basal branching
of the tree changed while the XPB and XPB-R dichotomies described here remained
(Attachment 1, Fig. S7). Therefore, it will require more whole genome sequences from protistan
organisms and a more comprehensive approach to solve the basal eukaryotic branching of the
XPB tree unambiguously. Until then our data suggest that the presence of two functionally
distinct XPBs is a phenomenon that exists beyond the Kinetoplastida.

5. Discussion
This is the first report of a eukaryotic XPB paralog that is specialized in DNA repair while
having no role in transcription. We showed that transcription of genes by all three nuclear RNA
pols was not impaired in XPB-R-/- cells. Moreover and in contrast to TFIIH subunits, XPB-R did
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not occupy the SLRNA promoter, the only trypanosome promoter known to assemble a RNA pol
II transcription pre-initiation complex, and depletion of XPB-R from extract did not affect SLRNA
transcription in vitro. On the other hand, removal of the XPB-R gene rendered trypanosomes
highly sensitive to UV irradiation and cisplatin, but not to methylmethane sulfonate, strongly
indicating that XPB-R, like its XPB homologs from yeast to humans, specifically functions in
NER and not in other DNA repair pathways. Interestingly, although not absolutely required for
cell viability, the expression level of XPB-R directly influenced the trypanosome doubling time.
Knockout of a single XPB-R allele increased the 8.5 h doubling time of wild-type to 12 h and a
complete knockout to ~14.7 h. Given that a specific down-regulation of XPB-R would result in
slow growth and impaired DNA repair, we speculate that regulation of its expression may play a
role in pathways of programmed cell death that have been described in trypanosomes (Michaeli,
2012; Welburn et al., 2006).
An interesting question emanating from our study is why XPB-R-/- cells take longer to
double than wild-type cells. One possibility is that XPB-R-/- cells accumulate mutations that lead
to increased cell death thus slowing culture growth. If this was the case, one would expect that
XPB-R-/- cell lines would grow slower over time because all cells would accumulate mutations
simultaneously. However, the doubling time of the knockout cells did not change over a period
of ~150 generations. In addition, we did not detect a substantial increase of aberrant or dead
cells in XPB-R-/- cell cultures when compared to wild-type cultures suggesting that accumulation
of mutations is not the major cause of the growth defect (Attachment 1, Fig. S3 and data not
shown). Instead, our results indicated that XPB-R-/- cells take substantially longer to complete
mitosis and/or initiate cytokinesis because a quarter of XPB-R-/- cells, compared to 6% of wildtype cells, was found to be in the precytokinesis stage with two kinetoplasts and two nuclei.
Given that XPB-R is a DNA-dependent helicase, this finding suggests that XPB-R has a role in
late mitosis. While this could be a trypanosome-specific function, a recent study did find human
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XPB but not other TFIIH subunits to be associated with centrosomes and adjacent parts of the
mitotic spindle during mitosis (Weber et al., 2010).
Thus far, eukaryotic XPB function has exclusively been described in the context of the
TFIIH complex (Compe and Egly, 2012; Naegeli and Sugasawa, 2011). The two TFIIH subunits
that interact with XPB and modify its enzymatic activities are p52 and p8 (Coin et al., 2007; Coin
et al., 2006; Fregoso et al., 2007). Accordingly, our analysis showed that trypanosome XPB-R
does interact with p52, and while trypanosomes do possess a p8 ortholog that is part of the
TFIIH complex (Lee et al., 2009), it remains to be determined whether it interacts with XPB-R.
However, our study strongly indicates, in accordance with previous comprehensive TFIIH
characterizations (Lecordier et al., 2007; Lee et al., 2009; Lee et al., 2007), that XPB-R does not
assemble into a TFIIH complex. In the sedimentation analysis, tagged XPB-R was found almost
exclusively near the top of the sucrose gradient and did not exhibit faster co-sedimentation with
the TFIIH subunits p52-HA and TSP2. Accordingly, TSP2 did not co-immunoprecipitate with
XPB-R from extract. Furthermore, isolation of XPB-R by tandem affinity purification did not copurify any TFIIH subunit suggesting that tagged XPB-R is not assembled into a stable protein
complex. Finally, while the TFIIH subunits XPD and TSP2 were predominantly localized in one
or two perinucleolar spots, XPB-R exhibited a more diffuse nuclear staining and rarely colocalized with p52-HA in its perinucleolar spots, further indicating that XPD and XPB-R are not
part of the same complex.
How does XPB-R function in NER in the absence of other TFIIH subunits? There are two
distinct pathways of NER, namely transcription-coupled NER and global genome NER, which
use different proteins to detect DNA lesions and recruit TFIIH to the sites of damage (Naegeli
and Sugasawa, 2011). In the Tritryp genome projects, most of the factors involved in NER
factors have been identified suggesting that both pathways are functional in trypanosomes
(Berriman et al., 2005; Ivens et al., 2005); recently reviewed in (Passos-Silva et al., 2010). A key
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factor in global genome NER is XPC (accession number for the T. brucei ortholog is
Tb927.9.11930) which, by directly interacting with XPB, recruits TFIIH to sites of DNA damage.
Moreover, it was shown in the human system that the R-E-D residue loop, the ThM domain and
the ATPase activity of XPB are important for recruitment of TFIIH to damaged sites (Oksenych
et al., 2009). All of these domains are conserved in XPB-R suggesting that it can be recruited to
DNA lesions by XPC in the absence of a TFIIH complex. Transcription-coupled NER removes
DNA lesions that stall RNA pol II at actively transcribed genes (Hanawalt and Spivak, 2008;
Laine and Egly, 2006). A key factor in this pathway is the so-called Cockayne syndrome type B
or CSB protein (Tb927.7.4080), which is important for the recruitment of TFIIH and other NER
factors to damaged DNA. Although it is not entirely clear how TFIIH is recruited in this pathway,
early evidence revealed a direct link between CSB and XPB (Tantin, 1998), which would allow
direct recruitment of XPB-R by trypanosome CSB for transcription-coupled NER.
After recruitment to DNA lesions, the function of TFIIH in global genome NER is to open
up the site of damage by XPB ATPase and XPD helicase activity. The ATPase activity of XPB
apparently drives the protein like a wedge into the damaged bubble enabling XPD, whose
helicase activity alone is important for NER, to unwind the DNA (Coin et al., 2007). Since
trypanosome XPB-R apparently does not function together with XPD, the XPB-R ATPase-driven
opening of the damaged DNA site may be sufficient in trypanosomes for nucleotide repair.
Alternatively, XPB-R may be a more processive helicase than its mammalian counterpart whose
activity is important for NER. Mammalian XPD has also been implicated in DNA damage
recognition and verification (Mathieu et al., 2010). Since there is no evidence that trypanosome
XPB-R and XPD form a common complex, this function is either absent in trypanosomes or
achieved independently of XPB-R. In the absence of a stable XPB-R complex, it appears that
XPB-R functions like its archaeal ortholog. In vitro assays have shown that XPB of the archaeon
Sulfolobus solfataricus can open up DNA lesions by 6-8 bp which is sufficient for the
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endonuclease Bax1 to cleave off the damaged DNA (Rouillon and White, 2010). Bax1 is thought
to be the functional homolog of the eukaryotic NER endonuclease XPG (Rouillon and White,
2010) which is encoded in the T. brucei genome (Tb927.9.11760; E value of 8e-20 derived from
a protein-protein blast with the human XPG amino acid sequence) and likely functions together
with XPB-R. In sum, it appears that trypanosomes have a simplified NER machinery that is
separate from the transcriptionally essential TFIIH complex.
We have been able to combine gene silencing with UV exposure to assess the function
of proteins in NER. This approach clearly demonstrated that XPD silencing did not alter cell
survival after UV exposure whereas XPB-R and p52 silencing clearly increased the UV
susceptibility of cells (Figure 2.5C). These data strongly support a model in which trypanosome
TFIIH has an essential role in RNA pol II transcription while NER is carried out through a
simplified, XPB-R-based machinery. This dichotomy in trypanosomes provides a unique
opportunity to decipher specific DNA repair and transcription functions of XPB. For example,
amino acids specifically required for DNA repair should be conserved in kinetoplastid XPB-R
sequences as well as in the bifunctional XPBs of model organisms but not in kinetoplastid
XPBs. Accordingly, several such positions were identified in the XPB multiple sequence
alignment (Attachment 1, Fig. S1). Moreover, the bifunctional nature of human and yeast XPB
has hampered XPB analysis in vivo since all mutations affecting the transcriptional function of
XPB are lethal, an obstacle absent in future XPB-R analyses.
Finally, specific NER machinery may not be restricted to Kinetoplastida. Our survey of
completely sequenced genomes revealed the presence of two highly divergent XPBs in several
protistan taxa that belong to different supergroups (Dacks et al., 2008). In addition to the
Excavata, the supergroup of kinetoplastids, highly divergent XPBs were found in the Ciliophora
of the supergroup Chromalveolata and in the genus Entamoeba which is part of the Amoebozoa
supergroup. Although our initial XPB phylogenetic analysis did not provide unambiguous
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branching at the base of the tree, which may be the reason why we did not observe an overall
dichotomy of XPB and putative XPB-R sequences, our results raise the possibility that a DNA
repair-dedicated XPB helicase is an ancestral eukaryotic trait.
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Chapter III

Trypanosome cdc2-related kinase 9 controls
spliced leader RNA cap4 methylation and
phosphorylation of the RNA polymerase II subunit RPB1

1. Abstract
Conserved from yeast to mammals, phosphorylation of the heptad repeat sequence Tyr1Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 in the carboxy-terminal domain (CTD) of the largest RNA
polymerase II subunit RPB1 mediates the enzyme’s promoter escape and binding of RNA
processing factors such as the m7G capping enzymes. The first critical step, Ser5
phosphorylation, is carried out by cyclin-dependent kinase 7 (CDK7), a subunit of the basal
transcription factor TFIIH. Many early-diverged protists such as the lethal human parasite
Trypanosoma brucei, however, lack the heptad repeats and, apparently, a CDK7 ortholog.
Accordingly, characterization of trypanosome TFIIH did not identify a kinase component. The T.
brucei CTD, however, is phosphorylated and essential for transcription. Here we show that
silencing the expression of T. brucei cdc2-related kinase 9 (CRK9) led to a loss of RPB1
phosphorylation. Surprisingly, this event did not impair RNA pol II transcription or cotranscriptional m7G capping. Instead, we observed that CRK9 silencing led to a block of spliced
leader (SL) trans splicing, an essential step in trypanosome mRNA maturation, that was caused
by hypomethylation of the SL RNA’s unique cap4.
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2. Introduction
In eukaryotes, RNA polymerase II transcription of protein coding and small nuclear RNA
genes is a highly conserved process involving a plethora of transcription and co-transcriptionally
active RNA processing factors. A key regulatory structure in this process is the carboxy-terminal
domain (CTD) of the largest RNA pol II subunit RPB1. Conserved from some protists to
humans, the CTD consists of 5 to 52 repeats of the heptad sequence Tyr1-Ser2-Pro3-Thr4-Ser5Pro6-Ser7 whose regulated serine phosphorylation cycle is essential for RNA pol II function
(Buratowski, 2009; Chapman et al., 2008; Hsin and Manley, 2012). RNA pol II that is recruited
to the core promoter has hypophosphorylated heptad repeats. Transcription initiation and RNA
pol II escape from the promoter then essentially depends on phosphorylation of Ser5 by cyclindependent kinase 7 (CDK7; the yeast ortholog is termed Kin28) which is a component of the
basal transcription factor TFIIH. The same phosphorylation event leads to binding of the m7G
capping enzyme to the CTD and co-transcriptional capping of pre-mRNA (Fabrega et al., 2003).
Further downstream of the transcription initiation site, phosphorylation of Ser2 by CDK9 (Bur1)
and CDK12/13 (Ctk1) transform RNA pol II into an actively elongating enzyme (Karagiannis and
Balasubramanian, 2007; Liu et al., 2009; Qiu et al., 2009). Finally, Ser7 phosphorylation appears
to be particularly important for transcription of snRNA genes since it mediates the interaction of
the integrator 3/ end RNA processing complex to RNA pol II. Ser7 is primarily phosphorylated by
CDK7 (Akhtar et al., 2009; Glover-Cutter et al., 2009; Kim et al., 2009) although CDK9 (Kim et
al., 2009; Tietjen et al., 2010) and DNA-activated protein kinase (Egloff et al., 2010) may play a
role as well.
The repetitive CTD structure, however, is not a universal feature of eukaryotes (Guo and
Stiller, 2004). Notably, protistan organisms such as amoebozoa, kinetoplastids, trichomonads
and diplomonads, which appear to have diverged very early from other eukaryotic lineages, lack
repetitive CTD motifs. Moreover, comparative genomics suggested that these organisms also
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lack a CDK7 ortholog (Guo and Stiller, 2004). It therefore remains to be determined whether
phosphorylation of non-repetitive CTDs is important for RNA pol II-mediated gene expression or
whether the essential coordinating function of the canonical CTD has evolved later in evolution.
The kinetoplastid Trypanosoma brucei is a lethal, vector borne parasite of humans and
livestock in sub-Saharan Africa. It has emerged as a model organism for deviating gene
expression mechanisms found in early-diverged eukaryotes. Its protein coding genes are
arranged in long directional tandem arrays which are transcribed polycistronically. The resulting
precursor RNAs are processed into individual mRNAs by spliced leader (SL) trans splicing and
polyadenylation. The SL is derived from the small nuclear SL RNA and trans spliced onto each
and every mRNA (Gunzl, 2010). The SL is 39 nt-long, pseudouridylated at position 28, and
carries the most extensively modified cap found in any eukaryote. The cap structure is
m7G(5/)ppp(5/)m6,6AmpAmpCmpm3Ump

and

was

termed

cap4

(Bangs

et

al.,

1992).

Trypanosome RNA pol II transcribes the protein coding gene arrays and the ~100 tandem
copies of the SL RNA gene (SLRNA) on chromosome 9 whereas other small nuclear RNAs in
trypanosomes are synthesized by RNA pol III. SLRNA transcription is monocistronic, initiates at
a distinct initiation site, and requires the assembly of a conventional, albeit extremely divergent
pre-initiation complex (Das et al., 2008; Lee et al., 2010; Lee et al., 2009). The T. brucei
genome encodes a full set of RNA pol II subunits, termed RPB1 to RPB12 (Kelly et al., 2005),
and biochemical characterization of the enzyme complex identified all subunits except RPB10
(Das et al., 2006; Devaux et al., 2006; Martinez-Calvillo et al., 2007). In T. brucei there are two
slightly different RPB1 genes (relevant T. brucei gene accession numbers are listed in
supplementary Table S1) which appear to be functionally redundant since deletion of three
RPB1 alleles did not impair trypanosome proliferation in culture (Ruan et al., 2004). All RPB1
homologs possess eight highly conserved regions, termed A-H, and the sequence downstream
of region H is generally considered to be the CTD (Chapman et al., 2008). The conserved
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regions can be clearly recognized in trypanosome RPB1 defining the CTD from residue 1481 to
residue 1765. Despite the lack of the heptad repeat motif, this region is serine-rich,
phosphorylated and essential for transcription (Chapman and Agabian, 1994; Das and
Bellofatto, 2009).
Characterization of the trypanosome phosphoproteome revealed 14 phosphorylated RPB1
residues which all reside in the CTD (Nett et al., 2009), yet the functional significance of CTD
phosphorylation in trypanosomes remains unclear. In accordance with the notion that organisms
with a non-canonical CTD lack a CDK7 ortholog, biochemical and structural characterization of
trypanosome TFIIH, which is a basal factor for SLRNA transcription, revealed a full core
complex of seven subunits but no kinase component (Lee et al., 2009; Lee et al., 2007). These
findings suggested that RNA pol II transcription initiation in trypanosomes does not depend on
TFIIH-based CTD phosphorylation as it does in eukaryotes with canonical CTDs. Moreover,
CTD phosphorylation seems not to be important for co-transcriptional RNA processing either.
Since SL trans splicing uncouples mRNA capping from RNA pol II transcription, trypanosomes
can utilize RNA pols other than RNA pol II to produce functional mRNA. T. brucei has evolved a
multifunctional RNA pol I which transcribes the large ribosomal gene units as in other
eukaryotes and, in addition, gene units that encode their major cell surface proteins procyclin
and variant surface glycoprotein (Gunzl et al., 2003). In addition, genetically modified
trypanosome cell lines that express T3 or T7 RNA polymerase are able to produce functional
mRNA from the corresponding phage promoters (Wirtz et al., 1994). Thus, the use of promoters
for different RNA pols showed that processing of a reporter pre-mRNA was not coupled to RNA
pol II (Stewart et al., 2010). On the other hand, there is strong evidence that m7G capping and
cap4 formation of the SL RNA occurs co-transcriptionally (Hury et al., 2009; Mair et al., 2000b).
Canonical CTDs are primarily phosphorylated by CDKs. T. brucei harbors 11 enzymes
of this class termed cdc2-related kinase (CRK)1-4 and CRK6-12. Sequence divergence
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prevents an unambiguous assignment of these enzymes to putative counterparts in other
eukaryotes although CRK3 appears to be the functional homolog of CDK1 (Hammarton, 2007;
Parsons et al., 2005). Here, we show that silencing CRK9 expression leads to both a loss of
RPB1 phosphorylation and a trans splicing defect due to hypomethylation of the first four SL
RNA nucleotides. Most interestingly and consistent with a CDK7-less TFIIH, loss of RPB1
phosphorylation did not impair RNA pol II transcription or m7G capping of SL RNA.

3. Materials and methods
3.1 DNAs
For CRK9, CRK1, CRK3 and CRK7 silencing, the coding regions from position 9 to
position 508, from position 5 to position 505, from position 431 to position 930, and from position
6 to 506, respectively, were integrated in a stem-loop arrangement (sense-stuffer-antisense)
into the pT7-stl construct (Brandenburg et al., 2007). The RNAi vector targeting the CRK9 3/
UTR was generated by inserting 501 bp of the CRK9 3/ UTR from positions 2326 to 2827
relative to the translation initiation codon into pT7-stl. For HA tagging of RPB1, 1077 bp of the
3/-terminal RPB1 coding sequence was inserted into the pC-HA-BLA vector (Lee et al., 2007)
utilizing the vector's ApaI and NotI restriction sites. The resulting vector was named pRPB1-HABLA. pCRK9-PTP-NEO was generated by inserting 1,532 bp of the CRK9 coding region
(position 791 to position 2322) into the ApaI and NotI sites of pC-PTP-NEO (Schimanski et al.,
2005a). pCRK9-HA-BLA and pCRK9-HAT533A-BLA were generated by inserting 1,532 bp of the
CRK9 coding region (position 791 to position 2322) into the ApaI and NotI sites of pC-HA-BLA.
An A1597G transition was generated through overlapping PCR which changed the threonine
codon 533 to an alanine codon. For transfection, pRPB1-HA-BLA, pCRK9-PTP-NEO, pCRK9HA-BLA, and pCRK9-HAT533A-BLA were linearized with restriction enzymes NarI, XhoI, SphI,
and SgrA1, respectively. DNA oligonucleotides that were used in semi-quantitative and
quantitative reverse transcription (RT)-PCR and in primer extension assays are specified in
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supplementary Table S2. Plasmids used in dot blots were described previously and contained
the complete coding regions of GPEET procyclin, α tubulin, HSP70, and 18S rRNA or the
tRNAThr/U6 snRNA gene association (Schimanski et al., 2006).
3.2 Cells
T. brucei cell culture, transfection, and the generation of stable cell lines by selection and
limiting dilution was carried out as described (Lee et al., 2007; Park et al., 2011). In RNAi
experiments, dsRNA synthesis was induced with 2 µg/ml of doxycycline. Cells were counted
and diluted daily to 2 × 106 cells/ml for procyclic cell culture and to 2 × 105 cells/ml for
bloodstream form culture. A procyclic clonal cell line that exclusively expressed CRK9 with a Cterminally fused PTP tag, was generated by targeted integration of linearized pCRK9-PTP-NEO
in one CRK9 allele and by knocking out the remaining allele with a PCR product in which 101 bp
of CRK9 5/ and 3/ gene flanks were fused to the hygromycin phosphotransferase coding region.
Clonal CRK9 RNAi cell lines that expressed RPB1 with a C-terminal HA tag were generated by
transfection of linearized pRPB1-HA-BLA.
3.3 RNA analysis
To determine the relative abundance of RNAs in RNAi cells, total RNA prepared from 8 x
107 cells using TRIzol reagent (Invitrogen) was analyzed by semi-quantitative and quantitative
RT-PCR. Reverse transcriptions were carried out with SuperScript II reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol and with oligo-dT and random
hexanucleotides (Roche) for the analysis of mature and pre- mRNAs, respectively. For each
semi-quantitative PCR, the number of cycles for the linear amplification range was determined
empirically. For RNA quantifications, cDNA preparations from two independent RNAi
experiments were analyzed by qPCR assays using the SsoFast EvaGreen Supermix (BioRad)
on a CFX96 cycler (BioRad) according to the manufacturer’s recommendations. For each
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amplification and RNAi experiment, triplicate qPCR samples were analyzed using the CFX
Manager software package (BioRad). Each amplification product was evaluated for specificity
by both agarose gel electrophoresis and melting curve analysis. Standard curves for
oligonucleotide pairs were obtained from serial dilutions of non-induced cDNA samples and
ranged in their coefficient of determination (R2) value from 0.98 to 1.0. Samples were
standardized with the 18S rDNA result from random hexamer-derived cDNA.
Labeling and analysis of nascent RNA using a permeabilized cell system was carried out
as described previously (Schimanski et al., 2006). For steady state analysis of SL RNA and U2
snRNA abundances 10 µg of total RNA prepared from induced or non-induced trypanosomes
was assayed by primer extension using the 5/

32

P-endlabeled oligonucleotides SLf and U2f

(Gunzl et al., 1992). The methylation status of SL RNA cap4 was analyzed by a modified primer
extension assay in which 4 µg of total RNA was reverse transcribed by unmodified Moloney
murine leukemia virus reverse transcriptase (Invitrogen) at a concentration of individual dNTPs
that was reduced from 0.5 mM to 0.1 mM. DNA sequence ladders were generated by using the
Thermo Sequenase Cycle sequencing kit (USB) and radiolabeled SLf according to the
manufacturer’s specifications. Sequencing ladder and cap4-specific primer extension products
were separated on high resolution 50% urea-6% polyacrylamide gels and visualized by
autoradiography.
The m7G capping status of SL RNA was analyzed by immunoprecipitation with a mouse
monoclonal anti-2,2,7-trimethylguanosine antibody coupled to agarose beads that also
recognizes the m7G cap nucleotide but not an unmethylated guanosine cap (Calbiochem). In
immunoprecipitations, 5 µg of total RNA were diluted in 220 µl of buffer PA-150 (20 mM TrisHCl, pH 7.7; 150 mM NaCl; 3 mM MgCl2, 0.5 mM dithiothreitol; 0.1% Tween 20), mixed with a
30 µl of a 1:1 slurry of beads, and incubated for 1 h at 4 °C. Immunoprecipitates were washed
six times with 0.8 ml of PA-150 buffer. Bound RNA was extracted from the beads using the
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TRIzol reagent and resuspended in 20 µl of RNase-free water. 10 µl of bound and unbound
fractions (equal amounts) were used for primer extension analysis using Superscript II reverse
transcriptase as described above.
3.4 Protein analysis
For the generation of a polyclonal anti-RPB1 immune serum, the CTD portion of RPB1,
comprising the C-terminal 228 amino acids, was expressed with an N-terminal glutathione Stransferase tag in Escherichia coli, purified by glutathione affinity chromatography, and used as
a GST fusion protein to immunize rats according to a previously published protocol (Schimanski
et al., 2006).
RPB1 was detected on immunoblots by 1:2000 dilution of the anti-RPB1 immune serum
followed by a 1:5000 dilution of a monoclonal, peroxidase-labeled anti-rat IgG secondary
antibody (Vector Laboratories). HA-tagged protein was detected with a commercial monoclonal
rat anti-HA antibody (Roche) and RPA1 with a polyclonal rabbit immune serum as described
previously (Schimanski et al., 2003). Blots were developed with BM chemiluminescence blotting
substrate (Roche) according to the manufacturer's protocol.
To demonstrate that the upper RPB1 band detected in immunoblots with anti-HA or antiRPB1 antibodies corresponded to phosphorylated RPB1, 8 x 107 parasites were resuspended in
25 µl of lysis buffer (2% SDS; 100 mM Tris-HCl, pH 6.8) and boiled for 5 min. To enable alkaline
phosphatase treatment the lysate was diluted twentyfold with tryp wash solution (100 mM NaCl;
3 mM MgCl2, 20 mM Tris–HCl, pH 7.5) to reduce the SDS concentration to 0.05% and
subsequently reduced to a volume of 100 µl using an Amicon ultra 0.5 ml filter device (Millipore).
The phosphatase reaction was carried out in a volume of 30 µl containing 20 µl of sample, 1x
NEB3 buffer, and 10 units of calf intestinal phosphatase (New England Biolabs), and by
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incubation at 37 °C for one hour. To block the phosphatase, 0.5 µl of phosphatase inhibitor
cocktail 2 (Sigma Co.) were added to the reaction.

4. Results
4.1 CRK9 silencing blocked SL trans splicing.
The research group of Dr. C.C. Wang (University of California San Francisco) had
previously studied all eleven T. brucei CRKs by RNAi-mediated gene knockdown. Their data
indicated that CRK1, CRK3 and CRK9 were the most important CRKs for trypanosome viability
(Gourguechon and Wang, 2009; Tu and Wang, 2004). Moreover, based on sequence similarity
it was previously proposed that CRK3 (Ivens et al., 2005) or CRK7 (Parsons et al., 2005) may
represent CDK7 orthologs. To explore the possibility that these CRKs regulate gene expression
and/or are involved in CTD phosphorylation, we generated clonal cell lines of the insect-stage,
procyclic form of T. brucei, in which each of these four CRK genes can be conditionally silenced
by doxycycline-induced dsRNA expression (Wirtz et al., 1999). The knockdowns of CRK9
(Figure 3.1A) and of CRK1 and CRK3 (Attachment 2, Fig. S1) were lethal, halting culture growth
after the first or second day of induction. While these growth defects were consistent with
previous results (Gourguechon and Wang, 2009; Tu and Wang, 2004), the much stronger
growth inhibition in our experiments was likely the consequence of our use of the well-regulated
pT7-stl RNAi construct (Brandenburg et al., 2007) which caused a rapid drop of the target
mRNA levels within 24 hours of induction (boxed panels in Figures 3.1B and Attachment 2, Fig.
S1). Analysis of RNAs synthesized by all three RNA pols showed that the CRK1 and CRK3
knockdowns had no strong effects on RNA abundances (Attachment 2, Fig. S1) whereas CRK9
silencing consistently resulted in a clear reduction of α tubulin and GPEET procyclin mRNA
abundances and a concomitant increase of the corresponding pre-mRNAs. Since procyclin and
α tubulin genes are transcribed by RNA pols I and II, respectively, it was unlikely that these
effects were connected to the transcription of these genes. In addition to these changes in pre	
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and mature mRNA levels, we found that SL RNA abundance sharply increased 48 hours after
induction of CRK9 silencing whereas there was no consistent effect on the abundances of rRNA
and U2 snRNA which, in trypanosomes, are synthesized by RNA pols I and III, respectively
(Figure 3.1B). According to reverse transcription-quantitative real-time (RT-q)PCR experiments
these were strong effects: after three days of induction the pools of mature α tubulin and
GPEET mRNA were reduced to approximately one quarter while the levels of SL RNA and premRNA were increased up to ~nine-fold (Figure 3.1C). Since SL RNA is consumed in the first
transesterification step of the splicing process, these findings strongly indicated that CRK9
silencing led to inhibition of SL trans splicing before the first step. In accordance with this notion,
a primer extension assay showed that the SL intron, the product of the first splicing step,
disappeared specifically upon CRK9 silencing (Figure 3.1B, bottom panel; compare with the
corresponding panels in Attachment 2, Fig. S1) CRK9 appears to have the same important
functional role in gene expression in the mammalian-infective bloodstream trypanosome
because a CRK9 knockdown in this life cycle stage was as lethal as in the procyclic form and
also led to a decrease of α tubulin mRNA and a concomitant increase of the corresponding premRNA (Attachment 2, Fig. S2). Importantly, this result is in direct contrast to a previous report
which found CRK9 to be essential only in the procyclic form (Gourguechon and Wang, 2009).
Again, this discrepancy may be explained by our use of the more suitable pT7-stl RNAi vector
(Brandenburg et al., 2007).
In accordance with previously published results (Gourguechon and Wang, 2009),
silencing of CRK7 did not impair trypanosome proliferation in culture, and abundances of rRNA,
GPEET mRNA and α tubulin mRNA remained unaffected by the knockdown (Attachment 2, Fig.
S3). Since these results strongly suggested that CRK7 is not a functional homolog of eukaryotic
CDK7 we did not further analyze this kinase. It should be noted though that these results are in
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contrast to a genome-wide RNAi screen which found CRK7 to be important for trypanosome
viability across different life cycle stages (Alsford et al., 2011).
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Figure 3.1 CRK9 expression silencing caused a decrease of mature mRNA levels and concomitant
accumulations of SL RNA and pre-mRNAs.
(A) A representative growth curve from one of three independently derived clonal cell lines was obtained
in the absence and presence of the dsRNA synthesis-inducing reagent doxycycline (-/+ dox).
(B) Relative CRK9 mRNA levels were determined by semi-quantitative RT-PCR of total RNA prepared
from non-induced (ni) cells and in cells that were silenced for 1, 2 or 3 days (boxed panel). In the same
RNA preparations, the relative abundances of α tubulin (α TUB) and of GPEET procyclin mature and premRNAs were determined by semi-quantitative RT-PCR, those of the large ribosomal RNAs by ethidium
bromide staining, and those of the SL RNA, the U2 snRNA, and the SL intron by primer extension assays.
Note that the SL intron signals were obtained through overexposure of the same gels; the asterisk
indicates overexposed U2 signal just above the SL intron signal.
(C) Corresponding RT-qPCR analyses. The relative level of the analyzed RNAs in non-induced cells was
arbitrarily set to 100. The quantitative data were calculated from two independent experiments each of
which was analyzed three times by qPCR. The boxed panel shows the silenced CRK9 mRNA levels.
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4.2 CRK9 silencing led to a loss of RPB1 phosphorylation.
Since we had speculated that RPB1 CTD phosphorylation is mediated by a CDK, we
wanted first to know whether CRK9 silencing did affect the phosphorylation status of the CTD.
We expressed a GST-CTD fusion protein in Escherichia coli and raised a rat polyclonal antiCTD immune serum against the purified recombinant protein. On immunoblots, the antibody
specifically detected two specific protein bands in the range of 200 kDa in whole cell lysates.
However, the larger band was consistently absent in cell-free extract suggesting that in extract
RPB1 is rapidly dephosphorylated (Figure 3.2A). This finding was in accordance with previous
studies in which detection of RPB1 phosphorylation in extract proved to be difficult (Chapman
and Agabian, 1994; Das and Bellofatto, 2009). Although we tested several phosphatase
inhibitor cocktails, the loss of the upper band in extract could not be prevented (data not shown).
To prove that the upper band detected with our anti-CTD antibody represented phosphorylated
RPB1, we lysed trypanosomes in an SDS buffer and then reduced the detergent concentration
to enable alkaline phosphatase treatment. As shown in Figure 3.2B, the upper band was
retained after mock incubation without enzyme while addition of alkaline phosphatase converted
the upper band into the lower band, and this conversion was completely blocked with
phosphatase inhibitor. Therefore, we concluded that the upper and lower bands in our
immunodetections

represented

phosphorylated

(pRPB1)

and

dephosphorylated

RPB1,

respectively. Immunoblotting of whole lysates from non-induced and induced cells then clearly
showed that the pRPB1 signal became diminished upon CRK9 silencing whereas
dephosphorylated RPB1 increased (Figure 3.2C). Quantification of immunoblot signals revealed
that the pRPB1 signal decreased to 31% and 21% of non-induced levels on days 2 and 3,
respectively, whereas the signal of dephosphorylated RPB1 increased to ~2.5 fold during the
same period (Figure 3.2D). To confirm this result, we generated a clonal procyclic cell line that
expressed RPB1 with a C-terminal HA tag. Anti-HA immunoblotting detected the same two
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RPB1 bands as our polyclonal antibody and CRK9 silencing again led to a signal decrease of
the upper band and a concomitant signal increase of the lower band (Figure 3.2D). To make
sure that loss of RPB1 phosphorylation is a specific CRK9-dependent effect and not a general
phenotype of dying trypanosomes, we analyzed RPB1 in CRK3-silenced cells which, like CRK9silenced cells, ceased to proliferate after the first day of induction (Attachment 2, Fig. S1).
Although we noted a general loss of RPB1 on day 3 of induction, the relative amounts of upper
and lower bands remained at a similar level during the course of this experiment (Figure 3.2E)
and allowed us to conclude that CRK9 is essential for the majority of, if not all, RPB1
phosphorylations.
Although our data showed that RPB1 phosphorylation depended on CRK9 they did not
show whether CRK9 directly phosphorylates the CTD. To detect a physical link between CRK9
and RNA pol II we generated a cell line which exclusively expressed CRK9 C-terminally tagged
with the composite PTP tag (Schimanski et al., 2005a). Since CRK9 is essential for
trypanosome viability we concluded that the tag did not interfere with the function of the kinase.
A pull-down of CRK9 under low stringency conditions, however, did not co-precipitate
detectable amounts of RPB1 (data not shown). Since this result may be due to a transient or
low affinity interaction between the kinase and RPB1, we speculated that if RPB1 was
phosphorylated at SLRNAs then the kinase should be cross-linkable to SLRNA chromatin.
However, chromatin immunoprecipitation (ChIP) of PTP-tagged CRK9 or equivalently tagged
RPB9, a specific subunit of RNA pol II, showed high occupancy of the SLRNA promoter by
RPB9 whereas a CRK9 association with this promoter could not be detected (Attachment 2, Fig.
S4). Although these experiments do not rule out that CRK9 directly phosphorylates RPB1 they
raise the possibility that a different, CRK9-dependent kinase carries out these phosphorylations.
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Figure 3.2 CRK9 silencing caused a loss of RPB1 phosphorylation.
(A) Cell-free extract (EXTR) or whole cell lysate (WCL) was separated by SDS-PAGE, blotted and probed
with anti-RPB1 pre-immune (pre-IS) or immune serum (IS). The immune serum specifically detected
phosphorylated (pRPB1) and dephosphorylated RPB1.
(B) Diluted whole cell lysate was mock-treated or incubated with alkaline phosphatase (alk pho) in the
absence or presence (+inh) of a phosphatase inhibitor cocktail.
(C) Anti-RPB1 immunoblot analysis of whole cell lysates prepared from CRK9-silenced cells. Detection of
the similar-sized RNA pol I subunit RPA1 served as a loading control.
(D) Densitometric quantification of the phosphorylated (phos.) and dephosphorylated (dephos.) RPB1
bands upon CRK9 silencing from three independent experiments. The signal of non-induced cells was
arbitrarily set to 100.
(E) Anti-HA immunoblot of a corresponding experiment with CRK9 RNAi cells that expressed RPB1-HA.
(F) Anti-RPB1 immunoblot analysis of whole cell lysates prepared from CRK3-silenced cells.
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4.3 CRK9 silencing does not impair RNA pol II transcription.
Since CTD phosphorylation is essential for transcription initiation in yeast and mammals,
we explored whether CRK9-dependent RPB1 phosphorylation is required for RNA pol II
transcription in trypanosomes. We employed a permeabilized cell system which supports
labeling of nascent RNA in a linearly increasing fashion for a period of 15-20 min (Ullu and
Tschudi, 1990). Upon separation of labeled RNA by denaturing PAGE, the 142 nt-long SL RNA
can be readily detected due to its strong overall synthesis rate (Figure 3.3A). The amount of SL
RNA was roughly the same in non-induced cells and in cells in which the CRK9 knockdown was
induced for one day. After two days of induction, the SL RNA was reduced by approximately
one half but the signals for tRNA and larger RNAs were similarly reduced, most likely due to an
increasing number of dying cells. Accordingly, when we used densitometry to adjust the tRNA
signal, labeled SL RNA remained at the same high level two days after induction (Figure 3.3A,
right panel). Signal quantification from independent experiments confirmed that nascent SL
RNA synthesis is not perturbed upon CRK9 silencing (Figure 3.3C). Due to a large number of
dead or dying cells, the experiment could not be performed meaningfully with cells that were
CRK9-silenced for three days. However, since trypanosome growth ceased already after one
day of CRK9 silencing and since the levels of pre-mRNA, mature mRNA and SL RNA were
already clearly perturbed after two days of induction (Figure 3.1), we concluded that the loss of
CRK9-dependent RPB1 phosphorylation did not impair SL RNA synthesis. Importantly, the
SLRNA promoter is the only characterized RNA pol II promoter in trypanosomes that assembles
a transcription pre-initiation complex including TFIIH, the factor responsible for initial CTD
phosphorylation in other eukaryotes. Therefore, this finding strongly indicated that, in
trypanosomes, TFIIH-mediated CTD phosphorylation is not required for RNA pol II escape from
the SLRNA promoter.
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To explore the possibility that RPB1 phosphorylation is important for transcription of
protein coding genes, we hybridized labeled nascent RNA to dot blots of plasmids carrying
trypanosome gene inserts (Figure 3.3B). The experiment was repeated three times and
revealed that labeling efficiency was reduced throughout the array two days after induction. For
comparison, we normalized all signals with the signal of the RNA pol III-transcribed threonine
tRNA/U6 snRNA gene association (Nakaar et al., 1997) which on day 2 was reduced on
average by ~35%. Quantification of hybridization signals did not detect a specific defect in RNA
pol II-mediated transcription of protein coding genes. Two days after induction, the α tubulin and
HSP70 signals were reduced by 14% and 3% respectively, RNA pol I-synthesized GPEET
procyclin RNA was reduced by 21%. While none of these reductions proved to be significant
(unpaired Student’s T test assuming equal variance and two-tailed distribution), the strongest
signal reduction of 33% was observed in RRNA transcription. Since it is well-known from other
systems that inhibition of rRNA synthesis in stationary or stressed cells is often a first measure
to down-regulate gene expression, this signal reduction could reflect the poor health of CRK9silencend cells.
In summary, these experiments failed to detect a specific defect in RNA pol II
transcription and thus strongly indicate that CRK9-dependent RPB1 phosphorylation is neither
required for transcription initiation at the SLRNA promoter nor an essential modification for
transcription elongation within the protein coding gene arrays.
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Figure 3.3 CRK9 silencing does not affect RNA pol II transcription.
(A) Nascent RNA of cells that were non-induced (ni) or CRK9-silenced for 1 or 2 days, was radio-labeled
in a permeabilized cell system, extracted, separated on a 50% urea-6% polyacrylamide gel, and
visualized by autoradiography. In the left panel, the loading of RNA was standardized to the number of
cells and on the right panel, the loading was standardized according to the tRNA signal as indicated. The
arrow points to an RNA band that most likely represents a previously described SL RNA that is extended
/
at the 3 end.
(B) The same labeled RNA preparations were used to probe dot blots of plasmids containing the coding
regions of T. brucei GPEET procyclin, α tubulin (α TUB), heat shock protein 70 (HSP70), and 18S rRNA
THR
as well as the associated threonine tRNA/U6 snRNA genes (tRNA /U6 snRNA). The plasmid without
insert (pTZ18U) served as a negative control. For each lane, upper and lower panels are from the same
image.
(C) The radioactive signals from four independent experiments were quantified by scintillation counting
THR
and normalized to the RNA pol III-mediated tRNA /U6 snRNA signal because CRK9 silencing did not
affect the abundance of the RNA pol III-synthesized U2 transcript. The SL RNA signal was quantified by
densitometry and normalized to the tRNA signal as shown in (A). The error bars represent standard
deviations.
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4.4 CRK9 silencing impairs cap4 formation of the SL RNA.
As detailed above, reporter gene expression by different RNA pols demonstrated that
pre-mRNA processing in trypanosomes is uncoupled from RNA pol II transcription (Stewart et
al., 2010). In accordance with these results, CRK9 silencing affected RNA pol I-synthesized
GPEET procyclin RNA in the same way as it did RNA pol II-synthesized α tubulin mRNA (Figure
3.1). However, these results did not exclude the possibility that SL RNA modification depended
on RNA pol II because SL trans splicing is an essential maturation step for all trypanosome
mRNAs independent of the transcribing RNA pol. Since trans splicing depends on the
methylation status of the SL RNA cap4 structure (McNally and Agabian, 1992; Ullu and Tschudi,
1991) and since there is evidence that SL RNA cap4 formation occurs co-transcriptionally (Mair
et al., 2000b), it was possible that the trans splicing block observed upon CRK9 silencing was
due to inappropriate cap4 formation. To monitor cap4 methylations on the SL RNA we
employed

a

modified

primer

extension

assay

with

a

reduced

concentration

of

deoxyribonucleotides and with unmodified MMLV reverse transcriptase that terminates
polymerization before the methylated nucleotide under these conditions (Mandelboim et al.,
2002; Zamudio et al., 2006). In non-induced cells, the SL RNA-specific extension products
spanned six positions: cap0 - cap4 in which, as previously noted (Zamudio et al., 2007), a cap3specific extension product is typically not observed because MTR3 methylates positions 3 and
4, and cap4 can generate two extension products (Figure 3.4A). The cap4 signals were the
strongest in these cells and the pattern did not change after one day of CRK9 silencing.
Conversely, on days two and three, the cap4 signals faded whereas the main extension product
of the accumulating SL RNA was the cap0 product indicating a complete loss of cap4
methylations (Figure 3.4A). Furthermore, loss of cap1 modification was previously shown to
correlate with ineffective trimming of the SL RNA 3/ end by the nuclease TbSNIP leading to
slightly larger SL RNAs (Zamudio et al., 2007). In accordance with this finding, we detected an
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accumulating signal above the correct SL RNA band in labeled nascent RNA (Figure 3.4A,
arrow). In summary, we concluded that CRK9 silencing caused a degree of cap4
hypomethylation that impaired SL trans splicing leading to SL RNA and pre-mRNA
accumulations and decreasing levels of mature mRNAs.
Next, we addressed the question whether cap4 hypomethylation is linked to the loss of
RPB1 dephosphorylation. We first analyzed the U1 snRNA cap. While the T. brucei U1 gene
appears to be transcribed by RNA pol III (Djikeng et al., 2001), the U1 snRNA has a cap1
structure consisting of a trimethylguanosine (TMG) cap and a methylated adenosine at position
1 that leads to a premature primer extension stop at position 2 (Djikeng et al., 2001; Zamudio et
al., 2007). Importantly, cap1 methylation of both SL RNA and U1 snRNA is carried out by the
same methyltransferase termed MTR1 (Zamudio et al., 2007). Hence, if CRK9 silencing led to a
direct deactivation of MTR1 we would expect to see a loss of cap1 in U1 snRNA. To test this,
we carried out the modified primer extension assay with total RNA prepared from CRK9- and
CRK3-silenced cells using a U1-complementary oligonucleotide (Figure 3.4B). We reproducibly
detected three U1-specific products in our assay: the two lower bands were specific for cap1
and unmodified cap0 whereas the fainter product with an extra nucleotide (position -1) was
possibly generated due to the TMG cap (as opposed to the SL RNA m7G cap). As expected,
treating the cells for six hours with sinefungin resulted in a signal shift from cap1 to cap0/pos-1
products. This shift was not observed in CRK9- or CRK3-silenced cells even after RNAi
induction for three days indicating that the MTR1 enzyme activity remained active.
Consequently, the specific loss of SL RNA cap1 methylation upon CRK9 silencing may be due
to a failure in MTR1 recruitment to the SL RNA 5/ end.
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Figure 3.4 CRK9 silencing resulted in specific hypomethylation of SL RNA cap4.
(A) Primer extension analysis with MMLV reverse transcriptase and reduced dNTP concentration (100
32
/
nM) of total RNA prepared from non-induced (ni) or CRK9-silenced cells using P-5 end-labeled
oligonucleotides SLf and U2f that are complementary to SL RNA and U2 snRNA, respectively. The
extension products were separated on a high resolution 6% sequencing gel and visualized by
autoradiography. The lower exposure of the SL RNA extension products at the bottom reveals that CRK9
silencing led to accumulation of larger extension products, particularly that of the cap0 product. For
comparison, a SL RNA-specific sequencing ladder was generated by linear amplification sequencing
using labeled SLf; the nucleotide specification for each lane corresponds to the coding strand sequence.
The sequencing ladder was co-separated on the same gel but required a longer exposure.
(B) A corresponding analysis of the U1 snRNA cap1 in CRK9- and CRK3-silenced cells. The first four U1
nucleotides of the sequencing ladder are marked by asterisks and the partial loss of cap1 in sinefungintreated cells (sin) is denoted by the arrow.
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To support this notion, we evaluated pseudouridylation of SL RNA at position 28 which is
carried out by the SLA1 ribonucleoprotein particle (RNP) that comprises several proteins
including the pseudouridine synthase CBF5 (54) and MTR1 (Zamudio et al., 2009b). We
hypothesized that if MTR1 is not recruited to the SL RNA cap in CRK9-silenced cells then
pseudouridylation may also be impaired because MTR1 and CBF5 belong to the same RNAprotein complex. However, the accumulating SL RNA in CRK9-silenced cells was clearly
pseudouridylated (Attachment 2, Fig. S5) indicating that the SLA1 RNP can interact with SL
RNA independent of CRK9-controlled RPB1 phosphorylations. As follows, our data do not
unequivocally support the notion that RPB1 phosphorylation mediates cap4 formation. Testing
this hypothesis is beyond the scope of this study because it requires the simultaneous
knockdown of the two T. brucei RPB1 genes and the ectopic expression of a tagged, RNAiresistant version of the large RPB1 gene carrying mutations of phosphorylated CTD residues.
Nevertheless, the results presented here strongly indicate that the unique methylations of cap4
that are essential for trans splicing depend on CRK9.
4.5 CRK9 silencing does not affect m7G capping of SL RNA.
The previous demonstration that prematurely terminated SL RNA transcripts as short as
30 nt were capped with an m7G residue led to the conclusion that m7G capping of T. brucei SL
RNA occurs cotranscriptionally (Mair et al., 2000b). It was therefore possible that CRK9
silencing and the resulting CTD dephosphorylation abrogated m7G capping of the SL RNA. To
analyze the SL RNA capping status in CRK9-silenced cells we performed immunoprecipitations
with an antibody directed against a TMG cap that also recognizes the m7G cap but does not
interact with an unmethylated guanosine cap or uncapped RNAs. As shown in figure 3.5, the SL
RNA was efficiently precipitated from total RNA of non-induced cells as well as of cells in which
CRK9 was silenced for up to three days. In contrast, SL RNA from sinefungin-treated cells that
lacked methylations and the uncapped U5 snRNA, which served as an internal negative control,
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were not precipitated. These results clearly demonstrated that CRK9-dependent CTD
phosphorylation is not required for SL RNA m7G capping indicating that a potential interaction
between trypanosome RNA pol II and the capping enzyme is independent of RPB1
phosphorylation.
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7

Figure 3.5 CRK9 silencing does not affect m G capping of SL RNA.
Total RNA preparations from non-induced cells (ni), cells in which CRK9 was silenced for 1, 2 or 3 days,
or cells which were treated with the methylation inhibitor sinefungin (sin) were immunoprecipitated with an
2,2,7
7
antibody that recognizes both m G and m G caps. Equal amounts of supernatants (S) and
immunoprecipitates (P) were analyzed by primer extension with oligonucleotides complementary to the
7
2,2,7
SL RNA (m G cap), the U2 snRNA (m G cap), and the uncapped U5 snRNA.
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4.5 RPB1 phosphorylation and SL RNA cap4 formation depend on CRK9 kinase activity.
Thus far, we have shown that inducible expression of dsRNA that targets the 5/-terminal
CRK9 coding region led to an efficient knockdown of CRK9 mRNA and to RPB1
dephosphorylation, SL RNA cap4 hypomethylation, and the described RNA processing defects.
To unequivocally demonstrate that these effects depended on CRK9 and its enzymatic activity
and not to an off-target effect of the 500 bp-long dsRNA, we generated a new procyclic RNAi
cell line in which we targeted the 3/ UTR of the CRK9 mRNA (Figure 3.6A). The corresponding
knockdown led to a similar, rapid decline of cell numbers as observed previously and, as
expected, the levels of mature and pre-mature α tubulin mRNA decreased and increased upon
induction of dsRNA synthesis, respectively. The cap4 methylation defect and RPB1
dephosphorylation were similarly obvious (Figure 3.6A). Moreover, when we integrated a
plasmid into an endogenous CRK9 allele that fused an HA tag sequence and the RPA1 3/ UTR
to the CRK9 coding region, we could rescue culture growth and all the defects (Figure 3.6B).
The corresponding RNA analysis showed that endogenous CRK9 mRNA was effectively
knocked down whereas CRK9-HA mRNA was resistant to the RNAi response. Correspondingly
CRK9-HA protein abundance remained unaffected upon doxycycline induction. These results
unequivocally demonstrated that RPB1 phosphorylation and SL RNA cap4 formation are
controlled by CRK9. In a final step, we wanted to make sure that the kinase activity of CRK9 is
important for this control. In general, phosphorylation of the T loop threonine residue (T161 in
human CDK1) leads to activation of a CDK/cyclin complex. The corresponding threonine
residue in CRK9 of T. brucei had been mapped to position 533 (Hammarton, 2007). We
therefore repeated the rescue experiment but this time we mutated the T533 to an alanine in the
CRK9-HA protein (Figure 3.6C). RNAi induction showed a growth defect after 24 h similar to the
other (non-rescued) CRK9 silencing experiments. However, these cells recovered after 2-3 days
to normal growth and this was observed with three independently obtained clonal cell lines.
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Concomitant with recovery we reproducibly noticed a slightly higher migrating band of CRK9HAT553A 3 days after induction (Figure 3.6C, arrow in CRK9-HAT553A immunoblot) suggesting that
compensatory

phosphorylations

or

other

post-translational

modifications

led

to

an

unconventional activation of CRK9-HAT553A. Nevertheless, while only a minor perturbation of α
tubulin (pre-)mRNA was apparent 3 days after induction, cap4 hypomethylation and RPB1
dephosphorylation were clearly detectable 2 days after induction. These data strongly indicated
that CRK9 enzyme activity is required for RPB1 phosphorylation and SL RNA cap4 formation.

	
  

93

Figure 3.6 RPB1 phosphorylation and SL RNA cap4 formation depend on CRK9 kinase activity.
/

A CRK9 RNAi parent cell line (A) was generated in which the inducibly expressed dsRNA targets the 3
UTR of CRK9 mRNA. This cell line was further modified by targeted integration of a plasmid into an
/
endogenous allele that fused an HA tag sequence and the 3 UTR of the largest RNA pol I subunit RPA1
/
to the 3 end of the gene (B). A third cell line was generated analogously except that the threonine codon
at position 533 was mutated to an alanine codon (C). For each cell line, culture growth curves were
obtained in the presence or absence of doxycycline and RNA and protein analyses were conducted with
non-induced cells (ni) and with cells that were induced for 1, 2, or 3 days. Semi-quantitative RT-PCR
analyses demonstrated efficient knockdown of endogenous (Castillo et al.) CRK9 RNA and RNAi
resistance of CRK9-HA RNA (boxed results). The CRK9 silencing effect on α tubulin mRNA (α Tub) and
pre-mRNA (pre-αTub) was assessed by semi-quantitative RT-PCR, and on SL RNA by primer extension
assays. Detection of rRNA (RRNA) by ethidium bromide staining served as a control for RNA amount.
Asterisks identify increased hypomethylated cap4 signals. Anti-HA and anti-RPB1 immunoblot analyses
confirmed RNAi resistance of CRK9-HA (boxed) and revealed the effects of CRK9 silencing on RBP1
phosphorylation. Detection of RPA1 served as a loading control. The arrow on the right identifies a slower
T553A
protein.
migrating band of CRK9-HA
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5. Discussion
We have analyzed the role in gene expression of four out of the eleven trypanosome
CDKs. Our hypothesis was that, in line with phosphorylation of heptad repeats, this type of
kinase phosphorylates the non-canonical RPB1 of trypanosomes and is of central importance
for gene expression in this early-diverged eukaryote. Accordingly, we could demonstrate that
silencing of trypanosome CRK9 led to a loss of RPB1 phosphorylation. Since it was shown that
the RPB1 CTD is phosphorylated (Chapman and Agabian, 1994; Das and Bellofatto, 2009) and
phosphoproteomics exclusively detected phosphorylated residues in the CTD of the large RPB1
protein (Nett et al., 2009), it is likely that most if not all RPB1 phosphorylations are located in the
CTD. It seems that all of these phosphorylations depend on CRK9 because silencing of its gene
led to a loss of the pRPB1 band in immunoblots and to a concomitant increase of
unphosphorylated RPB1 without the appearance of an intermediate band. Although we have not
been able to show so far that CRK9 directly phosphorylates the CTD, our results are informative
about the function of the non-canonical CTD. We found that reducing phosphorylated RPB1 to
30% on day 2 of CRK9 silencing, did not impact transcription of protein coding and SLRNA
genes indicating a mechanistic difference in transcription initiation between trypanosomes and
eukaryotes with a canonical CTD. In the latter, RNA pol II recruitment into the PIC involves the
mediator complex which binds to hypophosphorylated RNA pol II. TFIIH/CDK7-mediated CTD
phosphorylation disrupts this interaction, presumably facilitating promoter escape of the
polymerase (Sogaard and Svejstrup, 2007). Trypanosomes do possess a mediator complex that
is essential for SLRNA transcription, interacts with TFIIH, and is required for the formation of a
transcription pre-initiation complex at the SLRNA promoter (Lee et al., 2010). However, whereas
eukaryotic mediator consists of head, middle, tail and CDK8 modules, EM structure analysis of
the trypanosome complex indicated that it is confined to the head module (Lee et al., 2010).
Thus, the absence of a TFIIH kinase (Lee et al., 2009) and the presence of a minimal mediator
complex suggest that, in trypanosomes, a mediator-CTD interaction does not occur and a
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release of RNA pol II from mediator is not a prerequisite for promoter escape of the enzyme.
Accordingly, tandem affinity purification of trypanosome mediator did not co-purify detectable
amounts of RNA pol II subunits (Lee et al., 2010) and vice versa (Das et al., 2006; Devaux et
al., 2006).
Furthermore, RPB1 dephosphorylation did not impact m7G capping of SL RNA. In higher
eukaryotes, the capping enzyme binds to the CTD after Ser5 of the heptad repeat motif is
phosphorylated by CDK7 (Fabrega et al., 2003); capping then occurs co-transcriptionally. Since
in trypanosomes, SL RNA capping does occur co-transcriptionally as well (Mair et al., 2000b),
our results strongly suggest that the trypanosome capping enzyme interacts with the
transcription machinery in a trypanosome-specific manner independent of CTD phosphorylation.
Nevertheless, CRK9 silencing resulted in a striking defect in trypanosome gene
expression, namely a block of trans splicing before the first transesterification reaction caused
by hypomethylation of SL RNA cap4. Formation of the unique cap4 structure involves seven
methylations on the first four nucleotides by three or more different methyltransferases. Thus,
the most intriguing aspect of our work is the demonstration that cap4 formation is controlled by a
single enzyme. Since the trypanosome cap4 structure is unique, essential for trans splicing
(McNally and Agabian, 1992; Ullu and Tschudi, 1990), and important for translation (Zamudio et
al., 2009b), identification of the methyltransferases has been a priority and, thus far, the three 2/O-ribose methyltransferases MTR1, MTR2 (aka COM1, MT48) and MTR3 (aka MT57) which
methylate positions 1, 2 and 3/4, respectively, have been identified (Arhin et al., 2006a; Arhin et
al., 2006b; Hall and Ho, 2006; Zamudio et al., 2007; Zamudio et al., 2006). Surprisingly,
however, elimination of individual MTR genes left trypanosomes viable and did not impair trans
splicing. This functional redundancy of the known MTRs has dampened enthusiasm for these
enzymes being potential chemotherapeutic targets. However, the dependence of a critical
number of cap4 methylations on CRK9 alone reinstates cap4 formation as a target. CRK9
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appears to be particularly promising in this respect. Firstly, CRK9 has an essential central role in
trypanosome gene expression controlling RPB1 phosphorylation and SL RNA cap4 formation.
Secondly, SL trans splicing does not occur in mammals and, thus, the block of SL RNA
maturation is a parasite-specific defect. Thirdly, since SL RNA is consumed in trans splicing of
every mRNA, partial inhibition of SL RNA biogenesis may already be lethal. This notion is
backed up by independent observations that a reduction of SL RNA synthesis to ~30% is
already lethal to cultured trypanosomes (Ruan et al., 2004; Schimanski et al., 2006). Fourthly,
cyclin-dependent kinases in general are considered to be among the most promising drug
targets due to their key function in cell proliferation (Malumbres and Barbacid, 2009).
Accordingly, CRK9 silencing was shown to affect trypanosome mitosis and cytokinesis
(Gourguechon and Wang, 2009; Li, 2012).
How does CRK9 enable cap4 formation? A plausible explanation is that cap4
methylations occur co-transcriptionally requiring a phosphorylated CTD. This would be
consistent with previous observations that cap4 methylations can be detected on newly
synthesized, prematurely terminated SL RNA transcripts (Mair et al., 2000b). Part of our results
support this scenario: CRK9 silencing did not cause a detectable defect of cap1 formation in the
RNA pol III-synthesized U1 snRNA suggesting that MTR1, the methyltransferase that forms
cap1 in both U1 and SL RNA, remains functional during the CRK9 knockdown. Thus, the loss of
SL RNA cap1 may be explained by failed recruitment of MTR1 by dephosphorylated RNA pol II.
Although MTRs did not co-purify with T. brucei RNA pol II (Das et al., 2006; Devaux et al.,
2006), the interaction may have been lost due to rapid RPB1 dephosphorylation in extract. As
our data show (Fig. 3.2A), the phosphorylated form of RPB1 was only detected in whole cell
lysates and rapidly converted to the dephosphorylated form during extract preparation, possibly
due to the presence of 15 putative homologs of the CTD phosphatase FCP1 in the T. brucei
genome (www.TritrypDB.org).
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On

the

other

hand,

there

are

findings

which

suggest

that

the

T.

brucei

methyltransferases do not require RNA pol II for recruitment. T. brucei MTR1 was found to be in
a complex with the SLA1 RNP that contains several subunits including the pseudouridine
synthase CBF5, and which guides pseudouridylation of SL RNA position 28 (Zamudio et al.,
2009b). While SL RNA pseudouridylation is not essential for trypanosome viability (Hury et al.,
2009), CBF5 silencing affected cap4 formation indicating that the SLA1 RNP is important for
MTR1 function (Barth et al., 2005). Accordingly, we found that pseudouridylation was not
impaired during CRK9 silencing which indicates that the SLA1 RNP can interact with the SL
RNA independent of phosphorylated RNA pol II. Furthermore, MTR2 and MTR3 cap4
methylations depend on Sm protein binding to the SL RNA 3/ terminal domain (Mandelboim et
al., 2003; Zeiner et al., 2004a), suggesting that the SL RNP possesses RNA pol II-independent
determinants for MTR2 and MTR3 recruitment. However, these arguments are not conclusive
and there are other findings which are more in line with co-transcriptional cap4 formation.
Firstly, the interaction between SLA1 and SL RNA appears to be weak and transient since
purification of the SLA1 RNP did not co-purify detectable amounts of SL RNA, indicating that
base pairing alone may not be enough for SLA1 recruitment to the SL RNA (Zamudio et al.,
2009b). Taken together, it will require a dedicated study to decipher whether CTD
phosphorylation is directly linked to SL RNA cap4 formation or whether RPB1 phosphorylation
and cap4 formation are independent processes.
Overall, our study has identified a cyclin-dependent kinase that is of central importance to
trypanosome

gene

expression

being

essential

for

SL

RNA

maturation

and

RPB1

phosphorylation. Together with previous TFIIH and mediator characterizations, it has provided
compelling evidence for RNA pol II transcription initiation and m7G capping functioning
independently of a TFIIH-based, CDK7-mediated CTD phosphorylation event. Our data strongly
suggest that the essential CTD function in RNA pol II transcription initiation has evolved after
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the divergence of major protistan lineages because it appears to be coupled to the canonical
CTD with heptad repeat motifs.
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Chapter IV
The cyclin-dependent kinase CRK9, a new L-type cyclin and
a CRK9-associated protein cooperate in facilitating
spliced leader trans splicing in Trypanosoma brucei

1. Abstract
In eukaryotes, cyclin-dependent kinases (CDKs) control the cell cycle and critical steps
in gene expression. The lethal parasite Trypanosoma brucei, member of the phylogenetic order
Kinetoplastida, possesses eleven CDKs which, due to high sequence divergence, were
generically termed CDC2-related kinases (CRKs). While several CRKs have been implied in the
cell cycle, CRK9 is the first trypanosome CDK that was shown to control the unusual mode of
gene expression found in kinetoplastids. In these organisms, protein-coding genes are arranged
in tandem arrays which are transcribed polycistronically. Individual mRNAs are processed from
precursor RNA by spliced leader (SL) trans splicing and polyadenylation. CRK9 ablation was
lethal in cultured trypanosomes, causing a block of trans splicing at the first transesterification
step. Additionally, CRK9 silencing led to dephosphorylation of RNA polymerase II and to
hypomethylation of the SL cap structure. Here, we tandem affinity-purified CRK9 and, among
potential CRK9 substrates and modifying enzymes, discovered an unusual tripartite complex of
CRK9, a new L-type cyclin (CYC12) and a protein, termed CRK9-associated protein (CRK9AP),
that is only conserved among kinetoplastids. Silencing of either CYC12 or CRK9AP reproduced
the effects of depleting CRK9, identifying these proteins as functional partners of CRK9 in vivo.
While mammalian cyclin L binds to CDK11, the CRK9 complex deviates substantially from that
of CDK11, requiring CRK9AP for CRK9 complex integrity. Interference with this unusual CDK

	
  

100

rescued

mice

from

lethal

trypanosome

infections,

validating

CRK9

as

a

potential

chemotherapeutic target.

2. Introduction
Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are unicellular, vector
borne, human parasites belonging to the early-diverged phylogenetic order Kinetoplastida.
These parasites collectively affect millions of people worldwide primarily in developing countries,
causing debilitating to fatal human diseases. There is no preventive vaccine for these diseases
and the current medications are unsatisfactory due to poor efficacy, toxicity and developing drug
resistance (Barrett and Croft, 2012). Trypanosomatid parasites share a unique mode of protein
coding gene expression that is distinct from their hosts. A trypanosomatid genome is organized
in large gene clusters, containing tandemly linked protein coding genes which are transcribed
polycistronically. Individual mRNAs are resolved from pre-mRNA by spliced leader (SL) trans
splicing and polyadenylation. In SL trans splicing, the SL, derived from the small nuclear SL
RNA, is spliced onto the 5/ end of each mRNA (Gunzl, 2010; Michaeli, 2011). Like cis splicing,
e.g. the removal of introns, SL trans splicing comprises two transesterifications, generating a Yshaped structural intermediate after the first splicing step that is analogous to the lariat structure
in cis splicing (Murphy et al., 1986; Sutton and Boothroyd, 1986). The 39 nt-long SL harbors an
extensively modified cap structure, called cap4, that consists of a standard 7-methylguanosine
cap nucleotide followed by four methylated nucleotides (Bangs et al., 1992). Cap4 is important
for SL trans splicing (McNally and Agabian, 1992; Ullu and Tschudi, 1991) and for efficient
translation (Zamudio et al., 2009a). Since each and every mRNA carries a SL, trans splicing is
absolutely essential for the survival of kinetoplastids. In T. brucei, the cdc2-related kinase 9
(CRK9) appears to be of crucial importance for this unusual mode of gene expression since
depletion of this cyclin-dependent kinase (CDK) led to a lethal block of trans splicing (Badjatia et
al., 2013a).
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CDKs are serine/threonine kinases that require association with a cyclin for enzymatic
activity (Pines, 1995). CDKs were first identified as key regulators of cell cycle progression
(Beach et al., 1982; Nasmyth and Reed, 1980), although now it is well established that there is
a second group of CDK/cyclin complexes that have crucial functions in transcription and RNA
splicing (Lim and Kaldis, 2013; Loyer et al., 2005). There are 13 CDKs in humans all of which
share a conserved catalytic domain containing an ATP binding pocket, a PSTAIRE-like helix
domain responsible for cyclin binding and an activating T-loop motif (Cao et al., 2014;
Malumbres et al., 2009). While CDKs that are important for the cell cycle are regulated by their
sequential binding to different cyclins, each of which are transcribed and degraded at defined
cell cycle stages, the CDKs and cyclins that are involved in gene expression are constitutively
expressed throughout the cell cycle, typically forming a single CDK-cyclin complex (Lim and
Kaldis, 2013; Loyer et al., 2005). In metazoans, CDK7 has a dual role in both cell cycle and
transcription. Uniquely, CDK7 forms a trimeric complex with Cyclin H and the RING finger
domain protein MAT1 (ménage a trois 1) that phosphorylates and activates cell cycle CDKs in
their T-loops and, therefore, has been termed the CDK-activating kinase (CAK). CAK is also
part of the basal transcription factor TFIIH and, in this association, phosphorylates the carboxyterminal domain of RPB1 during transcription initiation, promoting promoter clearance of RNA
pol II (Akoulitchev et al., 1995; Dahmus, 1996; Serizawa et al., 1995; Shiekhattar et al., 1995)
and recruitment of RNA processing factors including the capping enzyme (Rodriguez et al.,
2000) reviewed in . The PITSLRE kinase CDK11 is another CDK that has a dual role (Loyer et
al., 2005; Satyanarayana and Kaldis, 2009). In murine and human cells it is present as two
isoforms, CDK11p110 and CDK11p58 (Cornelis et al., 2000; Gururajan et al., 1998; Li et al., 2004b;
Xiang et al., 1994). While CDK11p58 is implicated in mitosis, and is expressed due to a G2/Mspecific internal ribosome entry site present in the CDK11p110 mRNA (Cornelis et al., 2000; Li et
al., 2004b); CDK11p110 is constitutively expressed and involved in transcription and pre-mRNA
splicing (Hu et al., 2003; Loyer et al., 1998; Trembley et al., 2004). Orthologs of CDK11 are
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present in all metazoans and fission yeast but absent from budding yeast (Guo and Stiller,
2004; Liu and Kipreos, 2000).
Trypanosoma brucei harbors eleven CDKs that were generically termed CRK1-4 and
CRK6-12 since their high sequence divergence has prevented orthologous assignments with
CDKs of other eukaryotes. In addition, ten cyclins (CYC2-11) have been identified in T. brucei
so far (Hammarton, 2007; Naula et al., 2005). Due to their crucial importance for gene
expression and cell proliferation, CDKs are generally considered to be promising drug targets
and, therefore, trypanosomatid CRKs have been a research focus. RNAi-mediated gene
knockdowns identified CRK1-3, CRK6, CRK9 and CRK12 as essential CDKs in T. brucei
(Badjatia et al., 2013a; Gourguechon and Wang, 2009; Jones et al., 2014; Mackey et al., 2011;
Merritt and Stuart, 2013; Monnerat et al., 2013; Tu and Wang, 2004). Less is known about the
specific functions of these important enzymes. CRK3 was shown to be the functional homolog
of human CDK1; it partners with CYC6 (also referred to as Cyclin B2) and regulates mitosis
(Hammarton et al., 2003; Li and Wang, 2003; Tu and Wang, 2004). Depletion of both CRK3 (Tu
and Wang, 2004) and CYC6 (Hammarton et al., 2003; Li and Wang, 2003) results in a block of
G2/M progression and cell death in the PF as well as BF. Interestingly, CRK3 also forms a pair
with CYC2 (aka cyclin E1) in vivo (Van Hellemond et al., 2000). The knockdown of CYC2 is
lethal and causes a G1 arrest in cells (Hammarton et al., 2004; Li and Wang, 2003), but a
function of CRK3 in G1 phase if any, is yet unknown. CRK1 is important for G1/S progression
and interacts with CYC2 in a yeast two-hybrid screen but this interaction was not observed in
vivo (Gourguechon et al., 2007; Tu and Wang, 2004; Van Hellemond et al., 2000). CRK2, CRK4
and CRK6 appear to have accessory functions in the cell cycle although their cyclin partners are
unknown (Tu and Wang, 2005). Recently, CYC9 was shown to associate with CRK12 during a
tandem affinity purification of CRK12. Both CYC9 and CRK12 were essential in BF, but gene
silencing resulted in distinct phenotypes, suggesting that while CYC9 is important for
cytokinesis, CRK12 has a role in endocytosis (Monnerat et al., 2013).
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CRK9 is the first trypanosome CDK shown to have an essential role in gene expression.
In addition, like mammalian CDK7 and CDK11, this CDK seems to function in the cell cycle, too,
since ablation of CRK9 in insect-stage, procyclic form (PF) trypanosomes led to a defect in
basal body segregation during cytokinesis (Gourguechon and Wang, 2009). CRK9’s essential
function in gene expression became apparent by RNA analysis of CRK9-silenced PFs and BFs
both of which revealed a strong decline of mature mRNA and a concomitant increase of
unspliced pre-mRNA. Similarly, while the trans splicing substrate SL RNA was dramatically
increased in CRK9-silenced cells, the Y structure splicing intermediate exhibited a strong
decline in abundance (Badjatia et al., 2013a). Moreover, introduction of an RNAi-resistant CRK9
wild-type gene into these cells completely rescued this phenotype whereas introduction of an
equivalent CRK9 gene carrying a mutation in its T-loop sequence did not. Together, these
results showed that CRK9 enzyme activity is crucial for the first step of splicing.
Interestingly,

CRK9

ablation

also

caused

dephosphorylation

of

RPB1

and

hypomethylation of the SL cap, raising the possibility that CRK9 is a functional homolog of
mammalian CDK7, directly phosphorylating the CTD of RPB1. However, biochemical and
structural characterization of trypanosome TFIIH did not reveal a kinase sub-complex (Lee et
al., 2010; Lee et al., 2009) and CRK9 silencing did not lead to a RNA pol II-specific transcription
defect (Badjatia et al., 2013a). Conversely, the CRK9 silencing defects could be quantitatively
reproduced by depleting a subunit of the spliceosomal PRP19 complex that, in other systems,
was shown to be essential for spliceosome activation, indicating a potential role of CRK9 in the
RNA processing branch of gene expression (Ambrosio et al., 2015). Thus, while its importance
for trypanosome gene expression and viability has been clearly demonstrated, the nature of
CRK9 remains undetermined.
Here we have characterized the enzyme complex and validated CRK9 enzyme activity
as a potential drug target in the mouse. CRK9 forms a tripartite complex together with a novel,
previously unannotated L-type cyclin that we termed CYC12 and a kinetoplastid-specific protein
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that we call CRK9-associated protein (CRK9AP). CYC12 and CRK9AP silencing reproduced the
CRK9 silencing phenotypes, identifying them as essential, functional partners of CRK9 in vivo.
This is highly unusual as with the exception of CDK7, CDKs typically function in be reconstituted
in active form in vitro and do not require additional protein partners for their kinase activity.
Interestingly, CRK9AP appears to be important for the integrity of the complex as the
knockdown of CRK9AP resulted in a concomitant loss of both CRK9 and CYC12.

3. Results
3.1 Characterization of the CRK9 enzyme complex
Since trypanosome CRK9 enzyme activity was required for spliced leader trans splicing,
a parasite-specific step in the maturation of all mRNAs, we tagged and tandem affinity-purified
the enzyme to identify its cyclin partner and other co-purifying proteins by liquid
chromatography-tandem mass spectrometry (LC/MS/MS). By two consecutive transfections, we
generated the clonal PF cell line TbC9ee, in which the hygromycin phosphotransferase gene
(HYGR) replaced one CRK9 allele and targeted insertion of plasmid CRK9-PTP-NEO fused the
sequence of the composite PTP tag, which encodes the protein C epitope (ProtC), a tobacco
etch virus (TEV) protease cleavage site and a tandem protein A domain (ProtA), to the 3/ end of
the CRK9 coding region (Fig. 4.1A). To confirm that TbC9ee cells exclusively expressed tagged
CRK9, we raised a specific anti-CRK9 immune serum in rats against a partial recombinant GSTtagged CRK9 protein that was expressed and purified from Escherichia coli. In an immunoblot
of whole cell lysates, the immune serum detected a single protein band of ~100 kDa in wild-type
trypanosomes which is slightly larger than the predicted CRK9 mass of 85.6 kDa (Fig. 4.1B).
Accordingly to the molecular mass of 19 kDa for the PTP tag, in TbC9ee cells, this band was
replaced by a ~120 kDa band that was also detected by a ProtA-specific probe, confirming
exclusive expression of CRK9-PTP in TbC9ee cells. TbC9ee cells did not exhibit reduced
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culture growth as compared to the wild-type cells. Additionally, the phosphorylation status of
RPB1, which has been linked to CRK9 function, was comparable in wild-type and TbC9ee cells
(Fig. 4.1B, bottom panel). Hence, we concluded that the PTP tag did not interfere with CRK9
function.
Facilitated by the PTP tag, we purified CRK9-PTP by IgG affinity chromatography, TEV
protease cleavage and anti-ProtC immunoaffinity chromatography. An anti-ProtC immunoblot
analysis revealed efficient capture of the tagged protein in all steps of the tandem affinity
purification (Fig. 4.1C). Separation of the final eluate and, as controls, of the input material and
the TEV protease fraction, by SDS-PAGE and staining of proteins by Sypro Ruby and
Coomassie Blue, revealed a dominant band of ~105 kDa, representing CRK9-P (note that
CRK9-PTP was reduced by ~15 kDa to CRK9-P by TEV protease cleavage), and,
unexpectedly, many co-purified protein bands (Fig. 4.1D). Mass spectrometry of two
independent CRK9-PTP purifications revealed a total of 162 proteins that were identified with an
expect value smaller than 0.01 and at least by two unique peptides (Attachment 3, S1 Table).
The majority of proteins, including those with very high Mascot Scores, were proteins of both
ribosomal subunits. This massive co-purification of ribosomal proteins was surprising because
CRK9 is a nuclear protein and not enriched in the nucleolus (Gourguechon and Wang, 2009),
and previous PTP purifications of various nuclear complexes contained only few, low scoring
ribosomal proteins. Since the functional association of CRK9 with ribosomal complexes remains
unclear, we focused on non-ribosomal proteins. Table 4.1 lists the most significant
identifications. While no annotated cyclin was detected in the purification, the protein with the
second highest score is a new trypanosome cyclin (see below) which we termed CYC12
(Tb927.10.9160). Among the top scoring proteins are three dual specificity protein kinases
capable of phosphorylating serines and threonines as well as tyrosines. While these kinases
may be substrates of CRK9, it is equally possible that they modify CRK9 since phosphoproteomic studies revealed that residues threonine 533, serine 746, serine 750 and threonine
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752 of CRK9 are phosphorylated in the cell (Nett et al., 2009; Urbaniak et al., 2013).The list also
contains four proteins that are only conserved within the genus Trypanosoma, indicating that, in
addition to CRK9’s fundamental role in gene expression, there may be additional, trypanosomespecific functions associated with this kinase. Finally, as potential direct links to the trans
splicing mechanism, polyubiquitin-binding protein 2 (PABP2) and the SR protein TSR1 were
identified.

	
  

107

Figure 4.1. Tandem affinity purification of CRK9.
(A) Schematic depiction (not to scale) of the CRK9 locus in procyclic TbC9ee cells that exclusively
express CRK9-PTP and no untagged CRK9. In these cells one wild-type CRK9 allele (open box) was
R
knocked out by a hygromycin phosphotransferase gene (HYG , striped box). Integration of plasmid
CRK9-PTP-NEO introduced the PTP sequence (black box) and the neomycin phosphotransferase
R
(NEO ) to the second allele. Smaller gray boxes indicate gene flanks for RNA processing signals and
checkered boxes depict CRK9 sequences encoded in the plasmid.
(B) Immunoblot of whole cell lysates of wild-type trypanosomes and of TbC9ee cells, detecting CRK9 and
CRK9-PTP, respectively, with the newly generated anti-CRK9 polyclonal immune serum. On the same
blot, phosphorylated (p) and unphosphorylated RPB1 was detected as a loading control with a polyclonal
antibody, and CRK9-PTP specifically with the peroxidase anti-peroxidase reagent (PAP) that binds to the
ProtA domains of the PTP tag.
(C) Immunoblot monitoring of the CRK9-PTP purification detecting CRK9-PTP in crude extract (Inp) and
the flowthrough of IgG affinity chromatography (FT-IgG), and CRK9-P in TEV protease eluate, the
flowthrough of the anti-ProtC immunoaffinity chromatography (FT-ProtC) and the final eluate (Elu) with
the monoclonal HCPC4 anti-ProtC antibody. The x-values indicate relative amounts analyzed.
(D) Protein analysis of the CRK9-PTP purification. Proteins of crude extract, the TEV eluate and the final
eluate were separated on 10-20% SDS polyacrylamide gel and first stained with Sypro Ruby and,
subsequently, with Coomassie blue (right panel). Marker sizes in kDa are indicated on the left.
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Table 4.1 Mass spectrometric identification of CRK9 co-purified proteins

Rank Annotation 1
.
.

.

1
2
6
19
22
24
28
37
46
50
59
62
69
73
74
77
84
93

CRK9
CYC12
4
protein kinase
5
hypothetical, conserved
4
protein kinase
PABP2
4
protein kinase
CRK9AP
hypothetical, conserved
5
hypothetical, conserved
hypothetical, conserved
MRB1-assoc. protein
NRBD1 (RNA-binding)
5
hypo. conserved
RACK1 (kinase receptor)
5
hypothetical, conserved
PNO1 (pre-rRNA process.)
TSR1, splicing factor

Accession # 1 Mr (kDa)

Score 2 % Coverage emPAI 3

Tb927.2.4510
Tb927.10.9160
Tb927.7.3880
Tb927.9.13970
Tb927.10.350
Tb927.9.10770
Tb927.3.1610
Tb927.3.4170
Tb927.3.3740
Tb927.1.4680
Tb927.10.11600
Tb927.11.6320
Tb927.11.14000
Tb927.7.3080
Tb927.11.11360
Tb927.4.3150
Tb927.9.11840
Tb927.8.900

13,418
9,956
1,797
805
795
724
661
568
525
474
382
353
299
285
285
275
257
226

85.5
71.2
87.0
36.8
58.6
62.2
74.2
13.0
69.1
37.3
66.0
53.2
28.8
47.3
34.7
38.1
24.1
37.4

73.9
43.3
49.7
47.3
35.5
37.8
34.1
37.2
34.4
36.3
21.7
29.3
37.8
31.9
18.7
27.7
32.5
22.1

10.3
8.1
2.1
2.8
1.5
1.7
1.0
5.5
0.8
1.2
0.7
0.6
1.7
1.0
1.0
0.7
1.3
0.6

.
.

.

List of CRK9-PTP co-purified proteins, identified by LC/MS/MS, that were not a common contaminant of
previous tandem affinity purifications, not annotated a ribosomal protein, had a Mascot Score of at least
200 and an emPAI value equal or greater than 0.5. The rank number is according to the complete
protein list in S1 Table. The CRK9 kinase complex subunits are highlighted in gray.
1
Protein annotation and accession numbers are from the T. b. brucei 927 database at
www.TriTrypDB.org, although proteins were identified through the T. b. brucei 427 Lister genome
database whose annotation and assembly is not as complete.
2
The Mascot Score corresponds to -10 x LOG10(P), where P is the absolute probability that the observed
match is a random event.
3
The emPAI (exponentially modified Protein Abundance Index) is a measure for the relative amount of
an identified protein in the final eluate (Ishihama et al., 2005).
4
Dual specificity kinases for tyrosine and serine/threonine phosphorylation.
5
These proteins appear to be conserved only in the genus Trypanosoma.
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To potentially separate the kinase complex from co-purifying proteins, we sedimented
the eluate of a CRK9-PTP purification through a sucrose gradient by ultracentrifugation. While
part of the enzyme and nearly all other co-purified proteins migrated to the bottom of the
gradient, CRK9-P exhibited a strong sedimentation peak in fractions 9-11 (Fig. 4.2A). Protein
bands of ~80, 37 and 15 kDa co-sedimented in these fractions. Since transcriptional CDKs of
other systems are capable of autophosphorylating their T-loop motifs, we carried out a kinase
assay with fractions 9, 11, 13, and 20 detecting disproportionately high CRK9-P phosphorylation
in fractions 9 and 11, indicating that fractions 9-11 contain the active CDK9 complex (Fig. 4.2B).
Mass spectrometry identified the protein of the 37 kDa band, which exhibited a slightly different
sedimentation

profile

than

the

other

two

bands,

as

a

putative

ribosomal

protein

(Tb927.11.2050); it may be a direct interactor of CRK9 within the ribosome. The two other
bands were non-ribosomal proteins: The 80 kDa band contained CYC12 whereas the 15 kDa
band revealed a protein (Tb927.3.4170) whose conservation is conserved only among
kinetoplastid organisms and which we termed CRK9-associated protein or CRK9AP
(Attachment 3, S2 Figure). To enable verification of these protein identifications by reciprocal
co-immunoprecipitation, we manipulated one CYC12 allele in TbC9ee cells, fusing an HA tag Cterminally to CYC12, and raised a polyclonal immune serum in rats against recombinant, GSTtagged CRK9AP (Attachment 3, S3 Figure). As shown in figure 2C, precipitation of either CRK9PTP, CYC12-HA or CRK9AP specifically co-precipitated the other two proteins, indicating the
presence of a tripartite enzyme complex.
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Figure 4.2 CRK9 interacts and co-sediments with two unannotated proteins.
(A) CRK9-PTP tandem affinity-purified material was sedimented through a 10-40% linear sucrose
gradient by ultracentrifugation and fractionated into 20 aliquots from top to bottom. Proteins from each
fraction were separated by SDS-PAGE and stained with sypro ruby. Protein bands were excised and
identified by LC/MS/MS. Arrows point to the CYC12 and CRK9AP bands which co-sediment with CRK9 in
fractions 9/10. The 35 kDa band with a peak in fractions 10/11 was found to be the putative ribosomal
protein L5 (Tb927.9.15110/15150).
(B) Kinase assay with materials from indicated fractions suggest autophosphorylation of CRK9.
(C) Reciprocal co-IP assays of extracts prepared from a cell line in which CRK9 was exclusively PTPtagged and an HA tag sequence was inserted at the 3’end of one CYC12 allele. The precipitate (P) was
loaded at a fourfold excess relative to extract (Inp) and supernatant (S). Detection of the RNA pol II
transcription factor TFIIB served as a negative precipitation control.
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3.2 CYC12 is a new L-type cyclin
Mammalian cyclin L homologues exclusively partner with CDK11. There are two human
cyclin L paralogs, L1 and L2, which share 60% identity. These proteins have a ~200 amino acidlong N-terminal composite CCL1 domain that comprises the highly conserved Cyclin_N domain,
the less conserved Cyclin_C domain (Nugent et al. 1991) and additional sequence
conservation, characteristic for transcriptional cyclins, around these domains. In addition, cyclin
L is an SR-related protein that features a conserved, C-terminal, highly positively charged
arginine/serine-rich RS domain with repetitive “SR” dipeptide motifs (Fig. 4.3A). A standard
protein-protein BLAST search of the human proteome with the T. brucei CYC12 sequence
returned L1 and L2 cyclins (E=2e-09) but no other cyclins. A multiple sequence alignment of the
CCL1 domain of cyclin L orthologs from model organisms and of kinetoplastid CYC12
sequences showed convincing sequence conservation across the whole domain, although, as
expected, the Cyclin_C domain was less well conserved (Attachment 3, S4 Figure).
Interestingly, both cyclin domains were disrupted by extensive kinetoplastid-specific sequence
insertions which likely prevented recognition of CYC12 as a cyclin in trypanosomatid genome
annotations and of the cyclin domains by the NCBI BLAST algorithm (Fig. 4.3A, Attachment 3,
S4 figure). Analysis of the C-terminus of CYC12 revealed a strong reduction of SR dipeptide
motifs when compared to the human cyclin L domain (21 versus 7). However, conserved among
all kinetoplastid CYC12 orthologs, the C-terminal domain has a similarly high isoelectric point of
~12 as its counterparts in other eukaryotes.
To substantiate the notion that CYC12 is an L-type cyclin, we generated a phylogenetic
tree with the sequence alignment of all human cyclin sequences and four representative
kinetoplastid CYC12 sequences. To avoid a potential bias of the charged cyclin L/CYC12 Cterminal domain, we restricted the analysis to the CCL1 domain. As expected, CYC12
sequences unambiguously partitioned with the transcriptional cyclins and formed a branch with
human L cyclins with a bootstrap value of 87% (Fig. 4.3B). A more extensive phylogenetic
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analysis of complete sequence alignments of cyclins of model organisms and all known
kinetoplastid CYC12 orthologs revealed a similar tree although the bootstrap value of the cyclin
L/CYC12 cluster was reduced to 53% (Attachment 3, S5 Figure). Taken together, these data
strongly indicate that kinetoplastid CYC12 represents a L-type cyclin.
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Figure 4.3 Cyclin CYC12 is an L-type cyclin.
(A) Schematic drawing to scale of the human L1 and T. brucei CYC12 cyclins. The two cyclin folds (blue)
are embedded in the CCL1 domain (green). The charged RS domain (red) was defined by a hydrophilicity
Kyte & Doolittle blot score of < -2. Black lines indicate SR or RS dipeptides. Both cyclin domains of
CYC12 are disrupted by insertions.
(B) Phylogenetic tree, generated by the maximum likelihood algorithm and based on a multiple sequence
alignment of the cyclin domains of human cyclins and of CYC12s from T. brucei (Tb), T. cruzi (Tc), L.
major (Lm) and the bodonid Bodo saltans (Bs) (for accession numbers see Figure S5). Cyclins involved in
the cell cycle and in transcriptional control are indicated. Bootstrap values are indicated in percentages
and were derived from 1000 replicates. The common branch of human cyclins L and kinetoplastid
CYC12s is drawn in red.
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3.3 CYC12 and CRK9AP are functional partners of CRK9
To test whether CYC12 and CRK9AP are of similar importance as CRK9 for
trypanosome gene expression, we generated PF and BF cell lines for conditional silencing of
each gene. Since the culture growth defects upon gene silencing were very similar between the
lines for each gene (data not shown), we analyzed the knockdown phenotype in detail in one of
those cell lines. In PFs, CYC12- and CRK9AP-silencing strongly affected culture growth two
days after induction of the gene knockdown. Although the defects were delayed by one day
when compared to the CRK9 knockdown (Badjatia et al., 2013a), trypanosome numbers
diminished after the second day of induction (Figure 4.4A). The decline of PF trypanosome
numbers was not as strong in CYC12-silenced cells as it was with CRK9- and CRK9APsilenced cells, indicating a different dynamic of the lethal defect. In BFs, this variation of gene
silencing was not observed and the knockdown of each of the three genes was even more lethal
than in PFs. As was observed previously in the CRK9 knockdown (Badjatia et al., 2013a),
CYC12 or CRK9AP silencing caused a culture growth defect within 24 hours of induction and,
subsequently, cell numbers rapidly declined with no viable cells left on day 4 after induction
(Attachment 3, S6 figure, (Badjatia et al., 2013a). Thus, we concluded that CYC12 and CRK9AP
are generally essential genes in T. brucei.
The trans splicing block upon CRK9 silencing became apparent by a decrease of mature
mRNA and the Y structure intermediate, the concomitant increase of unspliced pre-mRNA, and
the accumulation of SL RNA with a hypomethylated cap structure (Badjatia et al., 2013a).
Analyses of total RNA from CYC12- and CRK9AP-silenced cells revealed similar defects
(Figure 4.4B). As analyzed for α tubulin and RPB7 (RPB7 encodes a subunit of RNA pol II) by
RT-PCR, the total coding RNA declined upon gene silencing whereas the abundance of
unspliced RNA from these genes strongly increased during this period. Furthermore, primer
extension assays of the same RNA preparations showed that, in both knockdowns, SL RNA
increased, predominantly in its hypomethylated form, whereas the Y structure intermediate
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declined during the time course experiments (Figure 4.4B). These experiments clearly indicated
a block of trans splicing before the first transesterification step in both gene knockdowns.
Analysis of α tubulin RNA in BFs revealed the same trans splicing defect (Attachment 3, S6
Figure).
Another specific effect of CRK9 silencing was dephosphorylation of the RNA pol II
subunit RPB1 (Badjatia et al., 2013a). To monitor the phosphorylation status of this RNA pol II
subunit, we probed an immunoblot of whole cell lysates with a specific immune serum raised
against the C-terminal domain of RPB1 (Badjatia et al., 2013a). As shown in Figure 4.4C, the
signal for phosphorylated RPB1 clearly decreased upon both CYC12- and CRK9AP-silencing
whereas the dephosphorylated signal concomitantly increased. Note that the disproportional
increase of the unphosphorylated RPB1 signal likely is due to an increase of antibodyrecognizable epitopes since the immune serum was raised against unphosphorylated protein.
Finally, as described previously, CRK9 silencing leads to an atypical rounding up of cells
(Badjatia et al., 2013a; Gourguechon and Wang, 2009). Virtually all PFs that survive 3 days of
CRK9 silencing exhibit a round shape (Attachment 3, S7 figure) reminiscent of FAT cells that
were observed in the discovery of the RNA interference pathway upon tubulin gene knockdowns
(Ngo). Silencing of CYC12 and of CRK9AP resulted to the same extent in the same
characteristic phenotype (Attachment 3, S7 figure). Rounding up of cells was also observed in
BFs in all three gene knockdowns although the number of round cells detected after three days
of induction was limited to 81%, 55%, and 50% (n = 50) in CRK9-, CYC12-, and CRK9APsilenced cells, respectively. Possibly, the rapid onset of the deleterious effect in BFs prevented
rounding up of all cultured cells.
Taken together, CYC12 and CRK9AP silencing resulted in the same block of trans
splicing and RPB1 dephosphorylation in both PFs and BFs as observed previously upon CRK9
silencing. Moreover, all three gene knockdowns caused cells to round up, an atypical death
phenotype. These data demonstrate that CRK9, CYC12 and CRK9AP are functional partners in
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facilitating SL trans splicing in trypanosomes. Moreover, since this function requires an intact Tloop of CRK9 (Badjatia et al., 2013a), our data indicate that all three proteins are required in
vivo for CRK9-dependent phosphorylation.
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Figure 4.4 CYC12 and CRK9AP are functional partners of CRK9.
(A) Cumulative culture growth curves were obtained for CYC12 and CRK9AP silencing in the absence
and presence of doxycyline (dox), the gene knockdown-inducing compound. For each knockdown a
representative growth curve is shown.
(B) Analysis of total RNA prepared from non-induced cells and cells in which CYC12 or CRK9AP were
silenced for 1, 2 or 3 days. CYC12 or CRK9AP mRNA as well as α tubulin and RPB7 mRNA were
analyzed by reverse transcription of oligo-dT and semi-quantitative PCR, whereas unspliced, pre-mRNA
of α tubulin and RPB7 were analyzed by reverse transcription of random hexamers and by PCR using an
oligonucleotide upstream of the SL addition site. rRNA was visualized by ethidium bromide staining after
separation in an agarose gel. SL RNA, U2 snRNA and the Y structure intermediate were detected by
primer extension assays using a SL RNA and a U2 snRNA-specific primer in the same reactions.
(C) Anti-RPB1 immunoblot analysis of whole-cell lysates prepared from CRK9AP-silenced cells. Detection
of the similar-sized RNA pol I subunit RPA1 served as a loading control.
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3.4 CRK9AP silencing causes rapid co-loss of CRK9 and CYC12
A tripartite CRK9 enzyme complex would be highly unusual since, to our knowledge,
eukaryotic CDK7 is the only CDK whose enzyme activity depends on three proteins. Thus, to
understand the specific function of CRK9AP, we investigated the effect of CRK9AP ablation on
the expression of its functional partners. While the CRK9 and CYC12 RNA abundances were
unaffected by CRK9AP silencing in both PFs and BFs (data not shown), both proteins were
rapidly lost upon CRK9AP depletion (Figure 4.5). This result indicates that CRK9AP is important
for CRK9 complex assembly and/or integrity. Alternatively, CRK9AP may mediate nuclear
import of the complex, although the amino acid sequence did not reveal a conventional nuclear
localization signal (data not shown).
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Figure 4.5 CRK9AP depletion results in rapid co-loss of CRK9 and CYC12. Immunoblot of whole cell
lysates derived from non-induced (n.i.) and CRK9AP-silenced PF and BF trypanosomes. The arrow
indicates the gene knockdown or CRK9AP. Detection of the class I transcription factor I subunit 6
(CITFA6) served as a loading control.
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3.5 Validation of CRK9 as a potential chemotherapeutic target in the mouse model
Since CRK9 enzyme activity is essential for SL trans splicing in T. brucei (Badjatia et al.,
2013a) and assembles into a unique complex with its functional CYC12 and CRK9AP partners,
this CDK is a promising chemotherapeutic target for trypanosomatid parasites. Thus, we
validated CRK9 as a drug target in the mouse host. We first used so-called single marker BF
(smBF) trypanosomes, the parent line for conditional gene silencing experiments (Wirtz et al.,
1999), to determine their lethal dose in intraperitoneal BALB/c mouse infections. Injection of 2
million smBFs was lethal to all mice tested within 3-5 days (data not shown). Accordingly, when
we repeated the mouse infections with a cell line in which doxycycline induced the expression of
CRK9 3/ UTR dsRNA (Badjatia et al., 2013a), mice died on days 4 and 5 in the absence of
doxycycline (n=15). However, when mice (n=16) obtained doxycycline in their drinking water,
they all survived for two weeks, the time doxycycline was administered (Figure 4.6A).
Interestingly, once doxycycline was removed from the drinking water, six out of sixteen mice
survived for another month until the experiment was terminated, indicating that they were fully
cured by the doxycycline treatment (data not shown). To control that this effect was due to
CRK9 ablation and not an off-target effect, we introduced a CRK9 transgene, which was
resistant to RNAi due to a different 3/ UTR sequence, into the CRK9 knockdown cell line. As
expected, these cells were not affected by doxycycline and were lethal to all mice in the
absence (n=15) and presence (n=15) of doxycycline (Figure 4.6B). Thus, we concluded that
inhibition of CRK9 is a valid strategy to combat trypanosome infections of mammalian hosts.
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Figure 4.6 Validation of CRK9 as a drug target in the mouse.
(A and B) Two cell lines derived from the T. brucei brucei 427 smBF cell line were used for mouse
infection studies. The line on the left (A) harbored a construct for conditional expression of dsRNA that
/
targets the 3 UTR of the CRK9 mRNA. This line was further modified (B) by targeted integration of a
/
plasmid into the endogenous CRK9 locus that fused a functional HA tag sequence and the 3 UTR of
/
RPA1 to the 3 end of one CRK9 allele, making the corresponding mRNA resistant to the RNAi response.
As the survival graphs of infected mice show in the bottom panels, doxycycline treatment rescued every
single mouse when CRK9 was depleted. This effect was completely abolished upon generating an RNAiresistant CRK9 gene in the same trypanosomes.
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4. Discussion
CRK9 is the first CDK of trypanosomes known to be crucial for the parasite-specific path
of gene expression. Ablation of CRK9 blocks SL trans splicing, leads to an accumulation of SL
RNA with a hypomethylated cap structure and causes dephosphorylation of RPB1, the largest
subunit of RNA pol II, indicating that CRK9 is a gene expression regulator of central importance
(Badjatia et al., 2013a). Here we identified two un-annotated proteins that co-purified and cosedimented with CRK9. Moreover, silencing of the respective genes was lethal and
recapitulated the defects seen upon CRK9 ablation, identifying these two proteins as functional
partners of CRK9 in vivo and suggesting that CRK9 may function in a tripartite enzyme
complex. Multiple sequence alignments and phylogenetic evidence suggests that the larger
protein is an L-type cyclin that was not recognized before due to unique sequence insertions in
both its Cyclin_N and Cyclin_C domains. The smaller protein, CRK9AP, is conserved only
among kinetoplastids without an established sequence motif.
CRK9 functionally partners with CYC12, which most likely is the kinetoplastid ortholog of
human cyclin L. Interestingly, a standard protein-protein BLAST search of the human or
Drosophila melanogaster proteome with the T. brucei CRK9 sequence returned various
isoforms of CDK11 (E=5e-43 & 2e-37 respectively). Since Cyclin L is a known functional partner of
CDK11 (Loyer et al., 2008), this together with the phylogenetic clustering of CRK9 with
CDK10/CDK11 in a previous study with a bootstrap of 45% (Monnerat et al., 2013), suggests
that CRK9 is a divergent kinetoplastid ortholog of CDK11 kinase of higher eukaryotes. The
members of CDK10/11 family have a conserved PIT/SSLRE-helix motif (Trembley et al., 2004)
instead of the PSTAIRE-helix box that is characteristic of the cell cycle-related CDKs (Morgan
and De Bondt, 1994) . This helix box is crucial for CDK-cyclin interaction and the activation of
kinase subsequent to cyclin binding (Jeffrey et al., 1995; Morgan and De Bondt, 1994).
Interestingly, while CRK9 appears to be related to CDK10/11 clade in phylogenetic analyses
(Monnerat et al., 2013), all CRK9 orthologs from kinetoplastids have a conserved PPYLLRE (or
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PPYMLRE for Leishmania species) motif instead of PITSLRE motif that is characteristic of
CDK10/CDK11 branch.
CDK11p110 isoform is essential for pre- mRNA splicing both in vivo and in vitro splicing
assays (Choi et al., 2014; Hu et al., 2003). CDK11p110 /cyclin L associates with RNA pol II, CK2,
transcription elongation factors as well as several splicing factors including PRP19 and the SR
proteins: RNPS1, 9G8 and ASF/SF1 (Choi et al., 2014; Trembley et al., 2002; Trembley et al.,
2003). In addition, 9G8, which is a crucial splicing factor (Cavaloc et al., 1994), was identified as
a substrate for CDK11p110 both in vitro and in vivo (Trembley et al., 2003). Our data clearly
shows that CRK9 and the associated L-type cyclin, CYC12 are crucial for trans splicing in T.
brucei and this suggests some functional overlap between trypanosome CRK9 and metazoan
CDK11. Consistent with this several SR proteins including TSR1 that functions in splicing in
trypanosomes and the trypanosome ortholog of ASF/SF1 were co-purified with CRK9. Since the
function of SR proteins in splicing is typically regulated by phosphorylations (Shepard and
Hertel, 2009), it will be interesting to find out if one of these co-purified SR proteins is a
substrate of CRK9.

Interestingly, a recent study shows that CDK11 homolog in S. pombe

regulates transcription by phosphorylating mediator subunits (Drogat et al., 2012). These
phosphorylations determined the assembly of the Mediator complex, an essential PIC
component. This function of CDK11 appears to be unique to budding yeast, since it is either
absent or yet to be identified for CDK11 from other eukaryotes. Nonetheless, all characterized
CDK11 orthologs are implicated in the regulation of gene expression but during evolution they
seem to have acquired specialized roles in gene expression in different organisms.
CRK9 is an unusual CDK since unlike most other CDKs that require only cyclin as a
functional partner, CRK9’s specific function seems to be dependent on both CYC12 and
CRK9AP and it consistently associates with both proteins during purifications. To the best of our
knowledge, CDK7 is the only other CDK that forms a bona fide tripartite complex called the CAK
complex, which is crucial for both gene expression and the cell cycle (Fisher, 2005). Could
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CRK9/CYC12/CRK9AP trimeric complex represent a divergent CAK complex? Similar to CAK’s
function in phosphorylation of RPB1’s CTD, we show that CRK9 as well as CYC12 and
CRK9AP are essential for RPB1 phosphorylations in T. brucei. However, while CAK mediated
CTD phosphorylations are important for RNA pol II transcription, we did not observe a specific
defect in RNA pol II transcription in CRK9-depleted cells. Moreover, CRK9 appears not to
interact with TFIIH because our long list of CRK9 co-purified proteins did not reveal a single
TFIIH subunit (Table S1), CRK9 was not discovered in eluates of several independent TFIIH
tandem affinity purifications (Lecordier et al., 2007; Lee et al., 2010; Lee et al., 2009), and CRK9
was not found to occupy the SLRNA promoter in vivo, the only known T. brucei promoter that
assembles a RNA pol II PIC (Badjatia et al., 2013a). Another function of CAK is to
phosphorylate and activate the CDKs involved in cell cycle control (Fisher, 2005). If the trimeric
CRK9 complex is important for activation of cell cycle-relevant CDKs of trypanosomes is yet to
be tested. Interestingly, CRK9 does seem to function in the cell cycle, and was shown to be
important for proper basal body segregation during cytokinesis (Gourguechon and Wang, 2009).
However, further work is required to understand the role of CRK9 in cell cycle regulation in
trypanosomes.
What is the functional role of CRK9AP in the trimeric CRK9 complex? In the CAK
complex, the presence of MAT1 significantly stimulates the kinase activity of CDK7 towards
CTD. MAT1 interacts directly with both Cyclin H and CDK7 (Busso et al., 2000), and functions
as an assembly factor (Fisher et al., 1995; Tassan et al., 1995) Interestingly, in MAT1 deficient
cells, the levels of CDK7 and cyclin H are significantly reduced (Korsisaari et al., 2002; Rossi et
al., 2001; Sano et al., 2007). In this context, CRK9AP appears to function in a similar manner to
MAT1, since presence of CRK9AP is crucial for the stability of both CRK9 and CYC12.
However, while a N-terminal RING finger motif is a conserved feature of MAT1 proteins from
different organisms (Busso et al., 2000), CRK9AP lacks any obvious functional motif and it is
conserved only amongst kinetoplastids. Another group of small proteins that are implicated in
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assembly of CDK-cyclin complexes is the Cip/Kip family of CDK inhibitor (CKI), which was
shown to important for assembly and activation of CDK4/6 - cyclin D complexes (Cheng et al.,
1999; LaBaer et al., 1997). Future work will determine if CRK9AP is a divergent ortholog of
MAT1 or Cip/Kip proteins or it is a unique kinetoplastid-specific protein dedicated for the
assembly/stability of CRK9 complex.
In summary, CRK9 assembles in a unique complex together with CYC12 and CRK9AP
and regulates trans splicing and possibly cell cycle in trypanosomes. We also show that CRK9
is crucial for trypanosomes to establish infection in a mouse model. Since trans splicing is a
parasite-specific process, and kinases including CDKs are considered suitable drug targets,
CRK9 is an attractive drug target against trypanosomatid parasites. It is interesting to note that
both CRK9 and CYC12 have large kinetoplastid specific insertions in their kinase and cyclin
domain respectively. These insertions could be a result of the complex’s specialized function in
trans splicing and might mediate association with trypanosome specific splicing proteins.
Nonetheless, the unique features of CRK9 complex may be exploited to selectively inhibit this
CDK in a parasite-specific manner. In the future, identification of a substrate(s) of CRK9 would
help to delineate the mechanism by which CRK9 affects gene expression. Potential substrate
candidates, including TSR1, are listed in Table 1.

5. Methods
5.1 DNAs
For gene silencing of CYC12 and CRK9AP, their coding regions from position 21 to
position 520 and from position 1 to position 414, were integrated in stem-loop arrangements into
the pT7-stl vector (Brandenburg et al., 2007) to reveal plasmids T7-CYC12-stl and T7-CRK9APstl, respectively. For HA-tagging of CYC12, 1140 bp of the 3/-terminal CYC12 coding sequence
was inserted into the pC-HA-BLA vector (Lee et al., 2007), utilizing the vector's ApaI and NotI
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restriction sites. The resulting vector, named pCYC12-HA-BLA, was linearized with BamHI
before transfection. DNA oligonucleotides that were used in semi-quantitative and quantitative
reverse transcription (RT)-PCR and in primer extension assays are specified in (Ambrosio et al.,
2015; Badjatia et al., 2013a).
5.2 Cells
BF and PF Trypanosoma brucei cell culture was maintained, transfected, and cloned as
described before (Lee et al., 2007; Park et al., 2011). Clonal cell lines for conditional CYC12
and CRK9AP silencing experiments were generated by transfection of linearized and RRNA
locus-targeted T7-CYC12-stl and T7-CRK9AP-stl constructs, respectively. For PF and BF lines,
the constructs were transfected into 29-13 and smBF cells, respectively (Wirtz et al., 1999).
dsRNA synthesis for gene knockdowns was induced with 2 µg/ml of doxycycline during RNAi
experiments. Cells were counted and diluted daily to 2 × 106 cells/ml for PF culture and to 2 ×
105 cells/ml for BF culture. CYC12 was fused C-terminally with an HA tag in CRK9AP PF and
BF knockdown cell lines by transfection of pCYC12-HA-BLA.
5.3 RNA analysis
Semi-quantitative and quantitative RT-PCR was performed to determine relative
amounts of various RNAs during gene silencing experiments. Total RNA was prepared from 8 x
107 PF or 1 x 108 BF cells using the TRIzol reagent (Invitrogen) or the hot-phenol method
(Nguyen et al., 2007) respectively. Reverse transcription reactions were carried out with
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s specifications.
Oligo-dT and random hexanucleotides (Roche) were used in reverse transcription for the
analysis of mature mRNA and unspliced pre-mRNA, respectively. For each semi-quantitative
PCR, the number of cycles for the linear amplification range was determined empirically. For
RNA quantifications, cDNA preparations were analyzed by qPCR assays using the SsoFast
EvaGreen Supermix (BioRad) on a CFX96 cycler (BioRad) according to the manufacturer’s
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recommendations.

For

each

amplification,

triplicate

qPCR

samples

were

analyzed.

Oligonucleotide pairs that were used in qPCR reactions were evaluated for specificity by both
agarose gel electrophoresis and melting curve analysis. Standard curves for oligonucleotide
pairs were obtained from serial dilutions of non-induced cDNA samples and ranged in their
coefficient of determination (R2) value from 0.98 to 1.0. Samples were standardized with the
18S rDNA result from random hexamer-derived cDNA. The methylation status of SL RNA cap4
was analyzed by a modified primer extension as described previously (Badjatia et al., 2013a).
5.4 Protein analysis
The polyclonal anti-CRK9 and anti-CRK9AP immune sera were generated by
immunization of rats (Schimanski et al., 2006) with N-terminal glutathione S-transferase fusion
proteins, either comprising amino acids 100 to 300 of CRK9 or the entire coding region for
CRK9AP that were expressed in Escherichia coli strain BL21Star(DE3) and purified by
glutathione affinity chromatography (GE Healthcare). The CRK9 sequence was chosen due to
its hydrophilic nature as determined by a hydrophilicity blot using the Kyte & Doolittle algorithm
on the ProtScale server at http://web.expasy.org/protscale/.
CRK9 and CRK9AP were detected on immunoblots by 1:1000 dilution of the respective
immune sera followed by a 1:5000 dilution of a monoclonal, peroxidase-labeled anti-rat IgG
secondary antibody (Vector Laboratories). HA-tagged protein was detected with a commercial
monoclonal rat anti-HA antibody (Roche), RPA1 with a polyclonal rabbit immune serum and
CITFA6 with a polyclonal rat immune serum as described previously (Nguyen et al., 2012;
Schimanski et al., 2003). Blots were developed with BM chemiluminescence blotting substrate
(Roche) according to the manufacturer's protocol. PTP-tagged proteins were detected either
with the peroxidase anti-peroxidase reagent (Sigma) or the monoclonal anti-ProtC antibody
HPC4 (Roche).
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Extract preparation and tandem affinity purification of PTP-tagged CRK9 was carried out
according to the standard PTP purification protocol (Schimanski et al., 2005a). Purified proteins
were separated on SDS–10 to 20% polyacrylamide gradient gels (BioRad) and stained either
with Sypro ruby (BioRad) or with Coomassie blue (Gelcode Coomassie stain; Thermo Fisher
Scientific). For the sedimentation analysis of the CRK9 complex, the final eluate of the CRK9
PTP purification was concentrated, dialyzed against E-80 buffer and sedimented in a linear 1040% sucrose gradient as described before (Ambrosio et al., 2015). Briefly, the gradient was
fractionated from top to bottom in twenty aliquots of 200µl each. Proteins from 150µl of each
fraction were collected by a hydrophobic resin (StrataClean, Stratagene), and resuspended in
SDS loading buffer for electrophoresis. The remaining 50µl aliquots were dialyzed against E-20
buffer (20 mM HEPES-KOH pH 7.7, 20 mM potassium glutamate, 20 mM potassium chloride, 3
mM magnesium chloride, 0.2 mM EDTA, 0.5 mM EGTA and 4 mM DTT) and used for in vitro
kinase assays. Proteins that co-purified with CRK9-P were analyzed by LC/MS/MSfrom the gel
lane of the final eluate by the Keck facility of Yale University as described previously (Ambrosio
et al., 2015). Individual protein bands obtained after sucrose gradient sedimentation were
analyzed equivalently.
5.5 Phylogenetic analysis
Amino acid sequences spanning

the CCL1 domain (COG5333) of various human

cyclins and of CYC12 from T. brucei, T. cruzi, Leishmania major and Bodo saltans were aligned
using the multiple sequence alignment tool ClustalW at the EMBL European Bioinformatics
Institute (http://www.ebi.ac.uk/Tools/msa/muscle/). The alignment was uploaded onto the
graphical

user

interface

Seaview

(Gouy

et

al.,

2010)

(http://pbil.univ-

lyon1.fr/software/seaview.html) to perform the phylogenetic analysis. A maximum likelihood tree
was generated employing the LG empirical matrix (Le and Gascuel, 2008) with optimized
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invariable sites, substitution rate categories of 4, estimated gamma distribution and model
equilibrium frequencies. Bootstrapping was performed with 1000 replicates.
5.6 Mouse infections
6-10 weeks old female BALB/c mice (The Jackson Laboratory, Bar Harbor, ME), were
injected intraperitoneally with 2 × 106 cells in 0.1 ml of cold phosphate buffer saline (PBS) that
was supplemented with 1% glucose. To ensure cell viability, the parasites and syringes were
kept on ice prior to injections. To induce RNAi, mice were given 1 mg/ml doxycycline in their
drinking water 2 days prior to injection and for up to 2 weeks post-injection. Drinking water was
replaced daily with fresh doxycycline solution. Mice were monitored daily and sacrificed upon
signs of distress Blood samples, randomly taken from sick mice, were investigated
microscopically, revealing, in each case, parasitemia ranging from 0.8 to 1 x 109 trypanosomes
per ml of blood.
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Chapter V
The spliceosomal PRP19 complex of trypanosomes

1. Abstract
In trypanosomes, mRNAs are processed by spliced leader (SL) trans splicing, in which a
capped SL, derived from SL RNA, is spliced onto the 5/ end of each mRNA. This process is
mediated by the spliceosome, a large and dynamic RNA-protein machinery consisting of small
nuclear ribonucleoproteins (snRNPs) and non-snRNP proteins. Due to early evolutionary
divergence, the amino acid sequences of trypanosome splicing factors exhibit limited similarity
to those of their eukaryotic orthologs making their bioinformatic identification challenging. Most
of the ~60 protein components that have been characterized thus far are snRNP proteins
because, in contrast to individual snRNPs, purification of intact spliceosomes has not been
achieved yet. Here, we characterize the non-snRNP PRP19 complex of trypanosomes. We
identified a complex that contained the core subunits PRP19, CDC5, PRL1, and SPF27, as well
as PRP17, SKIP and PPIL1. Three of these proteins were newly annotated. The PRP19
complex was associated primarily with the activated spliceosome and, accordingly, SPF27
silencing blocked the first splicing step. Interestingly, SPF27 silencing caused an accumulation
of SL RNA with a hypomethylated cap that closely resembled the defect observed previously
upon depletion of the cyclin-dependent kinase CRK9, indicating that both proteins may function
in spliceosome activation.

2. Introduction
Nuclear pre-mRNA splicing, in which introns are removed from exonic sequences, is an
essential step for the expression of many eukaryotic genes. The splicing process, which occurs
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by two consecutive transesterifications, is carried out by the spliceosome, a large and highly
dynamic complex of the U1, U2, U4/U6 and U5 small nuclear ribonucleoproteins (snRNPs) and
non-snRNP proteins (Smith et al., 2008; Wahl et al., 2009). After recognition of the splice sites
and before the splicing process, a large spliceosomal complex is formed on the pre-mRNA that
is known as the B complex, which contains all five snRNPs and many non-snRNP proteins.
Subsequently, substantial structural and compositional alterations, including the exit of the U1
and U4 snRNAs and the exchange of protein components, leads to spliceosome activation. The
first

transesterification

generates

spliceosomal

complex

C

which,

after

additional

rearrangements, carries out the second splicing step. While it has recently been established that
RNA catalyzes the splicing reaction (Fica et al., 2013), there are more than 200 spliceosomeassociated proteins known in the human system several of which are indispensable for the
splicing process (Hegele et al., 2012; Wahl et al., 2009). Among those is PRP19, a highly
conserved splicing factor that is essential for the activation of the spliceosome (Chan et al.,
2003; Makarova et al., 2004; Ohi and Gould, 2002). PRP19’s role in RNA splicing is through a
heteromeric protein complex known as the Nineteen Complex (NTC) in the budding yeast
Saccharomyces cerevisiae (Tarn et al., 1994) and the PRP19/CDC5L complex in humans
(Grote et al., 2010; Makarova et al., 2004). Although the protein composition of the human and
yeast complexes differ, they share the subunits PRP19, CDC5L/Cef1p (human/yeast
nomenclature), SPF27/Snt309, and PRL1/Prp46. In the human system, these subunits were
shown to form a salt stable core complex (Grote et al., 2010). Additionally, there are 3-4 nonhomologous proteins in each system that are considered bona fide subunits of these complexes
(Chanarat and Strasser, 2013) which, from here on, will be generally referred to as “PRP19
complexes”. Moreover, several other spliceosomal proteins were found to consistently co-purify
with the PRP19 complex, although their association appears to be less stable than that of the
bona fide subunits (Makarov et al., 2002; Ohi et al., 2002). In the human system, these proteins
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have been termed “PRP19-related” proteins, and they include factors such as SKIP, SYF1,
CRN, ISY1, etc. (Wahl et al., 2009).
Pre-mRNA splicing has been a focus in the protozoan parasites Trypanosoma brucei,
Trypanosoma cruzi, and Leishmania spp., which cause devastating human diseases, because
maturation of each and every mRNA in these organisms requires spliced leader (SL) trans
splicing (Gunzl, 2010; Michaeli, 2011; Preußer et al., 2012). Protein coding genes in these
trypanosomatids are arranged in long tandem arrays that are polycistronically transcribed.
Individual mRNAs are then processed from precursor RNA by SL trans splicing and
polyadenylation. In trans splicing, the SL is derived from the 5/ end of the small nuclear SL RNA
and spliced onto the 5/ end of each mRNA. The SL carries a so-called cap4 structure which
comprises a standard m7G cap nucleotide and methylations of the first four SL nucleotides
(Bangs et al., 1992). Cap4 formation appears to be a pre-requisite for trans splicing (McNally
and Agabian, 1992; Ullu and Tschudi, 1991) although individual methylations are dispensable
for the process (Arhin et al., 2006a; Arhin et al., 2006b; Zamudio et al., 2007; Zamudio et al.,
2006). SL trans splicing is achieved by the same two transesterification reactions as in “cis
splicing” (Murphy et al., 1986; Sutton and Boothroyd, 1986). Furthermore, dependence of trans
splicing on U snRNAs (Tschudi and Ullu, 1990) and on orthologs of various spliceosomal factors
(Liang et al., 2006; Luz Ambrósio et al., 2009; Tkacz et al., 2008; Tkacz et al., 2010)
demonstrated that trans splicing in trypanosomes is carried out by a spliceosomal complex that
is similar to its human and yeast counterparts. However, characterization of the trypanosomal
spliceosome has been difficult because, so far, a larger spliceosomal complex could not be
quantitatively purified from trypanosomatids. Furthermore, trypanosome protein sequences are
highly divergent from their human and yeast counterparts, making bioinformatic annotation of
proteins and their genes challenging in some cases. Nevertheless, tandem affinity purification of
the T. brucei snRNP proteins SmD1 (Luz Ambrósio et al., 2009), SmB (Palfi et al., 2009), and
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the Leishmania tarentolae snRNP proteins SmD3, LSm3 and U1A (Tkacz et al., 2010) led to the
identification of several new splicing factors increasing the trypanosomatid repertoire of known
spliceosomal proteins to ~60 (Gunzl, 2010; Preußer et al., 2012). Most of these proteins are
snRNP proteins and relatively few non-snRNP proteins have been identified so far, suggesting
that mainly individual snRNPs were purified and that many non-snRNP proteins remained
undetected in these purifications (Gunzl, 2010). PRP19 is such a spliceosomal non-snRNP
protein that was identified by sequence homology and shown to be essential for cell viability,
trans splicing and removal of the PAP (poly A polymerase) intron in T. brucei (Tkacz et al.,
2010). In addition, PRP19 silencing led to hypomethylation of the SL RNA cap. Little is known,
however, about PRP19 complex subunits. While CDC5 (Gunzl, 2010) and PRL1 (Tkacz et al.,
2010) co-purified with splicing complexes and were then identified bioinformatically, an SPF27
ortholog has been elusive. Furthermore, only a few homologs of PRP19-related proteins have
been identified so far (Gunzl, 2010). (Please note that since T. brucei is a parasite of humans,
when possible, we prefer to use the nomenclature of the human system for trypanosome
splicing factors).
Here we have tandem affinity-purified T. brucei PRP19 and mass spectrometrically
identified 47 co-purifying proteins. Among those were 35 spliceosomal orthologs, which included
the three newly annotated proteins SPF27, SKIP, and PPIL1, as well as six proteins which
appear to be conserved only among trypanosomatids. A sedimentation analysis revealed a
stable PRP19 complex of seven subunits that, although containing the four core subunits,
deviated in protein composition from its human and yeast counterparts. As expected, PRP19
complex subunits were primarily associated with the activated spliceosome. Finally, silencing of
SPF27 affected SL RNA cap methylation similarly to the previous PRP19 knockdown. However,
as our data indicate, cap4 methylation defects may be a general phenomenon of blocking
spliceosome activation in trypanosomes.
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3. Materials and Methods

3.1 DNAs
pPRP19-PTP-NEO was generated by inserting 627 bp of the C-terminal PRP19 coding
region (position 901 to position 1527 relative to the translation initiation codon) into the pC-PTPNEO tagging construct (Schimanski et al., 2005a) using the ApaI and NotI restriction sites.
pCDC5-PTP-NEO, pSPF27-PTP-NEO, and pORC1-PTP-NEO were obtained analogously by
cloning 519 bp (position 1663 to position 2181), 695 bp position -53 to position 642) and 326 bp
(position 983 to position 1308) of the CDC5, SPF27 and ORC1 genes into pC-PTP-NEO,
respectively. For pSPF27-HA-BLA, the 695 bp DNA fragment was cloned into pC-HA-BLA
(Nguyen et al., 2007), again using the ApaI and NotI restriction sites. The conditional
knockdown constructs pT7-SPF27-stl and pT7-ORC1-stl were obtained by cloning, respectively,
571 bp (position 7 to position 577) and 526 bp (position 7 to position 532) of the SPF27 and
ORC1 coding regions in a stem-loop arrangement into the vector pT7-stl (Brandenburg et al.,
2007). The constructs for conditional knockdown of LSm2 and CRK9 have been described
previously (Badjatia et al., 2013a; Luz Ambrósio et al., 2009).

3.2 Cells
Cell culturing and stable transfection of procyclic T. brucei brucei strain 427 and of cell
line 29-13 (Wirtz et al., 1999) was carried out as described previously (Laufer et al., 1999). After
each transfection, cell lines were cloned by limiting dilution. Cell line TbP19ee was generated by
inserting BmgBI-linearized pPRP19-PTP-NEO into one PRP19 allele and deleting the remaining
wild-type allele with a PCR product in which 100 bp of the PRP19 5/ and 3/ gene flanks were
fused to the hygromycin phosphotransferase (HYG) coding region. Cell lines that express
CDC5-PTP, SPF27-PTP or ORC1-PTP were generated by transfecting SnaBI-linearized
pCDC5-PTP-NEO, BsmI-linearized pSPF27-PTP-NEO, and XhoI-linearized pORC1-PTP-NEO,

	
  

135

respectively. Cells that express both PRP19-PTP and SPF27-HA were obtained by two
consecutive transfections, first with linearized pPRP19-PTP-NEO and then with BsmI-linearized
pSPF27-HA-BLA. Cell lines for conditional gene knockdowns were generated by targeting the
T7-stl constructs to the RRNA spacer region. For each transfection correct integration of DNA
was verified by PCR with at least one oligonucleotide hybridizing outside the transfected DNA
sequence. After selection, 427 cells with antibiotic resistance markers were grown in 40 µg/ml
hygromycin, 40 µg/ml G418, and/or 10 µg/ml blasticidin whereas 29-13 cell lines were kept in 50
µg/ml hygromycin, 15 µg/ml G418, and 4 µg/ml phleomycin. Conditional gene silencing
experiments were induced by adding doxycycline to a final concentration of 1 µg/ml. Cells were
counted and diluted to a density of 2 x 106 cells/ml daily.

3.3 Protein analysis
PTP-tagged proteins on immunoblots were detected either with the peroxidase antiperoxidase reagent (Kartalou and Essigmann) or a monoclonal anti-protein C epitope antibody
(Roche). Extract preparation and tandem affinity purification of PTP-tagged proteins were
carried out according to the standard protocol (Schimanski et al., 2005a) Purified proteins were
separated on SDS–10 to 20% polyacrylamide gradient gels (BioRad) and stained either with
sypro ruby (BioRad) or with Coomassie blue (Gelcode Coomassie stain; Thermo Fisher
Scientific). For the sedimentation analysis of PRP19 and CDC5 complexes, the final eluate of a
standard tandem affinity purification (~1.8 ml) was vacuum concentrated to ~100 µl, dialyzed
overnight against E-80 buffer (150 mM sucrose, 20 mM HEPES-KOH pH 7.7, 20 mM potassium
glutamate, 80 mM potassium chloride, 3 mM magnesium chloride, 0.2 mM EDTA, 0.5 mM
EGTA), loaded onto a 4 ml linear 10-40% sucrose gradient in E-80 buffer, and ultracentrifuged
at 41,000 rpm in a Beckman Sw55Ti rotor for 19 h at 4 °C. Subsequently, the gradient was
fractionated from top to bottom in 20 aliquots. Proteins in each aliquot were collected by a
hydrophobic resin (StrataClean, Stratagene), and resuspended in SDS loading buffer for
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electrophoresis. Proteins that co-purified with PRP19-P were analyzed from a gel lane of the
final eluate by the Proteomic Core facility of the Rockefeller University. The gel lane was cut into
multiple pieces and peptides, derived from trypsin-digested proteins, were separated by liquid
chromatography and analyzed by tandem mass spectrometry (LC/MS/MS) using an Ultimate
3000 HPLC system (Dionex) and a nanospray LTQ Orbitrap XL (Thermo Scientific) mass
spectrometer. Individual protein bands obtained after sucrose gradient sedimentation were
analyzed equivalently by the Keck facility (Yale University). Proteins were identified using
Mascot

and

NCBI

non-redundant

protein

sequence

database

of

eukaryotes,

with

carbamidomethyl (C) as static and oxidation (M) as variable modifications. Peptide Mass
tolerance was set to ±25 ppm and fragment mass tolerance to ±0.8 Da. Peptides were
considered as identified when their score was ≥22 and expectation values were ≤0.05.

3.4 RNA analysis
To analyze gene silencing effects on RNA abundances, total RNA was prepared from
non-induced or doxycycline-induced cells by the hot phenol method as described previously
(Nguyen et al., 2007). rRNA was separated by gel electrophoresis on reliant precast 1.25%
SeaKem Gold agarose RNA gels (Lonza) and detected by ethidium bromide staining. For the
analysis of mRNA and unspliced pre-mRNA, total RNA was first reverse transcribed with
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s protocol using,
respectively, oligo(dT) and random hexamers as primers. Secondly, the cDNAs were subjected
to semi-quantitative and quantitative (q)PCR analysis. Semi-quantitative PCR was performed
using cycle numbers that were empirically determined to be within the linear amplification range
for each oligonucleotide pair. The specificity of oligonucleotide pairs used in qPCR was first
verified in analyzing their products by standard agarose gel electrophoresis. To further confirm
the validity of the qPCR reactions, a melt curve analysis was included for each qPCR to ensure
that only a single product was amplified. In addition, a linear regression analysis of a serial
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dilution of input material was performed to make sure that the coefficient of determination (r2)
was within the 0.98 to 1.0 range.
Spliceosomal U snRNAs, SL RNA and, as a control, 7SL RNA were detected by primer
extension assays using 10 µg of total RNA, 5/-32P-end-labeled oligonucleotides and SuperScript
II reverse transcriptase. Primers SL_PE and SL40, 7SL_PE, U1_PE, U2f, U4_PE, U5_PE, and
U6_PE were used to detect SL RNA, 7SL RNA, U1, U2, U4, U5 and U6 snRNA, respectively.
Primer extension products were separated on 8% polyacrylamide – 50% urea gels and
visualized by autoradiography. The modified primer extension assay for characterizing the
methylation status of the SL RNA cap and generation of the sequencing ladder was conducted
with unmodified Moloney’s murine leukemia virus (MMLV) reverse transcriptase (Invitrogen) and
the Thermo Sequenase cycle sequencing kit (USB), as previously described (Badjatia et al.,
2013a). For the analysis of PRP19 complex-associated U snRNAs, PTP-tagged proteins were
precipitated by immunoglobulin G (Djikeng et al.) beads (GE Healthcare), and total RNA was
prepared and analzyed by primer extension assays as previously published (Luz Ambrósio et
al., 2009). DNA oligonucleotides that were used in primer extension assays and in competitive
and [semi-]quantitative reverse transcription (RT-)PCR reactions are specified in Attachment 4,
Supplementary Table S1.

3.5 Light microscopy
Immunofluorescence microscopy was performed as previously described (Luz Ambrósio
et al., 2009). For the detection of PRP19-PTP, a rabbit polyclonal anti-ProtA immune serum
(Kartalou and Essigmann) followed by an Alexa 594-conjugated anti-rabbit secondary antibody
(Invitrogen) was used, while HA-tagged SPF27 was detected by a rat monoclonal anti-HA
antibody (Roche) and an Alexa 488-conjugated anti-rat secondary antibody (Invitrogen). We
excluded the possibility that anti-HA antibodies were non-specifically bound by ProtA by
analyzing cells that expressed only PRP19-PTP with the antibody mix described above (data
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not shown). Images were taken on a Zeiss Axiovert 200 microscope equipped with DAPI (4′,6′diamidino-2-phenylindole), EGFP and Texas-Red filters using a 100x (1.3-numerical-aperture)
oil immersion objective. Quantification of the co-localization was done using the Zeiss Axiovision
4.6.3.0 software program for co-localization.

4. Results
4.1 Tandem affinity purification of PRP19 and identification of co-purified proteins
For tandem affinity purification (Biswas et al.) of PRP19 (accession number
Tb927.2.5240 at www.GeneDB.org or www.TriTrypDB.org) we generated the insect-stage,
procyclic T. brucei cell line TbP19ee which expressed PRP19 with a C-terminal PTP tag
(PRP19-PTP) and no untagged PRP19. The PTP tag is a composite tag consisting of a protein
C epitope (ProtC) followed by a tobacco etch virus (TEV) protease cleavage site and tandem
protein A domains (ProtA) (Schimanski et al., 2005a). The cell line was obtained by replacing
one PRP19 allele of wild-type procyclics with the coding region of the selectable marker
hygromycin phosphotransferase (HYG) and by targeted integration of plasmid PRP19-PTPNEO into the remaining PRP19 allele, thereby fusing the PTP sequence to the PRP19 gene
(Figure 5.1A). Since TbP19ee cell cultures did not exhibit a growth defect (data not shown) and
PRP19 is an essential gene in T. brucei (Tkacz et al., 2010), we inferred that the tag did not
disrupt PRP19 function. We then prepared extract from 5 x 1010 trypanosomes and performed
PTP tandem affinity purification of PRP19-PTP. While the expected size of PRP19-PTP is 74
kDa, anti-ProtC immunoblotting of extract revealed a single band of ~80 kDa (Figure 5.1B, lane
1). PTP-based TAP involves IgG affinity chromatography through ProtA, release of the tagged
protein by TEV protease cleavage, and recapture of the tagged protein by anti-ProtC
immunoaffinity chromatography (Schimanski et al., 2005a). Immunoblot monitoring of the TAP
procedure showed that both chromatography steps led to efficient depletion of the tagged
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protein from extract and from TEV protease eluate (lanes 2 and 4) and that the final eluate
contained a substantial amount of purified PRP19 (lane 5). Note, that removal of ProtA
decreased the molecular mass of PRP19-P by ~15 kDa. The final eluate was then separated on
a SDS-polyacrylamide gel and stained with Coomassie blue (Figure 5.1C). The profile of protein
bands exhibited a massive protein enrichment in the 55-65 kDa range, which included PRP19P, and three major protein bands with apparent sizes of ~85, 26 and 22 kDa. In addition, many
bands of minor abundance and different size were detected which could be components of the
spliceosome.
To identify co-purified proteins, we performed liquid chromatography-tandem mass
spectrometry (LC/MS/MS) with the final TAP eluate that was not separated electrophoretically.
By limiting the analysis to proteins that were identified by at least two unique peptides and
excluding recurrent PTP purification contaminants, we identified 47 proteins (Table 5.1). Of
those, 35 proteins were homologs of known spliceosomal proteins, two of the six proteins
without annotation (conserved hypothetical) were previously co-purified with trypanosomatid
splicing complexes (Luz Ambrósio et al., 2009; Palfi et al., 2009), and only six of the annotated
proteins did not have a known splicing function. Moreover, the list contains several orthologs of
human and yeast PRP19 complex subunits as well as PRP-related proteins (see below)
confirming that the tagged PRP19 was functionally incorporated into RNA splicing complexes
and indicating that the PRP19 purification was highly specific.
4.2 Identification of a stable T. brucei PRP19 complex of seven subunits
To determine the proteins that form a stable PRP19 complex, we sedimented PRP19PTP-purified proteins through a linear sucrose gradient by ultracentrifugation. We took 20
fractions of the gradient from top to bottom, collected the proteins from each fraction with a
hydrophobic resin and stained the proteins after electrophoretic separation in the gel with sypro
ruby (Figure 5.1D). The major protein bands of the purification co-sedimented with peak signals
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in fractions 14 and 15 which is between the ~230 kDa-large T. brucei SNAPc/TRF4/TFIIA
transcription factor complex (Schimanski et al., 2005b) and the 444 kDa-large apoferritin
marker. Furthermore, in fraction 20, major and minor bands were co-detected indicating that the
purified material contained larger complexes that sedimented to the bottom of the gradient.
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Figure 5.1 Trypanosoma brucei has a stable PRP19 complex of seven subunits A.Schematic (not to
scale) of a PRP19 wild-type allele and the PRP19 locus in procyclic TbP19ee cells that exclusively
express PRP19-PTP and no untagged PRP19. PRP19, HYG/NEO coding regions and PTP tag are
indicated by open, striped and black boxes, respectively. Gene flanks for RNA processing signals are
drawn as smaller gray boxes. Checkered boxes indicate plasmid-derived portions of the PRP19 coding
region. B. Immunoblot monitoring of the PRP19-PTP tandem affinity purification. PRP19-PTP and
PRP19-P (after removal of the ProtA domains) were detected with the monoclonal anti-ProtC antibody
HPC4 in crude extract (Inp), flowthrough of the IgG column (FT-IgG), TEV protease eluate (TEV),
flowthrough of the anti-ProtC column (FT-ProtC) and the final eluate (Elu). x-Values indicate relative
amounts loaded. C. Aliquots of extract, the TEV protease eluate and the final eluate were separated on a
10-20% SDS-polyacrylamide gradient gel and stained with Coomassie blue. Percentages indicate relative
amounts analyzed. D. The eluate of a PRP19-PTP tandem affinity purification was sedimented through a
10-40% linear sucrose gradient by ultracentrifugation and 20 fractions were taken from top to bottom.
Proteins from each fraction were separated on a 10-20% SDS-polyacrylamide gradient gel and stained
with Sypro Ruby. Proteins specified on the right were identified by excision of individual protein bands
and LC/MS/MS analysis. For comparison, sedimentations of Taq DNA polymerase (95 kDa), IgG (150
kDa, 6.6S), apoferritin (444 kDa, 17S) and thyroglobin (660 kDa, 19S) were analyzed in parallel gradients
(arrowheads). In addition, sedimentation peaks from previous, comparable experiments of TEV protease
(29 kDa) and the SNAPc/TRF4/TFIIA transcription factor complex (230 kDa) are indicated as well.
Asterisks indicate the sedimentation peak.
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Table 5.1 Mass spectrometric identification of PRP19 co-purified proteins
1

Annotation
PRP19
CDC5 / Cef1
CDC40 / PRP17
2,3
SKIP / Prp45
PRL1 / Prp46
2,3
SPF27 / Snt309
2
PPIL1
DHX38 / Prp16
U5-200K / Brr2
[U5-]PRP8
HSP73 (HSP70)
CRN / Clf1, Syf3
3
CACTIN
U5-116K / Snu114
SYF1
KIAA1604 / Cwc22
3
Conserved hypoth.
Conserved hypoth.
U5-CWC21
/
U2A (U2-40K)
3
Conserved hypoth.
SmD1
LSm2
LSm8
VSG pseudogene
aminopeptidase
AD002 / CWC15
U5-40K
SmF
PRP31
SSm2-1 (Sm15K)
ISY1
SmD2
PABP2 (PABP1)
Conserved hypoth.
Actin A
SSm2-2 (Sm16.5K)
SmE
SmB
//
U2B
Argonaute AGO1
ALBA3
3
Conserved hypoth.
Pumilo PUF2
LSm4
3
Conserved hypoth.
Cyclophilin (PPlase)

Accession #
Tb927.2.5240
Tb927.5.2060
Tb927.3.1930
Tb927.9.5880
Tb927.10.10170
Tb927.11.14150
Tb927.8.2090
Tb927.10.7280
Tb927.5.2290
Tb927.9.11110
Tb927.11.11330
Tb927.10.9660
Tb927.11.11610
Tb927.11.15430
Tb927.5.1340
Tb927.11.10750
Tb927.8.5650
Tb927.2.3400
Tb927.9.3480
Tb927.10.14360
Tb927.10.11230
Tb927.7.3120
Tb927.8.5180
Tb927.3.1780
Tb927.5.4980
Tb927.11.3570
Tb927.10.11950
Tb927.11.11150
Tb927.9.10250
Tb927.10.10700
Tb927.6.4340
Tb927.8.1930
Tb927.2.5850
Tb927.9.10770
Tb927.11.2960
Tb927.9.8850
Tb927.10.4950
Tb927.6.2700
Tb927.2.4540
Tb927.3.3480
Tb927.10.10850
Tb927.4.2040
Tb927.4.3540
Tb927.10.12660
Tb927.11.13960
Tb927.8.5840
Tb927.9.11740

Mr (kDa) Protein score # Unique pept.
54.2
65,296
32
80.1
31,713
57
52.8
9,959
33
50.4
8,862
25
48.8
6,349
23
24.5
5,775
16
21.7
5,615
11
121.2
4,398
63
249.3
3,936
67
276.8
3,811
79
76.0
3,523
36
87.6
2,654
25
64.6
2,303
24
105.4
2,165
33
92.1
1,846
21
66.8
1,737
20
103.2
1,233
22
36.6
852
10
20.4
693
10
36.5
662
15
34.7
567
11
11.7
528
4
13.3
507
5
14.0
435
6
48.5
428
5
98.0
408
9
22.4
403
6
35.0
398
5
8.4
394
4
39.6
371
4
12.8
342
3
31.7
313
5
12.5
282
4
62.2
282
7
12.0
280
5
41.9
266
3
14.7
255
4
9.7
217
3
12.3
169
5
13.6
167
5
99.2
162
3
20.8
153
2
41.2
136
3
92.2
126
2
14.2
122
2
21.5
118
2
20.3
103
3

% Coverage
75.1
82.0
83.7
50.3
68.2
74.8
67.0
66.6
37.2
36.0
65.1
45.8
57.2
43.8
35.9
35.3
34.8
32.9
55.2
65.3
42.7
45.3
44.8
43.4
20.0
15.5
33.2
18.7
56.0
13.2
33.3
29.0
35.1
15.5
40.7
11.4
31.3
37.2
40.4
27.4
3.7
10.5
12.9
4.5
15.0
10.7
24.0

# Pept.
39
64
37
30
23
23
13
63
67
79
40
25
24
33
21
20
22
10
10
15
11
4
5
6
5
9
6
5
4
4
3
5
4
7
5
3
4
3
5
5
3
2
3
2
2
2
3

PRP19 co-purifying proteins, identified by LC/MS/MS, are ranked according to protein score. Listed proteins have a
score of >100 and were identified by 2 or more unique peptides. Proteins that co-sedimented with PRP19 in linear
sucrose gradients are highlighted in yellow, proteins denoted as PRP19 subunits or PRP19-related proteins in other
systems in green, un-annotated proteins in blue, and [putative] spliceosome components in gray. Annotated proteins
without a known role in RNA splicing were not highlighted. In addition, standard contaminants of trypanosome TAPs
such as a/b tubulin, translation elongation factor, retrotransposon hot spot proteins, histones, low scoring ribosomal
proteins, and chaperones were eliminated from this list, although it should be noted that prefoldin chaperones were
particularly enriched in these purifications.
1
Annotation is according to the human/yeast systems unless there is a trypanosome-specific name. Names in
parentheses refer to alternative names published for T. brucei.
2
Proteins that were annotated in this study.
3
[putative] Spliceosomal proteins that co-purified in a trypanosome splicing complex for the first time.
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To identify the proteins in the bands seen in fractions 14 and 15, gel slices were excised and
their protein content analyzed by LC/MS/MS. We identified seven proteins which coincided with
the seven proteins that obtained the highest protein score listed in Table 5.1. The largest protein
was identified as trypanosome CDC5. The strong bands of 65 and 55 kD contained tagged
PRP19-P and PRP17 (Palfi et al., 2009), respectively. The strong PRP19 signal is consistent
with PRP19 forming a tetramer within a single PRP19 complex (Ohi et al., 2005). In contrast,
PRP17 was not a component of previously characterized human and S. cerevisiae PRP19
complexes and, therefore, has not been considered a bona fide component of the PRP19
complex (Chanarat and Strasser, 2013; Wahl et al., 2009). On the other hand, systematic yeast2-hybrid screens have identified PRP17 as a direct interactor of the PRP19 WD40 domain
(Figure 5.2A) in human and yeast systems (Hegele et al., 2012; Ren et al., 2011). Moreover, in
Schizosaccharomyces pombe, PRP17 was consistently detected in tandem affinity purifications
of PRP19 complexes, and it was determined that there are four PRP17 molecules per complex
(Ren et al., 2011). Our results corroborate these findings. In T. brucei, PRP17 co-purified and
co-sedimented with PRP19 identifying it as a bona fide subunit of the trypanosome PRP19
complex. Moreover, the strong signals of the 65 and 55 kDa bands suggest that there is more
than one PRP17 molecule present in the trypanosome complex. However, the strong 55 kDa
signal appears to be not confined to PRP17 alone because we detected a second protein in this
band. This protein is encoded in gene Tb927.9.5880 which has been annotated as a
“conserved, hypothetical protein” indicating that its sequence is conserved only among
kinetoplastids. A standard BLAST search identified an internal SKIP/SNW domain strongly
indicating that this protein is the ortholog of the spliceosomal Ski-binding protein (SKIP) and
PRP45p of mammals and S. cerevisiae, respectively (Figs. 5.2A, B). Interestingly, in the human
and yeast systems, SKIP/PRP45p is not considered to be a PRP19 complex subunit but a
PRP19-related/associated protein (Fabrizio et al., 2009; Makarova et al., 2004).
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The band of ~50 kDa has a lower strength signal and contained only a single protein,
namely the trypanosome ortholog of human PRL1 and yeast PRP46p. It is considered a core
component of the yeast and human PRP19 complexes (Fabrizio et al., 2009; Makarova et al.,
2004). Trypanosomatid PRL1 had been identified previously, co-purifying with LSm3 in
Leishmania tarentolae (Tkacz et al., 2010). Accordingly, T. brucei PRL1 shares clear sequence
homology to human PRL1 (E = e-80) including a C-terminal WD40 protein-protein interaction
domain (Figure 5.2A).
The sixth protein, with an apparent size of 25 kDa, was found to be encoded by gene
Tb927.11.14150. The corresponding amino acid sequence was conserved only among
kinetoplastid organisms and, in contrast to the SKIP identification, did not reveal a conserved
sequence motif. However, a key subunit of similar size of PRP19 complexes across systems is
SPF27. To analyze whether this trypanosomatid protein could be a SPF27 ortholog, we
performed a multiple sequence alignment of SPF27 orthologs from model organisms and of the
kinetoplastid orthologs of Tb927.11.14150. As shown in Figure 5.2C, we found four short
domains of sequence conservation between the two orthologous groups including a nearly
invariant LPY motif near the N-terminus of the protein. Although this degree of sequence
conservation is not strong, the findings that SPF27 is a bona fide PRP19 complex subunit in all
systems and that Tb927.11.14150 was a major protein in the PRP19 purification co-regimenting
with the PRP19 complex subunits argue that this protein is trypanosome SPF27.
Analysis of the smallest band of 21 kDa revealed a protein that is encoded by gene
Tb927.8.2090 and had been annotated as a cyclophilin-type peptidyl-prolyl cis-trans isomerase
in the genome data base because it harbors the conserved domain of this enzyme class (Figure
5.2A). The protein was identified previously co-purifying with SmB and annotated as cyclophilin
CYP2 (Palfi et al., 2009). However, a search for the closest homolog of this protein in the
human genome returned the PRP19-related factor PPIL1. A multiple sequence alignment of the
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trypanosomatid orthologs of this protein and PPIL1 sequences from different model organisms
showed sequence conservation along the whole protein (Attachment 4, Fig. S1). Moreover,
human PPIL1 binds to a 21 amino acid-long region in the N-terminal part of SKIP (Wang et al.,
2010). This region is highly conserved in trypanosome SKIP sequences including two key
residues (Figure 5.2D). Further support for Tb927.8.2090 being a PPIL1 ortholog comes from a
comparison with yeast genome databases. While S. pombe harbors PPIL1 and full-length SKIP
orthologs, S. cerevisiae does not have a PPIL1 ortholog (spliceosome database; (Cvitkovic and
Jurica, 2013) and its SKIP protein lacks the N-terminal domain including the PPIL1 binding site
(Wang et al., 2010). Accordingly, a blastp search of the S. pombe genome database with the
Tb927.8.2090-encoded amino acid sequence identified the PPIL1 ortholog Cyp1 as the most
similar sequence with a low Expect Value (E = 2e-25) whereas the same search of the S.
cerevisiae database returned the mitochondrial peptidylprolyl isomerase CPR3 as the most
similar sequence with a considerably higher Expect Value (E = 9e-14). We therefore concluded
that gene Tb927.8.2090 encodes T. brucei PPIL1.
Finally, to confirm the characterization of the PRP19 complex, we generated a cell line
that expressed CDC5 with a C-terminal PTP tag. Tandem affinity-purification of CDC5-PTP and
sedimentation analysis revealed a protein complex with similar banding pattern and
sedimentation property as the PRP19-purified complex (Attachment 4, Fig. S2). Accordingly,
mass spectrometry of the excised protein bands revealed the same seven proteins as in the
PRP19-PTP-purified complex. Thus, we have identified a stable PRP19 complex in T. brucei
consisting of seven subunits.

	
  

146

	
  

147

Figure 5.2 Domain structure and sequence conservation in PRP19 complex subunits
A. Domain structure drawn to scale of trypanosome PRP19 complex subunits and their human
orthologues. The protein domains were identified by NCBI blastp searches of the Conserved Domain
Database (Marchler-Bauer et al., 2011) (E-values are specified for T. brucei protein domains): CDC5:
-08
-10
SANT domain (cd00167), E=1.03e ; SANT/myb-like domain (cd11659), E=8.07e ; the very limited
sequence similarity between the human Myb_Cef domain (pfam11831) and the corresponding region
of trypanosomatid CDC5 sequences is indicated by the dashed box. PRP19: U-Box (smart00504),
-14
-20
E=1.06e ; PRP19 domain (coiled-coiled [C-C] protein interaction domain, pfam08606), E=4.87e ;
-18
-75
WD40 (cd00200), E=5.77e . PRL1: WD40 (cd00200), E=1.4e . SPF27: while the LPY motif is
present in T. brucei SPF27, the human BCAS2 domain (pfam05700) was not recognized. PRP17:
-37
WD40 (cd00200), E=2e . SKIP: PPIL1-binding domain (PBD); SKIP_SNW domain (pfam02731),
-08
e-27
E=7.51e . PPIL1: cyclophilin domain [cd00317], E= 2.18
(note that while the trypanosome
sequence returned the general cyclophilin domain, the more specific SpCYP2_like cyclophilin domain
(cd01922) was identified in the human ortholog.
B. Multiple sequence alignment of the SKIP/SNW domain of Homo sapiens (Hs, accession number
NP_036377), Drosophila melanogaster (Dm, AGB95213), Caenorhabditis elegans (Ce, CAA98552),
Arabidopsis thaliana (At, AEE35947), Schizosaccharomyces pombe (Sp, CAB41231),
Saccharomyces cerevisiae (Sc, P28004), and the kinetoplastids Leishmania major (Lm,
LmjF.15.1030), Leishmania braziliensis (Lbr, LbrM.15.1070), Trypanosoma cruzi (Tc,
TcCLB.509445.20), T. brucei (Tb, Tb927.9.5880), Trypanosoma vivax (Tv, TvY486_0902160), and
Bodo saltans (Bs, ACI16065). Since the N-terminal ~50 amino acids of the domain are only weakly
conserved among kinetoplastids, they were omitted from the alignment. Numbers indicate the
position within the SKIP/SNW domain. Positions with more than 50% similarity or identity are shaded
in gray and black, respectively. Identical positions in model organisms without any conservation in
kinetoplastids are shaded blue and identical position in kinetoplastids without conservation in model
organisms are shaded in red. A hyphen indicates lack of an amino acid at this position. Numbers in
parentheses specify lengths of non-conserved insertions. The highly conserved SNWKN motif is
indicated by asterisks.
C. Corresponding alignment of four short conserved domains in SPF27 orthologues. Asterisks mark the
highly conserved LPY motif which, among Leishmania species, is only present in L. tarentolae as
LPF. Accession numbers: Hs, NP_005863; Dr (Danio rerio), NP_001007775; Dm, NP_651596; Ce,
NP_498360; At, NP_566599; Sp, CAB57933; Sc, EEU07188; Ddis (Dictyostelium discoideum),
XP_640072; Tb, Tb927.11.14150; Tcon (Trypanosoma congolense), TcIL3000.11.14450; Tv,
TvY486_1114990; Tc, TcCLB.511727.110; Lta (Leishmania tarentolae), LtaP32.0970; Lm,
LmjF.32.0900.
D. Multiple sequence alignment of the 21 amino acid-long PPIL1 binding domain in SKIP orthologues.
Numbers indicate positions relative to the starting methionine. The two key residues for PPIL1 binding
are marked by asterisks.
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4.3 SPF27 silencing affects trans and cis splicing of pre-mRNA
Next, we wanted to verify for one co-purified subunit whether its depletion in cells had
effects on cell viability, RNA splicing and SL cap4 formation which corresponded with the
previous PRP19 silencing experiment (Tkacz et al., 2010). We chose SPF27 since it was the
least conserved subunit of the PRP19 complex. By stable integration of a tetracycline repressorregulated SPF27 stem-loop construct into procyclic 29-13 cells, which constitutively express the
tetracycline repressor and T7 RNA polymerase (Wirtz et al., 1999), we generated a cell line for
conditional SPF27 silencing. Induction of the SPF27 knockdown with the more stable
tetracycline derivative doxycycline, which was added to the medium, stopped culture growth
between one and two days of induction (Figure 5.3A). Subsequently, the cell density remained
nearly constant until day 5 of the experiment strongly indicating that SPF27 is an essential gene
(Figure 5.3A). Interestingly, while the previous PRP19 knockdown generated a similar growth
defect (Tkacz et al., 2010), depletion of the essential snRNP proteins LSm2 and U5-Cwc21 led
to rapidly declining cell numbers in our hands (Luz Ambrósio et al., 2009), suggesting that
disabling the PRP19 complex affected trypanosomes differently than depletion of snRNP
proteins. This difference appears not to be a consequence of inefficient gene knockdown
because a semi-quantitative RT-PCR analysis showed that SPF27 mRNA was rapidly and
strongly reduced in the presence of doxycycline (Figure 5.3B). Analyzing total RNA prepared
from non-induced cells and from cells in which SPF27 was silenced for 1 to 3 days clearly
revealed pre-mRNA splicing defects. While the amounts of the control RNAs, rRNA and the
non-spliceosomal 7SL RNA, which is the RNA component of the signal recognition particle
(Michaeli et al., 1992), did not change in these RNA preparations, semi-quantitative RT-PCR
analysis clearly indicated that the abundance of mature α tubulin mRNA decreased upon SPF27
silencing whereas, in random hexamer-derived cDNA of the same RNA preparations, the signal
of unspliced α tubulin pre-mRNA, lacking the SL, clearly increased (Figure 5.3B). Similarly, a
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competitive PCR of cDNA across the PAP intron showed a relative increase and decrease of
unspliced and mature PAP RNA, respectively (Figure 5.3B). Together, these results revealed a
splicing defect both in SL trans splicing (α tubulin mRNA) and in cis splicing (PAP mRNA).
To confirm that these changes in RNA abundances are specific to SPF27 silencing and
not due to pathways of death, we co-analyzed the knockdown of a non-spliceosomal gene that
affected trypanosome culture growth similar to SPF27 silencing. We chose the ORC1 gene
encoding subunit 1 of the origin recognition complex (Godoy et al., 2009) because, in our
hands, the ORC1 knockdown arrested culture growth after the second day of induction
(Attachment 4, Fig. S3). The RNA analysis showed that, while ORC1 mRNA abundance was
very strongly reduced after 1 day of induction, the level of α tubulin mRNA was unaffected even
after 3 days of ORC1 silencing (Figure 5.3C). Together, these results confirmed that SPF27 is a
spliceosomal protein.
Since the PRP19 complex is known to be important for spliceosome activation, we
expected that SPF27 silencing would affect the first step of splicing. In trans splicing such a
defect should lead to an increase of the SL RNA splicing substrate and a decline of the Y
structure intermediate that is formed after the first transesterification (Luz Ambrósio et al., 2009;
Tkacz et al., 2010). To test this we conducted a primer extension assay with three radiolabeled
oligonucleotides that specifically hybridize to the intronic sequence of the SL RNA and, as
controls, to the U2 snRNA and the 7SL RNA. In the Y structure, the 5/ end of the intron is
covalently linked to the branch site which forms a barrier for reverse transcriptase, leading to an
intron-specific primer extension product. Indeed, in SPF27-silenced cells, primer extension
showed a strong increase of SL RNA abundance on day 2 and 3 of induction and a concomitant
reduction of the Y structure signal in these total RNA preparations, a phenotype that was not
observed in ORC1-silenced cells (Figure 5.3D, left panel).
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To substantiate these findings, we carried out quantitative RT-PCR analyses with three
independently derived RNA preparations for each time point of SPF27 silencing. On days two
and three after induction, the amount of SL RNA increased ~6 to ~9-fold over the un-induced
level, respectively (Figure 5.3D, right panel). These numbers were in accordance with those of a
previous study in which silencing the gene of CDC2-related kinase 9 (CRK9) also resulted in a
block of trans splicing before the first step (Badjatia et al., 2013a). In agreement with such a
block, we found a ~3-fold increase of α tubulin pre-mRNA abundance in SPF27-silenced cells
which coincided with a ~50% reduction of the mature mRNA level on day three of induction
(Figure 5.3E, left panel; note that our analysis of mature mRNA did not discriminate between a
correct mRNA and a polyadenylated, unspliced mRNA). Comparable results were obtained
when we analyzed a second mRNA encoding the RPB7 subunit of RNA polymerase II (RNAPII;
Figure 5.3E, middle panel). Finally, while the PAP mRNA level strongly decreased upon SPF27
silencing as expected, a PAP intron-dependent qPCR detected only a small, insignificant
increase of PAP pre-mRNA in induced cells (Figure 5.3E, right panel). Possibly, unspliced PAP
mRNA is highly unstable, preventing an accumulation of this RNA in splicing-impaired cells.
In summary, the increase of SL RNA and unprocessed pre-mRNA levels paralleled by
the concomitant decrease of the Y structure intermediate and mature mRNA abundances
demonstrated that SPF27 depletion caused a block of the first trans splicing step, further
indicating a role of the PRP19 complex for spliceosome activation in trypanosomes and
corroborating SPF27 as a bona fide subunit of this complex.
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Figure 5.3 SPF27 silencing halted trypanosome proliferation and inhibited splicing of pre-mRNA.
A. Procyclic trypanosome culture growth in the absence and presence of doxycycline, which induced
SPF27 silencing.
B. Analysis of total RNA prepared from non-induced cells (n.i.) and cells in which SPF27 was silenced
for 1, 2 or 3 days. rRNA was detected by ethidium bromide staining,7SL RNA and [pre-]mRNA of α
tubulin (α tub) by semi-quantitative PCR and [pre-]mRNA of poly-A polymerase (PAP) by competitive
PCR.
C. Corresponding analysis of rRNA, ORC1 mRNA and α tubulin mRNA in ORC1-silenced cells.
D. Left panels, primer extension of total RNA prepared from SPF27- and ORC1-silenced cells with three
32
/
P-5 -endlabeled oligonucleotides detecting SL RNA, U2 snRNA, the SL intron after the first step of
SL trans splicing in the Y structure, and the 7SL RNA by denaturing PAGE and autoradiography.
Arrows indicate the loss of the Y structure intermediate in SPF27-silenced cells. The lower panel is a
lower exposure the SL RNA-specific product that better shows the increase of the SL RNA signal
upon SPF27 silencing. Right panel, RT-qPCR analysis of SL RNA abundance in SPF27-silenced
cells. The amounts are relative to that of non-induced cells which was arbitrarily set to 100. Averages
were derived from three independently conducted gene knockdown experiments.
E. Corresponding RT-qPCR analyses of pre-mRNA and of mature mRNA of α tubulin, RPB7 and PAP.
For pre-mRNA analyses, random hexamer-derived cDNA was amplified with a sense oligonucleotide
that hybridized upstream of the SL trans splice site (α tubulin and RPB7) or with an antisense
oligonucleotide that hybridized within the PAP intron.
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4.4 PRP19 and SPF27 co-localize in the nucleus
To further validate SPF27 as a component of the PRP19 complex, we examined if
SPF27 co-localizes with PRP19 in trypanosomes. We generated a procyclic cell line in which
PRP19 and SPF27 were C-terminally tagged with PTP and HA, respectively. Detection of both
proteins by indirect immunofluorescence microscopy revealed that both proteins localized to the
nucleus, exhibiting a speckle-like distribution that is characteristic of spliceosomal proteins,
including trypanosome and human PRP19 (Figure 5.4) (Marechal et al., 2014; Spector and
Lamond, 2011; Tkacz et al., 2010). Consistently, both proteins co-localized to a large extent
(Pearson coefficient of 0.73, n = 53), supporting our findings that both proteins are subunits of
the same spliceosomal protein complex. In comparison, PRP19 localization was previously
found to be not as widespread in the nucleus as in our analysis but more focused at the socalled SL RNP factory in which SL RNA is synthesized (Tkacz et al., 2010). This discrepancy
could be due to using different tags (PTP versus YFP), tagging different ends (C- versus Nterminus) or detecting PRP19 by indirect versus direct immunofluorescence microscopy.
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Figure 5.4 PRP19 and SPF27 co-localize predominantly in nuclear speckles
PRP19-PTP (red) was co-localized with SPF27-HA (green) in procyclic trypanosomes by indirect
immunofluorescence. DNA detected by DAPI staining revealed the large nucleus and the smaller
kinetoplast of trypanosomes. The black bar represents 10 µm.
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4.5 SPF27 silencing leads to SL cap hypomethylation
SL cap4 methylations at positions 1, 2 and 3/4 are carried out by the methyl transferases
MTR1 (Zamudio et al., 2007), MTR2 (also known as MT47 or COM1) (Arhin et al., 2006b; Hall
and Ho, 2006) and MTR3 (also known as MT57) (Arhin et al., 2006a; Zamudio et al., 2006),
respectively, and they occur sequentially from position 1 to 4 (Mair et al., 2000b) recently
reviewed by (Sturm et al., 2012). Previously, Tkacz et al. (2010) reported that PRP19 silencing
led to a loss of cap3/4 and an accumulation of SL RNAs with cap2 indicating a functional link
between PRP19 and MTR3. To test whether SPF27 silencing led to a comparable defect, we
performed a modified primer extension assay with MMLV reverse transcriptase and reduced
ribonucleotide concentrations, both of which promote polymerization stops at methylated
residues. We first extended oligonucleotide SL_PE which hybridizes to the single-stranded Sm
binding region of the SL RNA (positions 111 to 130) and which we had used previously to show
that CRK9 silencing caused the loss of all cap4 methylations (Badjatia et al., 2013a). As shown
in figure 5.5A, we found that the shorter extension product, indicative of SL RNA with a fully
methylated cap4 structure, disappeared after 2 days of SPF27 silencing and that the
accumulated SL RNA signal was found almost exclusively in the top band instead, suggesting
the predominant presence of SL RNA with a hypomethylated cap. Since a nearly congruent
primer extension pattern was obtained when CRK9 was silenced (Badjatia et al., 2013a), this
result suggested a complete loss of cap4 methylations instead of a specific cap3/4 loss upon
SPF27 silencing. However, Tkacz et al. had used an oligonucleotide that hybridized further
upstream of the SL RNA, precisely up to the GU splice site nucleotides of the SL RNA intron.
Since it was possible that the use of different primers led to different extension results, we
repeated the primer extension assay with oligonucleotide SL40 (Zamudio et al., 2006) that also
hybridized up to GU splice site. Although the same assay conditions and RNA preparations
were used, primer extension of SL40, in contrast to that of SL_PE, was different revealing cap4
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products on days 2 and 3, and a cap2-specific product that was clearly detectable on
accumulated SL RNA 2 days into the SPF27 knockdown (Figure 5.5B). Possibly, the shorter
extension of SL40 made reverse transcription more sensitive to methylated residues, resulting
in a better detection of methylated and partially methylated SL RNA caps. Nonetheless,
consistent with the SL_PE extension results, the cap4 product diminished over the time course,
the cap2 product disappeared on day 3, and the accumulating SL RNA predominantly had a
cap0. Thus, these findings did not reveal a specific cap3/4 defect but they clearly indicated that
SPF27 silencing led to an accumulation of SL RNA that is progressively hypomethylated with
most SL RNA having a cap0 structure.
Since SPF27 and CRK9 silencing led to similarly strong accumulations of SL RNA and,
according to the SL_PE primer extension results, to a similar loss of cap4 methylation, we coanalyzed total RNA from both gene knockdowns with primer SL40. In addition, we analyzed
RNA from the ORC1 knockdown as a negative control and repeated an LSm2 silencing
experiment which was shown previously to also affect the first step of trans splicing (Luz
Ambrósio et al., 2009). As shown in figure 5.5C, depletion of the U6 snRNP-specific LSm2
protein caused only a mild increase of SL RNA that did not exhibit any methylation defect. This
result is not due to ineffective gene silencing because LSm2 silencing rapidly and strongly
affected trypanosome proliferation in culture (Luz Ambrósio et al., 2009); data not shown). In
contrast, the extent of SL RNA accumulation and the very strong cap0 signal were nearly
identical in SPF27 and CRK9 knockdowns. The similarity of these phenotypes, despite the fact
that SPF27 silencing merely halted culture growth (Figure 5.1A) while CRK9 silencing led to a
strong decline of cell numbers (Badjatia et al., 2013), suggests that SPF27 and CRK9 function
in the same step of RNA splicing. LSm2 silencing led to a loss of U6 snRNA (Luz Ambrósio et
al., 2009; Tkacz et al., 2008) which should affect the formation of the B complex before
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spliceosome activation. Therefore, strong SL RNA accumulation and cap hypomethylation may
be specific consequences of interference with spliceosome activation.
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Figure 5.5 Accumulated SL RNA in SPF27-silenced cells is hypomethylated
A. SL RNA and, as a loading control, U2 snRNA primer extension products of total RNA, prepared from
non-induced (n.i.) cells and cells in which SPF27 was silenced for 1 to 3 days, were analyzed on a
sequencing gel that separates SL RNA cap4–derived signals from signals of hypomethylated SL RNA
caps (SL cap0). On the left, marker bands are indicated.
B. Corresponding primer extension analysis of the same RNA with oligonucleotide SL40 which
/
hybridizes just downstream of the 5 splice site in the SL RNA (position 40 to position 59 relative to SL
RNA 5’ end). For comparison, a sequencing ladder, which was obtained by linear amplification
sequencing with the same oligonucleotide, was co-analyzed. Each lane is marked with the
complementary base of the chain-terminating nucleotide used, so that the SL RNA sequence can be
directly inferred from top to bottom. The starting A residue is marked with an asterisk. M, marker. On
/
/
the left, the SL starting sequence 5 -AACTAA-3 is indicated while specific cap products and the signal
of the 7SL RNA, which was co-analyzed as a loading control, are specified on the right. Note that
primer extension of SL40 generated a product with an extra nucleotide (position -1) that has been
observed before and may be due to terminal transferase activity of reverse transcriptase (Zamudio
et al., 2009a).
C. SL RNA primer extension analysis, using primer SL40, of total RNA which was prepared from
uninduced cells or from cells in which ORC1, LSm2, SPF27, or CRK9 was silenced for three days.
Co-detection of U2 snRNA served as a loading control.
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4.6 The trypanosome PRP19 complex is associated with U2, U5 and U6 snRNAs
In a final step, we wanted to see whether the trypanosome PRP19 complex is
associated with a complex comparable to the activated spliceosome in the yeast and human
systems, which is characterized by the presence of U2, U5 and U6 snRNAs and the absence of
U4 and U1 snRNAs. For this analysis, we prepared extract from TbP19ee cells, and efficiently
pulled down PRP19-PTP by IgG beads (Figure 5.6A). Total RNA, prepared from the precipitated
material, was then analyzed by two distinct primer extension assays. In assay A, four
oligonucleotides were used to detect SL RNA and the Y structure intermediate as well as U2,
U4 and U6 snRNA, whereas assay B contained two oligonucleotides complementary to U1 and
U5 snRNAs (Figure 5.6B). In a positive control precipitation of the PTP-tagged SmD1 core
snRNP protein (Luz Ambrósio et al., 2009) all six snRNAs were efficiently detected by correctly
sized primer extension products (lanes 1 and 2) while in a negative control precipitation of PTPtagged ORC1 none of these RNAs co-precipitated (lanes 7 and 8). Since all PTP-mediated pulldowns were of similar efficiency (Figure 5.6A), these results confirmed the specificity of the
primer extension assays. In comparison, the pull-down of PRP19 mainly co-precipitated U2 and
U5 snRNA as well as the Y structure intermediate (Figure 5.6B, lanes 3 and 4). In addition, full
length SL RNA and U6 snRNA were co-precipitated although with a reduction in relative signal
strength whereas U4 and U1-specific products were hardly detectable. This snRNA pattern
shows that the PRP19 complex is predominantly associated with a complex that resembles an
activated spliceosome and it suggests that the trypanosome PRP19 complex assembles into
the spliceosome after the discard of U1 and U4 snRNA has been initiated. Moreover, the clear
detection of the Y structure in PRP19-precipitated material confirms that the trypanosome
PRP19 remains associated with spliceosome after the first step of splicing. Since SmD1 binds
directly to the SL RNA (Palfi et al., 2000) and PRP19 is associated with snRNAs only through
the spliceosome, the reduction of SL RNA signal versus the positive control is expected.
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Similarly, the reduction of the U6 signal is likely due to the presence of free U4/U6 snRNP in
extract that is not assembled into the spliceosome and, therefore, is precipitated with SmD1 but
not with a non-snRNP protein. When we repeated this experiment with two different cell lines
that expressed either PTP-tagged CDC5 (lanes 6 and 7) or PTP-tagged SPF27 (lanes 9 and 10)
the results were congruent with those for PRP19, further validating CDC5 and SPF27 as bona
fide subunits of the trypanosome PRP19 complex. Overall, we found that only minor amounts of
snRNPs co-precipitated with the PRP19 complex because, in contrast to the SmD1 precipitation
in which snRNAs were efficiently co-depleted from the supernatant, the pull down of SPF27 did
not detectably reduce the abundance of snRNAs in extract (Attachment 4, Fig. S4). This result
is consistent with the finding that in trypanosomal extracts the majority of snRNAs are
assembled in individual snRNPs rather than in large spliceosomes (Cross et al., 1991).
Finally, depletion of Sm and LSm proteins as well as of other snRNP proteins in
trypanosomes led to a loss of the cognate U snRNA (Liu et al., 2004; Luz Ambrósio et al., 2009;
Tkacz et al., 2008; Tkacz et al., 2010). In contrast, SPF27 silencing for three days did not alter
the abundance of spliceosomal snRNAs, verifying the non-snRNP nature of the trypanosome
PRP19 complex (Attachment 4, Fig. S5). Thus, the effective co-precipitation of the U snRNAs
with PRP19 complex components suggests that trypanosomes form splicing complexes that are
comparable to the B and C complexes described in other organisms and that these complexes
remained stable in our extracts.
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Figure 5.6 The trypanosome PRP19 complex specifically associates with U2, U5 and U6 snRNAs
A. Extract was prepared from procyclic cell lines that express SmD1, PRP19, CDC5, ORC1 or
SPF27 with a functional, C-terminal PTP tag. PTP-tagged proteins were precipitated by IgG
beads that bind the protein A domain of PTP and were detected with the peroxidase antiperoxidase complex that is bound by protein A. Inp, input; Sn, supernatant; P, precipitate. xValues indicate relative amounts analyzed.
B. Total RNA was prepared from the precipitates and analyzed by two primer extension reactions. In
reaction A, oligonucleotides were used that are specific to SL RNA, U2 snRNA, U4 snRNA and
U6 snRNA, whereas in reaction B, a U5- and a U1-specfic oligonucleotide were combined. The
SmD1 and ORC1 pull-downs served as positive and negative controls, respectively. Note that the
exposure time of the SmD1 analysis was much shorter than those of the other assays.
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5. Discussion
In this study we have characterized the spliceosomal non-snRNP PRP19 complex of T.
brucei. Since trypanosomes and the model organisms from yeast to humans belong to different
phylogenetic lineages, e.g. the Excavata and Opisthokonta, respectively (Katz, 2012), a
comparison of these complexes can distinguish between properties that are highly conserved
over extended evolutionary time and those that vary between species. Accordingly, the subunits
PRP19, CDC5, PRL1 and SPF27 are invariably present in the human, yeast and trypanosome
complexes indicating that these four proteins form the conserved core of the complex (Table
5.2).
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Table 5.2 PRP19 complex subunits in H. sapiens, T. brucei and S. cerevisiae

H. sapiens

T. brucei

PRP19
CDC5L
PRL1
SPF27
AD002
CTNNB1
HSP73
assoc.
assoc.
assoc.
assoc.
assoc.
assoc.

PRP19
CDC5
PRL1
SPF27
assoc.
n.k.h.
assoc.
PRP17
SKIP
PPIL1
assoc.
assoc.
n.k.h.
assoc.

S. cerevisiae
Prp19
Cef1
Prp46
Snt309
assoc. (Cwc15)
n.k.h.
assoc.
assoc.
n.k.h.
Isy1
Syf1
Syf2
Clf1 (Syf3)

assoc. associated; proteins that were co-purified
with PRP19 complexes but not considered
bona fide subunits. In humans they are
referred to as “PRP19-related” (Chanarat
and Strasser, 2013; Wahl et al., 2009)
n.k.h.

no known homologue

-

protein was not co-purified
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PRP17 is not a subunit of the human PRP19 complex and it is considered to be associated
with the S. cerevisiae PRP19 complex. Trypanosome PRP17, however, stably co-purified and
co-sedimented with the PRP19 complex independent of whether the complex was purified
through PRP19 or CDC5 (Fig. 5.1D). This finding confirmed the association of S. pombe PRP17
and PRP19 (Ren et al., 2011), and it strongly suggested that PRP17 functions in the
spliceosome through association with PRP19 across eukaryotes. In the model of the S. pombe
PRP19 complex, a PRP19 tetramer binds four PRP17 molecules through interaction of the
PRP17 N-terminus with the PRP19 WD40 domain (Ren et al., 2011). These domains are
conserved in the trypanosome orthologs (Fig. 5.2A) and the strong protein bands that contained
PRP19 and PRP17 (Fig. 5.1D) may indicate that this model does fit the trypanosome complex.
However, our sedimentation analysis revealed a complex of ~350 kDa which is substantially
smaller than the expected 675 kDa of a complex containing a PRP19 tetramer, four PRP17
molecules and monomers of each of the other subunits. Possibly, tandem purification and
sedimentation led to a partial disruption of the PRP19 complex. Alternatively, we cannot rule out
that there are two distinct PRP19 complexes of different composition that were not separated
during sedimentation.
An interesting deviation from the yeast and human system was the finding that SKIP and
PPIL1 were stably associated with trypanosome PRP19. Identification of these two proteins in
trypanosomes implies an early evolutionary origin of the SKIP-PPIL1 sub-complex (Wang et al.,
2010). Furthermore, although previous work demonstrated a direct interaction between the
yeast SKIP ortholog and PRP46p (PRL1) in vitro (Albers et al., 2003), these proteins have not
been considered bona fide subunits of the PRP19 complex and were classified as PRP19related proteins (Chanarat and Strasser, 2013; Wahl et al., 2009). Since organization of PRP19related proteins is in general not well understood, our finding suggests that the SKIP/PPIL1 subcomplex functions within the PRP19 complex independent of other PRP19-related proteins. This
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seems to be at least true for trypanosomes since we recently succeeded in characterizing a
distinct complex of PRP19-related proteins that does not contain PRP19 complex subunits
including SKIP and PPIL1 (DL Ambrósio and A Günzl, unpublished data).
Another important aspect of our study was the discovery that depletion of SPF27 led to a
strong accumulation of SL RNA with a hypomethylated cap. The extent of SL RNA accumulation
and the pattern of cap hypomethylation closely resembled the effects seen upon CRK9 silencing
but not those of the LSm2 knockdown which also affected trans splicing (Fig. 5.5C) (Badjatia et
al., 2013a; Luz Ambrósio et al., 2009). Thus, these findings suggested that CRK9 functions in
spliceosome activation. Originally, our interest in CRK9 stemmed from its apparent role in the
phosphorylation of RPB1, the largest subunit of RNAPII. In other systems, RPB1
phosphorylation is critically important for RNAPII transcription initiation and elongation
(Buratowski, 2009). However, in trypanosomes the loss of RPB1 phosphorylation upon CRK9
silencing did not lead to an RNAPII-specific transcription block but, instead, coincided with SL
RNA cap hypomethylation and the trans splicing block. Since cap4 formation was thought to be
co-transcriptional (Mair et al., 2000b) and cap4 methylations a pre-requisite for SL trans splicing
(McNally and Agabian, 1992; Ullu and Tschudi, 1991), we had speculated that CRK9’s primary
substrate is RPB1, and that cap methylation and splicing defects are downstream
consequences of RPB1 de-phosphorylation (Badjatia et al., 2013a). However, the possibility
that CRK9 functions directly in spliceosome activation may point to a regulatory loop in
trypanosomes in which the status of RNAPII phosphorylation is directly linked to the trans
splicing mechanism. Accordingly, it will be interesting to analyze whether blocking spliceosome
activation independent of CRK9 affects RNAPII phosphorylation.
Overall, this is the first characterization of a spliceosomal non-snRNP protein complex in
trypanosomes. It is an important step towards understanding the spliceosome of T. brucei and
related parasites. The human spliceosome is a validated anti-cancer drug with the first inhibitor
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in clinical trial (Eskens et al., 2013; van Alphen et al., 2009). Given the special use of this RNAprotein machinery in trypanosome SL trans splicing, and considering the great evolutionary
distance between trypanosomes and humans, a trypanosome-specific splicing inhibitor may
wait to be discovered.
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Chapter VI
Discussion and Future Directions

1. The conserved kinetoplastid XPB-R paralog is specialized in Nucleotide
Excision Repair (NER)
The multi-subunit and multi-functional transcription factor TFIIH is an important
component of the RNA pol II transcription pre-initiation complex (PIC) as well as the NER
machinery in eukaryotes (Compe and Egly, 2012). The TFIIH core complex includes the DNA
helicase XPB, which is essential for TFIIH’s function in both transcription initiation and DNA
repair. While model organisms such as yeast and humans have a single, bifunctional XPB that
functions exclusively within TFIIH, kinetoplastids harbor two divergent XPB helicases. Our
previous work showed that the larger of the two XPB paralogs is part of the trypanosome TFIIH
complex that is crucial for SLRNA transcription (Lee et al., 2009; Lee et al., 2007). However, the
functional significance of the smaller XPB paralog was unclear.
In this study, we functionally characterized the smaller XPB paralog that was termed
XPB-R (R for repair) due to its essential role for NER in T. brucei (Badjatia et al., 2013b). We
show that while XPB-R is dispensable of cell viability and transcription, it is important for NER in
cells. Our results also indicate that XPB-R is not assembled in a TFIIH complex but that it does
interact with the trypanosome p52 ortholog. p52 is a known regulator of XPB function in higher
eukaryotes (Coin et al., 2007). Furthermore, gene silencing of p52 but not of XPD rendered
trypanosomes susceptible to UV light in a manner comparable to XPB-R silencing. This strongly
indicates that the interaction of XPB-R with p52 is important for its function in NER. Consistent
with our results, in a parallel study it was shown that RNAi of XPB-R increases the susceptibility
of cells towards UV and cisplatin-induced DNA lesions that are repaired by NER (Machado et
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al., 2014). Furthermore, this study also demonstrated that XPD and the larger XPB paralog do
not function in DNA repair in trypanosome.
To the best of our knowledge, this is the first study that demonstrates a role of the XPB
helicase in repair independent of the TFIIH complex. Our data support a model in which
trypanosome TFIIH complex including the DNA helicases XPD and the larger XPB paralog is
crucial for RNA pol II transcription but not required for DNA repair while XPB-R and its functional
partner p52 are part of a TFIIH independent NER machinery (Figure 6.1). Since a similar XPB
dualism is also found in other phylogenetically early-diverged eukaryotes such as ciliates and
species of Entamoeba, it is possible that a repair-specialized XPB helicase is an ancient
eukaryotic trait and that combining the repair and transcriptional functions in a single XPB
helicase occurred later during evolution.
While our results clearly demonstrate that XPB-R is not essential for cell survival in T
brucei, the XPB-R−/− knockout cell lines exhibited consistent slow growth when monitored for a
period of over three months. This slow growth could be a result of accumulating DNA mutations
in culture or it is possible that XPB-R has other functions in cells. Nonetheless, successful
generation of clonal XPB-R−/− cell lines shows that XPB-R is not essential for culture growth of
T. brucei. However, XPB-R could still be an important virulence factor in T. brucei for
establishing successful infections in its host where growth conditions are very distinct from
those in culture. This can be tested in a mouse model by injecting equal number of wild-type
and XPB-R−/− parasites into mice and monitoring parasitemia and survival over a period of time.
This will determine if XPB-R plays a role in virulence of the parasites.
Our results show that XPB-R−/− cells are more susceptible to NER inducing agents such
as UV light and cisplatin as compared to the wild-type cells. This susceptibility is dose
dependent. In order to further strengthen this finding, we can perform IF to determine if XPB-R
localizes to the site of DNA damage specifically at DNA lesions induced by UV light and
cisplatin. This can be done by colocalizing XPB-R and DNA lesions in cells that have been
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exposed to UV or cisplatin. Commercially available monoclonal antibodies against 6-4
photoproducts and cyclobutane pyrimidine dimers (CPD) can be used to detect DNA lesions
that are generated after UV exposure and anti-cisplatin antibody can be used to visualize
cisplatin adducts. Since we have already established a clonal cell in which XPB-R is exclusively
expressed as a fusion with the PTP tag, XPB-R and DNA lesions can be co-detected in this cell
line using our established IF protocol. We would expect XPB-R to accumulate at the sites of
DNA lesions after exposure to DNA damaging agents. This will be a strong support for our
previous results that demonstrate XPB-R’s involvement in NER.
Furthermore, IF can be used to determine if absence of XPB-R impedes the repair of
Cisplatin- or UV-induced DNA lesions. DNA lesions can be visualized in wild type and XPB-R−/−
cells at different time points after exposure to DNA damaging agents. We would expect to see a
delay/loss in the repair of the lesions in XPB-R−/− cells. This will demonstrate a direct role of
XPB-R in NER in trypanosomes.
Alternatively, a recently established more sensitive and quantitative NER assay termed
Oligonucleotide Retrieval Assay (ORA) can be employed to compare repair efficiency in XPBR−/− and wild-type cell lines (Shen et al., 2014). In this assay, 5′-biotinylated duplex DNA that
contains a CPD adduct is transiently transfected into cells to serve as a substrate for NER.
Thereafter, DNA is extracted from cells and the transfected oligonucleotide is isolated using
capture by streptavidin beads. Finally, qPCR can be used to quantify the proportion of CPD
lesions that were repaired in vivo. This sensitive assay can be employed to quantify the
differences in NER efficiency in XPB-R−/− and wild-type cell lines.
A detailed analysis of NER in T. brucei showed that the trypanosome orthologs of CSB
and XPG as well as XPB-R are crucial for the trypanosome NER pathway (Machado et al.,
2014). In other eukaryotes, CSB is known to function in detection of DNA lesions specifically in
the TC-NER pathway while XPC detects damage in the non-transcription coupled genomic NER
pathway (Compe and Egly, 2012). XPG is one of the two endonucleases that mediate excision
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of damaged DNA (Compe and Egly, 2012). Interestingly, while CSB seems to be important for
NER in T. brucei, XPC appears to be dispensable. It is possible that trypanosome CSB detects
DNA lesions in both TC-NER and genomic NER. However, since the crystal structure of archeal
XPB revealed a DNA damage recognition domain, it can also be speculated that trypanosome
XPB-R is capable of damage detection independent of XPC or CSB. In the archeon Sulfolobus
solfataricus, a complex of XPB and Bax1 endonuclease (functional equivalent of XPG), can
recognize, unwind and cleave NER substrates in vitro (Rouillon and White, 2010). If XPB-R and
trypanosome XPG form a similar complex is not yet clear. This possibility can be tested by
tandem affinity purification of XPG and/or by reciprocal co-immunoprecipitation analysis of XPBR and XPG. Furthermore, NER efficiency of cellular extracts that are immmunodepleted of
either XPB-R or XPG can be measured in vitro NER assays such as the ORA described above.
Recombinant XPB-R and/or XPG can be added back to the extracts for reconstitution of the
NER activity. Moreover, interaction of recombinant XPG with XPB-R can be examined in pulldown experiments. Lastly, it can be tested if recombinant XPB-R and XPG complex can
recognize, open and cleave model NER substrates in vitro in a manner similar to repair by the
archaeal XPB/Bax1 doublet.
Finally, the role of XPB-R in TC-NER, if any, can be tested in similar experiments as
described above. TAP of CSB can potentially reveal novel factors that are important for TC-NER
in T. brucei. Whether or not XPB-R interacts with CSB can be analyzed by reciprocal
immunoprecipitations in extracts and in vitro pull-down experiments. Also, whether or not CSB
specifically functions in TC-NER can be tested by measuring the NER activity of extracts
depleted of CSB in vitro. However, since repair of model NER substrates is not coupled to
transcription, depletion of CSB should not affect repair of in vitro substrates.
In conclusion, various experiments described above can help to further delineate the
NER pathway in trypanosomes which is not well-characterized. It will also help us to understand
the precise role of XPB-R in NER. These analyses can reveal unique features of trypanosome
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NER machinery that are distinct from the NER machinery of the model organisms and they may
elucidate the evolution of this important pathway in the eukaryotic kingdom.
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Figure 6.1 A model for the comparison of TFIIH composition and function in human and T. brucei.
The human TFIIH complex (model modified from (Compe and Egly, 2012)) consists of two structural
and functional sub-complexes, namely the core complex, which includes the DNA helicases XPB and
XPD, and the cyclin-dependent kinase (CDK)-activating kinase (CAK) complex. The XPB subunit of TFIIH
has essential functions in both RNA pol II transcription and DNA repair. Trypanosomes contain two
divergent paralogs of the XPB helicase of which only the larger termed XPB-T (T for transcription) is
associated in a TFIIH complex together with orthologs of all core subunits as well as two trypanosome
specific subunits called TSP1 and TSP2. T. brucei TFIIH is essential for SLRNA transcription by RNA pol
II but lacks the CAK complex that is conserved amongst model eukaryotes. The smaller XPB paralog
termed XPB-R (R for repair) in T. brucei is specialized in nucleotide excision repair (NER), and has no
role in RNA pol II and RNA pol I transcription. It interacts with the p52 subunit of TFIIH, a known regulator
of XPB in other systems, but does not appear to assemble in a TFIIH complex. This suggests a model in
which trypanosomes possess a TFIIH, containing XPB-T, that is specialized in RNA pol II transcription
while NER is carried out via a XPB-R based machinery.
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2. Characterization of the unique CRK9 complex, which is crucial for SL trans
splicing
Our biochemical and structural characterization of TFIIH revealed that trypanosome
TFIIH lacks the CAK sub-complex (Lee et al., 2009; Lee et al., 2007; Rouillon and White, 2010),
composed of CDK7, cyclin H and MAT1, which is typically conserved in all model eukaryotes.
Given CDK7’s essential role in the phosphorylation of the RPB1 CTD (Fisher, 2005), and the
finding that the corresponding trypanosome CTD is phosphorylated as well (Chapman and
Agabian, 1994; Das and Bellofatto, 2009), we analyzed the four most essential trypanosome
CDKs, namely CRK1, CRK3, CRK7 and CRK9, in an attempt to identify the trypanosome CDK
that is involved in CTD phosphorylation. Indeed, our study showed that ablation of CRK9
resulted in a loss of CTD phosphorylation. In addition, we found that this kinase is indispensable
for the essential parasite-specific process of SL trans splicing in T. brucei. Silencing of CRK9
led to the inhibition of SL trans splicing before the first transesterification step and it resulted in
SL RNA cap hypomethylation and loss of RPB1 phosphorylation (Badjatia et al., 2013a).
Since trypanosomatids transcribe their protein coding genes in a polycistronic fashion,
the processes of SL trans splicing and polyadenylation are required for resolving individual
mRNAs from polycistronic pre-mRNA. Thus, SL trans splicing is a crucial RNA processing step
for the maturation of each and every mRNA in these parasites. Accordingly, factors that are
involved in SL trans splicing are typically essential for parasite survival. In this study, we found
that CRK9 is vital for parasite survival and that CRK9 silencing led to arrest in culture growth
just after one day of inducing the gene knockdown (Badjatia et al., 2013a). Furthermore, we
showed that CRK9 is crucial for trypanosomes to establish infection in a mouse model (Chapter
V). This is important since CDKs are considered to be suitable drug targets for dividing cells and
several CDK inhibitors such as Flavopiridol have been tested or are in clinical trials for cancer
therapy (Cicenas et al., 2014; Peyressatre et al., 2015). Since we have validated CRK9 as a
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potential chemotherapeutic target for trypanosomes in a mouse model, characterization of the
CRK9 complex is an important next step for the development of specific small molecule
inhibitors of this enzyme in the future.
For this, we tandem affinity-purified CRK9 and sedimented the final eluate in a sucrose
gradient. The sedimentation profile led to identification of a putative tripartite complex of CRK9
together with a previously unannotated cyclin, termed CYC12, and the novel protein CRK9AP.
Expression silencing of both CYC12 and CRK9AP recapitulated the phenotypes of the CRK9
knockdown, confirming that CYC12 and CRK9AP are functional partners of CRK9 in vivo.
The newly identified cyclin CYC12 is conserved amongst all kinetoplastids. Our
bioinformatic and phylogenetic analyses strongly indicated that CYC12 is a L-type cyclin with a
C-terminal arginine/serine-rich RS domain of high positive charge that is characteristic of L-type
cyclins in other eukaryotes with the exception of S. pombe L-type cyclin that lacks this domain
(Dickinson et al., 2002). Thus far, CYC12 is the only known ‘transcriptional’ cyclin of
trypanosomes that is crucial for the parasite-specific mode of gene expression. Interestingly,
kinetoplastid CYC12 deviates from known cyclins by

large insertions in both of its cyclin

domains, e.g. Cyclin_N and Cylin_C. It is likely that these sequence insertions prevented
recognition of CYC12 as a cyclin in the annotation of the genome (Parsons et al., 2005). These
insertions might reflect functionally important enzyme features that are kinetoplastid-specific .
However, this remains to be tested.
Consistent with the identification of CYC12 as a putative L-type cyclin, a standard
protein-protein BLAST search of the human or Drosophila melanogaster proteome with the T.
brucei CRK9 sequence returned various isoforms of CDK11 (E=5e-43 & 2e-37 respectively).
Cyclin L is a known functional partner of CDK11 in model organisms (Loyer et al., 2008).
CDK11p110 isoform is implicated in the regulation of gene expression in eukaryotes, and was
shown to be essential for pre-mRNA splicing in both in vivo and in vitro splicing assays (Choi et
al., 2014; Hu et al., 2003). Since our results demonstrate CRK9’s indispensable role in SL trans
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splicing, this finding together with the association of CRK9 with an L-type cyclin, strongly
suggests that CRK9 is a divergent ortholog of CDK11.
Our study also identified a small 15 KDa protein termed CRK9AP that is required for
trans splicing in vivo. CRK9AP appears to be kinetoplastid-specific with no recognizable
orthologs in other systems and no identifiable functional motifs. Nonetheless, knockdown of
CRK9AP mirrored the defects observed in CRK9 and CYC12 silencing. Our studies indicate that
CRK9AP associates with CYC12 and CRK9 to form a stable tripartite complex. This is unique
since with the exception of CDK7’s CAK complex, CDKs function in heterodimeric complexes
together with their cyclin partner. Silencing of CRK9AP leads to co-loss of CRK9 and CYC12
from cells strongly indicating that CRK9AP is important for stability and/or assembly of the
complex. Interestingly, similar to the phenotype we observe upon CRK9AP silencing, in MAT1
deficient cells, the levels of CDK7 and cyclin H are significantly reduced (Korsisaari et al., 2002;
Rossi et al., 2001; Sano et al., 2007). It is possible to speculate that CRK9AP’s function in
CRK9 complex is similar to that of MAT1 in CAK complex. However, it remains to be tested if
CRK9AP is essential for CRK9’s kinase activity in vitro. Previously, it has been shown that the
C-terminal hydrophobic domain of MAT1 is sufficient for its association in the CAK complex and
for activation of the kinase activity of CDK7 (Busso et al., 2000). It is interesting to note that
CRK9AP also has a large hydrophobic region at the C-terminus. In the future, a mutational
analysis of CRK9AP may help to decipher important domains/residues that mediate CRK9AP’s
interaction with CRK9 and CYC12.
Another family of small proteins that are implicated in assembly of CDK-cyclin
complexes is the Cip/Kip family of CDK inhibitors (CKI). Although members of this protein
family are typically considered as inhibitors of cell cycle-related CDKs, they were also shown to
be important for the assembly and activation of CDK4/6 - cyclin D complexes (Cheng et al.,
1999; LaBaer et al., 1997). However, the function of Cip/Kip family is restricted to CDKs
involved in the regulation of the cell cycle and so far no study has demonstrated their role in
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activation or inhibition of transcriptional CDKs. Nonetheless, future work will determine if
CRK9AP is a divergent ortholog of MAT1 or Cip/Kip proteins or if it is a unique kinetoplastidspecific protein dedicated for the assembly/stability of CRK9 complex.
Our infection studies in mice with cells where CRK9’s expression can be silenced by
induction with doxycycline validated CRK9 as a suitable chemotherapeutic target. However, in
order to screen for a large number of small molecule inhibitors of CRK9, a functional
recombinant enzyme is required. Although our initial attempts to express full-length CRK9 and
CYC12 in E. coli were not successful, recently we have effectively expressed CRK9, CYC12
and CRK9AP in vitro in wheat-germ extracts. This is very promising as this system can allow us
to tether the interactions of individual proteins with the others. Our preliminary results indicate
that CRK9AP can interact with both CRK9 and CYC12 independently. Future pull-down
experiments will determine if CRK9 can interact with CYC12 independent of CRK9AP or if
CRK9AP functions as an assembly factor to mediate interaction between CYC12 and CRK9.
Additionally, this system can be utilized to perform mutational analysis for identification of
domains/regions of ALP or CYC12 that mediate interaction with CRK9 and each other. For
example, pull down experiments after deletion of the RS domain of CYC12 and C-terminal
hydrophobic region of ALP will determine if these regions are important for protein-protein
interactions.
We do not yet know if CRK9 can assemble in a functional kinase complex in wheat-germ
extracts. This can be tested by purifying the CRK9 complex from wheat-germ extract in which all
three proteins are co-expressed and by subjecting the purified enzyme complex to
autophosphorylation in kinase assays. If autophosphorylation of CRK9 is observed, then we can
test if CRK9AP is essential for this phosphorylation. However, the CRK9 complex purified from
wheat-germ may not be competent in autophosphorylation of CRK9. One possible reason for
this could be that activation of CRK9 is dependent on post-translational modifications that are
absent in wheat-germ extracts. Previous phospho-proteomic studies of T. brucei have identified
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phosphorylations of CRK9 threonine 533 (T533), serine 746 (S746), S750 and T752 (Nett et al.,
2009; Urbaniak et al., 2013). While our results showed that mutation of T533, which resides in
the activating T-loop of the kinase, is deleterious to CRK9’s function in cells, the significance of
the remaining phosphorylations remains unknown. Phosphomimetic mutations of these four
residues can determine if these phosphorylations are crucial or inhibitory for CRK9 kinase
activity. Finally if we could establish a functional CRK9 complex from wheat germ extract, a
small-scale screen of inhibitors can be performed which can give some leads for establishing a
high-throughput screening (HTS) assay in the future.
In order to measure the activity of CRK9 in vitro kinase assays, we need to first identify
the substrates(s) of CRK9 enzyme. Not only will this allow us to develop a robust in vitro kinase
assay for CRK9 activity but it will also help delineate the mechanism by which CRK9 functions
in SL trans splicing in vivo. A number of proteins were co-purified with CRK9 during TAP. Most
significant proteins with high Mascot Scores are listed in Table 4.1. These are potential
substrate candidates, including TSR1, which is a trypanosome SR protein shown to be
important of splicing in Trypanosoma brucei (Gupta et al., 2014).
Expression of an analog-sensitive mutant of CRK9 in cells is another powerful strategy
to identify its targets in vivo (Gregan et al., 2007). Methionine at position 438 was identified as
the gatekeeper residue of CRK9 by bioinformatic analysis (data not shown). The gatekeeper
residue is a conserved bulky hydrophobic amino acid that resides in the ATP binding pocket of a
kinase. Mutation of this amino acid to small residue such as alanine or glycine enlarges the ATP
binding site such that the kinase can accommodate a hydrolysable ATP analog (e.g. N6(benzyl)ATP) or specific cell-permeable inhibitors (e.g. 1-NA-PP1, 3-MB-PP1) (Gregan et al.,
2007). These analogs or inhibitors can only bind to the mutant kinase and not to any other wildtype kinase. Thus, analog-sensitized CRK9 can be used to identify its substrates in two
independent approaches. First, in an indirect approach, cells that exclusively express analog
sensitive CRK9 (asCRK9) will be grown in a medium containing cell permeable inhibitors such
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as 1-NA-PP1 that specifically inhibits asCRK9. In a control experiment cells will be grown in
medium lacking the inhibitor but containing amino acids labeled with heavy isotopes.
Subsequently, equal number of cells will be harvested from both cultures, combined and
analyzed by mass spectrometry to identify phosphoproteins in the sample. This SILAC based
mass spectrometry approach will determine relative abundance of phosphoproteins in the two
cell populations analyzed. In this approach we will be able to identify candidate proteins whose
phosphorylation is directly or indirectly dependent on CRK9 kinase activity. In a second, more
direct approach, cellular extract prepared from cells that express asCRK9 will be subjected to
an in vitro kinase assay with an ATP analog carrying a thio-phosphate group (N6B-ATPγS)
(Blasius et al., 2011). Subsequently, proteins will be digested with trypsin and thiophosphorylated peptides will be enriched with iodo-acetyl agarose beads (SulfoLink Coupling
Resin, Thermo Scientific). Subsequently, the thio-phosphorylated peptides will be eluted with an
oxidizing agent and analyzed by mass spectrometry. This approach will allow identification of
direct CRK9 substrates. Commercially available antibodies against thiophosphate-ester (e.g.
from Epitomics Inc., Burlingame, CA, USA) can be used in immunoblotting experiments to
validate potential substrates or autophosphorylation of asCRK9.
In order to perform a HTS for specific CRK9 inhibitors we might need functional
recombinant enzyme in large amounts. For this a Baculovirus-insect cell expression system can
be established. Insect cell expression systems have been used in the past to purify active CDKcyclin complexes in large quantities for structural analysis. Thus, this system might be useful to
obtain functional CRK9 enzyme in amounts needed for HTS. Once a functional recombinant
CRK9 enzyme can be obtained, it will be possible to establish a sensitive fluorescence-based
HTS assay to screen for a wide range of (potential) kinase inhibitors. We will collaborate with
drug screening centers to test for lead compounds. An important candidate is the Drug
Discovery Unit in Dundee, UK which is led by Dr. Micheal Ferguson, a well-known
trypanosomatid researcher.
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In summary, different approaches described above can be used to further characterize
the CRK9 complex, identify substrates of CRK9 and to discover specific small molecule
inhibitors against CRK9. This study has significant medical implications for the treatment of
trypanosomatid diseases since we have validated CRK9 as potential chemotherapeutic target.
Furthermore, identification of CRK9 substrates in vivo will elucidate the mechanism by which
CRK9 regulates the essential parasite-specific process of SL trans splicing and it may reveal
other potential targets upstream or downstream of CRK9 function in this essential gene
expression pathway.

3. Characterization of the trypanosome PRP19 complex
Having identified CRK9’s crucial role in SL trans splicing, we wanted to further
characterize

the

splicing

machinery

of trypanosomes. In

recent years, biochemical

characterizations of protein complexes and bioinformatics approaches have led to the
identification of orthologs of almost all known spliceosomal snRNP proteins in trypanosomes.
However a majority of non-snRNP splicing proteins remain unidentified (Gunzl, 2010; Preußer

et al., 2012). In this study, we biochemically and functionally characterized the non-snRNP
PRP19 complex of trypanosomes, which in other eukaryotes is essential for spliceosome
activation (Ambrosio et al., 2015). By TAP and subsequent sedimentation of the purified PRP19
complex in a sucrose gradient and mass spectrometry of co-sedimented proteins, we identified
a PRP19 complex that contained the orthologs of the known core subunits PRP19, CDC5,
PRL1, and SPF27 that are also invariably present in yeast and human PRP19 complexes as
well as PRP17, SKIP and PPIL1 orthologs which are not considered bona fide subunits of the
PRP19 complex in the model organisms. This demonstrated that the trypanosome PRP19
complex consists of a conserved, albeit divergent core but, otherwise, deviates substantially in
protein composition from its human and yeast counterparts. Moreover, this study is the first
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characterization of a non-snRNP protein complex in trypanosomes. In the future, further
biochemical characterizations, for example by TAP, will help to expand the repertoire of nonsnRNP splicing factors in trypanosomes. These analyses may eventually lead to the
identification of a trans splicing-specific protein that can be targeted in an antiparasitic strategy.
Recently, the human PRP19 complex was characterized by electron microscopy (EM)
after TAP (Grote et al., 2010). This work revealed that the PRP19 complex has an asymmetric
and elongated structure with a maximum dimension of ~20 nm and width of ~9 nm.
Interestingly, the yeast PRP19 complex also has a similarly elongated morphology but a larger
size with a side length of 40 nm (Ohi et al., 2005), indicating differences in the composition of
the two complexes. In the future, we can perform EM analysis of the structure of the
trypanosome PRP19 complex which might reveal unique structural features of the PRP19
complex in trypanosomatids.
Interestingly, gene silencing of components of the PRP19 complex led not only to
defects in trans splicing but also to hypomethylation of cap4 and a loss of RPB1
phosphorylation. These phenotypes were very similar qualitatively and quantitatively to those
we observed upon CRK9 silencing. This suggests that CRK9 and PRP19 depletion affects trans
splicing in a similar fashion and that cap4 hypomethylation and RPB1 dephosphorylation are a
consequence of a block of trans splicing. Since PRP19 is important for activation of the
spliceosome and our results strongly suggest that trypanosome PRP19 associates with the
active spliceosome, it is possible that both PRP19 and CRK9 function in spliceosome activation.
These findings also allude to a cross-talk between SL trans splicing and the status of RNA pol II
phosphorylations. It will be interesting to decipher the signaling pathway that leads to the coregulation of transcription, SL RNA biogenesis and trans splicing. Potential proteins involved in
this pathway may have purified either with CRK9 (see above) or with the PRP19 complex.
Finally, our previous PTP purifications of SmD1 and PRP19 co-purified several so called
‘conserved hypothetical’ proteins. These are proteins that are conserved only amongst
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trypanosomatids with no known ortholog in other systems. One of these conserved hypothetical
proteins is encoded by a gene with the accession number Tb927.11.2960 and it was found to be
enriched in the PRP19-PTP purification with a high protein score. Tb927.11.2960 is an essential
gene and silencing of its expression led to comparable defects in trans splicing and cap4
methylations as observed upon silencing of PRP19 or CRK9. Our preliminary TAP analysis of
this protein co-purified several proteins which, in the human system, have been termed PRP19related proteins because they consistently co-purify with PRP19 subunits but are not stably
associated with the PRP19 complex (Wahl et al., 2009). Most interestingly, a sedimentation
analysis discovered a distinct complex of these proteins that has not been described in any
other organisms and our initial analysis revealed that the complex enters the spliceosome
before the PRP19 complex (data not shown). Thus, it is possible that the “PRP19-related”
complex facilitates recruitment of the PRP19 complex into the spliceosome. This can be
investigated by a conditional knockdown of genes encoding subunits of the newly identified
complex and the parallel assessment of the snRNA profile that co-precipitates with PRP19. If
the proposed functional relationship between these two distinct complexes can be established,
this would provide new insight into spliceosome activation for the RNA splicing field in general.
Overall, the spliceosome is difficult to investigate because it is such a huge and dynamic
machinery. However, the methodology established in the laboratory and employed and further
developed in this thesis project provides the means for a comprehensive analysis of the
spliceosome and its signaling pathways to the other essential processes of gene expression.
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CLUSTAL O(1.1.0) multiple sequence alignment
Hs
Mm
Drer
Dm
Ce
Sc
Sp
Ca
Nc
Tb-1
Tco-1
Tv-1
Tc-1
Lm-1
Li-1
Lb-1
Lmx-1
Bs-1
Tb-R
Tco-2
Tv-2*
Tc-2
Lm-2
Li-2
Lb-2
Lmx-2
Bs-2
Ng-1
Ng-2
Trva-1
Trva-2
Gl
Ehis-1
Ehis-2
Edis-1
Edis-2
Dd
Ac**
Pf
Toxg
Eimt**
Ta
Tett-1
Tett-2
Part-1
Part-2
At-1
At-2
Orys-1
Orys-2

-----------------------MGKRD-----RADRDKKKSRKRHYEDE----------------E-DDEEDAPG------------------------------------MGKRD-----RVDRDKKKSKKRQYEEE----------------E-EDEDDIPG------------------------------------MGRKD-----KSDREKK-SKKRYYEDE----------------E--EDEEVIG------------------------------------MGPPKKSRKDRSGGDKFG-KKRRAEDEAFTQ------------L-VDDNDSLD------------------------------------MATKERKRR-----GKWD----TYKA-----------------E-EAPSLYSG-NA----------MTDVEGYQSKSKGKIFPDMGESFF----SSDEDSP------ATDAEI-DENYDDNRETL---EGRGE-RDTGAMVT-GL--------KKP
-----------------------M----SLKRKNN------AR-EGTPDEDLEEYSDY-SDVDNYGE-EDDDSYKP-AP---------------------------------M----SSRNREP------VNYADLEDENFSDEDVYVSNKTGAKD-NDDDEYNT-PS--------QKS
------MPPKRKAVGAPQAGVAKAGRTSALSTPGP------ATPRSLE-------SSFQS--DGDDD-LNDDDVDE-VI--------KRK
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MNNS--Q----------------QEETNQTQHS------------NNPNPTNEKNE--------KKR
----------------------MLNNH--L----------------HDQTTG-----------------TSSNRLQSED--------KKR
-----------------------------------------MS-----DAEYHEN---------------LKN-LDVGH-----SRQNRK
-----------------------------------------MT-----EEELDDF---------------KEEQTTQNL-----VKKKRT
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MSSGDSNL-----KRRRGGNT-GQSSKSYNTWTDYEE------D-LEE---------------------------------------------------------------------------------------------------------------------------------------------------MMN-SLKDSSNYSPNLSHTRGSRKRSD-IFNENYYAKNLKRRKLKAAKKL
----------MEPGAFPCSGTFSSEARSPFRASSPPAAKRFRR-SEPDDEDWDPDTCLYEASQADRESRASRTWPAAQVPRVAPPVALRV
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MA---------DKKVNPKSR------EQSKRL
-----------------------MSV----------------------------PVQYIA---------DYSNTPEA-----------RL
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------MGNGERGRPNKKMKYGGKD-DQKMKNIQNAEDYYD------D-ADE-------------------------------------------MGNDERKRPTKKMKYGGKD-DQKMKNIQNVEDYYD------D-ADE-----------------------------------------MAGGDGDRARAPKRHKSSA---PSRSIDETAELDYTD------D-VDD-----------------------------------------MAGGDGDRARAPKRHKSSA---PSRSIDETAELDYTD------D-VDD-------------------

Hs
Mm
Drer
Dm
Ce
Sc
Sp
Ca
Nc
Tb-1
Tco-1
Tv-1
Tc-1
Lm-1
Li-1
Lb-1
Lmx-1
Bs-1
Tb-R
Tco-2
Tv-2*
Tc-2
Lm-2
Li-2
Lb-2
Lmx-2
Bs-2
Ng-1
Ng-2
Trva-1
Trva-2
Gl
Ehis-1
Ehis-2
Edis-1
Edis-2
Dd
Ac**
Pf
Toxg
Eimt**
Ta
Tett-1
Tett-2
Part-1
Part-2
At-1
At-2
Orys-1
Orys-2

-----------NDPQEAVPS-----------------AAGKQ---VDESGTK-VDEY-----GAKDYRLQMPLKDDHTSRPLWVAP-D------------NESQEAVPS-----------------AAGKQ---VDESSTK-VDEY-----GAKDYRQQMPLKGDHTSRPLWVAP-D------------GESQEAVPA-----------------AAGKQ---VDESSTK-LDEY-----GAKDYRLQMLLKNDHSSRPLWVAP-D------------ATESEGIPG-----------------AASKN-AETNDEQIN-TDEY-----GAKDYRSQMQLRPDHGNRPLWVAP-N------------DKETSSVPK-----------------AASHNLNGENASSVM-TDEF-----GAKDYRKDMPLKGDFTARPLWVAP-D-RKKT-K-SSRHT----AADS---SMNQMDAKDKALLQDTNSDIPADFVPDSV-SGMF-----RSHDFSY-LRLRPDHASRPLWISPSD-RIRI---NNNKTKAQT------------------------TTNSNEARQSGI-SAMF-----GQNDFSNLLGLKLDHTARPLWINPID-RKST-GNNSKKRKAQESVDSLKQNLDETNYS-DNELIELTPDVPADYIPDAV-SKNF-----GKGDFSY-LKLKPDHFSRPIWISPND-EE------VIAREADEFVNTWA--------VDSSRFQA--RQDGGGSHRDGA-TQFFG---SGKRDFSY-LNLKPDHDQKPLWIDPEK----------------------------------------------------------------------------------MILGP-G----------------------------------------------------------------------------------MILGP-G----------------------------------------------------------------------------------MIVGQ-G----------------------------------------------------------------------------------MIVGA-N----------------------------------------------------------------------------------MNIGD-S----------------------------------------------------------------------------------MNIGD-S----------------------------------------------------------------------------------MNIGD-S----------------------------------------------------------------------------------MNIGD-S----------------------------------------------------------------------------------MFLDR-D---------------------------------------------------------------------MQCLFLEERIK--------K---------------------------------------------------------------------MQCLFLEERTA--------K-------------------------------------------------------------------MPMQCLFLRERTA--------T---------------------------------------------------------------------MQCLFLEERVS--------A----------------------------MAH-------------------SL----------SGDARTGEKCLFVESRIE--------S----------------------------MAH-------------------SL----------SGDARAGEECLFVESRIE--------S----------------------------MAY-------------------SL----------NGDALIGEKCLFVESRAQ--------S----------------------------MTH-------------------SL----------SGDARTDEKCLFVESRIE--------S-----------------------------------------------------------------MQQGECCFFLVDCTDKR------L-RKSETKSKNKKTKYDN------------------IENDTDSQISK-QAEKLA-TDIFKQKEGIQFDH-SSMDLKSDHESRPIWVCSGD-KKKEKEAKKKKQKYEE------------------ILNDLDNEVAKKAQEKLV-SDIFSQKKDVQFDH-SNLELKPDHKLRPVWVCSGT-RKSEN-----KIKLEN--------------------ITNEYFNGETSARS------------EVSKSFDDLTFIPGSENRPAIVFP-D-RSHAP-----KQKLLQ--------------------LEANYFDGETRARS------------NKYKYFKDLYILENSDNRPAIVMP-D-------------------------------------------------------------MSSKDAPLSFEDLKPDHHKRPLSVFPYSTN
------------------------MHKK------------RDTSDDSS-----DDSLE---DMKESTDYDMRLKPNHPELPMWVSS-N---------------------------------------------------MK-STIE----N---DDSEEFKLQIINTSNPYWICP-N-------------------------MHKK------------RDTSDDSS-----EDSLE---DMKESTDYDMRLKPNHPELPMWVSS-N---------------------------------------------------MK-SNIE----NNNDEDLEEYNVEIINTSNPYWVCP-N---------------------------------SGEFNQSIKKTTNTSSATLT-SSEEK---GSLLDYSKRCILKQDNKSRPIWVCP-D------------------------------------------------------------------------------------------KDSTNGEFTKKVK-KQ----------LKDY---YEM----RFDKKVINLPFS-TDSINIQQRGFHDYSKDMKLKKNHMNKPLWICS-D-R--EEGMAEKSAGKTK----------DARP---SET----AQGGVYGSLPLT-ADSLSLGVGGFRDFGSKLALKVDHAHRPLWVCP-D---------------------------------------------------------------------------------------------------------------------MSK---KSI----LVENTWGSLPFT-IDGSEQWIRNFRDYS-NLKLKTNHTARPLWVCP-D-KS-------NSQKQNQN--G---------KQQKNEEGDDGLFGQKQGKAQVEGN-----QFQQFYDYS-TLELKDDYRERPILICP-D-KK-------NHQKY------------------------------------------CLYLKPADRDYSSSFEI----QENRGFFPE-T----------------------------------------MSFEVKKRKLQTQPPEVQKLLIGDNMDYR-NIEI--VQSNKPLILSP-D-------------------------------------------------MRIDEPQ--------N-----EQQLKK-TKNSNDTQWK-K---------------------------------DSR------------------DGEGE---EKKRDF-TKLELKPDHGNRPLWACA-D---------------------------------DSR------------------DGEGE---EKRRDF-TDLELKPDHGNRPLWACA-D---------------------------------DVR------------------DADRE---VKKRDF-TKLELKPDHANRPLWACA-D---------------------------------DVR------------------DADRE---VKKRDF-TKLELKPDHANRPLWACA-D--
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XPB domain
*********
** **********************************
-----GHIFLEAFSPV-------------------------------------YK-YAQDFLVAIAEPVCRPTHVHEYKLTAYSLYAAVS
-----GHIFLEAFSPV-------------------------------------YK-YAQDFLVAIAEPVCRPTHVHEYKLTAYSLYAAVS
-----GHIFLEAFSPV-------------------------------------YK-YAQDFLVAISEPVCRPTHAHEYKLTAYSLYAAVS
-----GHVFLESFSPV-------------------------------------YK-HAHDFLIAISEPVCRPEHIHEYKLTAYSLYAAVS
-----GHIFLESFSPV-------------------------------------YK-HARDFLIAISEPVCRPQHIHEYQLTAYSLYAAVS
-----GRIILESFSPL-------------------------------------AE-QAQDFLVTIAEPISRPSHIHEYKITAYSLYAAVS
-----GRIILEAFSPL-------------------------------------AE-QAIDFLVTISEPVSRPAFIHEYRITAYSLYAAVS
-----GRIILESFSPL-------------------------------------AE-QAQDFLITIAEPISRPSHIHEYRITAYSLYAAVS
-----GTIILEKFSPD-------------------------------------AD-RVTDFLVTIAEPKSRPHFLHEYQLTAHSLYAGVS
-----GRIFINHGHPA-------------------------------------YP-HLMDFLTACCEPVCRTLYVSEYTISPSSLSAATA
-----GTILVNHSHSA-------------------------------------YP-HLRDFLTACCEPVCRTLHMSEYVISPSSLSAAST
-----GSIYVRHAHPA-------------------------------------YP-LLRDFLTACCEPVCRTAHMSEYVISPSSLSAASA
-----GSLFVNNTHPA-------------------------------------YP-HLVDFLTSCCEPVSRTLRMSEYVISPSSLSAASA
-----GNIFVEKAHPA-------------------------------------YA-HVIDFLISCCEPVSRTQHMEQYRMDSSSLSSATA
-----GNIFVEKAHPA-------------------------------------YT-HVIDFLISCCEPVSRTQYMEQYRMDSSSLSAATA
-----GNIFVEKAHPA-------------------------------------YA-HVIDFLISCCEPVSRTQHMEQYRMDSSSLSAATA
-----GNIFVEKAHPA-------------------------------------YA-HVIDFLISCCEPVSRTQHMEQYRMDSSSLSAATA
-----GRLFVETFGEE-------------------------------------YRENVRNFVLSCAEPVSRPEFVNEYAVTPASLAAASA
--EGCVVLFAEAFRPS-------------------------------------FA-NIQGFLTTIAEPVSRLSLMHEYRMTYFSLGAAAS
--EGCVVLLAEAFRTV-------------------------------------FN-DIQGFLTTIAEPVSRLSLIHEYRITHSSLGTAVS
--EDCITVLAEAFRSS-------------------------------------FP-AIQNFLTTIAEPTSRLALLHEYRITRFSLGTAVS
--EGYVVLLAETFRSS-------------------------------------FQ-RIQFFLTTIAEPTSRPSLMHEYRMTPFSLGAAVS
--DGYITIIAESFRRS-------------------------------------YV-NIRPFLTTLAEAISRPSLMHEYLLTPFSLGAAVS
--DGYITIIAESFRRS-------------------------------------YV-TIRPRLTTLAEAISRPSLMHEYRLTPFSLGAAVS
--DGYIMILAESFRGS-------------------------------------YE-TIRPLLTTLAEAVSRPSLIHEYRLTPFSLGAAVS
--GGYITIIAESFRRS-------------------------------------YV-IIRPLLTTLAEAISRPSLMHEYRLTPFSLGAAVS
--AGHISVVVEVFRGTDERRRISEQSRIDQQQQQQDDDGSAPTNRQTSSTAVNTT-SWKLFLQQVAEAVSRPAYLHLFHITPFSLGTAVS
--NGDYHIFMETNTPV-------------------------------------YQ-QAYDFLVAIAEPISRMENLHEYQLKEFSLYGAVS
--DGKFHIFMETFSPI-------------------------------------YQ-QAYDFLVAVAEPVSRPENLHEYVLTEYSLYAAVS
-----GHIFLETFSPF-------------------------------------YS-KTVDFIIAIAEPCSRPKYMQEYQISPYSLFAAVS
-----GHIFVETFSPF-------------------------------------YS-KVVDFIIAIADPCSRPKYVQEYQINPYSIFSAVS
ALSADHVVLLETFSPM-------------------------------------YD-EAYNFLVSLAEAETRPTYVHEYRITEESLHIGLS
-----LRIVVETSNDM-------------------------------------FK-EVSDYLSRVAQVKSRMEHMHEYQLTPTSIMTAFS
-----GLIIIERDNKN-------------------------------------YQ-IASEFIKKISKVKCLLEHMEEYIITEYTIYSAIS
-----LRIVVETSNDM-------------------------------------FK-EVSDYLSRVAQVKSRMEHMHEYQLTPTSIMTAFS
-----GLIIIERDNKN-------------------------------------YQ-IASEFIKKISKVKSLLEHIEEYIITEYTIYSAIS
-----GHIFLETFSAI-------------------------------------YK-QASDFLVAIAEPVCRPQNIHEYQLTPYSLYAAVS
----------------------------------------------------------------------------------------------GFIYLEMFNSC-------------------------------------SK-QASDFLITIAEPICRPELIHEFQLTIFSLYAAIS
-----GTILLETFSAA-------------------------------------NR-QATELLLTMAEPICRGDFVHEFQITIFSLYAGIS
----------------------------------------------------------------------------------------------GYLYLELFTPV-------------------------------------SK-QALDFIVTIAEPVCRPELIHEYQVTVFSLYTAVS
-----GIIFLETFNPL-------------------------------------YR-VAYQFLISIGEPVQRPLSMHKFTLTKYSLYTAMV
-----LYIFVEAFHEK-------------------------------------YK-EVYEFLIKIAEPVNKPNFIHVYKITLFSMYTAMS
-----LGIIVEKFNPL-------------------------------------YE-IAFEFLMCVAEPISRSELIHEYVLTQMSMYTAMV
-----YEIILEKFHRD-------------------------------------AA-AAEETLIQFAEPSSTTTNIQTFIITFYSLYTAMT
-----GRIFLETFSPL-------------------------------------YK-QAYDFLIAIAEPVCRPESMHEYNLTPHSLYAAVS
-----GKIFLETFSPL-------------------------------------YK-QAYDFLIAIAEPVCRPESMHEYNLTPHSLYAAVS
-----GRIFLETFSPL-------------------------------------YK-QAYDFLIAIAEPVCRPESMHEYNLTPHSLYAAVS
-----GRIFLETFSPL-------------------------------------YK-QAYDFLIAIAEPVCRPESMHEYNLTPHSLYAAVS
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*****
VGLQTSDITEYLRKLSKT-------GVPDGIMQFIKLCTVSYGKVKL------------------------------VLKHNRYFVESCH
VGLQTSDITEYLRKLSKT-------GVPDGIIQFIKLCTVSYGKVKL------------------------------VLKHNRYFVESSH
VGLQTSDIIEYLQKLSKT-------SVPDGIVQFIKLCTVSYGKVKL------------------------------VLKHNRYFVESAF
VGLQTHDIVEYLKRLSKT-------SIPEGILEFIRLCTLSYGKVKL------------------------------VLKHNKYFIESPH
VGLQTKDIIEYLERLSKS-------QLPKGVITFVQMCTVSYGKVKL------------------------------VLKHNRYFVESRH
VGLETDDIISVLDRLSKV-------PVAESIINFIKGATISYGKVKL------------------------------VIKHNRYFVETTQ
VGLKTEDIIAVLDRLSKT-------PIPPSIVDFIRACTVSYGKVKL------------------------------VLKKNRYFIESGD
VGLETDDIISVLNRLSKV-------PVAESIINFIKAATVSYGKVKL------------------------------VLKHNRYFVESTQ
IGLQSKDIIDTLDRFLKT-------PLPESIRLFIESCTKSYGKVKL------------------------------VLNNNKYFVESSD
EGTYSMEMVRNVIRYFRLDEQ---QQIPVDVERYAALERRVRDSVQDTSLDLPMEV-------------------------GEAKVSANG
EGTYSMGMIRNVLRYFRLNEQ---QRLPVDIARYNRLEQKVWNNLQNSTAEAALFE-------------------------TD---DADG
EGTYSVAMIRNVVRYFRLDAK---FRLPVDIVKYVELQQRVQDGSQDASLGILGD----------------------------EDRVTNG
EGTYSTAMIRNFIRYFRLDEQ---HRLPVDLAKLSALERQLENGEDV-----AMGT-------------------------THESEESQG
EGTYSLAMIENVLRHFRLNAA---QELPVDLERCAALERLASALDES-TESAEVDGSRVSQEALATTTASSSFDARIPLPRCLCDVDLTG
EGTYSLAMIESVLRHFRLNAA---QELPVDLERCAALERLAAALDES-NGSAEVDGFRTSQEALATKTASSSFAARIPLPRCLSDVDLTG
EGTYSLAMIEVILRHFRLNTA---QELPVDLERCAALERLASELDES-NESAEVDGLWASQAAVATKAASSLFAVHTPLPRCLYDVDLTG
EGTYSLAMIENVLRHFRLNAA---QELPVDLERCAALERLASALEES-SEGAEVDRSRTSQEAMATKTSSSSFAARIPLPRCLCDVDLTG
EGSYTGEDVREFLLRRSEDCD---ARLPAAVDD--------------------------------------------------------ASISVSEVIQFLDDHVYFFRDKCFASYRESVCAFAEMYMSRCNLARV------------------------------VIDESRTLLECKD
ADISAAEVVQFLSEHVYFFNEEHFRPHRNRVELFAERCMSRYNLARI------------------------------VIDDTRTMLECND
ANISAAEVIKFLDNYVYFFCDESLVEKRKRVCAFVETYMSRYNLARI------------------------------VIDEEQTSVVCKD
ASIPVSDVICFLDEYVYGFCDEGENSRRARVCAFLEMCMSRYNLARI------------------------------VIEDARTFVECDN
NGIDAAEATAFLETHAYGLAESS--ERRQLVRQFIESCMKRYNLARI------------------------------IIDAERTLVQCKN
NGIDAAEATAFLETYAYGLAESS--ERRQLVRQFIESCMMRYNLARI------------------------------IIDAERTLVQCKN
NGIDATEATTFLETYAYGLATCS--ERRQRVRQFIESCMRRYNLVRV------------------------------IIDSERTLVQCKN
NGIDAAEATAFLETYAYGLAESS--ERRKLVRQFIESCMTCYNLARI------------------------------IIDSDRTLVQCKN
SGWTPTAVISCLSAYSYHDTT-------TAMNNFITSHMERHNKAQI------------------------------VVDERQRFQLCIR
IGLTCDYIIQVLDKLSKV-------KLPTDLIDFIRKTTSKYGSVKF------------------------------VLQKNRFFLESPI
IGMNTEQIIQVLEKLSKV-------KLSEALINFIRDVTRKYGNVKL------------------------------VLQKNRFFVESPH
IGLTGDKIVHVLSLISKT-------ALTDTFKEHIINCCQAVGKLKL------------------------------VLKEQKYYIESIE
IGLKAKEIIRILAIISKT-------PLTDEFKEHIELCCLSVGKLKS------------------------------VLRNTKYYIESNE
LGYTATEIEIRLGYYSKY------RRLPPTLLSALRRLANNQGTISFS-----------------------------IYDSNRFLLRVPQ
FGSTPEAMISTLEKYSKN-------YLPDNVKSQIRQAGEKKQNFRL------------------------------VLINGKYYLQAES
SGIKPEIIIYQLKKYSKN-------NIPERIEQLIEKTIKSRIITVI------------------------------CNYEGRRICEG-D
FGSTPEAMISTLEKYSKN-------YLPDNVKSQIRQAGEKKQNFRL------------------------------VLINGKYYLQAES
IGIEAETIIYQLKKYSKN-------NIPERIKTLIEKTINNRIITII------------------------------CNYEGKRICEG-D
VGLETNDIITVLGRLSKL-------ALPKEVEQFVRQCTQSYGKVKL------------------------------VLQKNKYFVESAY
--------------------------------------MKNYYTVKL------------------------------VLKDGEYFVESHS
VGITLDELLINLDKFSKN-------VLPNELISNITKSAESFGKVKL------------------------------VLRENKYYIEATN
IGLSCEDMLLNLEKFSKN-------AIPEDLVVQIQKVASAFGKVKL------------------------------VLNENKYYIESAE
-----------------------------------------------------------------------------------------VGLSFEELLNNLNKFSKN-------ELPKKLKESILNTSSAFGKIKL------------------------------VLRDSRYWIESFE
LQYEPKDIILCLEKLSKNK------KIPKEVERYITENTQNYGAARL------------------------------FLDDSSYYLDIDS
LNLNAEKIIESLMQYSKNE------VIPKSFIEFIENKTKKAGSAYL------------------------------YMIKKNYYLKIHQ
LQYSADDIIRLLDLLSKN-------KVPQRMEQFIRHHTNNIGQAKF------------------------------FLQDKSYYIDIGE
LGWNEERIKSEIDRLAKNE------RIPKDITDFIEKNTQYFNRAYF------------------------------YLEKDSYYIDIEM
VGLETETIISVLNKLSKT-------KLPKEMIEFIHASTANYGKVKL------------------------------VLKKNRYFIESPF
VGLETETIISVLNKLSKT-------KLPGEIIDFIHASTANYGKVKL------------------------------VLKKNRYFIESPF
VGLETSTIISVMSKLSKT-------KLPREIIDFIHASTANYGKVKL------------------------------VLKKNRYFVESPF
VGLETSTIISVMSKLSKT-------KLPREIIDFIHASTANYGKVKL------------------------------VLKKNRYFVESPF
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-------------------------PDVIQHLLQDPVIRECRLRNSEGEATELITETFT-------------------------------------------------------PDVIQHLLQDPVIRECRLRNAEGEATELITETFT-------------------------------------------------------PDVIQRLLQDTVIRDCRLRSAEGEETELITETIS-------------------------------------------------------PEVLQKLLKDPVIQKCRLIRSEGEDF--IQGTLD-------------------------------------------------------SDVMQKLLKDSVIQSCILDDRVQPAQQT---ELP-------------------------------------------------------ADILQMLLNDSVIGPLRIDSDHQVQPPEDVLQQQ-------------------------------------------------------ASVLRLLLRDPVIGPLRIDYSTQSSKQKSSKP---------------------------------------------------------ADILQMLLKDPVIGPLRIQSSENIVTSNGLITSA-------------------------------------------------------AELLQKLLRDEVIGKWRVQGSGDITTSYAPTM--------------------------------DVKAEEG--------------------------------CEEATDELSPLAG--------QVKKEETKEVAAEPRRRFLSL--------SSDAEQE--------------------------------ECEGTEALSPCGE---FASPKRFKRDPGGGGAAPPKHRVLSL--------ATLENGG--------------------------------TCHSEPAVKKL--KKEDEEFVPEVKVNSLENTEKPRRRFLSL--------K--KQQK--------------------------------QEEDEDGLGPKRAKKENGERVSLVKQEATEETAAPSRRFFSL--------TILASLNRTSADDAPSPAVTAHHVGNDSLETLVKREKVEEEEMGDRLSAGGAAASALKTVSSRSAAPSG---SPTSRLLQLFRPLLPTPA
TILASLNRTGADDVASPAVSAPHVSNDSWKTLVKREKVEEEAVGDRLSAGDAAASALETVSSRAAAPSG---SPTSRLLQLFRPLLPTPA
TLLASLNRPSADDAASSTLFSPHMRNDTLKTRIKSEKVEEE-EGELLSAGGEGASALEPVLPRTAAPFPRPRSPATRVLQLFRPSSPAPA
TILASLNGASADGVTSPAVPTPHVSNDRLKSLVKRENVEEEEVGDRLSAADAAASASETVSSRTAAPSS---SPTSRLLQLFRPLLPTPA
------------------------------------------------------------------------------------------------------------------IVTAKTLLKDRVVRSLCCQPKETVGE---------------------------------------------------------------IETANILLRDLTVRSLCAEPPEIVTT---------------------------------------------------------------ASTAKALLEDRVVRSLCAHPPKASRT---------------------------------------------------------------VETAETLLLDPVVRSLCAEPPQIVPV---------------------------------------------------------------EETAQMLLRDAVIASVAATPLRIFYEESS------------------------------------------------------------EETAQMLLRDAVIASVAVTPLRIFYEKSS------------------------------------------------------------EETAQMLLCDAVITSVAATPPQIFYETSS------------------------------------------------------------EETAQMLLRDAVIASVAATPLRIFYEESS-----------------------------------------G------------------RRLAEAILRDQRIVSLCAVRDTSVGATAAAT---VRNRQQQT-----------------------------------------------LQIIEKLRNDSVIGKAALIPNPNEFEYLDSS----------------------------------------------------------LTIMEKLYEDKIISAAAIVPDPNEFPNVDRS----------------------------------------------------------EKLISELIKERFFAEKIVSPPSGVMTHPKYP----------------------------------------------------------IRRLLELLEIPFFEERHVYPEPDEKT-YKHT---------------------------------TLDLTPDIKDLLED-----ASDNVADTLFEELLRKKRNDTAEEL----------------QKRELKTH----------------------------------------------QEQMKKVMEENFKQFY-------------------------------------------------------------------------KKIIEEIK---------------------------------------------------------------------------------QEQMKKVMEENFKQFY-------------------------------------------------------------------------KKIIEEVK---------------------------------------------------------------------------------PEVLEFLLKDSSIATARIKPTLEESVVDP------------------------------------------------------------PSILNIIQQR-VLGQVEMS----------------------------------------------------------------------KSELDYLLNNDTIQNARIYSTDNNNDKNMISLYNLNNRHRDNNKNDN------------------------------------------KKELDYLLSNPLIRSSAVAHRRPE----LAQTPQVPAA--------------------------------------------------------------------------------------------------------------------------------------------RSELDLLLTNQEIKNSRIHSNIWDKQPQLQ------------------------------------------------------------QVWTSIIERNPHIKDLVSQTQFNFDNIINQNKELRD-----------------------------------------------------EFLEKIIRIDEEPY----------KSIIE------------------------------------------------------------TVLNQIMMNLQDKNSL--------QEVIQEEQIIHN-----------------------------------------------------KLLQELKHRKFGQMH-----------------NLT-----------------------------------------------------PEVLKRLLSDDVINRARFSSEPYYG----------------------------------------------------------------PEVLKRLLSDDVINRARFTSEPYYG----------------------------------------------------------------PEVLKTLLKDDIICRARISPEDSVG----------------------------------------------------------------PEVLKTLLKDDIICRARISPEDSVG----------------------------------------
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--------------------------------------------------------------------SKSAI----------------S
--------------------------------------------------------------------SKSAI----------------S
--------------------------------------------------------------------SKSAI----------------S
--------------------------------------------------------------------GKAIT----------------Q
--------------------------------------------------------------------AQEKI--------------KFS
--------------------------------------------------------------------LQQT-------------------------------------------------------------------------------------SNEDN--------------VED
--------------------------------------------------------------------SEPSN--------------IVI
-----------------------------------------------------------------------GG--------------LVI
---------------SKRISAKSEPLVTRAVVNT-GALQPLPADLEQMLREEENSSRVRIVLQPCLRPVKRRAV-GGDKQHSD---------------------CKRSVSSAEPFVSRAVINA-DALRPLPDDIEAMLQEEENSSKVRIVLQPCLQSRKLRT---GKFVHSN---------------------VRKPPAPLEPLVARTLVNP-DALLPLPDDLEQMLQDEERSSKVRIVLQRRLQGRQRCSS-------SQ---------------------VKGVTIQPEPLISHALCFP-DALRPLPPDLEQMLLEEERSSRVRIVLQPQLRSFQRQQP-Q----H--------SAAAPTHSPTTRSQLEQGAPIAARPLISLAVVRPADVRRPLPESLAQMLEEEENASRVQIVLQPRLRRFHQFEASRGASFASTTATSRAT
SAAAPIHSPTAGSPLEQGTPIAARPLISLAVVRPADVHRPLPESLAQMLKEEEHASRVQIVLQPRLRRFHQFEASRGASFASTTATSRAT
STAVMLRSPTADSQLKQAAPSAARPLISLAVVRPADVQRPLPELLAQMLKEEEKASRVQIVLQPGLRRFHQFEASRGAFFASTSATCRAT
SAAAPLHSPTTGSQLEQGAPIAARPLISLAVVRPADVHRPLPELLAQMLKEEENASRVQIVLQPCLRRFHQFQASRGASFASTTATPRAT
-----------------------------------------------MIAVEIMSEKISLTLAPDLRGDFDARSSGGASRS-------------------------------DA---------------------------------------------------------------------------------------SA---------------------------------------------------------------------------------------EA---------------------------------------------------------------------------------------VP------------------------------------------------------------------------------WEE----SPAP------------------------------------------------------------------------------WEE----SPAP------------------------------------------------------------------------------WAE----NPAP------------------------------------------------------------------------------WDE----NPAP----------------------------------------------------------------------STKTSDKKIEE----GDES-------------------L---------SHLYITR---------RII----------------R
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----------------------------------DKDEEEE-E-----E--TQTVSFEVKQ---EMIEELQ-KRC-IH--LEYPLLAEYD
----------------------------------DKDEEEE-E-----E--TQTVSFEVKQ---EMIEELQ-KRC-IC--LEYPLLAEYD
----------------------------------DKEEEEE-E-----E--TQTVSFEIRQ---EMIEELQ-KRC-IQ--LEYPLLAEYD
----------------------------------DKEEEDE-D-----EANLKTVSFEVAQ---EKIEVIQ-KRC-IE--IEHPLLAEYD
----------------------------------DGDDEEDAE-----IRNLQLLTFEIKQ---ETIETVQ-KRC-IE--LEYPLLAEYD
---------------------GG-----------DNEREEE-D-----DDIDAVHSFEIAN---ESVEVVK-KRC-QE--IDYPVLEEYD
---------------------GL---------------QEE-E-----DDEDAVHLFEIKH---SSVETIK-KRC-AE--IDYPLLEEYD
---------------------GN---------------RDD-D-----DDMDTIHSFEIAH---DSVEIVK-RRC-QD--IEYPVLEEYD
------------------------------------NEEDD-E-----DDKDAVHAFEIPE---TAVEIVQ-RRC-LD--LGFPILEEYD
TAESGRAKTLRRLFEAPSSASGRSVASKSLT--NEGANGDGLGGGVGRRCTRIVYKSQVMD---GKMRNVRERLY-KE--LSVRADLFYD
TVESGRASVLRWLFDTPSRLPVFQCHGKEGAGATATPYSTGTGGGLG-RCTRIVYKSQVAD---GKMRNVRERLY-KQ--LGVRADLFYD
VVEDGRARTLRILFDTPSGQKSELQS-----------ANSSRMARSEKKYTRIVYKSQVMK---GRLRNVRERLF-KQ--LGVRVDLSYD
VVESGRAKTLRRLFDTPSVSFASAMD-------DVGSCATAAANSTGRKYSRVVYKSQVKD---GRLRNVRERLF-KE--LGVRADLFYD
ARDAGRPAVLRLLYEPPRVGTQYEKA------------------EATPSASRFLYKCQVRD---GKLREVKECLF-SK--FDIRADCYYD
ARDAGRPAVLRLLYESPRAGTRHEKA------------------AATPSASRFLYKCQVRD---GKLREVKECLF-SK--FDIRADCYYD
TRDAGRPAVLRLLYEFPHVGTVSERT------------------TTASTASRFVYKCQVRD---GKLREVKERLF-SK--FGIRADCYYD
ARDAGRPAVLRLLYEPPRVGTRYEAA------------------AATPSASCFVYKCRVRD---GKLREVKECLF-SK--FDIRADCYYD
---SGSL--L---------------------------RERRLNGSSGPVTKQMVYKCRIRA---GCQRQIKEALY-QR---SIRVICTYD
-----------------------------------------------------CPHFLLKSR--AAARVVAER-C-VL--LGYPLQQQYE
-----------------------------------------------------RPYSLLRNR--AVTKVVAER-C-AA--LGYPLQQQYD
-----------------------------------------------------CSF-LLRSR--AAARPVAER-C-VA--LGFPLQQQYD
-----------------------------------------------------HSLLVLRSR--AVARRVAER-C-VL--LGFPLQQQYD
-----------------------------------------------------YPSFLLQSR--AMSKVVAAQ-C-VV--LGLPIQQQYD
-----------------------------------------------------YPSFLLQSR--AMSKVVAAQ-C-VV--LGLPIQQQYD
-----------------------------------------------------YPSFLLQSR--AMSKVVAAR-C-MV--LGFPIQQQYD
-----------------------------------------------------YPSFLLQSR--VMSKVVAAQ-C-VV--LGLPIQQQYD
--SEAKNAAI-----------VA-----------DKEEHDDDG-------ELEEVQVLLQDH--AASRLVSDVLW-AH--HHLPICQVYH
---------------------HS-----------NYEEEYEDDNDLDSEPHETLYSFEISS---KSIESVK-KQC-IV--IGHPTLDEYD
---------------------QI-----------GDDEDDDADDDFDIS-------------------------------------------------------------RL-------------TEGFD-EIFE--VEKPKIYRFELKP---ETVRDVR-KHA-VD--NNLFLSDEYD
---------------------RL-------------TEGID-DLLDTPLEKQTILRFQIKT---ESVREIR-QYA-VD--HNLFISDEYD
LLDEGIDAVR-------------------------NEQVQRLQSLMAAEINTEAEMCEL--------KKIKEE-----------FAKAY------------------------------------EVKESDELYRELDLDHHVFIIEVKQ---TSVFKLK-KKC-KK--KKVRVYEEYH
---------------------------------------------------INKNEYELK----SNIIVFK-KKC-QE--KGILINEKIE
------------------------------------EVKESDELYRELDLDHHVFIIEVKQ---TSVFKLK-KKC-KK--KKVRVYEEYH
---------------------------------------------------INKKEYEIK----NNIIEFK-KKC-QE--KGILINEKIE
----------------------------------EEEEEDTVN-----NSDQHFHSFEIDP---QQVEEVK-KRC-IQ--LDYPVLEEYD
------------------------------------------------ETGAQVLVYALPISTVQEVAEIK-KLL-LA--HNHPFIEEFD
------------------------------------KKHANLNANENSTNSAEVYSFEVNC---DKIEEVK-QEA-LQ-TMQRPLLMEYD
GAEEARGKAQVPL-ASPHASASP-----------TGEDGDSAKRKTMSAPTRQVFSFQVSS---DRVEEVK-RVS-VE-SMHRPLLNEYD
-----------------------------------------------------------------------------------------------------------------------------TTTAKFAGRSDKTTTRQVFSFEVQQ---EKIEDLK-REA-LQ-TMRRPLVMEYD
--D------------DEDEEDSD-----------DGDDDFVYNFIMNNKTKRSFKRIQI-I---GDHFEVT-KAV-IN--CSVPLIQEYD
----------------------Q--------------E-------ESRVWNFKFYRIKQ-K---HNLFQIT-EKI-IK--EGISLINEYH
--K------------EADIEQMA-----------KEIDTFKDWLAQDKIQTIKFKRFRI-V---GDYFDVA-QAL-IR--SSVPLIQEYD
----------------QD------------------------SLLNDN---KTFVKFKIKA---NEHFSVN-RELVED--FNVPVKQEFD
-----------------------------------NEAEFAAA-----AEEKETHSFEIDP---AQVENVK-QRC-LPNALNYPMLEEYD
-----------------------------------NEAELAAA-----AEEKETHSFEIDP---ALVENVK-QRC-LPNALNYPMLEEYD
-----------------------------------DGMELAAA-----TEDKETHSFEIDP---SQVENVK-QRC-LPNALNFPMLEEYD
-----------------------------------DGMELAAA-----TEDKETHSFEIDP---SQVENVK-QRC-LPNALNFPMLEEYD
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WM I
*****
FRNDS--------------------------VNPDINI-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG
FRNDT--------------------------LNPDINI-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG
FRNDT--------------------------VNPDINM-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG
FRNDT--------------------------NNPDINI-DLKPAAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG
FRNDT--------------------------LNPNLGI-DLKPSTTLRPYQEKSLRKMFGNS---------RARSGVIVLPCGAGKTLVG
FRNDH--------------------------RNPDLDI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG
FRNDN--------------------------INPDLPI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG
FRHDA--------------------------RNPDLEI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG
FRNDS--------------------------NNADLEI-DLRPNTQIRPYQEQSLSKMFGNG---------RAKSGIIVLPCGAGKTLVG
YVQDH---------------------------SLHVCDLELSENVRLRPYQVASLERFRSGN---------KAHQGVIVLPCGAGKTLTG
YLQDQ---------------------------SLHVCGLELSENVRLRPYQVASLERFRSGN---------KAHQGVIVLPCGAGKTLTG
YNEDC---------------------------TLHVCDLELAGHARLRPYQVASLERFRSGN---------KAHQGIIVLPCGAGKTLTG
YVQDG---------------------------TLDVRDLALAEHVRLRPYQVASLERFRCGN---------KAHQGVIVLPCGAGKTLTG
YMQDH---------------------------TLYVPNLSLASHVRLRPYQVASLERFRRGR---------KAHQGVIVLPCGAGKTLTG
YMQDR---------------------------TLHVPNLNLASHVRLRPYQVASLERFCRGR---------KAHQGVIVLPCGAGKTLTG
YVQDR---------------------------TLYVPNLTLARHVRLRPYQVASLERFRRGQ---------RAHQGVIVLPCGAGKTLTG
YMQDR---------------------------TLHVPNLHLASHVRLRPYQVASLERFRRGQ---------KAHQGVVVLPCGAGKTLTG
YMRDL--------------------------QTPTVANFSLRLGVRLRPYQAASLERFRRDD---------KAHHGVVVLPCGAGKTLTG
YEK--------------------------DTSIRNVNI-ALKSQTRPRPYQIAAVDAAASDG---------ALRSGCIVLPCGSGKTLVG
YER--------------------------DTTIRNVNI-ALKAQTKPRPYQIDAVDAATADG---------SLRSGCIVLPCGAGKTLVG
YER--------------------------DMSIRSINI-MLKTQTKPRPYQIDAVDAAVSDG---------FLRSGCIVLPCGAGKTLVG
YER--------------------------DSGVRNINV-MLKTQTKPRPYQIDAVNAAATEG---------SLRSGCIVLPCGAGKTLVG
FEN--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG
FEN--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG
FEN--------------------------DTSVRKAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCILLPCGAGKTLLG
FEK--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG
FSASDDSVVHDDKGGADHVLNSAASRDHAANDVRSINL-VLRPQCRPRPYQIAAVEAALAHG-------GTAVRSGVLLLPCGAGKTLVG
FRNDK--------------------------RNSSLVI-DLKPTTTIRSYQEKSLNKMFSNG---------RARSGIIVLPCGAGKTLVG
-----------------------------------------------------------------------------------------FMNDK--------------------------SLKNLNI-RLRTETNIRPYQEKALSKMFSGG---------RAKSGIIVLPCGAGKTLVG
FMNDK--------------------------TIDNLGI-QLKNTTRIRPYQEKALTKMFSGG---------RSISGIIVLPCGAGKTLVG
-----------------------------QVKAPQINA-QLKPTTDLRDYQDHASKKVISEVQLDTSQIVKRCNSGLVVLPCGAGKSLLG
FLRDK--------------------------QKE-LPI-QLR-KDCLRPHQERALQQIFDNE---------MARSGIVVLPCGAGKTLTA
I------------------------------GEKTIPI-ALKDDTVLRKYQISGISSVFRKG---------FAQSGIIILPCGAGKTLMT
FLRDK--------------------------QKE-LPI-QLR-KDCLRPHQERALQQIFDNE---------MARSGIVVLPCGAGKTLTA
I------------------------------GKKRINI-SLKDDTVLRTYQIKGINSVFKKG---------FAQSGIIILPCGSGKTLMS
FRNDT--------------------------VNPNLNI-DLKPTTMIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLSG
FLTNRWSEK----------------------ACANLAI-NLKEGTGVRPYQKRAAFSLFWDN---------KAHSSILVLPCGAGKTLVG
FRRDK--------------------------KNPNLIC-SLKSHVQIRYYQEKALRKMFSNG---------RSRSGIIVLPCGVGKTLTG
FRRDK--------------------------TNKNLSSLLLKSSTKIRYYQERALRKMFSNG---------RARSGIIVLPCGAGKTLTG
---------------------------------------------------------MFSNG---------RARSGIIVLPCGAGKTLTG
FRKDN--------------------------NSPSLNC-CIRSNIKIRYYQERALRRMFSNG---------RARSGIIVLPCGAGKTLTG
FENK---------------------------SFKQLEI-ELKPKIKVRYYQERALKNIFIQK---------KARSGLIILPCGAGKTIVG
DDKESQNDLSSN----------------VQIPYKKLDI-ELRQITQPRIYQQKALKNIFVCE---------KPRSATIVLPCGAGKTLLG
FTKE---------------------------K-QKLDI-NLKPSTKPRLYQLRAAKTVIMGD---------YAKSGLIVLPCGAGKTLVG
YLKDLENTKQ-D----------------I--QKKLQQF-RMKAIYQLYSHQNRALKKIFQND---------KAHSGVIILPCGAGKTLLG
FRNDN--------------------------VNPDLDM-ELKPHAQPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG
FRNDN--------------------------VNPDLDM-ELKPHAQPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG
FRNDT--------------------------VNPDLEM-ELKPQARPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG
FRNDT--------------------------VNPDLEM-ELKPQARPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG

WM IA
****
VTAACTVRKRCLVLGNSAVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-VTAACTVRKRCLVLGNSAVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-VTAACTVRKRCLVLGNSSVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-VTACCTVRKRALVLCNSGVSVEQWKQQFKMWSTADD-----------------------------------SMICRFTSEAKDK-PMG-VTAVTTVNKRCLVLANSNVSVEQWRAQFKLWSTIQD-----------------------------------KQLVRFTREAKDP-APSGA
ITAACTIKKSVIVLCTSSVSVMQWRQQFLQWCTLQP-----------------------------------ENCAVFTSDNKEM-FQT-ITAACTIKKSVIVLCTSSVSVMQWRQQFLQWSNIKP-----------------------------------DHIAVFTADHKER-FHS-ITAACTIRKSVIVLCTSSVSVMQWRQQFLQWCTIQP-----------------------------------ENVAVFTSENKEM-FAS-ITAACTIKKGVIVLCTSSMSVVQWRQEFLKWSNINP-----------------------------------DDIAVFTAESKNK-FSG-IGAAATVKKRTIVMCINVMSVLQWQREFIRWTNLSE-----------------------------------DQVTVCIADKKQM-----IGAAATVKKRTIVMCINVMSVLQWQREFLRWTNLTE-----------------------------------EQVTVCISDKKQM-----IGAATIVKKRTIVMCINVMSVLQWQQEFVRWTNLTE-----------------------------------DQVTVCISDKKQM-----IGAATILKKRTIVMCINVISVLQWQREFFRWTDLSE-----------------------------------DQVTVCISDKKQM-----IGAAATMQTTTIVMCINHMSVFQWQREFLRWTNLAE-----------------------------------EEVTVCTAKVKQR-----IGAAATMQTTTIVMCINNMSVFQWQREFLRWTDLAE-----------------------------------DEVTVCTAKVKQR-----IGAAATMQTTTIVMCINNMSVFQWKREFLRWTDLTE-----------------------------------DEVTVCTAKVKQR-----IGAAATMQTTTIVMCINNMSVFQWQREFLRWTDLAE-----------------------------------DEVTVCTAKVKQR-----IAASSIVSKKTIVMCCNVLSVMQWRKEFLRWTDLRE-----------------------------------DQVTVCVRGMKQR-----IMLLCKVKKPTLILCAGGVSVEQWRNQILEFASVCAPANNEEGDPSNS-----T-----TGEKVRTAAVGAARISCLTGKQKDE-I---VMLLCKVKKPTLILCTGGISVEQWRNQILEFASLSAPSGGEEGSSSTAC----A-----TSKRARPPAVGAARISCLTGKQKDE-I---IMLLCKVKKPTLILCAGSVSVEQWKNQILEFSTLGCSLGNDENRSSSGS---GT-----ASGRQRTRIEGVARISCLTAKQKDD-I---IMLLCKVKKPTLILCAGSVSVEQWKNQILEFASICAHDTDDEM----------A-----AAEKHRSRLEGAARIACLTGKQKDP-V---IMLMCKVKKPTLVLCAGSVSVEQWKSQILDYATLETPPRTDDGDASDAH-----------GGRPHQIKDGAARIACLTGKQKDP-I---IMLMCKVKKPTLVVCAGSVSVEQWKSQILDYATLEAPPPTDDGDAANAH-----------SGRSHQIKNGAARIACLTGKQKDP-I---IMLMCKVKKPTLVVCAGSVSVEQWRSQILDYATLEAPPPTDNDDAADTQ-----------GGCSHQIKSGATRIACLTGKQKDP-I---IMLMCKVKKPTLVVCAGGVSVEQWKSQILDYAVLEAPPPTDDGDAADAH-----------GGRPHQIKNGAARIACLTGKQKDP-I---VLLAAVVKKRTIIVCAGSISVEQWKNQLLEWADLTPLDEEDTATTHNIAARGGRGGGRGGSRGGQGRAVGGDRVACLTGKHKDP-I---VTAASTIKKHTLVLCINTVSVFQWKNQFRLWSTIDD-----------------------------------DSILVHTSQQKAT-LPK------SAVETFYLFEINPTECIEWKNQFKLWSTIDE-----------------------------------NRVVVFTSQEKDA-LPK-ITAVATINKPAVVVCNSVEPVKQWANQFNLWTNVPG-----------------------------------GVVVVLTSENKQA-LP--IAALATINKPTVIVCNNRLTVKQWYNQILQYATMDM-----------------------------------KKIFLFSDTEKQA-LPQ-VACACRLGHSCIVVTNGNLSSKQWKSQFLQFSTVES-----------------------------------DRVYIFSANKDEETEFI-IAACSKIKRSTIVLTHTTQSVFQWKEEFLKWSTIKP-----------------------------------DAIKLCVSSKKEQ-LGD-IGIICTFQQPTIIICTTTISIEQWRDEIRKWSTIPL-----------------------------------NKIKCFSSIIKET-----IAACSKIKRSTIVLTHTTQSVFQWKEEFLKWSTIKP-----------------------------------DAIKLCVSSKKEQ-LGD-IGIICKFQEPTIIICTTTISIEQWRDEIRKWTNIPL-----------------------------------NKIKCFSSIIKEE-----ITAACTVKKSILVLCTSAVSVEQWKYQFKLWSNIEE-----------------------------------RQISKFTSDNKEK-ISN-ITVSSIIKKCILVFCTSMMAVNQWREQFLKWSDIEP-----------------------------------SRISRFISDTRKKGEWD-ITAASTIKKSALFLTTSAVAVEQWKKQFEDFTNIHP-----------------------------------RHIRILTSDYKLD-LWP-ITAACTLRKSVMILTTSAVAVDQWRKQFEEYTTIDS-----------------------------------SRLLTLTAETKQT-LWP-ITAVCTLQRSAVVLTTSAVAVEQWKRQFLENSSIKE-----------------------------------KEIMLLTAESKQQ-LWG-IVAACTVRKSIFVLTTSAVAVEQWIKQFLDFTNISR-----------------------------------TNLISLTSEHKTD-LWD-VIAIERIKQSTVIICDSDVSVDQWRDELERWTTINK-----------------------------------NKIVRLTGRIVDE--WPTR
IIVTEKIKGNTIVICDIDTATKQWKNEFIRWTTVKP-----------------------------------DRIKIYTGKTKNL--QE-VLCMSLIKSSTVIICDSNVSVEQWKREIEGYTTIDN-----------------------------------RRIIRVTGFAKDK--WQGINVALKIKRKTLIICDQVNDVYQWQKSFIKFTEMDK-----------------------------------NNLAIILRTQQEV--PMAV
VSAAARIKKSCLCLATNAVSVDQWAFQFKLWSTIRD-----------------------------------DQICRFTSDSKER-FRG-VSAAARIKKSCLCLATNAVSVDQWAYQFKLWSTIKD-----------------------------------DQICRFTSDSKER-FRG-VSAACRIKKSCLCLATNAVSVDQWAFQFKLWSTIKD-----------------------------------EHISRFTSDNKEK-FRG-VSAACRIKKSCLCLATNAVSVDQWAFQFKLWSTIKD-----------------------------------EHISRFTSDNKEK-FRG-.
:* .:
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WM II
****
----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWLKTQEWGLMILDEVHTIPA
----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWLKTQEWGLMILDEVHTIPA
----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWMKSQEWGLIILDEVHTIPA
----CGILVTTYSMITHTQKR----------------------------------------SWEAEQTMRWLQEQEWGIMVLDEVHTIPA
DATKPVVCISTYSMVAYSGRR----------------------------------------TLQAEEAMKFIEKQEWGLLLLDEVHTIPA
---ESGLVVSTYSMVANTRNR----------------------------------------SHDSQKVMDFLTGREWGFIILDEVHVVPA
---EAGVVVSTYSMVANTRNR----------------------------------------SYDSQKMMDFLTGREWGFILLDEVHVVPA
---ESGLVVSTYSMVANTRNR----------------------------------------SHDSQKVMDFLRSREWGFIILDEVHVVPA
---NTGIIVTTYSMVTNNRER----------------------------------------SHDSKKMMDFLKSREWGLMLLDEVHVVPA
---PGDVFITTYSMLIARRSNVPEM-EQSAD------------------------------AKLTAKILASVGEQPWGLLLLDEVHTALA
---PGDVFITTYSMLIAKRPNVSDQ-EQSAD------------------------------AKLTSKILASVSEQPWGLLLLDEVHTALA
---PGDVFITTYSMLIARRTSNLGQ-EQGED------------------------------AKLTSKILFAVEEQPWGLLLLDEVHTALA
---PGDVFITTYSMLVAKRPTAPEQ-EQGED------------------------------ARLTSRILASVEEQAWGLLLLDEVHAALA
---PGKVFITTYSMVVAKRGSADG-----AA------------------------------AEESRAILQVMTAQPWGLLLLDEVHTALA
---PGKVFITTYSMVVAKRGSTDG-----AA------------------------------AEESRAILQAMTAQPWGLLLLDEVHTALA
---PGKVFITTYSMVIAKRGNADG-----AA------------------------------AEESRAILQAMAAQPWGLLLLDEVHTALA
---PGKVFITTYSMVVAKRGNADG-----AA------------------------------AEESRAILQAMTAQPWGLLLLDEVHTALA
---PGDVFITTYSMLTAQRATRPADAVVTED------------------------------ALLTKEILSDIANSTWGMLLLDEVHIAPA
-TDETDIVLTTYSMLVTAHKAQARCQVEGFE----------M------------NADGRGRNPRRANPKERLFQ-PYGLLIMDEVHMMPA
-TDDTDIVLTTYNMLVTAHKMQRRQQCSSAG----------G------------ATGEQRAKTRRPNPKERLFQ-PYGLLIMDEVHVMPA
-TDDTDIVLTTYNMLVTAHKAQARYHAEHCK----------V------------AVDTQRKRGRRSNPKERLFQ-PYGLLIMDEVHVMPA
-TEETDIVLTTYSMLVTAHRAQMRQRAAHAS----------G------------LADDRHQKRRRANPKEKLFQ-PYGLLIMDEVHVMPA
-TEETDVVLTTYSMLVTAHRAKMRQQATTTS-------SEDG------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPA
-TEETDVVLTTYSMLVTAHKAKMRQQATTTS-------SEDG------------LFTERGLRKRKENPKEKLFA-PYGLLILDEVHVMPA
-TEETDVVLTTYSMLVTAHKAKLRQHATTTA-------GEDD------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPA
-TEETDVVLTTYSMLVTAHKAKMRQQATAIS-------SEDG------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPA
-TEDTDVVITTYTMLGVAQEHYRREQQQRLERRKLQNRGEDDDDMTRRSCGAAPDRRSSAQSKRSRNPKEALFDTTWGLMILDEVHMAPA
DPNKAVVLITTYSMISFKGRR----------------------------------------SEESKQMMEYIENREWGLLMFDEVQVYPA
DDD-PLIIITTYTMITHTRKR----------------------------------------SGEAKEVMDYIQSREWGLLILDEVHVVPA
--DKPCILVTTYGMLTSSARR----------------------------------------SAESQKVIDQITGRDWGILVMDEVQEAAA
--TGPCIVISTYSMLSNPNKR----------------------------------------SDKSQQIIDQIKSRDWGLLILDEVQDSAA
-PGYHIVFISTYQMLTNAKSA------------------------------------------KSKETLNKVHSLMWGIVLFDEAHQVMA
---DACVLITSYSMLSHTGER----------------------------------------EYAGQRIIDDLLKREWGFIIFDEVHGSTT
-IEESYIVITTYQMIQS-------------------------------------------------KEIEEIRKKKYGMMILDEVHSSVA
---DACVLITSYSMLSHTGER----------------------------------------EYAGQRIIDDLLKREWGFIIFDEVHGSTT
-IX-XYIIITTYQMIQS-------------------------------------------------KEIEEINKKRYGMMILDEVHSSVA
---VAGVTITTYTMVAFGGRR----------------------------------------SAESLKIMNEITNREWGLVLLDEVHVVPA
--HTCGLLITTYNMFTS-EKR----------------------------------------AEHSTRMIEKCKERTWGLMILDEVHLAPA
-INEAGVLISTYTMLSYSGKR----------------------------------------SEQSLRIVNDIRRREWGLLVFDEVQFAPA
-VDEAGVLVSTYTMLAFSGRR----------------------------------------SLAAERIMQQIREREWGLLIFDEVQFAPA
-PAAAGVLLSTYTMLAFSGRR----------------------------------------SAAAAAVLSQIQSREWGILIFDEVQFAPA
-EKDAGVLISTYTMMSYTRKH----------------------------------------RENTERILNQIKQREWGMLIFDEVQFVPA
TTDEPIIVITTYYMLVKKREDLPPT-----Q-------------I---------AQKS---K--KRQYIDSMKERKWGVCVIDEVHKLPA
KQTKPFILITTFKQLSSIIKSNKLQKEKRQD-------------M---------DTSS---KYETKMDHYIQEEMEWDLCIADETQYSAA
--EQPIVILTTYSWLIAQFRNN----------------------------------SS---S--TKTVWNQISEVSWGICIVDEVHRLPA
LGREHIIVITNKDMISS-----------------------------------------------NRKDIKHVTTLEWPLLIMDEVHGLPA
---NAGVVVTTYNMVAFGGKR----------------------------------------SEESEKIIEEMRNREWGLLLMDEVHVVPA
---NAGVVVTTYNMIAFGGKR----------------------------------------SEEAEKIIEEMRNREWGLLLMDEVHVVPA
---MAGVVVTTYNMVAFGGKR----------------------------------------SEDSEKIIEEIRNREWGLLLMDEVHVVPA
---MAGVVVTTYNMVAFGGKR----------------------------------------SEDSEKIIEEIRNREWGLLLMDEVHVVPA
: ::.
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ThM domain
***** ***
************ *
KMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K
RMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K
KMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K
KMFRRVL----------TIVQSHCKLGLTATLLREDDKIADLNFLIGPKLYEANWLELQKKGYIARVQCAEVWCPMSPEFYREYLTT--K
KMFRRVL----------TIVQAHCKLGLTATLVREDDKITDLNFLIGPKIYEANWMELQKAGHIAKVQCAEVWCPMTSAFYSYYLRS--Q
AMFRRVV----------STIAAHAKLGLTATLVREDDKIGDLNFLIGPKLYEANWMELSQKGHIANVQCAEVWCPMTAEFYQEYLRE--T
AMFRRVV----------TTIAAHTKLGLTATLVREDDKIDDLNFLIGPKMYEANWMDLAQKGHIAKVQCAEVWCAMTTEFYNEYLRE--N
QMFRRVV----------TTIAAHAKLGLTATLVREDDKIDDLNFLIGPKLYEANWMDLAQKGHIANVQCAEVWCPMTAEFYQEYLRE--N
DVFRRVI----------SSIKSHSKLGLTATLLREDDKISHLNFLIGPKLYEANWMELSEKGHIAKVQCAEVWCPMPTEFYDEYLRA--N
HNFQEVL----------NKVKYKCVIGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLARVECAEIQCPLPKAFLTEYLESQSD
HNFREVL----------NKVKFKCVVGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLARVECAEVQCPLPRPFLVAYLDNQKQ
QNFQEVL----------NKVKYKCVVGLSATLLREDGRIDDLRHLVGPKLYEANWLDLTNAGFLARVECAEVQCPLPISFFSEYLIAQQE
HHFQEVL----------NKVKYKCVVGLSATLLREDDKIGDLRHLVGPKLYEANWLELTRAGFLARVECAEVQCPLPLPFFREYLDSQAE
HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLQEYYGIQRT
HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTCAGFLANVECAEVQCPMPPLFLQEYHDIQST
HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLQEYRDIQRT
HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLEEYHAIQRT
QRFQEVI----------NCVKHHCVLGLSATLLREDQRIDNLRFLVGPKLYEANWLELTNQGFLADVVCVDVRCPMPPAYLRMYLDPQST
DAYKDSL----------GFINAKGVVGLTATYVREDSKIRDLFHLVGPKLFDISWERLASSGYLAHVTCIEVLTPLARRFSLEYLERSSE
DVYKESL----------GYVNSKGVIGLTATYVREDAKIRDLFYLVGPKLFDMSWERLASSGYLANVTCVEVLTPLTRQFNLEYMERSGS
ETYKESL----------GFINAKGVIGLTATYVREDAKIRDLFHLVGPKLFDVSWETLASSGYLANVTCVEILTPLTRQFSLEYMERSSS
EAYKESL----------SLVDAKGVVGLTATYVREDAKIQDLFHLVGPKLYDVSWETLASSGYLANVTCIEVLTPLTRQFSLEYMQRSGE
ESFRGSL----------GFVDAKGVIGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLAKVHCVEVRTPMTKEFGLEYMQRSSK
ESFRGSL----------GFVDAKGVIGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLAKVHCVEVRTPMTKEFGLEYMHRSSK
ESFRGSL----------GFIDAKGIVGLTATYVREDHKILDLFHLVGPKLYDISMEALASQGYLANVHCVEVRTPMTKEFGLEYMDHRRR
ESFRESL----------GFVDAKGVVGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLSKVHCVEVRTPMTKEFGLEYMDRSSK
AGVRESI----------SHVVSKAVVGLTATYVREDHRIRDTFHVVGPKLFDISWEELHQQGFLASITCVEVHCPMTPDFMVEYTQRLHT
DSFRA------------SHLKAHCKLGLTATLLREDNKQEDLNFLIGPKLYEANWLDLQKKGHLANVQCVEVWCPMTAEFYAEYLSS--N
NMFRHV-----------ASVKSHCKLGLTATLLREDNKTDDLYFLIGPKLYEANWLDLQQKGHLANVQCVEVWCPMTAEFFAEYLTA--N
EKFRNVT----------DMVKAHTRLGLTATMVREDGKIDDLKYLVGPKLYEANWIELSESGYLARVKCFEILVTMSQEFYKKYLTLDKD
NTFRNVT----------DIAKAHTRLGLTATLIREDDKISDLRYLVGPKLYEANWLELSEQGYLARVKCFEVTVPMTASFYKYYLLS--D
ETYRTLFVTDNVNTKANLFLRSYCKIGLTATPLREDDEMTNL-YLLGNKLYESNWSDLAKRGFIAKLQCAEIRCPMHHIFYDDWLDQNTA
DNIEKFV----------CKIKAQCKLGLTATLIREDDRIRDLEFMIGPMLYEASWQELAKQGYIANAKCFEVICPMTKTYYSAYVEAD-D
KEFRKIY----------YLIEARCRIGITATPIREDCKIKDLDYLIGPILYQESWKELIKEKYIANVQCIDIKCPMTIPFYEEYINNS-N
DNIEKFV----------CKIKAQCKLGLTATLIREDDRIRDLEFMIGPMLYEASWQELAKQGYIANAKCFEVICPMTKTYYSAYVEAD-D
KEFRKIY----------YLIETRCKIGITATPIREDYKIKDLDYLIGPILYQENWKDLIKEKYIAKVQCIEIKCPMTIPFYEEYINNS-K
AMFRKVL----------TVTKAHCKLGLTATLLREDEKIQDLNFLIGPKLYEANWLDLQKAGFLANVSCSEVWCPMTAEFYKEYLIND-S
TTFKRVT----------TEFRAHVKLGLTATMVREDELIAELPTLVGPRLDEVDLLSLKIHNHVANVHCYRIVCPLTSAFGAAYRTAR-S
PSFRRIN----------DIVKSHCKLGLTATLVREDLLIRDLHWIIGPKLYEANWVELQNKGFLAKALCKEIWCSMPCSFYKYYLKS--N
PAFRRIN----------DLVKSHCRLGLTATLVREDDLIKDLQWLIGPKLFEANWIELQDQGFLARVSCQEVWCPMTADFYREYLRC--S
PAFRKIN----------ALVRAHCRLGLTATLVREDDLIKDLQWIIGPKLYEANWIDLQNQGYLAKVSCQEVWCPMTAEFYREYLRA--P
PAFRRIN----------EIIRSHCKLGLTATLVREDDLIRDLQWLIGPKLYEANWLELQQKGYLAKVICKEIWCPMTAPFYREYLRS--S
NTFQNVL----------KQYKFHFKLGLTATPYREDEKIINLFYMIGPKLYEENWYDLVSQGFLAKPYCVEIRCEMSQLWMSEYNKKDLK
STYKKIF----------EEFNFKLKIGLTATPYREDNKIDDLFHVIGPKLYEANISELIQDSYLAKPYCVVFRCKMHECCEDFMKDR--VQFQNVL----------KQIKCAIKIGLTATLLREDQKLDNLYFMIGPKLYEENLIDLMTQGFLAKPHIIEIQCDMPPIFLQEYQTKNNM
EQINAEI----------SKLKANMKIGLTATPYRQDNKIKEIFYKVGPKLHESMIVDLKQMGYVSKIYCIQVYVGMQDLYKQKYEEYRRV
HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N
HMFRKVI----------SITKSHCKLGLTATLVREDEKITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N
HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N
HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N
.
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***********
-------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIKFHE-RR
-------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIKFHE-RR
-------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIRFHE-RR
-------------------------------------------------------------TSKKMLLYVMNPSKFRSCQFLIKYHE-QR
-------------------------------------------------------------IARKLLLAVMNPNKFRICQFLIKFHE-RR
-------------------------------------------------------------ARKRMLLYIMNPTKFQACQFLIQYHE-RR
-------------------------------------------------------------SRKRMLLYIMNPKKFQACQFLIDYHE-KR
-------------------------------------------------------------ARKRMLLYIMNPTKFQACQFLIHYHE-KR
-------------------------------------------------------------SRMKRTLYAMNPRKFQACQYLINYHE-AR
GDPFA--------------------------------------------RRGT--------TRMAHSVVCLNPYKLWCTQALLEFHR-NR
GDLST--------------------------------------------RRGT--------SPMARAVVCYNPYKLWCAQALLEFHR-NR
EDPSA--------------------------------------------RRGT--------SSLARALVCLNPYKLWCTQALLEFHR-NR
EDPFA--------------------------------------------RRGT--------SSLARAVVCFNPYKLWCTQALLEFHR-NR
RALLGAHARRNHRGGCGGNGKRCRESVFQDDEDAGEDGDSDGEDNGARGGRGRGHDAYGPLTSRSLRLASCNPYKLWCAQALLAFHQ-QR
RALLGAHARLNHRGGRRGNGKRCRESVFQDDEDAGEDGDSDGEDNGARGGRGRGHDAYGSLTSRSLRLASCNPYKLWCTQALLAFHQ-QR
RTLLGTHAHRSHSGSRAGNGKRRRESVFQDDEDAREDEDHDEENGGAYRGRGRGHDLCGYLPSRSLRLASCNPYKLWCTQALLAFHQ-QR
RALLGAHARCNHRR---GNGKRRRESVFQDDEDASEDGDGNGEDNGAYGRRGRGHDSCGPLTSRSLRLASCNPYKLWCTQALLAFHQ-QR
DESLC-------------------------------------------------------------DISSVNPHKLWATQALLHFHG-SR
L------------------------------------------------------TSPQHGTPLLVMLAAANPNKMLCVMEIVKRHV-AE
GF-----------------------------------------------------TVQRRKVPLLVMLAAANPNKMLCVAELVQRHI-VE
DS-----------------------------------------------------TGAHRRIPLLVMLAAANPNKMLCVMELIRRHL-AE
DH-----------------------------------------------------TLQQRKMPLLVMLAAANPNKMLCVLELVRRHV-AD
V-------------------------------------------------------ARAGTAPVLVMLAAANPNKMMCVRELVRQHL-DA
T-------------------------------------------------------ARARTAPVLVMLAAANPNKMMCVRELVRQHL-DA
A-------------------------------------------------------AGTSKTSVLVMLAAANPNKMMCVRELVWQHL-DV
A-------------------------------------------------------ARAGKAPALVMLAAANPNKMMCVRELVWQHL-DA
SLSSRSNSSKSSSA-------------------------------------G---VSALAAAPMLQAIAASNPNKMLCVWELVHRHL-HQ
-------------------------------------------------------------YAKQSLYYVMNPNKFRACEFLIRYHE-KH
-------------------------------------------------------------AKKKTLLYVMNPNKFRACEFLIRYHE-KQ
-------------------------------------------------------------PIKRRVLAASNPNKIDVLESLLQYHE-AR
-------------------------------------------------------------HFRQRILCSSNPNKIRTVAGIIKFHE-RR
QATNQ---DR--T-------TVCV------------------------------NDVMITRKTYMKYLTILNPYKVQTAWYLKEYHT-RR
-------------------------------------------------------------SKLKQCLAQLNPNKIDACKYLLEQHK-AH
-------------------------------------------------------------YRHKIILSALNPNKIEVTKFLIKQHL-KR
-------------------------------------------------------------SKLKQCLAQLNPNKIDACKYLLEQHK-AH
-------------------------------------------------------------YRHKIILTALNPNKIEVIKFLIKEHL-KR
-------------------------------------------------------------QGKKKLLYTMNPNKFRACEYLIRFHE-QR
-------------------------------------------------------------PAEKRLLHITNPNKARIVFTLLKRHL-RR
-------------------------------------------------------------SFIKRRLYTCNPRKLMMCEYLIKYHE-QN
-------------------------------------------------------------HAKQRKLWVCNPTKLMTCEWLLRYHE-AR
-------------------------------------------------------------YAKQRKLWVCNPSKLMVCEFLLKFHE-AK
-------------------------------------------------------------SVKKRRLWSCNPVKLITCEYLLRFHE-SR
TG------------------------------------------------------KNYYRGPQRELIHTSNPRKFKTLEYLIKVHE-ER
---------------------------------------------------------KF---KNKPSLQSGNPEKFKLLYYLIKFHE-SR
--------------------------------------------------------------TVRQLLHTGNPGKYKALQFLIKNHE-ML
NN-----------------------------------------------------------QFVTNTLYQMNPKKFEVLQSLINIHR-TR
-------------------------------------------------------------SKKKQALYVMNPNKFRACEFLIRFHEQQR
-------------------------------------------------------------SKKKQALYVMNPNKFRACEFLIRFHEQQR
-------------------------------------------------------------SKKKQVLYAMNPNKFRACEFLIRFHEQQR
-------------------------------------------------------------SKKKQVLYAMNPNKFRACEFLIRFHEQQR
** *
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WM IV
*******
----NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-----------------------NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-----------------------NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-----------------------GDKTIVFSDNVFAL------KHYA--IKMNKPFIYGPTSQNERIQILQNFKFNSKVNTIFVSKVAD-----------------------NDKIIVFSDNVFAL------KRYA--IEMQKPFLYGETSQNERMKILQNFQYNPRVNTIFVSKVAD-----------------------GDKIIVFSDNVYAL------QEYA--LKMGKPFIYGSTPQQERMNILQNFQYNDQINTIFLSKVGD-----------------------GDKIIVFSDNVYAL------RAYA--IKLGKYFIYGGTPQQERMRILENFQYNELVNTIFLSKVGD-----------------------GDKIIVFSDNVYAL------QEYA--LRLGKPFIYGSTPQQERMKILQNFQHNDQINTIFLSKVGD-----------------------GDKIIVFSDELYSL------KQYA--LKLNKVFIYGGTGQAERMQVLENFQHNPQVNTLFLSKIGD---------------------SPPDKVIIFCDQIDGI------QYYA--QHLHVPFMDGKTSDMERENLLQYFQHSDNINAIILSRVGD---------------------SPPDKVIIFCDQIDGV------QYYA--QHLNVPFMDGRTSDAERANLLQYFQHSSDINAIILSRVGD---------------------SPPDKVIIFCDDVEGV------QYYA--QHLHVPFMDGKTSDSERANVLQHFKNSSKTNAIILSRIGD---------------------SPPDKVIIFCDDLEGV------QYYA--RHLNVPFMDGKTTEVERENLLQYFQHSNDINAIILSRVGD---------------------SPPDKVIIFCDYLADV------RFFA--HHLHLPFMDQRTSEAERTNLLQYFQHSDGVNAIILTRVGD---------------------SPPDKVIIFCDYLADV------RFFA--HHLHLPFMDRRTSEAERTNLLQYFQHSDSVNAIVLTRVGD---------------------SPPDKAIIFCDYLADV------RFFA--HHLHLPFMDQRTSEAERANLLQYFQHSNDVNAIILTRVGD---------------------SPPDKVIIFCDYLSDV------RFFA--HHLHLPFMDQRTSEAERTNLLQYFQHSSGVNAIILTRVGD---------------------SPPDKTIIFCDSIPAL------QFYA--TQLCIPFMDGRTPEDERAKLLEYFKTSPNVNTIILSRVGD-----------------------SSKILVFCDHIMLL------KEYS--KLLGAPVVCGDTPHRERLMIFSDFQSTSKVNVVCLSRVGD-----------------------SSKILVFCDHIVLL------MEYG--KFLGAPVICGDTPHRERLMIFSDFQSTSKVNVICLSRVGD-----------------------SSKILVFCDHIALL------KEYS--KVLNAPVICGETPHRERLMIFSDFQSTSKVNVICISRVGD-----------------------SSKILVFCDHLLLL------REYG--TLLHAPVICGQTPHRERLMIFSDFQSTSKLNVICLSRVGD-----------------------GAKILLCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-----------------------GAKILLCCDHITLL------KEYG--ELLNAPVICGTTQHKERLMIFSDFQSTSKINVICVSRVGD-----------------------GAKILVCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-----------------------GAKILLCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-------------------QEHHTAKILVFCDHIALL------KEYA--KLLGAPLVHGETSHAERMAIFSEFQSTRRVNVICISRVGD-----------------------GDKIIVFSDNTFTL------EQYA--IKLKLPYIYGKTRESERLDVLNRFKS-GNFNTVFLSKVGD-----------------------GDKIIVFSDNVFAL------QEYA--EKLGVPYIFGNTKQQERVYYLNQFRNTNHYNTIFISKVGD-----------------------GDKILVFCDYLQII------EKLA--RRLDRPHLHGGISNNERTKLFNKFKTTKKVNTIILSKIGD-----------------------GDKVLVFCDIIHIL------IHLA--GLLHCPEIHGETPENVRSSIFHEFKNGSKVNTLILSSVGD-----------------------GDQVLLFCDTIMAA------KMYA--RMFDVPFIMGACSDDERECLVNAFA-TRTISCLMLSSVGD-----------------------GDKIIIFCNELKPA------GFYKEKLKLQKCYMDGNTSEEHRRNLLDQFRR-DEISVIFCSKIGD-----------------------NEQIILFCDSIIVL------KEIG--YQINCPIFFGESPNKERLDILNKFKL-KDINCIGMSSVGD-----------------------GDKIIIFCNELKPA------GFYKEKLKLQKCYMDGNTSEEHRRNLLDQFRR-DEISVIFCSKIGD-----------------------KEQIIIFCDSIIVL------KEIS--YQINCPIFFGESPNKERIDILNKFKL-KEINYIGMSSVGD-----------------------GDKIIVFSDNVYAL------QKYA--KGLGRYFIYGPTSGHERMSILSKFQHDPTVRTIFISKVGD-----------------------GHKCLVFCDDLFGL------QWFS--QVLGSPYIDGETKNEDREKSLNMFRTTKSSAYVLISKVGD-----------------------NDKIIVFSDNIFAL------LHIA--KTLNKPFIYGKLSPIERIAIINKFKHDSSINTILLSKVGD-----------------------GDKILVFSDNVFAL------LHTA--KALNRPFIYGQVSAVERVAILNKFKHESTFNSLFLSKVGD-----------------------GDKIIVFSDNVFAL------LHAA--RALNRPFIYGKVCPPERMAILTKMKAPSTPF--FFRKSETMQLTFRAQTSSYKSPSTLLP
----GDKVIVFSDNLFAL------LHAA--KLLNRPFIYGKVSSAERIVILNKFKNETTFNTIFLSKVGD-----------------------GDKILVFCDRPMII------DYYG--NILKYPVIYGDVSQDERKKIFNLFKVSNQINTIFLSRVGD-----------------------KDKILVFCDQIPVL------KYYS--QKMGYPAIYGEVGLLEKLVWLDLFR-KGEINTLFLSRVGD-----------------------GHKIIVFCDSLLIL------NYYA--LLLGYPVIDGDLNTDEKNKIFSIFKNSNEIKTIFVSRVGD-----------------------KDKILVFCEKVNKLADTGTLEKFA--KLNNCPIISQKVEQTERSAIYKLYQ-EDKLDVIIFGQIAD-----------------------GDKIIVFADNLFAL------TEYA--MKLRKPMIYGATSHIERTKILEAFKTSKDVNTVFLSKVGD-----------------------GDKIIVFADNLFAL------TEYA--MKLRKPMIYGATSHIERTKILEAFKTSKTVNTVFLSKVGD-----------------------GDKIIVFADNLFAL------TSYA--MKLRKPMIYGSTSHVERTRILHQFKNSSDVNTIFLSKVGD-----------------------GDKIIVFADNLFAL------TSYA--MKLRKPMIYGSTSHVERTRILHQFKNSSDVNTIFLSKVGD-------------------: :: .:
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WM VI
*********
********
-----------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV--------------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV--------------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV--------------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRILRAKKGAI--------------------------TSFDLPEANVL------------------------IQISAHGGSRRQEAQRLGRILRAKKHS---------------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN---------------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN---------------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN---------------------------TSLDLPEATCL------------------------IQISSHFGSRRQEAQRLGRILRAKRRN---------------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPAS---------------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPPS---------------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPPS---------------------------VALDIPCASVI------------------------IQVSGLGASRRQEAQRLGRILRPKPPS---------------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS---------------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS---------------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS---------------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPLS---------------------------IALDIPEASVI------------------------IQLSGLGASRRQEAQRLGRILRPKPAS---------------------------VSVNLPSANVV------------------------VQVSSHGGSRRQEAQRLGRILRPKEKAS--------------------------VSVNLPSANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKAKAG--------------------------VTVNLP-----------------------------------------------------------------------------------VSVNLPSANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKARAS--------------------------VSVNLPNANIV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA--------------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA--------------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA--------------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA--------------------------VSVNLPCANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKQQND--------------------------TAIDIPEATVI------------------------IQISSHFGSRRQEAQRLGRILRPKNGT---------------------------TAIDIPEATVI------------------------IQISSHFGSRRQEAQRLGRILRPKGGG---------------------------KAIDLPSANVL------------------------IQLCSHFGARMQESQRLGRVLRPKPGR---------------------------KAIDLPSASVV------------------------VQVCSNYGARMQESQRLGRVLRPKSGN---------------------------TSLDLPDANVI------------------------IELDWQERSRRQEAQRMGRISRPKSGD---------------------------VGLDLPDASVA------------------------IQLSSSSGSRRQEAQRLGRILRAKDGT---------------------------TSLDIPDASVI------------------------IQISTNNGSRKQQLQRLGRISRIKKNE---------------------------VGLDLPDASVA------------------------IQLSSSSGSRRQEAQRLGRILRAKDGT---------------------------TSIDIPDASVI------------------------IQISTNNGSRKQQLQRLGRISRIKKNE---------------------------TSIDIPEATVI------------------------IQVSSHYGSRRQEAQRLGRILRPKPKS---------------------------HSIDLPEANVV------------------------IQVGVVDGSRMQEAQRLGRVQRKKPGA---------------------------NAIDIPIANVV------------------------IQISFNFASRRQEAQRLGRIIRPKNKANEKKN
-----------------------NAIDIPCANVV------------------------IQISFNFASRRQEAQRLGRILRAKPQAGDE-GQQQQQQHSSSSSTSSTAAAAAPARVAAPAARAAVALEGVAAGLAPKNEQEHHHQQQQQQQQQQQRGVRQEAQRLGRILRAKPRGAEE------------------------NALDIPCANVV------------------------IQISFNFASRRQEAQRLGRILRPKSKTDEH------------------------TAIDLPQANVG------------------------IQIGMHFKSRRQEVQRLGRIMRAKENY---------------------------TALDLPIANVC------------------------IQIGFQFGSRRQEVQRLGRIMRRKEGQ---------------------------TGIDIPSASVG------------------------IEIGYLGGSRRQKVQRLGRVMRPKQNT---------------------------QGLDLPSANVG------------------------IQISFNFKSVRQEFQRMGRIQRKKENQ---------------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKLEDRMA
-----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKLEDRMA
-----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKHQDRMA
-----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKHQDRMA
. *

XPB signature
****************
--AEEYNAFFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------D-----------LA
--AEEYNAFFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------E-----------LA
--AEEYNAYFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------D-----------LM
--AEEYNAFFYTLVSQDTMEMSYSRKRQRFLVN-QGYSYKVITHLKGMDTD-------S-----------------D-----------LM
--TDQFNAFFYSLVSQDTVEMGYSRKRQRFLVN-QGYAYKVVNNLPGMEL--------E-----------------D-----------LK
--DEGFNAFFYSLVSKDTQEMYYSTKRQAFLVD-QGYAFKVITHLHGMENI-------P-----------------N-----------LA
--DEGFNAFFYSLVSKDTQEMYYSSKRQAFLID-QGYAFKVITNLKGMENL-------P-----------------N-----------LA
--DEGFNAFFYSLVSKDTQEMYYSTKRQAFLVD-QGYAFKVITHLSGMEQL-------P-----------------D-----------LA
--DVGFNAFFYSLVSKDTQEMYYSSKRQAFLVD-QGYAFKVITQLANIENT-------P-----------------D-----------LA
--LDNVCSYFYTLVSQDTHEISQSYERQSWLRD-QGFSYRVLQSDMVLQHFL-------------------------RTGGKLCCVGPPR
--LDNSCSFFYTLVSQDTHEISQSYSRQSWLRD-QGFSYRVLQSDTVLQHFQ-------------------------KTGGRLCCVGHPK
--LDSSCSYFYTLVSQDTYEMSQSYERQSWLRD-QGFSYRVLQCETVFGHLL-------------------------RTGGKPCCVGAPR
--LDNTCSYFYTLVSQDTHEVQQSYGRQSWLRD-QGFAYRVLQCDSLLKELR-------------------------RTGGKPCCVGHPQ
--LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ
--LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ
--LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLHEFV-------------------------RVGGRLCCVGPPQ
--LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ
--VDSTTAYFYTLVSEDTDESRNAFGRQEWLRD-QGFAYRMMSFRDILQHYAPNSKMFLDNGQGRAPSTMQPSNDCNRRRSRLLCVGPPK
-NGKPTDAWFYTVISTDTVEMSYAAHRTAFLVD-QGYTCSVTEFNPDGAPEAA-------------------------------------NGKAVDAWFYSVISTDTVEMSFAARRTAFLVD-QGYTCRVMEFYPDDVAQTA------------------------------------------------------------------------------------------------------------------------------NGKMVDAWFYTIISTDTLEMAYAAHRTAFLVD-QGYTCRIIEFQPDELSNDE-------------------------------------NGRTVDAWFYSIISTDTVEINYAAHRTAFLVD-QGYTCRIMEYSPFTSSVDT-------------------------------------NGRTVDAWFYSIISIDTVEMNYAAHRTAFLVD-QGYTCRVMEYNPFTSSVDT-------------------------------------NGRAVDAWFYSIISMDTIEMNYAAHRTAFLVD-QGYACRVMEYIPFESSANT-------------------------------------NGRTVDAWFYSIISMDTVEMNYAAHRTAFLVD-QGYACRVMEYNPFASSVNT-------------------------------------SAGPVDAFFYSLISRDTMEVAYAAHRSEFLVD-QGYRCRFIVFEPPPPVHENDEEEEG-----------------NTTGGGGAVVVVAA
----NKQAYFYSLVSQDTKEMFFATKRQQFLTN-QGYSFRVLADIQKYYSSNRVE---------------------T-----------KF
--LKNQQAYFYTLVSQDTQEMFFSTKRQQFLIN-QGYSFRVLPDIQKYYRQGANEMGLT-----------------L-----------KH
--TDEYNAFFYTLVSQDTEEIYYSAKRQQFLVD-QGYSYEPVVNAMERWPN------SA-----------------P-----------LS
--REEFNAFFYSCISDMTTDLKYSARRQQFLVD-QGYVYEPVSDARERWPW------PE-----------------D-----------LL
-----QNAYFYILVSEDTNEQHTAAERRTYLSYNQGYPYSIMNCKEIWETCNLSEL----------------FNDCE--------FTRFD
-----NSAYFYTLTSKDTREMYFSQRRQRVMRQ-NGYTFKVIDSAVIKPLR-------------------------K-----------ED
-----RIGYFYTLTSIDTHEEYFIHKKQIYMQN-LGFGFECINSTIITHMN-------------------------------------------NSAYFYTLTSKDTREMYFSQRRQRVMRQ-NGYTFKVIDSAVIKPLR-------------------------K-----------ED
-----GIGYFYTLTSIDTHEEYFIYKRQIYMEN-LGFEFENIISKLITNMN----------------------------------------DGLYNAFFYSLVSKDTQEMYYSTKRQQFLID-QGYSFKVISELPGIDQE-------V-----------------N-----------LK
----DVSAYFYTIVSEGTDEVGYSDRRREFMEE-HGYLYHEYDYKHFMHAE-------------------------T-----------EE
--INDPDSFFYSLVSKDTIEMCYSDKRQRFLIN-QGYAYNVLSDNIVDFNK-------L-----------------N-----------LV
--GENFNAFFYSLISKDTLEMVYADKRQQFIID-QGYAYKVIHSRDLPMQP-------D-----------------K-----------LI
--DGGFNAYFYSLISKDTLEMVYADKRQQFIID-QGYSYKVLHCRDLPLQQ-------Q-----------------T-----------LV
----GFNAFFYSLVSKDTQEMVFADKRQQFIID-QGYAYNVTSFSTIVKDT-------S-----------------N-----------LL
--DGQYNAFWYTLVSKGTDETSYCLARQKCLIN-QGFKYEIIDEKDLPYSQNPQK---------------------------------FK
--KGEYNAFFYTIVSKNTEQAQFYYRRQKSLMD-LGINFEVIDIDE----QNGNK---------------------------------FK
--NHEIQAFFYSLASKDTTESEYSYKRQKYITEQLGLNTELILEGDLPYNKNPQK---------------------------------YK
--IGEYDCFFYSIVTKGTREVEIQFERQIAVIN-QGYPYEIISADELKPPQSEAD---K-----------------K-----------LQ
GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPDAG-------S-----------------S-----------LS
GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPDAG-------S-----------------S-----------LG
GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPEEL-------P-----------------N-----------LK
GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPEEL-------P-----------------N-----------LK
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FSTK-------EEQQQL---LQKV-LAATDLDA----EEEVV--------A---G-EF----GSRS-----------------------FSTK-------EEQQQL---LQKV-LAATDLDA----EEEVV--------A---G-EF----GSRS-----------------------FSTR-------DEQQQL---LQKV-LAASDLDA----EEEVV--------M---G-EV----GGKP-----------------------YGTQ-------EEQGQL---LQLV-LSASDLDC----EDEKL--------P---G-EP----GYRP-----------------------LASK-------ESQLQL---LQQV-LATSDADA----EEEDV--------K---E-EL----AD-------------------------YASP-------RERREL---LQEV-LLKNEEAA----GIEVG--------DDADN-SV----GRGSNG---------------------YASK-------AERLEL---LQEV-LLQNEEAA----DLDDG--------EDT---SF----GSRS-----------------------YSSA-------RERREL---LQQV-LLKNEDAA----GLEIG--------DDADT-NF----ISKEKR---------------------FATA-------QERREL---LQRT-LVDNEKGA----EDDVE--------T--DD-LF----GKVGRG---------------------WWYE-------CAGPSCD-------------SAVAAKGTYWIP-------------------FSQEAALRM---QSRFV---AGVRGCDL
WWYE-------CTASSSP-------------LSVAAKGSYWTP-------------------FSRMASARL---QSRFV---AGVCSCEL
WWYE-------SDRAADS-------------AAISWKGSYWLP-------------------FSPEAARCI---QRRFI---DGSASCEL
WWYE-------TLERKLP-------------SAVAAKGSIWLP-------------------FSQEASRRM---HRFFV---NGREVCEL
WWYQ-------THNTASATPSSET-AAAVDVGWVHYDGFYWAP-------------------FSADAAALI---EAAFQ---HGRATCIV
WWYQ-------THNTASATPSSET-AAVADAGVVHYDGLYWAP-------------------FSVDAAALI---EAAFQ---HGRVTCTL
WWYQ-------THLTVSAAASSEM-EVGAGVGVAHHDGLYWAR-------------------FSAEASALV---EAAFQ---HGRATCTL
WWYQ-------MHNTASATPSSET-AAVADVGVVHYDGLYWVP-------------------FSADAAALI---EAAFQ---HGRATCTL
WYWL-------SDELESPEFVNAT-H---SSDAENGRIGRWKL-------------------FSRAHSVAI---DEAFQ---RGQLSLPL
----------------------------VEG-VDDTAPGDVVSIRQAKLRGTFKK-QELKCS-------------VA-----SP-TAQGS
-----------------------------PEVAEEPVMGDVVSIKQERLRGDFSK-QRLKCS-------------SP-----SS-AIRGN
---------------------------------------------------------------------------------------------------------------------TDDVAVAAEAGDAVSLKQEKLRSALRE-KKLQCE-------------SL-----T--VPQGS
------------------------ALGGVKQQVKKHRIGDVVSIKQESLYETLHQ-SSVLRPRSGE--------CSG-----RD-ADAGD
------------------------ALGGVKQQVKKHRIGDVVSIKQESLYETLHH-SSVLQPRSGE--------RSG-----RG-ADAGD
------------------------SLGRMKQLAKKERVGDAVSIKQEFLYETVHQ-SSVLWSRAAE--------RSG-----HG-AGADD
------------------------ALGGVKEQVKKHRVGDVVSIKQESLYETLHQ-SSVLRPRSGE--------RSG-----CG-ADAGD
YGEA-------SE-KNV---KRETNHGGEHSSPHNGRTGDAATVKRETLMNDVNH-ERRLVFGASETTRIAHANHSTFGGG-GGAPHTSI
MKTK-------EDELEF---LKLV-KNAKDVNG----KLEDI--------PNDDF-QS-------------------------------MNTK-------KEELDM---LAIV-KKAEDARG----QEEKI--------NVDDE-VE-------------------------------LDTQ-------EKREDW---LRQM-MDTDDSLG----LDADA--------TVPDE-DRS---FD--------------VPQGGGQR---SD-E-------KSEEEW---LRKM-LKVEKIQS----EETEY--------ESYSS-D-E---YE-------ESQ-SDYIDTIGKSA---TWKKVRIFYDDVRQAAIEQKLSE------------------------------------------------------------------PAKE-------GKDINY---VTEM-LKKKDEKG----VKEVV--------KKTKK-KT----------------------------------T-------NEQLNL---IKYI-LNESDKRYFNSKSKKES--------IID---F--------------------------------PAKE-------GKDINY---VTEM-LKKKDEKG----VKEIV--------KKTKK-KTFLN-------------------------------I-------NEQLNL---IKYI-LNESDKRYFNSKSKKEI--------NIN---D-----F--------------------------YSSK-------QDQLDL---LAQV-LGEGEDSG----KNEIL--------EE----DF----DDITRG---------------------FTRD-------SKQDNL---LAAI-RQEMEKNPEGRSEYSEL--------DDKPT-KRETKKKGTTRQRLNK----IVNKRTGGREAREYKNK-------KIQENL---LKCI-LASTDDGN----MDEDD--------DLFED-----QSFKKDNTKVNKTN-SNIL----------L
YGDP-------QRQREI---LTDI-LASDDNDK----TLDDD--------EDDPS-RQVLSAVAGDRGRFFRVN-SNLGDGWGGSEECQL
YGDR-------DRQQAL---LRDI-LLSDDLDK----SLDED--------EDEGA-YLPQQQEQQ------------------------YSKP-------SIQQEL---LQDI-ITSAEDVD----DEEE----------VNPT-----DLFTPTNE----SS-LQVS----------WMSQ-------LDESDY---LYTL-LMNSEQNQQNGK----MSS------EEESSSGDSSGSDSEESEG--------------------YDPD-------ILDQKI---IR-----ASDEIIKDVKKDAWFLI------QDQPDKKV-DEQDDD------------------------YIKQ-------MNEMDL---LEQI-MLSSNDLTNKVI----DQI------EEEVQ--VVTNTFSQEFGG--------------------LDKI-------VDEM-----------------QRKVL-------------ETCTQ----KGDDDREEDG--------------------YHSQ-------EEQLSL---LGKV-MNAGDDLV----GLEQL--------EE----DT----DGMA-----------------------YHSQ-------EEQLSL---LGKV-LNAGDDMV----GLEQL--------EE----DT----DGKA-----------------------YYTL-------NDQLEL---LAQL-LSARDDMI----GIEHL--------EE----DS----DGKA-----------------------YYTL-------NDQLEL---LAQS-LSARDDMI----GIEHL--------EE----DS----DGKA------------------------
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-------------SQA-SRRFGTM-SSMSGAD-DTVYMEYHSSRSKA--P----------------------------------------------------GQA-SRRCGTM-SSLSGAD-DTVYMEYHSSRSKA--S-----------------------------------------------------QF-SRRAGTM-SSMSGAD-DALYMEYQMPRGSKASV-------------------------------------------------SGSGGA-VRRVGGL-SSMSGGD-DAIYYEHRKK------N--------------------------------------------------GTIRI-SRREATM-ASMSGGQ-GAQYHSK-------AKA-----------------------------------------------HKRFKSKA-VRGEGSL-SGLAGGE-DMAYMEYSTNKNKELKE-----------------------------------------------LSRAPAKA-KRSSGSL-STLAGAD-NMAYVEYNKSANKQLKK-------------------------------------------MRLEQERNGGGA-TYSSGSL-AGLAGGE-DMAYIEYGKNKNKELRE-------------------------------------------RG-GAKGRAAAV-RRMAGTL-GELSGGQ-DMAYIEQNKAANKGLKK---------------------------------------TATVLR-----DTPRPPE--LKN--MGVEEKW-TVCFSDSCAPETFGTVQLV-----------------EG------------------TSSVLG-----DTPRPEG--LRD--SGVEERW-TVRFSDSNAPETFGTVQVS-----------------EG------------------DGSVLV-----GTPRPEG--LGG--SSLEDSW-TVRFSDSNAPETFGIVQFV-----------------KE------------------DSTVLN-----DTPRTAE--LAV--SGLGEKW-IVRFSASNAPETFGTVQMA-----------------ED------------------RGSELG----RGTPRPSSEELGRYPLLSFESW-KVTFSSVDAPQTFGTVLIG-----------------EG------------------RGGELG----RGTPRPSSEELGRYPLLSSESW-KVTFSSVDAPRTFGTVLIG-----------------EG------------------RGSDLG----RDTPRPSSEELGRYPLLSTESW-KVTFSSADAPQTFGTVLIG-----------------EG------------------RGSELG----RGTPLPSSEELGRYPLLSSESW-KVTFSSVDAPQTFGTVLIG-----------------EG------------------RVSHAL----PSSSQRGSAALTLR--PGQLTL-RVTFSSADAPITFGTVQCFS--------------VAEG----------------------------VNPRSL-DYQEKLL-CRVVASW-ELDYQN---ATSQQNEPGVANDTATG------------------------LID-------------INVRSA-QYQLDLL-ARVVSNW-EMDYHN---AVSTQKGSGKSEGLQRG------------------------DLK------------------------------------------------------------------------------------------------------VDARKI-EYQLDLL-SRVVSNW-ELEYHS---QGLKQASSGHDGFPPDD------------------------DANVSE----------CRAESL-SYQLKLL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ANETDS----------CRTESL-SYQLELL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ANETES----------RRTESL-SYQLGLL-SKVVSSW-EMEFQQ---ECRKRRRTAAEDVAENA------------------------T---DD----------CRTESL-SYQLELL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ADETGS----------VDVGRR-KWQLRLL-ASMVGRW-ELQYLQ---ATSRGAVSAKTNARRTNQKGNRRNNQDEGNESESSVSSSSGSSDADNG
--------------GS-HSGDTSL-ALLSGGANEVYYHTFEASNSSKK----------------------------------------KK
--------------KS----SSSL-ASI-SGGNEIYYHSYEASTTTSRRRGK------------------------------------AT
-------NQFKAIVK---------------------------------------------------------------------------------PHFSLLN--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------AKKSKSSAPTVS-RTTGGST-RALSGGN-DMNYMEYQAPAIYK-----------------------------------------------------------------------------------------------------------------------------------------NKKEDSLKKI-DNTTGGL-LKLSSNM-DVTFADKKKIP---------------------------------------------T
ESFGESLRGFGDAPHV-QPLQGGL-GRLAGDG-GAAYGARPGGRGGGRSGRS------------------------------------GG
--QQQQQQQHEQQPNV-RVVQGGL-AGISGKP-STHSFASP---------------------------------------------------------------I-SQKKTGL-ASLSGSL-KNQLQYKHLLPPS-EKPAK------------------------------------KS
--------HFNITTKA-ANPLQNL-ALYKETQ----LNKY--------------------------------------------------------------------------------------------------------------------------------------------------VYKFQ------------------------------------------------------------------------------------Y--------------------------------------------------------------------------------------------LQKA-RRSMGSM-SVMSGSK-GMVYMEYNSGRHKSGQQFK------------------------------------KP
------------LK-T-RRSMGSM-SAMSGAN-GRVYMEYNSGRQKSGNQSK------------------------------------KP
------------LMKA-RRSAGSM-SAFSGSG-GMVYMEYSTGKGKAGA-SK------------------------------------KP
------------LMKA-RRSAGSM-SAFSGSG-GMVYMEYSTGKGKAGA-SK------------------------------------KP
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--SKHVHPLFKRFRK----------------------------------------------------------------------SKHVHPLFKRFRK----------------------------------------------------------------------GKNIHPLFKRFRK----------------------------------------------------------------------IGSVHPLFKKFRG----------------------------------------------------------------------IAERHPLFKRFRQ-------------------------------------------------------------------------HHPLIRKMYYKNLKK----------------------------------------------------------------DSKEHHALFRKHLYTKRR--------------------------------------------------------------------SHHPLIQKMYYKQNKAKK--------------------------------------------------------------KGAAKA--EQSAFFKKLQREKERSRAL-----------ARQG-------------------------------------------NP---LLVRRI--------------CC-------GPLAVEHDCLHGG-----EECLQYAVQQMKVMVAKNSKNRIPLTT----DP---LAVRRI--------------CC-------GSLLLNHNCLSEE-----EGCLLDLVERMRSAVEKVSKH----------KP---LFVRRV--------------CC-------GPIGTDHNCLK-------EECLQHALQHAKSVATKRSTR----------NP---TLVRRI--------------CY-------GPLDAAHDCLKGE-----EECIQYILGQMRYRIKRRSNPR---------APSSPLRERRV--------------RR-------GCLDRSHRCIPATA-DQESRCISFARNTVLRARDTRGSDAVTEVE----APSSSLRERRV--------------RR-------GCLDRSHRCIPATA-DQESHCISFVRNTVLRARDTRGSDAVTEAE----APSSPLRERRV--------------RR-------GCLDRSHQCISAAA-DHESRCISFARGAVLHGRNTRDSDSVIVAE----APSSPLRERRV--------------RR-------GCLDRSHRCIPATA-DQESRCIRFARNTVLCVRDTRGSGAVTETE----GSQQLVGERRI--------------AKHLWNEPLGDTEEDHCCTD------HDECLMWLLQRVGDAKQLHKRGRQD-------------------KKMKRARDETAEDIKREWNSGAQTTQPRG-----------DFCRLPLQR------LVGANDDVVYHES---------------KEVKAGVSDSPEAIKREWAPRAAAQNQGA-----------ALYRTSLQD------LVGVSDDFIYHEL------------------------------------------------------------------------------------------------GRDVMEIVPDSDLAAIKREWAGGTRMDQFQF-----------GHSCTSLQG------LVSVDENFVYHEL-------------ADDVVEVRPIRTYAAIKSEWRGGADSAA----------------RVTALRD------LVGVDDGFVYHEL-------------ADDVVEARPIRTYAAIKSEWRSGADSAA----------------RVTALRD------LVGVDDGFVYHEL-------------ADGVTEARSMRTYATIKNEWRVSGDHET----------------RATALHN------LVGVDDGFVYHEL-------------ADDVVEARPIRTYAAIKSEWRGGADSAN----------------RVTALRD------LVGVDDGFVYHELSDVEIVEPAISKKGNKAQQSTNHRSLIDIKKEYGVTAGVPARGMTVVTTTTLQQQQDASMMLAR------FTTSADGIVYHELR
KVAKTVHPLFKKRN---------------------------------------------------------------------KVPSTVHPLFKTRTQHKD-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------SIPTQHALFKQRAKNKQ----------------------------------------------------------------------------------------------------------------------------------------------------KKFADKHILFRKFLSQNK-----------------------------------------------------------------ADATSMHPLFRGLHGKK-----------------------------------------------------------------------------------------------------------------------------------------------------KSSSEQHPYFKKLYSTK--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------KDPTKRHNLFKKRYV--------------------------------------------------------------------KDPTKRHNIFKKRYV--------------------------------------------------------------------KDPSKRHYLFKKRYQ--------------------------------------------------------------------KDPSKRHYLFKKRYQ---------------------------------------------------------------------

Fig. S1. Multiple sequence alignment of XPB amino acid sequences
The encoded protein sequences of specified XPB genes were aligned using the Clustal Omega server of the
European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo) at default
parameters (Sievers et al., 2011).
The XPB domain, Walker motifs (WM I, WM Ia, WM II-VI), RED residue loop, thumb-like domain (Thm) and XPB
signature motif were highlighted in the members of the Opisthokonta supergroup, comprising the eukaryotic model
organisms for TFIIH research (top nine sequences). If a position within the Opisthokonta was more than 50%
identical or similar, the residue was highlighted in black or gray, respectively, and the highlighting was then applied
to the kinetoplastid sequences (blue lettering) to demonstrate the conservation of these domains in the latter.
To detect putative DNA repair-specific sequence conservation in kinetoplastid XPB-R sequences, positions of XPBR-specific identity (one mismatch allowed) that was not present in any of the kinetoplastid XPB sequences was
highlighted in purple. If this position was also conserved in the Opisthokonta model organisms (more than 50%
similarity) the identities were highlighted in red.
If a species contained two XPB sequences, the one with greater similarity to T. brucei XPB received the name affix
1 and the other sequence the affix 2.
Kinetoplastid accession numbers were derived from www.GeneDB.org. Ac, Acanthamoeba castellanii (XP_004356478); At1/At-2, Arabidopsis thaliana (Q38861 / NP_568591); Bs-1/Bs-2 Bodo saltans (BS16690.1:pep / BS91250.1:pep); Ca, Candida albicans
(EEQ43396); Ce, Caenorhabditis elegans (NP_499487); Dd, Dictyostelium discoideum (XP_647819); Dm, Drosophila melanogaster
(NP_001137931); Drer, Danio rerio (Q7ZVV1); Edis-1/Edis-2, Entamoeba dispar (EDI_083940 / EDI_292260); Ehis-1/Ehis-2, Entamoeba
histolytica (XP_649651 / XP_654948); Eimt, Eimeria tenella (ETH_00032995); Gl, Giardia lamblia (GL50803_16512); Hs, Homo sapiens
(accession number P19447); Lb-1/Lb-2, Leishmania braziliensis (LbrM.29.0600 / LbrM.32.4160); Li-1/Li-2, Leishmania infantum (LinJ.29.0610 /
LinJ.32.4070); Lm-1/Lm-2, Leishmania major (LmjF29.0590 / LmjF32.3920); Lmx-1/Lmx-2, Leishmania mexicana (LmxM.08_29.0590 /
LmxM.31.3920); Mm, Mus musculus (NP_598419); Nc, Neurospora crassa (XP_957329); Ng-1/Ng-2, Naegleria gruberi (XP_002674455 /
XP_002683056); Orys-1/Orys-2, Oryza sativa (EEE55219 / EEC71313.1); Part-1/Part-2, Paramecium tetraurelia (XP_001448651 /
XP_001425941); Pf, Plasmodium falciparum (PF10_0369); Sc, Saccharomyces cerevisiae (CAY80363); Sp, Schizosaccharomyces pombe
(NP_593474); Ta, Theileria annulata (XP_952567.1); Tb-1/Tb-R, Trypanosoma brucei XPB/XPB-R (Tb927.3.5100 / Tb927.11.16270); Tc-1/Tc2, Trypanosoma cruzi (TcCLB.510149.50 / TcCLB.511527.20); Tco-1/Tco-2, Trypanosoma congolense (TcIL3000_3_3090 / TcIL3000.11.
16180); Tett-1/Tett-2, Tetrahymena thermophila (XP_001032673 / XP_001470758); Toxg, Toxoplasma gondii (XP_002365647); Trva-1/Trva-2,
Trichomonas vaginalis (XP_001582312 / XP_001326086); Tv-1/Tv-2, Trypanosoma vivax (TvY486_0304470 / TvY486_1117180).

*
**

The T. vivax XPB-2 gene appears to be a partial gene, missing sequence for ~220 C-terminal amino acids
The single E. tenella and A. castellanii XPB genes miss a large portion of the XPB N-terminus including the
XPB domain, suggesting that the reading frames of these genes are incomplete.
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Fig. S2. XPB-R is not essential for trypanosome proliferation in culture.
Growth curve of a representative bloodstream form cell line in which doxycycline-induced XPB-R dsRNA
synthesis led to RNAi-mediated XPB-R silencing. The lower panel shows a semi-quantitative PCR
analysis of total RNA that was reverse transcribed with oligo-dT and prepared from non-induced cells (ni)
and cells that were induced with doxycycline for one or two days. The spliceosomal U2A/ coding
sequence was amplified as a control.
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Fig. S3. XPB-R knockout appears to affect completion of mitosis
A. Diagram showing the number of wild-type procyclic (n=100) and XPB-R knockout cells (XPBR KO; n= 100) that are in the 1K1N (1 kinetoplast and 1 nucleus), 2K1N, and 2K2N stages of
the cell cycle. “Other” combines aberrant cells that have no nuclei (zoids) or more than two
nuclei.
g of XPB-R KO cells stained with DAPI showing
g an accumulation of 2K2N cells ((white
B. Image
arrows).
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Fig. S4. PTP tagging and tandem affinity purification (TAP) of XPB-R
A. Schematic depiction (not to scale) of a XPB-R wild-type (WT) allele and of the XPB-R locus of procyclic TbXRee
cells that exclusively express XPB-R-PTP and no wild-type, untagged XPB-R. XPB-R, HYGR /NEOR coding regions
and PTP tag are indicated by open, striped and black boxes, respectively. Gene flanks for RNA processing signals
are drawn as smaller gray boxes.
B. Whole cell lysates and crude, cell-free extracts of two TbXRee cell lines were analyzed by immunoblotting with
the monoclonal anti-Protein C epitope antibody HPC4 that recognizes the PTP tag.
XPB-R-PTP is N-terminally degraded upon extract preparation.
C. Immunoblot monitoring of XPB-R-PTP tandem affinity purification. Aliquots of crude extract (Inp), the flowthrough
of the IgG affinity chromatography (Ft-IgG), the TEV protease elution (TEV), the flowthrough of the anti-ProtC
affinity chromatography (Ft-ProtC), and the final eluate (Elu) were probed with the HPC4 antibody. The x-values
indicate relative amounts analyzed. Note that during the TEV protease digest ~19 kDa of protein is removed from
XPB-R-PTP resulting in XPB-R-P. Asterisks indicate the XPB-R degradation product.
D. Aliquots of input material (Inp), the TEV protease eluate (TEV) and the final eluate (Elu) were separated on a 1020% SDS-polyacrylamide gradient gel and stained with sypro ruby. Percentages indicate relative amounts
analyzed. Band assignments on the right are guided by apparent protein size.
E. List of proteins that were unambiguously identified by liquid chromatography/tandem mass spectrometry in the
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final TAP eluate.
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Fig. S5. XPB-R-PTP co-localizes with p52-HA outside putative SLRNA expression foci in the nucleus
p52-HA (green) was co-localized with XPD-PTP (red; left panels) or with XPB-R-PTP (red, right
panels). White bars represent 10 m.
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Ciliophora

Fig. S6. Divergent XPB paralogs are present in several protistan taxa.
Multiple eukaryotic XPB amino acid sequences were aligned and phylogenetically analyzed using
maximum likelihood. Bootstrap values were obtained by sampling a thousand replicates and are
indicated as percentages. The scale bar indicates the number of amino acid substitutions per site.
Open circles mark the splits of two divergent XPB paralogs within a taxon. If a species contained two
XPB genes/sequences, the one with greater similarity to T. brucei XPB received the name affix 1 and
the other sequence the affix 2. Accession numbers are specified in Fig. S1. Ac, Acanthamoeba
castellanii; At-1/At-2, Arabidopsis thaliana; Bs-1/Bs-2, Bodo saltans; Ca, Candida albicans; Ce,
Caenorhabditis elegans; Dd, Dictyostelium discoideum; Dm, Drosophila melanogaster; Drer, Danio
rerio; Eimt, Eimeria tenella; Gl, Giardia lamblia; Hs, Homo sapiens; Lb-1/Lb-2, Leishmania
braziliensis; Li-1/Li-2, Leishmania infantum; Lm-1/Lm-2, Leishmania major; Lmx-1/Lmx-2, Leishmania
mexicana; Mm, Mus musculus; Nc, Neurospora crassa; Ng-1/Ng-2, Naegleria gruberi; Orys-1/Orys-2,
Oryza sativa; Part-1/Part-2, Paramecium tetraurelia; Pf, Plasmodium falciparum; Sc, Saccharomyces
cerevisiae; Sp, Schizosaccharomyces pombe; Ta, Theileria annulata; Tb-1/Tb-R, Trypanosoma
brucei; Tc-1/Tc-2, Trypanosoma cruzi; Tco-1/Tco-2, Trypanosoma congolense; Tett-1/Tett-2,
Tetrahymena thermophila; Toxg, Toxoplasma gondii; Trva-1/Trva-2, Trichomonas vaginalis; Tv-1/Tv2, Trypanosoma vivax.
*

The T. vivax XPB-2 gene appears to be a partial gene, missing sequence for ~220 C-terminal amino acids

**

The single E. tenella and A. castellanii XPB genes miss a large portion of the XPB N-terminus including the
XPB domain, suggesting that the reading frames of these genes are incomplete.

Method of Phylogenetic Analysis
XPB amino acid sequences from 33 organisms representing the major eukaryotic supergroups (Dacks et
al., 2008) were aligned using the multiple sequence alignment tool MUSCLE at the EMBL European
Bioinformatics Institute (http://www.ebi.ac.uk/Tools/msa/muscle/). The alignment was uploaded onto the
graphical user interface Seaview (Gouy et al., 2010); http://pbil.univ-lyon1.fr/software/seaview.html) to
drive the GBlocks program using the less stringent option for the selection of conserved sequence blocks
that are likely to be aligned correctly and for the removal of poorly aligned positions (Talavera and
Castresana, 2007). The best-fit evolution model for phylogenetic analysis was determined by using the
ProtTest Server 2.4 (Abascal et al., 2005); http://darwin.uvigo.es/software/prottest2_server.html). A
maximum likelihood tree was generated employing the LG empirical matrix (Le and Gascuel, 2008) with
estimated invariable sites, substitution rate categories of 4, estimated gamma distribution and model
equilibrium frequencies.
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Fig. S7. XPB-derived phylogenetic tree with the archaeon Sulfolobus solfataricus as an outgroup
The phylogenetic analysis corresponds to that shown in figure 7 except that the XPB sequence from
Sulfolobus solfataricus (Ss, accession number NP_342443) was included.
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Table S1. Oligonucleotide used in this study
pGene

Sequence

Usage

XPB-R

5′-GGAGTGGAACTGCGAGGCCAGTAGTG-3′ /
5′-CCAAATCCACCTGAATACGGCGACG-3′

5′-TAAGGGCCCAGCACACCGAACTGCATTCCTCG-3′/
5′-TAACGGCCGCGATGACGTTGTCTATCATGAGAG
T-3′

Sense/antisense oligonucleotides that
hybridize in the 5/ and 3/ XPB-R gene flanks,
respectively; used to analyze correct
integration of transfected DNA constructs that
replace the wild-type XPB-R alleles.
Sense/antisense oligonucleotides that
hybridize within the coding region of XPB-R;
used for RT-PCR of XPB-R mRNA.

U2A

5′-TAGGGCCCTCCAAAAACGGCAGTGCCGATACTG
C-3′ / 5′-TACGGCCGTGATGTGCGAGTCTTCTTTGTC
CCTTTAGAAGC-3′

Sense/antisense oligonucleotides that
hybridize within the coding region of U2A/;
used for RT-PCR of U2A/ mRNA.

SL RNA

5′-CTACCGACACATTTCTGGC-3′ / 5′-GGTATGAGAA
GCTCCCAGTAGCAGC-3′

Sense/antisense oligonucleotides that
hybridize in the SLRNA promoter region; used
for PCR / qPCR amplifications in ChIP
experiments.
Sense/antisense oligonucleotides that
hybridize in the SLRNA intergenic region; used
for PCR / qPCR amplifications in ChIP
experiments.

5′-ATGGCTTATACGTGCTCGTTTCTCC-3′ / 5′-CACAT
ATAGGCGCTTTAAAGTCTGCT-3′

α-Tubulin

5′-GTGCATTGAACGTGGATCTG-3′ / 5′-GCCTACCAC
GAGCAACTCTC-3′

Sense/antisense oligonucleotides that
hybridize within the coding region of α-tubulin;
used for PCR / qPCR amplifications in ChIP
experiments.

p52

5′-TAGGGCCCGCAGCCCCTTCAACAACAGTGG-3′ /
5′- TACGGCCGATCCGGAGTAATGAAATTGGAC-3′

Sense/antisense oligonucleotides that
hybridize within the coding region of p52; used
for RT-PCR of p52 mRNA.
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Table S1 Accession numbers of relevant T. brucei genes
Gene

Accession number 1

RPB1
CRK1
CRK3
CRK7
CRK9
MTR1
MTR2
MTR3
SNIP

Tb927.4.5020, Tb927.8.7400
Tb927.10.1070
Tb927.10.4990
Tb927.7.1900
Tb927.2.4510
Tb927.10.7940
Tb927.11.4890 (previously Tb11.02.2500)
Tb927.9.12040 (previously Tb09.211.3130)
Tb927.8.3710

1

Accession numbers are from the GeneDB (www.genedb.org)/TritrypDB (www.tritrypdb.org) genome
data bases.
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FIG S1 CRK1 and CRK3 expression silencing. For each knockdown, representative growth curves from one of
three independently derived clonal cell lines were obtained in the absence and presence of the dsRNA synthesisinducing reagent doxycycline (-/+ dox). CRK mRNA levels were determined by semi-quantitative RT-PCR of total
RNA in non-induced (ni) cells and in cells that were silenced for 1 to 3 days (boxed panels). In the same RNA
preparations, the relative abundances of a tubulin (a TUB) and of GPEET procyclin mature and pre-mRNAs were
determined by semi-quantitative RT-PCR, those of the large ribosomal RNAs by ethidium bromide staining, and
those of the SL RNA, the U2 snRNA, and the SL intron by primer extension assays.
CRK1 and CRK3 silencing did not lead to a clear disturbance in gene expression patterns. In case of CRK1
silencing, however, we did notice a reproducible, minor reduction in rRNA and compensatory increases in other
RNAs suggesting a minor function of this kinase in the control of ribosome biogenesis.
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FIG S2 CRK9 silencing in bloodstream trypanosomes. A representative growth curve in the absence and presence
of the dsRNA synthesis-inducing reagent doxycycline (-/+ dox) of one of two independently derived clonal cell
lines. Mature mRNAs of CRK9, the spliceosomal protein U2A/ and a tubulin (a TUB) as well as pre-mRNA of a
tubulin (pre-a TUB) were analyzed by semi-quantitative reverse transcription (RT)-PCR in non-induced (ni) cells
and cells that were silenced for 1, 2 or 3 days. The relative RNA abundances show the same trend as in procyclics:
mRNA abundances decrease whereas the pre-mRNA level increases in CRK9-silenced bloodstream trypanosomes.
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FIG S3 CRK7 silencing in procyclic trypanosomes. A representative growth curve of one of three independently
derived clonal cell lines obtained in the absence and presence of doxycycline (-/+ dox). Abundances of CRK7, a
tubulin (a TUB) and of GPEET procyclin mRNA were analyzed in total RNA prepared from non-induced (ni) cells
and from cells that were silenced for 1, 2 or 3 days by semi-quantitative RT-PCR. The large ribosomal RNAs were
detected by ethidium bromide staining.
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FIG S4 Anti-CRK9-PTP chromatin immunoprecipitation (ChIP). ChIP experiments were carried out with two cell
lines expressing either the RNA pol II subunit RPB9 or CRK9 with a functional fusion of the composite PTP tag.
Chromatin was precipitated with a ChIP-grade rabbit polyclonal anti-ProtA antibody (a-PTP IP). In negative
control immunoprecipitations (ctrl IP) a comparable, rabbit-derived non-specific antibody was used. Precipitated
DNA was analyzed by amplification of the SLRNA promoter region and, as a negative control, of the 18S rRNA
coding region. For comparison, DNA of total chromatin (INP) was analyzed. The percent precipitation values
specified under each lane were determined by qPCR.
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FIG S5 CRK9 silencing does not affect SL RNA pseudouridylation. Total RNA, prepared from non-induced cells
(ni), from cells in which CRK9 was silenced for 2 days and from cells which were incubated with the general
methyltransferase inhibitor sinefungin (sin) for six hours, was analyzed by primer extension with 5 / radiolabeled
oligonucleotide SLf. RNA was either mock incubated or treated with N-cyclohexyl-N/ -b-(4methylmorpholinium)ethyl-carbodiimide p-tosylate (-/+ CMC) according to a published protocol (Bakin and
Ofengand, 1993, Biochemistry 32, 9754-9762) to create an extension stop before the pseudoruridylated residue at
position 28 (Ψ 28). To account for the SL RNA increase in CRK9-silenced and sinefungin-treated cells the amount
of RNA in these samples was reduced by one half.
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Table S2 List of oligonucleotides
Sequence (5/ – 3/)

Gene

Name

Usage

CRK1

CRK1 ApaI

RT-PCR of CRK1 mRNA

TAGGGCCCGTTACGAGCGGCTTCAGAAGATTG

CRK1 NotI

RT-PCR of CRK1 mRNA

TACGGCCGGAACTCGACAGAAAAGTATGGGTG

CRK3
CRK7
CRK9

CRK3 ApaI

RT-PCR of CRK3 mRNA

TAGGGCCCCGGAATCTGGAAAGCGCGAGC

CRK3 NotI

RT-PCR of CRK3 mRNA

GATCGCGGCCGCTACAATGCTTGGGGCGTTAACC

CRK7 ApaI

RT-PCR of CRK7 mRNA

TAGGGCCCGACCGATTTGTCGGCGGTGCTCTG

CRK7 EagI

RT-PCR of CRK7 mRNA

TACGGCCGGTACTCGTTGAAATATGTATGAC

CRK9 RNAi-S

RT-PCR of CRK9 mRNA

GTTGTTAAGAAAGAAAATTGAGG

RT-(q)PCR of CRK9 mRNA

CGCCGCCGCTGCCAACCCCACTC

RT-qPCR of CRK9 mRNA

GAGGAAGTGCAACAGCAGCG

RT-PCR of CRK9 mRNA

GATAAGCTTACGCGTAGGATGGAAGGGGTTGTGAC

/

CRK9 3 RT
CRK9 qPCR 5

 tubulin

/

CRK9 UTR RNAi 5

/

CRK9 UTR RNAi 3

/

RT-PCR of CRK9 mRNA

GATCTAGACTCGAGGCACTCGATACTTCAAAGAGC

CRK9 Apa1

RT-PCR of CRK9 mRNA

TAGGGCCCGCTCTGTGAATGAATATGTTCCCG

HA antisense

RT-PCR of CRK9 mRNA

TTAAGCGTAGTCAGGTACGTCGTAAGGGTA

-Tub Fw q1

RT-(q)PCR of  tub. pre-mRNA

ACAGTTTCTGTACTATATTG

-Tub Rv q1

RT-(q)PCR of  tub. pre-mRNA

GTGGATGCAGATAGCC

-Tub Fw q3

RT-(q)PCR of  tub. mRNA

GTGCATTGAACGTGGATCTG

RT-(q)PCR of

GAGAGTTGCTCGTGGTAGGC

-Tub Rv q3

GPEET

Pre-GPEET 5

RT-(q)PCR of GPEET pre-mRNA

Pre-GPEET 3

/

RT-(q)PCR of GPEET pre-mRNA

GCAGATAAAGGGAACGAGGTGC

RT-(q)PCR of GPEET mRNA

ATGGCACCTCGTTCCCTTTATCTGC

RT-PCR of GPEET mRNA

TTAGAATGCGGCAACGAGAGCAGC

RT-qPCR of GPEET mRNA

CCTTTGCCTCCCTTCACGATAAC

18SrRNAcoding5

/

RT-(q)PCR of 18s rRNA

TCATCAAACTGTGCCGATTAC

18SrRNAcoding3

/

RT-(q)PCR of 18s rRNA

CTATTGAAGCAATATCGG

GPEET 5

/

GPEET 3

/

GPEET qPCR 3

18S rRNA
SLRNA

tub. mRNA

/

SL_PE

/

CATGTTCTCGTGATCGCTGC

Primer extension of SL RNA &
RT-(q)PCR of SL RNA

CGACCCCACCTTCCAGATTC

SL sense

RT-(q)PCR of SL RNA

ACAGTTTCTGTACTATATT

U1 snRNA

U1_PE

Primer extension of U1 snRNA

CACTCAAAGTTTACTGCA

U2 snRNA

U2_PE

Primer extension of U2 snRNA &

U2 5

U5 snRNA

/

U5_PE

RT-(q)PCR of U2 snRNA

ACAGGCAACAGTTTTGATCC

RT-(q)PCR of U2 snRNA

ATATCTTCTCGGCTATTTAGC

Primer extension of U5 snRNA

CCGCTCGAGGACACCCCAAAGTTT
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Badjatia et al. – Supplemental material
S1 Table. CRK9-PTP co-purified proteins
S2 Figure. CRK9AP is conserved among kinetoplastid organisms.
S3 Figure. Generation of a highly specific rat anti-CRK9AP immune serum
S4 Figure. Multiple sequence alignment of the CCL1 domain of eukaryotic cyclin L and kinetoplastid CYC12 proteins.
S5 Figure. CYC12 clusters phylogenetically with cyclin L of model organisms.
S6 Figure. CYC12 and CRKAP silencing in BFs.
S7 Figure. Depletion of CRK9, CYC12 or CRK9AP leads to round-up of cells
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S1 Table. CRK9-PTP co-purified proteins
Score Expectation Accession #
MW (Da) % Coverage
13418
0 Tb927.2.4510 / Tb427.02.4510 *
85,465
73.90
9956
0 Tb927.10.9160 / Tb427.10.9160 *
71,208
43.30
2551
0 Tb927.1.2340 / Tb427.01.2340 *
49,756
60.10
2419
0 Tb927.1.2330 / Tb11.v5.0469 *
49,672
60.20
1897
0 Tb927.11.11330 / Tb427tmp.01.3110 * 76,002
52.70
1797
0 Tb927.7.3880 *
87,018
49.70
1358
0 Tb11.v5.1046 *
49,075
41.50
1179
2.50E-114 Tb927.3.5050 / Tb427.03.5050 *
41,830
57.10
1080
1.90E-104 Tb927.10.3930 / Tb11.v5.0501 *
29,404
52.70
1014
8.90E-98 Tb927.10.14600 / Tb427.10.14600 *
28,624
77.20
1010
2.30E-97 Tb927.11.3590 / Tb427tmp.02.1085 * 30,611
63.60
1006
4.60E-97 Tb927.11.2050 *
34,606
39.10
991
1.80E-95 Tb927.11.3590 / Tb11.v5.1059 *
30,625
59.60
965
6.40E-93 Tb927.9.6070 / Tb427tmp.160.4450 *
30,361
44.60
936
5.00E-90 Tb927.9.5690 / Tb427tmp.160.4200 *
11,083
99.20
878
2.90E-84 Tb927.8.6150 / Tb427.08.6150
25,004
35.20
874
8.40E-84 Tb927.7.1730 / Tb427.07.1730 *
27,696
54.00
817
4.40E-78 Tb927.11.11820 / Tb427tmp.01.3675
16,212
61.70
805
7.20E-77 Tb927.9.13970 / Tb427tmp.211.4520 * 36,766
47.30
800
1.90E-76 Tb927.9.15110 / Tb427tmp.244.2730 * 34,615
52.80
796
5.50E-76 Tb11.v5.0243
17,499
48.40
795
6.30E-76 Tb927.10.350 / Tb11.v5.0564 *
58,564
35.50
742
1.30E-70 Tb927.11.9710 / Tb427tmp.01.1470
24,601
60.80
724
7.60E-69 Tb927.9.10770 / Tb427tmp.211.2150
62,195
37.80
692
1.20E-65 Tb927.11.6300 / Tb427tmp.02.4170 *
21,372
44.80
689
2.30E 65 Tb927.11.10790 / Tb427tmp.01.2560
27,592
61.80
2.30E-65
683
1.10E-64 Tb927.9.3920 / Tb427tmp.160.2490 *
23,826
48.90
661
1.80E-62 Tb927.3.1610 / Tb427.03.1610
74,199
34.10
648
3.40E-61 Tb927.9.8070 / Tb427tmp.211.0110
24,720
46.30
36.40
647
4.00E-61 Tb927.9.15360 / Tb427tmp.244.2630 * 28,405
641
1.50E-60 Tb927.7.5180 / Tb427.07.5180
24,667
49.50
634
7.40E-60 Tb927.10.190 / Tb427.10.190 *
28,433
39.10
632
1.40E-59 Tb927.10.11390 / Tb427.10.11390
21,172
68.60
605
5.90E-57 Tb927.4.1100 / Tb427.04.1100
18,013
73.90
588
3.20E-55 Tb927.7.2370 / Tb427.07.2370
19,952
45.80
588
3.40E-55 Tb927.10.3370 / Tb427.10.3370
11,528
63.00
568
3.30E-53 Tb927.3.4170 / Tb427.03.4170 *
13,001
37.20
567
4.30E-53 Tb927.10.15290 / Tb427.10.15290
178,152
21.50
555
6.70E-52 Tb927.10.1100 / Tb427.10.1100
21,938
52.10
541
1.80E-50 Tb927.4.1790 / Tb427.04.1790 *
54,402
45.10
539
2.30E-50 Tb927.10.560 Tb427.10.560
20,075
38.90
535
6.10E-50 Tb927.10.10970 / Tb427.10.10970 *
80,780
31.60
532
1.20E-49 Tb927.10.6400 / Tb427.10.6400
59,466
37.40
529
2.50E-49 Tb927.9.11470 / Tb427tmp.211.2650
16,284
51.30
527
3.80E-49 Tb927.4.3550 / Tb427.04.3550
39,091
26.70
525
6.80E-49 Tb927.3.3740
69,133
34.40
501
1.60E-46 Tb927.1.3180 / Tb427.01.3180
20,047
39.00
493
9.30E-46 Tb927.7.1040 / Tb427.07.1040
16,987
57.00
475
6.30E-44 Tb927.9.11380 / Tb427tmp.211.2630
14,953
45.60
474
7.80E-44 Tb927.1.4680 / Tb427.01.4680
37,288
36.30

emPAI
10.28
8.09
3.46
3.12
3.12
2.13
1.99
2.97
4.35
4.6
6.49
1.92
6.49
4.07
11.73
2.72
4.1
8.6
2.84
4.28
7.11
1.5
4.28
1.71
2.15
2.81
5.62
0.95
4.24
3.91
2.21
3.91
5.89
6.71
3.19
7.16
5.5
0.29
3.44
1.49
3.16
0.76
1
2.48
0.88
0.82
3.16
5.82
2.88
1.17

Annotation
CRK9
CYC12
alpha tubulin
beta tubulin
HSP70
protein kinase
elongation factor 1-alpha
60S ribosomal protein L4
40S ribosomal protein S3A, putative
40S ribosomal protein S2, putative
40S ribosomal protein S4, putative
60S acidic ribosomal subunit protein, putative
40S ribosomal protein S4, putative
40S ribosomal protein S3, putative
60S acidic ribosomal protein, putative
40S ribosomal protein S8, putative
60S ribosomal protein L7, putative
40S ribosomal protein S17, putative
hypothetical conserved
60S ribosomal protein L5, putative
40S ribosomal protein S18, putative
protein kinase, putative
60S ribosomal protein L10a, putative
Polyadenylate-binding protein 2
40S ribosomal protein S5, putative
40S ribosomal protein SA, putative
ribosomal protein S7, putative
protein kinase, putative
60S ribosomal protein L10, putative
40S ribosomal protein S6, putative
60S ribosomal protein L23a, putative
40S ribosomal protein S6, putative
60S ribosomal protein L6, putative
ribosomal protein L21E (60S), putative
40S ribosomal protein S15, putative
60S acidic ribosomal protein P2, putative
CRK9AP
hypothetical conserved
60S ribosomal protein L9, putative
ribosomal protein L3, putative
40S ribosomal proteins S11, putative
heat shock protein, putative
chaperonin HSP60, mitochondrial precursor
60S ribosomal protein L27a
60S ribosomal protein L13a, putative
hypothetical conserved
40S ribosomal protein S11, putative
40S ribosomal protein S16, putative
60S ribosomal protein L23, putative
hypothetical conserved
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Comment

Domain PKc_DYRK_like (E=8.77e-135)

Trypanosoma-specific, no human homolog

Domain PKc_DYRK_like (E=1.77e-129)

Domain PKc_CLK (E=5.90e-57)

domain TBCC (E=1.13e-09) Tubulin binding cofactor C

Zn finger (RING) protein, potential dsRNA-binding

Trypanosoma-specific, no human homolog

469
465
464
454
418
413
406
406
382
378
367
353
335
335
334
333
316
313
299
296
295
295
285
285
282
278
275
273
273
270
268
262
262
257
254
252
251
249
245
230
229
226
226
224
223
219
204
199
198
197
197
196
194

2.40E-43
6.20E-43
8.00E-43
8.50E-42
3.40E-38
9.90E-38
5.30E-37
5.70E-37
1.10E-34
3.30E-34
4.30E-33
1.10E-31
6.00E-30
6.70E-30
7.70E-30
9.40E-30
4.70E-28
1.10E-27
2.80E-26
5.70E-26
6.00E-26
6.60E-26
5.80E-25
6.90E-25
1.20E-24
3.10E-24
6.60E-24
9.70E-24
9.90E-24
2 20E 23
2.20E-23
3.50E-23
1.30E-22
1.40E-22
3.80E-22
8.70E-22
1.40E-21
1.60E-21
2.70E-21
6.70E-21
1.80E-19
2.80E-19
4.90E-19
5.00E-19
7.30E-19
1.10E-18
2.50E-18
9.00E-17
2.70E-16
3.30E-16
4.50E-16
4.20E-16
5.10E-16
8.10E-16

Tb927.8.1110 / Tb427.08.1110
22,124
Tb927.10.5360 Tb427.10.5360
19,274
Tb927.10.7330 / Tb427.10.7330
15,674
Tb927.9.12200 / Tb427tmp.211.3270
21,651
Tb11.0290
15,503
Tb927.9.7590 / Tb427tmp.160.5580
22,355
Tb927.7.710 / Tb427.07.710 *
70,168
Tb927.11.16280 / Tb427tmp.01.7960
28,320
Tb927.10.11600 / Tb427.10.11600
66,008
Tb927.11.3510 / Tb427tmp.02.1000 *
91,873
Tb927.11.2990 / Tb427tmp.02.0490
46,419
Tb927.11.6320 / Tb427tmp.02.4190
53,247
Tb927.11.14130 / Tb427tmp.01.5720
20,965
Tb927.6.2640 / Tb427.06.2640
57,920
Tb927.6.5120 / Tb427.06.5120
10,438
Tb927.10.5460 / Tb427.10.5460
14,586
Tb927.9.5750 / Tb427tmp.160.4250
22,410
Tb927.10.15360 / Tb427.10.15360
192,223
Tb927.11.14000 / Tb427tmp.01.5570
28,774
Tb927.10.1590 / Tb427.10.1590
12,367
Tb927.10.270 / Tb427.10.270
15,386
Tb927.5.1820 / Tb427.05.1820
10,126
Tb927.7.3080 / Tb427.07.3080
47,288
Tb927.11.11360 / Tb427tmp.01.3170
34,668
Tb927.11.6140 / Tb427tmp.02.4000
14,636
Tb927.2.820 *
60,490
Tb927.4.3150 / Tb427.04.3150
38,135
Tb927.10.9880 / Tb427.10.9880
21,858
Tb927.11.11230 / Tb427tmp.01.3020
21,514
Tb927 11 15880 / Tb427tmp
Tb927.11.15880
Tb427tmp.01.7535
01 7535
15 572
15,572
Tb927.11.6180
16,850
Tb927.7.230 Tb427.07.230
11,163
Tb927.6.4280 / Tb427.06.4280 *
39,023
Tb927.9.11840
24,059
Tb927.10.8430 / Tb427.10.8430
16,051
Tb927.11.6790 / Tb427tmp.02.4620
88,968
Tb927.3.3310 / Tb427.03.3310
25,412
Tb927.10.14580 / Tb427.10.14580
19,048
Tb927.7.700
74,204
Tb927.4.1860 / Tb427.04.1860
18,834
Tb927.9.9950 / Tb427tmp.211.1480
55,884
Tb927.5.4170 / Tb427.05.4170
11,135
Tb927.8.900 / Tb427.08.900
37,395
Tb927.10.2890 / Tb11.v5.0650
46,563
Tb927.9.13820 / Tb427tmp.211.4511
11,069
Tb927.4.2180
17,010
Tb927.11.9720 / Tb427tmp.01.1475
9,622
Tb927.3.1370 / Tb427.03.1370
12,552
Tb927.6.3740 / Tb427.06.3740
71,430
Tb927.11.3340 / Tb427tmp.02.0840
26,640
Tb927.8.6180 / Tb427.08.6180
16,444
Tb927.8.1330 / Tb427.08.1330 *
30,860
Tb927.11.10160 / Tb427tmp.01.1920
15,257

55.70
56.50
29.50
40.10
58.20
48.70
17.10
35.00
21.70
8.10
20.60
29.30
50.40
28.30
52.70
40.00
46.10
11.00
37.80
47.10
25.70
57.60
31.90
18.70
48.10
25.50
27.70
27.20
46.00
37 40
37.40
49.60
59.10
26.20
32.50
52.10
27.00
37.70
37.00
19.60
47.90
18.50
47.40
22.10
26.50
54.70
44.00
80.00
58.70
24.80
21.90
40.80
25.00
57.00

4.3
3.4
1.83
2.11
1.85
2.61
0.42
1.76
0.65
0.14
0.09
0.59
2.22
0.9
5.89
3.04
3.31
0.16
1.72
8.96
3.87
1.22
1.01
1.04
3
0.51
0.72
1.11
1.59
5 25
5.25
2.35
1.94
1.33
1.34
1.75
0.45
1.24
1.92
0.25
1.95
0.34
3.28
0.55
0.43
3.28
1.61
2.48
2.64
0.5
0.59
1.7
0.95
1.23

40S ribosomal protein S9, putative
40S ribosomal protein S10, putative
40S ribosomal protein S24E, putative
60S ribosomal subunit protein L31, putative
40S ribosomal protein S14, putative
60S ribosomal protein L11, putative
HSP70, putative
60S ribosomal protein L2, putative
hypothetical conserved
hypothetical conserved
RNA-editing complex protein KREPB4
MRB1-associated protein
ribosomal protein L18, putative
importin alpha subunit, putative (TbKap60)
60S acidic ribosomal protein P2, putative
60S ribosomal protein L24, putative
tryparedoxin peroxidase
hypothetical conserved
RNA-binding protein NRBD1
ribosomal protein L36, putative
60S ribosomal protein L32, putative
60S acidic ribosomal protein, putative
hypothetical conserved
receptor for activated C kinase 1 (RACK1)
40S ribosomal protein S15A, putative
retrotransposon hot spot protein, putative
hypothetical conserved
60S ribosomal protein L18, putative
40S ribosomal protein L14, putative
60S ribosomal protein L27,
L27 putative
60S ribosomal protein L28, putative
40S ribosomal protein S33, putative
glyceraldehyde 3-phosphate dehydrogenase
hypothetical conserved
40S ribosomal protein S12, putative
predicted WD40 protein
60S ribosomal protein L13, putative
60S ribosomal protein L17, putative
hypothetical conserved
ribosomal protein S19, putative
hypothetical conserved
histone H4, putative
splicing factor TSR1
enolase
kinetoplastid membrane protein KMP-11
60S ribosomal protein L35a, putative
40S ribosomal protein S27, putative
40S ribosomal protein S25, putative
HSP70, mitochondrial precursor, putative
RNA-binding protein RBP34, putative
60S ribosomal protein L26, putative
60S ribosomal protein L7a, putative
60S ribosomal protein L22, putative
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RS domain, Trypanosoma-specific, no human homolog
no human homolog

DEAD-like helicase

Trypanosoma-specific, no human homolog

Trypanosoma-specific, no human homolog

homolog of human pre-rRNA-processing protein PNO1 (E=9e-65)
BOP1

domain COG2319 (E=5.35e-08; WD40 repeat)
no human homolog

189
188
185
178
171
170
169
169
161
154
152
150
149
148
144
137
133
131
126
125
117
115
113
110
110
108
107
106
105
105
103
97
97
96
95
95
93
92
91
90
89
89
89
87
86
84
84
83
83
83
82
81
81

2.50E-15
3.10E-15
6.10E-15
3.20E-14
1.60E-13
2.20E-13
2.50E-13
2.30E-13
1.50E-12
7.80E-12
1.20E-11
2.20E-11
2.60E-11
3.40E-11
8.60E-11
4.20E-10
9.20E-10
1.40E-09
4.70E-09
6.20E-09
4.20E-08
6.00E-08
1.10E-07
1.90E-07
2.20E-07
3.30E-07
4.50E-07
4.90E-07
7.00E-07
7 00E 07
7.00E-07
0.0000011
0.0000037
0.0000039
0.0000057
0.0000061
0.0000067
0.0000093
0.000014
0.000018
0.000022
0.000023
0.000024
0.000028
0.000039
0.000051
0.000083
0.00009
0.000092
0.00011
0.00011
0.00013
0.00016
0.00016

Tb927.2.5910 / Tb427.02.5910
Tb927.8.760 / Tb427.08.760
Tb927.10.1080 / Tb427.10.1080
Tb927.9.8200 / Tb427tmp.211.0180
Tb927.2.5130
Tb927.10.2240 / Tb427.10.2240
Tb927.10.220 / Tb427.10.220
Tb927.10.4740 / Tb427.10.4740
Tb927.11.10960
Tb927.11.4190 / Tb427tmp.02.1670
Tb927.9.5150 / Tb427tmp.160.3670 *
Tb927.11.8200 / Tb427tmp.01.0355
Tb927.2.6090 / Tb427.02.6090
Tb927.10.10460 / Tb427.10.10460
Tb927.08.6030 / Tb427.08.6030
Tb927.9.1810 / Tb427tmp.160.0700
Tb927.9.8740 / Tb427tmp.211.0560
Tb927.4.4060 / Tb427.04.4060
Tb927.7.2820 / Tb427.07.2820
Tb927.10.14700
Tb927.11.15180 / Tb427tmp.01.6835
Tb927.9.5320
Tb927.10.3500 / Tb427.10.3500
Tb927.11.11330 / Tb427tmp.02.5450
Tb927.9.11270 / Tb427tmp.211.2570
Tb927.10.2370 / Tb427.10.2370
Tb927.8.1720
Tb927.1.180 / Tb427.01.180
Tb927.8.3530 / Tb427.08.3530
Tb927 3 1920 / Tb427
Tb927.3.1920
Tb427.03.1920
03 1920
Tb927.1.2430 / Tb427.01.2430
Tb927.11.9550 / Tb427tmp.01.1310
Tb927.10.4110 / Tb427.10.4110
Tb927.7.3680 / Tb427.07.3680
Tb927.3.3950
Tb927.11.8050 / Tb427tmp.01.0490
Tb927.7.1780 / Tb427.07.1780
H25N7.12
Tb927.8.4660 / Tb427.08.4660
Tb927.9.5730 / Tb427tmp.160.4240
Tb927.11.10030 / Tb427tmp.01.1790
Tb927.8.3750 / Tb427.08.3750
Tb927.10.4560 / Tb427.10.4560
Tb927.2.1140 / Tb427.02.1140
Tb927.10.10360 / Tb427.10.10360 *
Tb927.3.3130 / Tb427.03.3130
Tb927.11.16890 / Tb427tmp.01.8650
Tb927.11.740 / Tb427tmp.03.0410
Tb927.10.13720 Tb427.10.13720
Tb09.v4.0126
Tb927.2.560 / Tb427.02.560
Tb927.8.7530 / Tb427.08.7530
Tb927.10.15870 / Tb427.10.15870

17,308
35,022
15,919
76,367
43,530
66,436
10,464
7,401
71,727
59,183
13,563
12,798
12,446
12,562
17,566
15,090
36,961
104,023
14,245
37,678
12,938
55,412
96,597
71,403
61,414
37,648
68,077
94,247
37,810
66 646
66,646
14,741
37563
11545
16972
62209
59922
25956
97751
117829
47586
8217
54281
94274
52161
367419
177874
228855
17809
40636
55005
95966
39779
26965

48.90
15.10
33.90
20.20
31.10
21.40
43.10
40.10
12.90
21.60
21.90
44.70
42.40
34.20
14.40
42.30
13.70
13.30
26.30
14.90
39.10
16.70
5.00
10.80
19.00
22.20
6.60
6.70
34.00
16 00
16.00
45.50
5
45.7
31.8
9.7
12.5
16.5
18.7
7.9
10.6
62.9
13.4
11.3
20.7
3.5
10.1
11.4
8
6.5
17.8
27.9
8.8
8.2

2.25
0.26
1.16
0.18
0.33
0.21
1.16
3.97
0.12
0.23
0.35
0.89
2.68
1.63
0.26
2.85
0.4
0.17
1.36
0.39
0.87
0.35
0.09
0.19
0.14
0.24
0.06
0.09
0.39
0 06
0.06
0.73
0.12
1.01
0.62
0.07
0.15
0.17
0.09
0.07
0.19
3.3
0.16
0.09
0.17
0.01
0.02
0.02
0.26
0.11
0.08
0.09
0.11
0.16

40S ribosomal protein S13, putative
nucleolar RNA-binding protein Nopp44/46
40S ribosomal protein S23, putative
hypothetical conserved
hypothetical conserved
hypothetical conserved
60S ribosomal protein L37a, putative
nucleolar RNA-binding protein, putative
hypothetical conserved
hypothetical conserved
ribosomal protein S6, putative
ribosomal protein S26, putative
60S ribosomal protein L44
histone H2B, putative
60S ribosomal protein L12, putative
60S ribosomal protein L35, putative
RNA-binding protein DRBD3
hypothetical conserved
histone H2A, putative
hypothetical conserved
hypothetical conserved
nucleolar RNA binding protein, putative
RNA-binding protein RBSR4, putative
HSP70
T-complex protein 1, eta subunit, putative
La protein
phosphatidylglycerophosphate synthase, putative
retrotransposon hot spot protein 1, putative
glycerol-3-phosphate dehydrogenase
NOT5 protein
histone H3, putative
replication factor C, subunit 4, putative
60S ribosomal protein L30
ubiquitin/ribosomal protein S27a, putative
hypothetical conserved
hypothetical conserved
Adenine phosphoribosyltransferase, putative
retrotransposon hot spot protein, RHS4
hypothetical conserved
nucleosome assembly protein-like protein
60S ribosomal protein L29, putative
nucleolar protein, putative
elongation factor 2
retrotransposon hot spot protein, putative
microtubule-associated protein, putative
hypothetical protein, conserved
hypothetical protein, conserved
eukaryotic translation initiation factor 5a, putative
RNA-binding protein, putative (RBP29)
variant surface glycoprotein, pseudogene
retrotransposon hot spot protein, putative
3,2-trans-enoyl-CoA isomerase, putative
RNA binding protein, putative
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NOP7
Trypanosomatid-specific, no human homolog
Domain NTF2 (E=6.74e-15)

similar to human alpha-ketoglutarate-dependent dioxygenase (E=2e-24)
domain Proliferation-associated_protein_2G4 (E=4.66e-58)

putative chromosome segregation protein
no human homolog
no human homolog

no unambiguous human homolog
putative SAS10 homolog (U3 processome complex, E=1.67e-17)

putative homolog of human exportin-7 (E=3e-23)

no human homolog
Tetratricopeptide repeat protein (TPR), putative

80
79
78
76
76
75
75
73
73
72
71
71
70
70
70
69
67
66
65
65
64
63
63

0.00022
0.00027
0.0003
0.00047
0.00057
0.0006
0.00065
0.00094
0.0011
0.0012
0.0015
0.0015
0.0019
0.0021
0.0022
0.0027
0.0039
0.0054
0.0059
0.0068
0.0089
0.0093
0.0094

Tb927.1.1350
Tb927.1.2100 / Tb427.01.2100
Tb927.10.170 / Tb427.10.170
Tb927.7.2980 / Tb427.07.2980
Tb927.10.14750
Tb927.6.5040 / Tb427.06.5040
Tb11.v5.0537
Tb927.2.2390 / Tb427.02.2390
Tb927.7.5000 / Tb427.07.5000
Tb927.4.2040 / Tb427.04.2040
Tb927.9.13650 / Tb427tmp.211.4460
Tb927.2.100
Tb927.11.3120 / Tb427tmp.02.0620
Tb927.4.3060 / Tb427.04.3060
Tb927.6.2790 / Tb427.06.2790
Tb927.8.4450 / Tb427.08.4450
Tb927.11.10280 / Tb427tmp.01.2050
Tb927.10.9400 / Tb427.10.9400
Tb927.1.1700 / Tb427.01.1700
Tb927.11.9590 / Tb427tmp.01.1350
Tb927.10.8170 / Tb427.10.8170
Tb927.10.15180 / Tb427.10.15180 *
Tb11.v5.0366

96521
126075
48363
21229
31653
24494
70086
16769
29405
20796
20639
94873
74731
17694
36934
47151
131127
31611
55121
48456
144316
41221
120510

9
5.6
8.6
12.4
30.9
26
5.3
33.5
26.9
39.7
13.9
5.3
15.7
15.5
18.5
12.4
3.4
13.6
11.8
10.4
8
5.6
8.4

0.04
0.03
0.09
0.47
0.3
0.65
0.13
0.28
0.15
0.48
0.22
0.09
0.12
0.59
0.25
0.09
0.03
0.14
0.16
0.09
0.03
0.11
0.03

kinesin heavy chain, putative
calpain-like cysteine peptidase, putative
pseudouridine synthase, Cbf5p
hypothetical protein, conserved
fibrillarin, putative
ribosomal protein L15, putative
polyubiquitin, putative
hypothetical protein, conserved
60S ribosomal protein L19, putative
ALBA3
ADP-ribosylation factor, putative
retrotransposon hot spot protein 1, putative
nucleolar GTP-binding protein 1
hypothetical protein, conserved
L-threonine 3-dehydrogenase, putative
RNA-binding protein, putative (RBP11)
zinc carboxypeptidase, putative
SF1 (branch point binding protein)
AATF protein, putative
S-adenosylhomocysteine hydrolase, putative
nuclear pore complex protein (NUP155), putative
nucleosome assembly protein, putative
hypothetical protein, conserved

Nitroreductase 4

no human homolog

no human homolog

putative chromosome segregation ATPase

List of proteins that were identified in two CRK9-PTP tandem affinity purifications by LC/MS/MS. The list shows the protein IDs of the second, more comprehensive mass
spectrometric analysis. All protein identifications with an Expect value smaller than 0.001 are listed and ranked according to their Mascot Scores. Proteins that were also identified in
the first analysis are marked with an asterisk after their accession numbers. Peptides were identified in both the T. brucei brucei 927 and 427 genome databases at
www.TriTrypDB.org. Annotations are according to the 927 database. Top-scoring and “hypothetical, conserved” proteins were analyzed by standard BLASTP searches of the Human
Genome database. CRK9 complex subunits are highlighted in yellow, ribosomal proteins in green, non-ribosomal proteins in orange, and standard PTP purification contaminants in
gray.
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Tb427
Tb927
Tv
Tc-el
Tc-nel
Tgr
Cfa
Lbr
Lta
Lmx
Lm
Li
Ld
Bs

----------MSSNNPSDIRIRTELLQEMQLLHAQQEGMKNIRQSEASHSDENDKKERGT
----------MSSNNPSDIRIRTELLQEMQLLHAQQEGMKNIRQSEASHSDENDKKERGT
----------MPAVDPLQV--QTELLERMKTLHVQHMQSLGRRTVNKGS--GASNGVKGT
MDLPPSERPAMPESGPLAFRARTVLLEQLRDLHRQEQQQKKRRGQLRPSNNGPQTGT--MDLPPSENPALSESGPLAFRARTALLEQLRDLHRQEQQQQKRRGQLRLSNNGPQTGT------------MSENVSSKFCARTALLQQLLETC--EEQQKQQRAVQRWSRPEAVSGERTE
----MSSDPNNGTSAGGALRLRTSLLEAVERYNTAQLASAAASDK-----N-----------MQSRKDTPTRHTGGTLRIRTALLESVCHYNEAYLSTLTAAAA-----MEEPLET-----MPGGKDTTTTGRGGRLQIRTALLESVRRYNEDCLNTSTATAV-----VEEPLGT-----MQGTKGAPTTNSGGKLQIRTALLESVRRYNEECLNMSTATTA-----AEEPLAT-----MQGAKDTPTANSGGKLQIRTTLLEAVRRYNEDCLNTSTAAAA-----AEEPLAT-----MRGTNDTPTANSGGKLQIRTALLESVRRYNEDCLNTSTAA-A-----AEEPLAT-----MRGTNDTPTANSGGKLQIRTALLESVRRYNEDCLNTSTAA-A-----AEEPLAT--------------------------MMQELRQQQQQQQQSVGSTSSSRLT-----------
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50
46
57
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42
49
49
49
49
48
48
25

Tb427
Tb927
Tv
Tc-el
Tc-nel
Tgr
Cfa
Lbr
Lta
Lmx
Lm
Li
Ld
Bs

RSGSTTGTCSEFDVCAVYDDDDVPLAAQFVRSCPPLTDPSWAMEELLRINSHVAVWT-GS
RSGSTTGTCSEFDVCAVYDDDDVPLAAQFVRSCPPLTDPSWAMEELLRINSHVAVWT-GS
VAHGSD-GGKDMVNCEGIREDDLPLAVQFVRSCPPLTNPTWAMEELLRINPNVAVWT-GS
ESN-------NDDDSDDESDNSAPMAVRFVRGCPPLTDPSWAMEELLRIDPNVALWT-GT
ESN-------NDDDSDDESDNSAPMAVRFVRGCPPLTDPSWAMEELLRIDPNVALWT-GT
AVH---TAKSDSEDDGEESDNNVSTAVWLMRNCAPLTNPSWAMEELQRIHRGTPVWAAGT
---------------DGEFS---SLVKVLVQRAPNVTNPSWAMEECGRLCPSAELWS-GS
----------SKQSVDRFPD---VLPRMIAQLNPSLTNPSWAMEECMRLCPSAEVWC-GT
----------PTQRVDKFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPSAEVWC-GT
----------QTQRIDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT
----------PTQRVDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT
----------PTQRGDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT
----------PTQRGDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT
-------------------S---SEITDAIRQDEEMSHPNWTHEEMARTNKACPSGG-DS

109
109
104
109
109
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83
95
95
95
95
94
94
62

Tb427
Tb927
Tv
Tc-el
Tc-nel
Tgr
Cfa
Lbr
Lta
Lmx
Lm
Li
Ld
Bs

ALPNSVWALPGS---------GHCPFGSTDADFARIR
ALPNSVWALPGS---------GHCPFGSTDADFARIR
TLSSTVWAPPAS---------GHCPFGTTSGDFVRHR
GLSTAVWAPPGS---------GHCPFGTTQADFIRHR
GLSTAVWAPPGS---------GHCPFGTTQADFIRHR
QLSSAVWAPPGT---------ANCPFGTKPTDFLRHS
ALPLDVWAPPGT---------PDCPFGTTPADFRVHH
ALPKDVWAPPGT---------AECPFGTEPMDFNAHR
ALSKDVWAPPGT---------AECPFGTEPMDFNAHR
ALPKDVWAPPGT---------AECPFGTEPMDFNAHR
ALPKDVWAPPGT---------AECPFGTEPMDFNAHR
ALPKDVWAPPGT---------AECPFGTEPMDFNAHR
ALPKDVWAPPGT---------AECPFGTEPMDFNAHR
RLMSTVWTPPRRQPPAAHLPSFPCPFNLQYQDVISVQHRSH

137
137
132
137
137
133
111
123
123
123
123
122
122
103

S2 Figure. CRK9AP is conserved among kinetoplastid organisms. Kinetoplastid CRK9AP
sequences were aligned using the Clustal Omega server of the European Bioinformatics Institute
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo) at default para-meters [1]. Positions
with more than 50% identity or similarity are highlighted in black or gray, respectively. Dashes indicate
that a corresponding residue is missing. Sequences were obtained from www.TriTrypDB.org or
www.GeneDB.org and comprise those of T. brucei brucei strains 427 (Tb427, accession number
Tb427.03.4170) and 927 (Tb927, Tb927.3.4170), Trypanosoma vivax (Tv, TvY486_0303410),
Trypanosoma cruzi CL Brener Esmeraldo-like (Tc-el; TcCLB.509669.80) and Non-Esmeraldo-like (Tcnel; TcCLB.506175.30), Trypanosoma grayi (Tgr, Tgr.163.1040), Crithidia fasciculata (Cfa,
CfaC1_25_1880), Leishmania braziliensis (Lbr, LbrM.29.1690), Leishmania tarentolae (Lta,
LtaP29.1740), Leishmania mexicana (Lmx, LmxM.08_29.1585), Leishmania major (Lm, LmjF.29.1585),
Leishmania infantum (Li, LinJ.29.1710), Leishmania donovani (Ld, LdBPK_291710.1), and the bodonid
Bodo saltans (Bs, BS14910.1..pep).
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pre-IS
wcl
ext

IS
wcl

ext

250
100
75
50
37
25
20
15

CRK9AP

75
50
37

TFIIB

S3 Figure. Generation of a highly specific rat anti-CRK9AP immune serum. CRK9AP was
expressed in Escherichia coli as a C-terminal fusion to glutathione S-transferase and purified
from bacterial extract by glutathione affinity chromatography. By injecting the purified protein
into the rat bloodstream, [pre-]immune serum was obtained according to a published protocol
[1]. Pre-immune (pre-IS) and a-CRK9AP immune sera (IS) were used to probe whole cell
lysates (wcl) and crude extract (extr) of procyclic Trypanosoma brucei brucei strain 427. As a
loading control, transcription factor TFIIB was detected on the same blots. Marker sizes in kDa
are indicated on the left.
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.xx.
Hs_L1
Hs_L2A
Mm_L
Dr_L
Ce_L
At L
Sp_L

74
69
80
54
97
26
19

|xxxxxxxxxxxxxxxxx Cyclin_N domain xxx
xxxxxxxxxxxxxxxxxxxxxxxxx
LDLPSETDLRILGCELIQAAGILLRLPQVAMATGQVLFHRFFYSKS[00]FVKHSFEIVAMACINLASKIEEAPR
LDTDTETDLRVVGCELIQAAGILLRLPQVAMATGQVLFQRFFYTKS[00]FVKHSMEHVSMACVHLASKIEEAPR
LDLPSETDLRILGCELIQAAGILLRLPQVAMATGQVLFHRFFYSKS[00]FVKHSFEIVAMACINLASKIEEAPR
LDHETETDLRILGCERIQSAGILLRLPQVAMATGQVIFQRFFFSKS[00]FVKHNFEIVAMACVNLASKIEESPR
LSKETESELRYLGCELIQQGAILLKLPQTAAATGQILFQRYYYQKS[00]FVRYHFEHAVQACLLLASKIEEEPR
IDETTEISLRIYGCDLIQEGGILLKLPQAVMATGQVLFQRFYCKKS[00]LAKFDVKIVAASCVWLASKLEENPK
DSFEYAEELCTLGSEWIQEAGVLLNLTQNCVIVCLILFRRYCTLYP[00]PRVPDLDAIVMACVSIGSKTTETPA

Tb_CYC12
Tc_
Lm_
Bs
Bs

9
7
2
22
22

WLCDARRAFCAYGVDLIRTGSILVRTTPSVTYRASVLFQRFQAAAE[74]EDHDDIVYLAAACILVAAKVEDPST
WIDDARRGYSSYGVDLIRTGCLLLRTTPSVTYRAAVLFQRFQAVAE[64]REHDDITYLTAACVLIATKMEDHSM
TDAAARDAYTAYGVDLIRTTGLLLRTTPSTIYRASILFQRFEASVE[93]SDHEDIMYLVAACLLIATKMEDPST
SAARADQIFNTYTADLLRTLCCLMGVGPTVVFRAQALFQRLTTIVK[50]FTDDSMLYFVAAVVLITCKLECPQA
11111111111111: ::1111*:111111111111:*:*111111111111111111111:1:1:11*111111

145
140
151
125
168
97
90

xxxxxxxxx|
|?----------?-??????????|
|xxxxxxxxxx
RIRDLINVFHHLRQLRGKRTPS-----------P-LILDQNYINTKNQVIKAERRVLKELGFCVHVKHPHKIIVM
RIRDVINVFHRLRQLRDKKKPV-----------P-LLLDQDYVNLKNQIIKAERRVLKELGFCVHVKHPHKIIVM
RIRDVINVFHHLRQLRGKRTPS-----------P-LILDQNYINTKNQVIKAERRVLKELGFCVHVKHPHKIIVM
RVRDVINVFHHLKQGKGKK-ST-----------P-LILDQNYINTKNQVIKAERRILKELGFCVHVKHPHKIIVM
RPREVYNVFHRLERLHRLQQSGHDINKETTRGMKPPAVDMNYINTKQHMINSERRILATLGFVVHVKHPHRLIVA
KARQVIIVFHRMECRRENLPLE-----------HLDMYAKKFSELKVELSRTERHILKEMGFVCHVEHPHKFISN
SVQDICNVVVYLKERFKDTNF------EARGFIAHDLYSEEMYSSRNRLSNMELEVLRALNFDTHIVIPHKLAIH

..
Hs_L1
Hs_L2A
Mm_L
Dr_L
Ce_L
At L
Sp_L

Tb_CYC12 154 RIRSIVSVFMRLNQRRRNEPVI--------E--LLQPPPERYENFKTRVREAEEIVLQTLGFQTFVECPFKYAII
Tc_
142 RVRLIVGVFMRLNQRRRGEPVI--------E--QLQPPPERYDDFKSCILEAEEVVLQALGFQTFVESPFKYAIL
Lm_
166 RIRAVVNVCMRLSLRRSGIPVT--------E--QSKPSLPRYEDFKACVIEAEEVVLHQLGFQTFVESPYKYVLL
Bs
143 KIRLVVHAVHRLNYRRKQRTPVSGSLAAAAT--LPPISPEVYDALKRQVVQAEWIVLVQLGFQVTVECPHKFVFP
1111111111111:1:111111:111111111111111111111111111111111:11:111*11:*11:1*111:11*1:111111
..
Hs_L1
Hs_L2A
Mm_L
Dr_L
Ce_L
At L
Sp_L

208
203
214
187
273
161
159

xxxxxxx?-?x----xxx Cyclin_C domain xxxxxxxxxxxxxxxxxxxxxxxxxxxx|
YLQVLECE-RN[00]QTLVQTAWNYMNDSLRTNVFVRFQPETIACACIYLAARALQIPL--PTR-PHWFLLFGTT
YLQVLECE-RN[00]QHLVQTSWNYMNDSLRTDVFVRFQPESIACACIYLAARTLEIPL--PNR-PHWFLLFGAT
YLQVLECE-RN[00]QTLVQTAWNYMNDSLRTNVFVRFQPETIACACIYLAARALQIPL--PTR-PHWFLLFGTT
YLQVLECE-KN[00]QMLVQTAWNYMNDALRTSAFVRFEPETIACACIYLAARVLQIPL--PSK-PHWFLLFGAT
YGHTLGITQSR[00]PDILQRSWNYMNDGLRTDIFMRYKPETIACACIFLAARTVENPIALPSTPFHWFEAFDTS
YLATLETP---[00]PELRQEAWNLANDSLRTTLCVRFRSEVVACGVVYAAARRFQVPL--PEN-PPWWKAFDAD
YLQTLQLI-DN[00]KKLLQITWNFLNDASRTRLCVLYPPFSLACGCIAMAARVIGMKL-----PKDWYRVFDTT

Tb_CYC12 219 FLGILVGNDPV[45]KKWLADAVCWLNDIPRWRELYAEEAYVLAVCALYWTRPPD-----VSGLPEEWTAAFGVE
Tc_
207 FLGMLIEEDKV[25]KKWLADAVSWLNDIPRCVELYAEEAHVLAVCSLFATRPSN-----ITALPDNWSLAFGLE
Lm_
231 YLNILSEPASD[38]TQWMIRAVQVVNDLPRCRRLLAVPADALAIYAIQQSCPPD-----L-TLPDKWSTAFGVS
Bs
216 FLAFMIDRSAS[07]VSWSMEACKWLNDCSRFADVNSFDAPLLACVALETTQPME----ATAGLPMLWYVAFGIS
1111111111111:111:1111111111111111:1111**11*11111111111:*111:11:1111111111111111*111*111

S4 Figure. Multiple sequence alignment of the CCL1 domain of eukaryotic cyclin L and
kinetoplastid CYC12 proteins. Cyclin L and CYC12 sequences were aligned using the Clustal Omega
server at default parameters. Shown are the sequences of the CCL1 domain (COG5333) as defined in
human cyclin L1 according to the Conserved Domain Database [3]. Dashes indicate that a corresponding
residue is missing. Numbers in parentheses specify number of residues without significant sequence
similarity. Positions with more than 50% identity or similarity are highlighted in black or gray, respectively.
Identical positions in model organisms without similarity in kinetoplastids were highlighted in blue and
insertions or unique identical positions in kinetoplastids were highlighted in red. Stars and colons denote
positions that are identical or similar in all sequences analyzed. Yellow highlighting indicates cyclin folds
1 and 2 within the CCL1 domain and question marks indicate positions of the human cyclin L1 sequence
that were not recognized as part of the CCL1 domain. Cyclin L sequences are from Homo sapiens (Hs;
L1, accession number NP_064703; L2A, NP_112199), Mus musculus (Mm, NP_064321), Danio rerio
(Dr, NP_956034), Caenorhabditis elegans (Ce, NP_506007), Arabidopsis thaliana (At, NP_565622) and
Schizosaccharomyces pombe (Sp, NP_593045). Kinetoplastid CYC12 sequences, obtained from
www.TriTrypDB.org or www.GeneDB.org, were from T. brucei (Tb, accession number Tb927.10.9160),
Trypanosoma cruzi (Tc, TcCLB.503525.20), Leishmania major (Lm, LmjF.36.5640), and the bodonid
Bodo saltans (Bs, BS70770.1).
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S5 Figure. CYC12 clusters phylogenetically with cyclin L of model organisms. Amino acid
sequences of cyclins from Homo sapiens (Hs), Mus musculus (Mm), Drosophila melanogaster
(Dm), Caenorhabditis elegans (Ce), Arabidopsis thaliana (At), Saccharomyces cerevisiae (Sc),
and Schizosaccharomyces pombe (Sp) as well as kinetoplastid CYC12 from Trypanosoma
brucei brucei strains 427 (Tb427) and 927 (Tb927), Trypanosoma congolense (Tco),
Trypanosoma vivax (Tv) Trypanosoma cruzi (Tc), Leishmania major (Lm), Leishmania infantum
(Li), Leishmania donovani (Ldon), Leishmania mexicana (Lmex), Leishmania tarentolae (Ltar),
Leishmania braziliensis (Lbr), and the bodonid Bodo saltans (Bs) were aligned using the Clustal
Omega server at http://www.ebi.ac.uk [4]. The multiple sequence alignment was imported into
the ClustalX software package [5] and phylogenetically analyzed using the neighborhood joining
method. Bootstrap values were obtained by sampling a thousand replicates and are indicated
as percentages. The node for the cyclin L/CYC12 cluster is drawn in red. Cyclin clusters of cell
cycle-regulating and transcriptional CDKs, according to Ma et al. [6], are indicated. The cyclin
sequences were obtained from the following accession numbers: Hs_A (CAA35986.1), Hs_B1
(CAO99273.1), Hs_B2 (AAI05087.1), Hs_B3 (CAC94915.1), Hs_C (AAH41123.1), Hs_D1
(AAH23620.1), Hs_D2 (CAA48493.1), Hs_D3 (AAA52137.1), Hs_E1 (AAH35498.1), Hs_E2
(AAC78145.1), Hs_F (AAB60342.1), Hs_G1 (AAC78145.1), Hs_G2 (AAC41978.1), Hs_H
(AAA57006.1), Hs_I (AAF43786.1), Hs_J (AAH43175.1), Hs_K (AAH43175.1), Hs_L1
(AAH43175.1), Hs_L2A (Q96S94.1), Hs_O (NP_066970.3), Hs_T1 (AAC39664.1), Hs_T2
(AAW56073.1), Hs_Y (AAH94815.1), Mm_A (CAA81331.1), Mm_B1 (AAH85238.1), Mm_B2
(AAH08247.1), Mm_B3 (AAI38356.1), Mm_C (AAH03344.2), Mm_D1 (AAO13813.1), Mm_D2
(AAH49086.1), Mm_D3 (AAC53363.1), Mm_E1 (AAI38663.1), Mm_E1 (AAC80527.1) Mm_F
(AAA63152.1), Mm_G1 (AAC42082.1), Mm_G2 (AAC32372.1), Mm_H (AAH38861.1), Mm_I
(AAF43391.1), Mm_J (AAI20923.1), Mm_K (AAH27297.1), Mm_L1 (AAH94383.1), Mm_L2
(AAI32296.1), Mm_O (AAI47760.1), Mm_T1 (AAD13656.1), Mm_T2 (AAH54122.1), Mm_Y
(NP_080760.2), Dm_A (NP_524030.2), Dm_B (AAF46904.1), Dm_C (CAA44720.1) Dm_D
(NP_523355.2), Dm_E (AAF53477.1), Dm_H (NP_524207.1), Dm_K (AAN11146.1), Dm_L
(putative, Dm_T (AAS64974.1), Dm_Y (AAF53122.1), Ce_A (AAA84393.1), Ce_B1 (Q10653.1),
Ce_B3 (AAA84395.1), Ce_C (Q9TYP2.2), Ce_D (AAC35273.1), Ce_E (AAM78547.1), Ce_H
(NP_494564.2), Ce_L (AAS64750.1), Ce_T1.1 (P34425.1), Ce_T1.2 (P34424.2), Ce_Y1
(NP_498857.2), Ce_Y2 (NP_498858.2), At_A1 (Q9C6Y3.1), At_A2 (AED93433.1), At_A3
(NP_199122.1), At_B1 (P30183.2), At_B2 (Q39068.2), At_B3 (NP_173083.3), At_D1
(P42751.3), At_D2 (P42752.3), At_D3 (P42753.3), At_H (BAB72144.1), At_L (Q8RWV3.2),
At_T1 (NP_174775.1), Sc_CLB1 (CAA97112.1), Sc_CLB2 (CAA44195.1), Sc_CLB3
(CAA49201.1), Sc_CLB4 (CAA49202.1), Sc_CLB5 (AAA34503.1), Sc_6 (NP_011623.3),
Sc_CLN1 (NP_013926.1), Sc_CLN2 (CAA97982.1) Sc_CLN3 (NP_009360.1), Sp_C
(NP_595953.1), Sp_H (NP_595776.1), Sp_L (NP_593045.1), Sp_T (NP_596149.1) Sp_Puc1
(NP_596539.1), Sp_Btype1 (NP_588110.2), Sp_Btype2 (NP_595171.1), Sp_Btype3
(NP_593889.1), Tb927_CYC12 (Tb927.10.9160), Tb427_CYC12 (Tb427.10.9160), Tc_CYC12
(TcCLB.503525.20), Tv_CYC12 (TvY486_1009010), Tco_CYC12 (TcIL3000_10_7930),
Lm_CYC12 (LmjF.36.5640), Ltar_CYC12 (LtaP36.5790), Lmex_CYC12 (LmxM.36.5640),
Ldon_CYC12 (LdBPK_365890.1), Li_CYC12 (LinJ.36.5890), Lbr_CYC12 (LbrM.35.5920) and
Bs_CYC12 (BS70770.1).
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S6 Figure. CYC12 and CRKAP silencing in BFs. (A) Growth curves of uninduced (- dox) BF
cultures or cultures in which CYC12 or CRK9AP was conditionally silenced by the addition of
doxycyline to the medium (+ dox). Note that a second cell line for each gene knockdown was
analyzed in parallel, producing nearly congruent growth curves (data not shown). The cross
indicates that subsequent to day 3 of induction no intact cells were detected in cultures. (B)
RNA analyses. Total RNA was prepared from [un-]induced cells and the relative amounts of
mature CYC12/CRK9AP and a tubulin mRNA was determined by reverse transcription using an
oligo-dT primer and semi-quantitative PCR, performed in the linear range of the amplification
reaction. Unspliced, a tubulin pre-mRNA was analyzed by reverse transcription using random
hexamers and PCR with an oligonucleotide that hybridized upstream of the a tubulin SL addition
site. rRNA served as a loading control and was detected after RNA separation on agarose gel
by ethidium bromide staining. (C) Both gene knockdowns led to dephosphorylation of the RNA
pol II subunit RPB1. Immunoblot analysis of whole cell lysates of [un-]induced cells detecting
RPB1 with an immune serum directed against the CTD. As a loading control, the similar sized
protein RPA1, the largest subunit of RNA pol I, was detected on the same blot.
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S7 Figure. Depletion of CRK9, CYC12 or CRK9AP leads to round-up of cells. Microscopic
images of un-induced procyclic cells that look normal (top row) and of rounded cells from the
same cell lines (bottom row) when CRK9, CYC12 or CRK9AP was depleted for three days.
White scale bars correspond to 10 mm.
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Table S1. List of oligonucleotides
Purpose
RT-PCR

Description
SPF27 mRNA

RT-PCR

7SL RNA

RT-PCR

ORC1 mRNA

RT-[q]PCR

 tubulin
pre-mRNA
 tubulin mRNA

RT-[q]PCR
Competitive
RT-PCR
RT-qPCR

SL RNA

RT-qPCR

RPB7 pre-mRNA

RT-qPCR

RPB7 mRNA

RT-qPCR

PAP pre-mRNA
(exon 1-intron)
18S rRNA

RT-qPCR
Primer extension

PAP [pre-]mRNA

SL_PE (SL RNA)
SL40 (SL RNA)
7SL_PE (7SL RNA)
U1_PE (U1 snRNA)
U2f (U2 snRNA)
U4_PE (U4 snRNA)
U5_PE (U5 snRNA)
U6_PE (U6 snRNA)

Sequence

5/-AAGCTTACGCGTCCCATGGTGCTTCCTTAC-3/
5/-TCTAGACCCGAACGTTTCTCAGCC-3/
5/-TTGCTCTGTAACCTTC-3/
5/-TCTACAGTGGCGACCTCAAC-3/
5/-AAGCTTACGCGTCGAAGGAGGGACAGTAAC-3/
5/-TCTAGAAAAACGCATACGGTAGAC-3/
5/-GTAAGTGGTGGTGGCGTAAG-3/
5/-CAATGTGGATGCAGATAGCC-3/
5/-ACAGTTTCTGATCTATATTGATCTT-3/
5/-GAGAGTTGCTCGTGGTAGGC-3/
5/-GTGCAGCGGCACTCCCAAAAC-3/
5/-CGTTAAAACAGATGGACAAATC-3/
5/-ACAGTTTCTGTACTATATTG-3/
5/-CGACCCCACCTTCCAGATTC-3/
5/-CCACTCGAAGGAGTAGTTTTC-3/
5/-TTATGTGCACTTGCTGGTG-3/
5/-CATGGGCCCGAGAGGAATATAAAAGTGGAGCCT
.
..C-3/
5/-ATTCTGATTTGTGCGGGC-3/
5/-GTGCAGCGGCACTCCCAAAAC-3/
5/-GGGATTAAGGAAAGAACTCAC-3/
5/-TCATCAAACTGTGCCGATTAC-3/
5/-CTATTGAAGCAATATCGG-3/
5/-CGACCCCACCTTCCAGATTC-3/
5/-CTACTGGGAGCTTCTCATAC-3/
5/-GAACCCCCGCTTGTC-3/
5/-AGCACGGCGCTTTCGTGATG-3/
5/-ACAGGCAACAGTTTTGATCC-3/
5/-TACCGGATATAGTATTGCAC-3/
5/-GGGAGAGTGCTAATCTTCTC-3/
5/-GAACCCCCGCTTGTC-3/

The gene-specific sequence is underlined when oligonucleotides carry additional nucleotides.
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Hs
Dr
Dm
Ce
Sp
Nc
At
Lbr
Lm
Ld
Tv
Tb
Tcon
Bs

-----------MAAIPPDSWQPPNVYLETSMGIIVLELYWKHAPKTCKNFAELARRGYYN
-----------MAGIPPDSWQPPTVSLDTTMGTIVLELYWNHAPKTCKNFAELGRRGYYN
MLS--LSDPNNAGGIPDKAWQPHFVTLETSMGEITVELYWKHAPNTCRNFAELSRRGYYN
-------------MPAPINDQAPYVILDTTMGKIALELYWNHAPRTCQNFSQLAKRNYYN
---------------------MANVELQTSLGKILIELYTEHAPKTCQNFYTLAKEGYYD
--------------------MATDVAVETTMGTFTLELYTNHAPKTCKNFATLADRGYYD
-----------MSAR--PEGSPPEVTLETSMGPFTVEMYYKHSPRTCRNFLELSRRGYYD
-----------------MEKAARVVQLQSTAGALSFELYSNFC---ADSFWQLASSGQLR
-----------------MGQVARVVQVQSSAGALSIELYNNFC---ADSFWQLARSDQLR
-----------------MERVARVVQLQSTAGALSIELYNNFC---ADSFWQLARSGQLR
----------MPNTTPYSCSYSRVVELYTNCGVISVELYDDESHCVAESFYRLAASGQLD
-------------MKVVVNEMSQVVEIITNEGVISVELYDTFAPRAAESFRRFAESGQLD
-------------MKL-IDNGVSVVELYTNEGVVSIELYELEAPCAAKSFLQLAESGQLN
MAAPSSGTSSTTATTRSSSLSCRVVTFHTTAGAFSIELYDTYAPRLTHHMYELAKSNAYN

49
49
58
47
39
40
47
40
40
40
50
47
46
60

Hs
Dr
Dm
Ce
Sp
Nc
At
Lbr
Lm
Ld
Tv
Tb
Tcon
Bs

GTKFHRIIKDFMIQGGDPTGTGRG[.0]GASIYGKQFEDELHPDLKFTGAGILAMANAGP
STKFHRIIKDFMVQGGDPTGTGRG[.0]GASIYGKQFEDEFHPELKFTGAGILAMANAGP
NVVFHRIIRDFMIQGGDPTGTGRG[.0]GASIYGSEFADELHGDLRHTGAGILSMANSGP
GTIFHRIIADFMIQGGDPTGTGRG[.0]GASIYGDKFSDEIDERLKHTGAGILSMANAGP
GVIFHRVIPDFVIQGGDPTGTGRG[.0]GTSIYGDKFDDEIHSDLHHTGAGILSMANAGP
STVFHRIIKDFMIQGGDPTGTGRG[.0]GSSIYGEKFEDEIHPGLKHTGAGVLSMANAGP
NVLFHRIVKDFIVQGGDPTGTGRG[.0]GESIYGSKFEDEINKELKHTGAGILSMANAGP
RLVFRQLLCGFALLGEVEAVQGHS[.5]----VDAAAESPDGLSLLHVGAGLLTCSPTVG
RLTFRKLLGGFALLGEVEAVQGHS[.5]----VDAAAQSPDDVPLLHVGAGLLSCRPTVG
RLTFRQLLGGFALLGEVETVQGHS[.5]----VDAAARSPDGVPLLHVGAGLLSCRPTIG
GVVVSRLIPSFVIEFSV-------[.0]GHPVFGEWMDVDVCNSLHHTGAGIVSCPR--R
GAVFDRMVPTFLLECRL-------[.0]EFSVYGELVGREENNHLHHTGAGILTCFG--T
GARFERMVPGFLLECRV-------[.0]GDMAYGELTEAEEGKTLRHTGAGIVSCYG--S
NTLFHKLVPGQYLQGGAATLSPSS[13]KQHLLSVFQDDEIHSSLRFTGAGIVGFASAGP

105
105
114
103
95
96
103
97
97
97
98
95
94
129

Hs
Dr
Dm
Ce
Sp
Nc
At
Lbr
Lm
Ld
Tv
Tb
Tcon
Bs

DTNGSQFFVTLAPTQWLDGKHTIFGRVCQGIGMVNRVGMVET--NSQDRPVDDVKIIKAY
DTNGSQFFLSLAPTQWLDGKHTIFGRVCQGIGVLNRIGMVET--NSQDRPVDDIKILRVN
DTNGSQFFITLAPTQWLDGKHTIFGRVYTGMEVVKRIGMVET--DKNDRPVDPLRIIKAK
NTNGSQFFITLAPTQHLDGKHTIFGRVAAGMKVIANMGRVDT--DNHDRPKIEIRILKAY
NTNSSQFFITLAPTPWLDGKHTIFGRVVSGLSVCKRMGLIRT--DSSDRPIEPLKIIKAV
NTNGSQFFITLAPTPWLDGKHTIFGRVKKGMGVIRRMGMVPT--DKEDRPATEVKIVKAR
NTNGSQFFITLAPQPSLDGKHTIFGRVCRGMEVIKRLGSVQT--DNTDRPIHEVKILRTK
AVTASRFLITLSPQPQLDKTHVIFGRVYSGIQTLERMSHMQV--DADFVLYSPVTVIKWS
AVTASRLLITLSPQPQLDKTHVVFGRVYSGIHTLEQISHMQV--DADFVLYSPVTVMKCS
AVTASRLLITLSPQPQLDKTHVVFGRVYSGIHTLEQISRMQV--GADFVLYSPVTVVKCS
GLEAGSFFITLGPQPFLDEACIIFGRVYSGMRVVQNISQLSV-SAETFHLFSPVVIERCN
VLESGAFFITLGPQPELDNVCTIFGRVRSGMRVVEKISRSRV-AEKTFRLYTPVVVERCL
VVEKGRFFITLAPQPKLDGVCTIFGRVYSGMSIVRKISQSRV-MEENFRLYTPVVIQRCT
DLNSSQFFITLAPQPKFDGVFSVIGRVSSGMKVLQTLSTQYQVDPSTSAPYNPIRISHCS

163/166
163/166
172/176
161/169
153/155
154/163
161/164
155/192
155/192
155/192
157/196
154/194
153/192
189/243

Fig. S1. Multiple sequence alignment of PPIL1 orthologues.
Clustal Omega (McWilliam et al., 2013) was used at default parameters to align PPIL1 amino acid
sequences from Homo sapiens (Hs, accession number NP_057143), Danio rerio (Dr, NP_001029350),
Drosophila melanogaster (Dm, NP_523874), Caenorhabditis elegans (Ce, NP_501118),
Schizosaccharomyces pombe (Sp, NP_593308), Neurospora crassa (Nc, XP_964739), Arabidopsis
thaliana (At, NP_181157), and from the kinetoplastid species Leishmania braziliensis (Lbr,
LbrM.23.0140), Leishmania major (Lm, LmjF.23.0125), Leishmania donovani (Ld, LdBPK_230140.1),
Trypanosoma vivax (Tv, TvY486_0801580), Trypanosoma brucei (Tb, Tb927.8.2090), Trypanosoma
congolense (Tc, TcIL3000_8_2090), and Bodo saltans (Bs, BS78785.1..pep). Positions with more than
50% similarity or identity are shaded in gray and black, respectively. Identical positions in model
organisms without conservation in kinetoplastids are shaded blue and identical position is kinetoplastids
without conservation in model organisms are shaded in red. A hyphen indicates lack of an amino acid at
this position. Numbers in parentheses specify lengths of non-conserved insertions. Saccharomyces
cerevisiae and Trypanosoma cruzi appear to lack a PPIL1 homolog.
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Fig. S2. PTP tagging and tandem affinity purification of CDC5 isolated the complete PRP19 complex
A. Schematic (not to scale) of the CDC5 locus after integration of pCDC5-PTP-NEO, fusing the PTP
coding sequence (black box) to an endogenous allele.
B. Immunoblot monitoring of the CDC5-PTP tandem affinity purification CDC5-PTP and CDC5-P (after
removal of the ProtA domains) were detected with the anti-ProtC HPC4 antibody in crude extract (Inp),
flowthrough of the IgG column (FT-IgG), TEV protease eluate (TEV), flowthrough of the anti-ProtC
column (FT-ProtC) and the final eluate (Elu). x-Values indicate relative amounts loaded. Apparently,
during extract preparation and purification, part of CDC5 was converted into a truncated form in which an
N-terminal domain was cleaved off (trCDC5).
C. The final eluate of a CDC5-PTP tandem affinity purification was sedimented through a linear sucrose
gradient, fractionated, and visualized by Sypro Ruby staining of an SDS-PAGE gel, the same as with
PRP19 shown in figure 1D. Protein bands were excised and protein identities confirmed by LC/MS/MS.
Asterisks indicate the sedimentation peak.
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Fig. S3. ORC1 silencing
Procyclic trypanosome culture growth in the absence and presence of doxycycline which
induced ORC1 silencing.
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Fig. S4. Only a minor amount of spliceosomal U snRNAs are bound to the PRP19 complex in extract
Primer extension analysis of total RNA prepared from the SmD1-PTP and SPF27-PTP pull-downs
documented in figure 6A. The analysis shows the snRNA profiles of crude extracts (Inp), supernatants
(Sn) and precipitates (P) in reaction A which detects SL RNA, U2/U4/U6 snRNAs and the Y structure
intermediate, and reaction B which detects U5/U1 snRNAs. x-Values indicate relative amounts loaded.
Note that the high volume of the P sample for the SPF27 analysis (right panel) led to a slight upward shift
of signals. Also note that the SmD1 and SPF27 reactions were separated on 6% and 8% polyacrylamide
gels, respectively, leading to different spacing of primer extension products. Nevertheless, the results
clearly show that SmD1 precipitation depleted U2, U4, U5, and U1 snRNAs and, to a lesser extent, SL
RNA and U6 snRNA, whereas SPF27 precipitation did not lead to a detectable reduction of snRNAs.
This indicates that, in extract, only a minor amount of snRNAs are stably associated with SPF27 in a
spliceosomal complex.
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Fig. S5. Spliceosomal U snRNAs remain stable upon TbSPF27 silencing
Total RNA was prepared from non-induced cells (n.i.) and from cells in which either SPF27 or, as a
control, ORC1 was silenced (KD for knockdown) for 3 days. RNA abundances were determined by two
primer extension assays. In assay A, 32P-5/-endlabeled oligonucleotides were combined that specifically
hybridize to SL RNA and U2, U4 and U6 snRNAs. In assay B, U1- and U5-specific oligonucleotides were
used. Primer extension products were separated on 8% polyacrylamide-50% urea gels and visualized by
autoradiography. M, marker MspI-digested pBR322. On the right, SL RNA and U snRNA products are
specified. Y denotes a product of the SL RNA-specific oligonucleotide that is generated by the Y
structure intermediate after the first step of splicing. The arrows point to increased and decreased signals
of SL RNA and Y structure intermediate in RNA of SPF27-silenced cells, respectively. Other signal
strengths remained comparable confirming that the trypanosome PRP19 complex is a non-snRNP
component of the spliceosome.
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a b s t r a c t
Trypanosoma brucei is a vector borne, lethal protistan parasite of humans and livestock in sub-Saharan Africa. Antigenic variation of its cell surface coat enables the parasite to evade adaptive immune responses and to live freely
in the blood of its mammalian hosts. The coat consists of ten million copies of variant surface glycoprotein (VSG)
that is expressed from a single VSG gene, drawn from a large repertoire and located near the telomere at one of
ﬁfteen so-called bloodstream expression sites (BESs). Thus, antigenic variation is achieved by switching to the expression of a different VSG gene. A BES is a tandem array of expression site-associated genes and a terminal VSG
gene. It is polycistronically transcribed by a multifunctional RNA polymerase I (RNAPI) from a short promoter
that is located 45–60 kb upstream of the VSG gene. The mechanism(s) restricting VSG expression to a single
BES are not well understood. There is convincing evidence that epigenetic silencing and transcription attenuation
play important roles. Furthermore, recent data indicated that there is regulation at the level of transcription initiation and that, surprisingly, the VSG mRNA appears to have a role in restricting VSG expression to a single gene.
Here, we review BES expression regulation and propose a model in which telomere-directed, epigenetic BES silencing is opposed by BES promoter-directed, activated RNAPI transcription.
© 2014 Elsevier B.V. All rights reserved.

1. Introduction
The tsetse borne, unicellular parasite Trypanosoma brucei, which belongs to the phylogenetic order Kinetoplastida, is the only known organism that has evolved a multifunctional RNA polymerase I (RNAPI)
system. This system is used to transcribe ribosomal gene units (RRNA)
in the nucleolus, as in all eukaryotes, yet also to transcribe gene units
that encode the parasite's major cell surface antigens (Günzl et al.,
2003; Kooter and Borst, 1984). Trypanosomes have a unique mode of
protein coding gene expression that allows them to utilize other RNA
polymerases than RNAPII for the production of functional mRNA. In
their genome, protein coding genes are arranged in long tandem arrays
which are polycistronically transcribed. The precursor RNA is processed
by spliced leader (SL) trans splicing and polyadenylation, resulting in
mature, monocistronic mRNAs (Günzl, 2010; Michaeli, 2011; Preußer

Abbreviations: BES, bloodstream expression site; BF, bloodstream form [trypanosome];
CITFA, class I transcription factor A; DOT1B, disruptor of telomeric silencing; ESAG,
expression-site associated gene; ESB, expression site body; FACT, “facilitates chromatin
transcription” factor; NEO, neomycin phospho-transferase; NLP, nucleoplasmin-like protein; ORC1, origin recognition complex subunit 1; RNAP, RNA polymerase; RRNA, ribosomal
RNA gene unit; SL, spliced leader; VSG, variant surface glycoprotein.
⁎ Corresponding author at: Department of Genetics and Developmental Biology,
University of Connecticut School of Medicine, 400 Farmington Avenue, Farmington, CT
06030-6403, USA.
E-mail address: gunzl@uchc.edu (A. Günzl).

et al., 2012). Since in trans splicing the same capped leader sequence,
derived from the SL RNA, is spliced onto the 5′ end of each mRNA, this
process represents a post-transcriptional mode of capping that is
decoupled from RNAPII transcription. Consequently, trypanosomes, in
contrast to mammals (Grummt and Skinner, 1985), are able to use
RNAPI to effectively and speciﬁcally express endogenous gene units
that encode their major cell surface antigens (Rudenko et al., 1991;
Zomerdijk et al., 1991a). This antigen, in mammalian-infective
metacyclic and bloodstream form (BF) trypanosomes, is known as the
variant surface glycoprotein (VSG), while the major cell surface antigen
in insect-stage procyclic trypanosomes is procyclin.
T. brucei causes Human and Animal African Trypanosomiasis (also
known as Sleeping Sickness and Nagana, respectively) throughout
sub-Saharan Africa (Fevre et al., 2006). The parasite lives freely in the
bloodstream of its mammalian host, evading the immune system by antigenic variation of its cell surface coat. The coat consists of ten million
copies of the same VSG, shielding invariant membrane proteins from
immune recognition (Schwede et al., 2011). T. brucei possesses roughly
2500 different VSG genes and pseudogenes (Cross et al., 2014), and periodic switching to the expression of an alternative VSG gene leads to
antigenic variation. VSG genes are located in subtelomeric regions of
11 megabase, 5 intermediate-sized and ~100 minichromosomes covering, in total, ~30% of the genome (Ersfeld, 2011; Horn, 2014). However,
the active VSG gene is invariably located next to the telomere within an
expression site, with the coding region ending ~200–1800 bp upstream
of the telomeric repeats. Metacyclic trypanosomes express a single VSG

http://dx.doi.org/10.1016/j.gene.2014.09.047
0378-1119/© 2014 Elsevier B.V. All rights reserved.
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monocistronically from one of ﬁve metacyclic expression sites in which
the RNAPI promoter is located ~1–4 kb upstream of the coding region
(Cross et al., 2014; Ginger et al., 2002; Kolev et al., 2012). Conversely,
BFs express the active VSG from one of ﬁfteen polycistronic “bloodstream expression sites” (BESs) which comprise a tandem array of typically 8–9 expression-site associated genes (ESAGs) and a terminal VSG
gene (Fig. 1) (Hertz-Fowler et al., 2008). ESAGs appear to be important
for the successful infection of the mammalian host since they encode a
variant heterodimeric transferrin receptor (ESAG6 and ESAG7), whose
varying afﬁnity for transferrins of different host species is thought to expand the parasite's host range (Bitter et al., 1998). These also encode
adenylate cyclases (ESAG4) that inhibit the innate immune system
upon trypanosome lysis (Salmon et al., 2012).
The BES promoter resides 45–60 kb upstream of the telomere
(Zomerdijk et al., 1990). It extends only 67 bp upstream of the transcription initiation site and comprises two short sequence elements (Pham
et al., 1996; Vanhamme et al., 1995). Both elements are required for efﬁcient binding of the multi-subunit class I transcription factor A (CITFA),
which is essential for RNAPI transcription in the trypanosome
(Brandenburg et al., 2007). The active BES is transcribed outside the nucleolus (Chaves et al., 1998), apparently in a small compartment termed
the expression site body (ESB) (Navarro and Gull, 2001). In BFs the
switch to the expression of another VSG occurs by two principal ways:
either the active BES is silenced while one of the silent BESs is activated,
or a DNA recombination event replaces the VSG gene in the active BES
with a VSG gene from the repertoire.
Antigenic variation and mono-allelic VSG expression in T. brucei have
been a research focus for decades. Several factors involved in BES silencing have been identiﬁed (see below) and BES silencing has been linked
to DNA replication/ORC1 (Benmerzouga et al., 2013; Tiengwe et al.,
2012), chromosome maintenance (Kim et al., 2013), and association of
BESs with the nuclear lamina (DuBois et al., 2012). In addition, cohesin
plays a critical role in maintaining the activated state of the BES during
the cell cycle (Landeira et al., 2009). Recently, excellent and detailed reviews have addressed antigenic variation in trypanosomes and the biology of BES silencing (Alsford et al., 2012; Glover et al., 2013; Horn, 2014;
Horn and McCulloch, 2010; Rudenko, 2010). Here we focus on the most
recent ﬁndings of factors that appear to be directly involved in BES regulation, and propose a model in which BES-speciﬁc telomeric silencing
is opposed by a mechanism that activates transcription initiation at
the promoter of the active BES.
2. Telomeric silencing
The active VSG gene, independent of whether it resides in metacyclic
or bloodstream expression sites, is invariably located near the telomere,
indicating that the telomere has an essential function in regulating VSG
expression. Accordingly, repression of RNAPI-mediated transcription by
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the telomere was directly demonstrated by integrating a plasmid with
seeds for de novo telomere formation either at BESs or, internally, at
RRNA loci (Glover and Horn, 2006). At the latter, tight repression extended only 2 kb upstream of telomeric repeats whereas, at inactive
BESs, repression reached at least 5 kb in these experiments. The more
extended repression of silent BESs was consistent with previous ﬁndings in which integration of RNAPI promoter-driven reporter cassettes
at different positions of a silent BES were repressed, even when placed
14 kb upstream of the telomere (Horn and Cross, 1997). Several lines
of evidence suggest that the pronounced silencing of BESs is dependent
on the telomere. Depletion of the telomeric protein RAP1 led to derepression of silent BESs, co-expression of multiple BES-encoded VSG
genes, and the formation of additional extranucleolar RNAPI foci
(Yang et al., 2009). Furthermore, depletion of the disruptor of telomeric
silencing B (DOT1B), which methylates lysine 76 of trypanosome histone H3 (Janzen et al., 2006), similarly led to de-repression of silent
BESs (Figueiredo et al., 2008). Direct evidence for repression of a BES
from the telomere stems from a recent study in which induced expression of a VSG transgene, inserted into one of the RRNA loci, surprisingly
led to a short-term, reversible attenuation of the active BES, indicating
that VSG mRNA plays a direct role in the regulation of mono-allelic
VSG expression (Batram et al., 2014). Interestingly, a time course experiment showed that this silencing of the active BES spread from the telomere towards the BES promoter in a DOT1B-dependent manner
(Batram et al., 2014). Together, these data strongly indicated that BES silencing is directed by the telomere. Furthermore, it is likely that the VSG
gene on silent BESs is protected from RNAPI transcription by more than
one mechanism because DOT1B knockout cells could still shut down the
active VSG gene upon ectopic VSG expression but were unable to attenuate expression of the remainder of the active BES (Batram et al., 2014).
3. BES transcription attenuation
Inactive BESs are completely silent only in regard to their telomereproximal regions, including the terminal VSG gene. VSG mRNA from inactive BESs is 104 to 105-fold less abundant than that from the active BES
(Figueiredo et al., 2008; Yang et al., 2009). Despite this strong difference,
several observations have shown that transcription does initiate at silent BESs at a clearly detectable level. The ﬁrst evidence came from a
study in which insertion of a selectable marker gene 1 kb downstream
of a “silent” BES promoter led to resistant parasites (Navarro and
Cross, 1996). BES sequences are highly similar, especially at the promoter and in the proximal downstream region, differing from each other
only by a few single nucleotide polymorphisms. However, the ﬁrst
genes within BESs are ESAG7 and ESAG6 which encode the heteromeric
transferrin receptor and harbor short hypervariable regions that distinguish them from each other (Zomerdijk et al., 1991b). Analysis of ESAG6
cDNA sequences, which on BESs are located ~5 kb downstream from the

Fig. 1. Schematic outline of BES5 and interacting proteins. Depiction of BES5 (to scale) as a representative BES according to the published sequence (Hertz-Fowler et al., 2008). The diagram
includes ESAGs (labeled 1, 2, 4–8 and 12), a VSG pseudogene (Ψ), 70 bp repeats preceding the terminal VSG gene, and the telomeric repeats (T). Note that some BESs have an additional
promoter and an ESAG10 gene ~14 kb upstream of the depicted promoter (not shown). The green arrow and red X represent the promoter when the BES is in the active state and silent
state, respectively. Activating factors that are predominantly associated with the active BES are indicated above the diagram in green whereas factors which are implied in BES silencing are
listed below the diagram in red. Filled and empty arrowheads indicate positive and negative ChIP results, respectively. Histone H1 and SPT16 associate predominately with silent sites
whereas TbISWI and NLP were shown to interact equally with expression sites in both states.
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promoter, revealed that 20% of the ESAG6 mRNA in BFs was derived
from various silent BESs whereas 80% stemmed from the active BES,
demonstrating that, even in the absence of selective pressure, productive transcription did occur in the promoter-proximal domain of inactive BESs (Ansorge et al., 1999). Subsequently, a vast cDNA clone
analysis along whole BESs showed that silent BESs contributed much
more to the promoter-proximal cDNA pool than to pools of promoterdistant cDNAs, revealing that transcription that initiated at silent BESs
was attenuated along the BES (Vanhamme et al., 2000). Recently, this
approach was repeated with single cells, conﬁrming that silent BESs
are transcribed in their promoter-proximal region and that transcription was attenuated further downstream within a single trypanosome
(Kassem et al., 2014). Finally, the demonstration that BES silencing
spreads gradually from telomere to promoter and BES reactivation occurs gradually in the opposite direction (Batram et al., 2014) strongly
supports the notion that transcription is attenuated at silent BESs.

access of CITFA to silent BES promoters and/or ensuring maximal promoter occupancy of CITFA at the active BES.
It should be noted that this mechanism is not an “all or nothing”mechanism because, in these experiments, the marked silent BES promoter was consistently occupied by CITFA above the level of negative
control experiments. This ﬁnding is in accordance with promoterproximal transcription occurring at silent BESs (see above) and it likely
explains why hypersensitive DNase I sites in the promoter region, indicative of a bound transcription factor, were not restricted to the active
BES but were also detected at a silent BES (Navarro and Cross, 1998).
It appears that trypanosomes cannot completely shut down transcription initiation from silent BESs. Alternatively, low level transcription of
the promoter-proximal part of silent BESs might serve a biological function. For instance, co-expression of different forms of the heteromeric
transferrin receptor, e.g. ESAG6 and ESAG7, could ensure initial survival
in different mammalian hosts.

4. Regulation of BES transcription initiation

5. Factors involved in BES transcription regulation

Although the promoters of inactive BESs are not “silent”, there is
now convincing evidence that there is substantial regulation at BES promoters. Consistently, promoter-proximal RNA levels were found to be
much higher from the active versus silent BESs. Thus, when the neomycin phosphotransferase gene (NEO) was inserted 1 kb downstream of
the promoter of an inactive BES, it conferred parasite resistance to a
low concentration of the drug G418 (1 μg/ml) while the same gene,
when inserted at the identical position of an active BES, boosted resistance at least 100-fold (Navarro and Cross, 1996). The ﬁnding that in
BFs 80% of ESAG6 mRNA stemmed from the active BES suggested that
there is at least a 50-fold stronger ESAG6 expression from the active
BES than from the average silent BES. When Yang et al. (2009) introduced a luciferase gene immediately downstream of the active or a silent BES promoter, the active BES produced 1500–4000-fold more
light units than the silent BES.
More direct evidence for BES regulation at the level of transcription
initiation came from the analysis of CITFA. CITFA consists of seven subunits, CITFA1-7, which are conserved only among kinetoplastid organisms, and the dynein light chain DYNLL1 (also known as LC8).
Silencing of CITFA1, CITFA2 and CITFA7 was lethal to BFs grown in culture
and strongly and speciﬁcally reduced the abundance of rRNA and VSG
mRNA (Brandenburg et al., 2007; Nguyen et al., 2012; Park et al.,
2014). Accordingly, depletion of CITFA2 from extract virtually abolished
RNAPI transcription in vitro, as assayed by ~100 bp-long primer extension products, and the puriﬁed CITFA complex produced a speciﬁc gel
shift with the BES promoter (Brandenburg et al., 2007). Moreover, a
ChIP-seq analysis indicated that within a BES, CITFA7 occupancy was restricted to the promoter region (Nguyen et al., 2014). Together, these
ﬁndings identiﬁed CITFA as a basal and general transcription initiation
factor for RNAPI transcription in trypanosomes.
Interestingly, marking the active BES and a silent BES ~500 bp downstream of the transcription initiation site (Figueiredo et al., 2008) revealed that CITFA2 and CITFA7 predominantly occupied the promoter
of the active BES relative to that of the marked silent BES, a phenotype
that was maintained after consecutive in situ switches between the
two marked sites (Nguyen et al., 2014). In accordance with CITFA's
role as an RNAPI transcription initiation factor, higher CITFA occupancy
at the active versus the silent BES promoter correlated with a ~70-fold
higher abundance of promoter-proximal, unspliced RNA and a ~ 17fold higher occupancy of the RNAPI-speciﬁc subunit RPB6z at the marker gene (Nguyen et al., 2014). Finally, CITFA7 silencing led to a strong reduction of RNAPI occupancy and of promoter-proximal RNA levels,
which directly demonstrated that CITFA binding to the promoter is required for high transcription rates in vivo (Nguyen et al., 2014). These
data unequivocally showed that mono-allelic BES expression entails a
mechanism that functions at the BES promoter, apparently limiting

There is strong evidence that inactive BESs are silenced epigenetically. Thus, while silent BESs have a nucleosomal structure, the active BES
is largely depleted of nucleosomes (Figueiredo and Cross, 2010; Stanne
and Rudenko, 2010). Direct evidence that nucleosomes are important
for BES promoter silencing stems from depleting histone H3, which rapidly led to a ~ 11-fold de-repression of a GFP gene introduced downstream of the promoter of a silent BES (Alsford and Horn, 2012). In
addition, CAF-1b, a replication-dependent histone chaperone, and the
replication-independent chaperone ASF1A, were shown to be important for the inheritance and maintenance of the silenced state of BESs
(Alsford and Horn, 2012). Interestingly, silencing the gene of either
chaperone led to apparent nucleosome depletion and a de-repression
of the promoter-proximal BES region. However, it did not affect expression of the corresponding VSG gene suggesting that nucleosomal structure is particularly important for the regulation of BES promoter activity.
Several chromatin remodeling and modifying proteins have been
implicated in BES repression so far. The ﬁrst epigenetic factor found to
play a role in BES regulation was the chromatin remodeler TbISWI
(Hughes et al., 2007). Depletion of this factor increased the mRNA abundance of a reporter gene inserted promoter-proximally into a silent BES
up to 60-fold, whereas only a ﬁvefold increase of the corresponding silent VSG mRNA was observed. TbISWI was found to occupy the entire
length of both silent and active BESs, but was not enriched at BES promoters (Stanne et al., 2011). Although the speciﬁc function of TbISWI
remains to be determined, these results suggest that TbISWI controls
RNAPI transcription elongation rather than initiation.
Similar de-repression of a promoter-proximal reporter gene was observed when the histone deacetylase DAC3 (Wang et al., 2010), the linker histone H1 (Pena et al., 2014; Povelones et al., 2012), or the
nucleoplasmin-like protein NLP (Narayanan et al., 2011) was depleted.
The function of DAC3 appears to be promoter-speciﬁc since expression
of the VSG gene in the marked BES was unaffected at both the mRNA and
the protein level (Wang et al., 2010). However, direct association of
DAC3 with BESs has not been demonstrated yet and it remains a possibility that DAC3's control of BES silencing is indirect.
The role of histone H1 in BES promoter repression has been more
deeply investigated. Histone H1 is important for chromatin architecture
and generally functions in chromatin condensation and transcription
repression (Happel and Doenecke, 2009). Accordingly, co-silencing of
the T. brucei H1 multigene family opened up chromatin globally with
the strongest effect on silent BES promoters (Pena et al., 2014). Metabolic labeling of nascent RNA then showed that histone H1 depletion resulted in an approximately six-fold higher promoter-proximal
transcription rate at a silent BES, indicating that relaxation of the nucleosome structure in the promoter region led to an increase of the transcription initiation rate at the silent BES (Pena et al., 2014).
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NLP is a ubiquitous nuclear protein and, accordingly, was found to be
associated with all genomic loci analyzed, including the active and silent
BESs (Narayanan et al., 2011). Despite this apparent general association
with genomic DNA, NLP seems to be particularly important for BES promoter regulation. Depletion of NLP de-repressed a silent BES 45–65fold, as measured by ﬂuorescence derived from a promoter-proximal
GFP gene. Moreover, NLP silencing also reduced promoter-proximal
gene expression from the active BES about threefold (Narayanan et al.,
2011). While it was speculated that NLP may have a dual function in
BES silencing and in promoting processive transcription at the active
BES (Narayanan et al., 2011), it is equally possible that loss of NLP enabled competition between silent and the active BES for the RNAPI transcription machinery. However, the speciﬁc function of NLP in BES
regulation remains to be determined.
SPT16 is a subunit of the trypanosome FACT (“facilitates chromatin
transcription”) complex (Patrick et al., 2008) and appears to have a direct role in BES promoter silencing because it was found highly enriched
at a silent BES promoter (Denninger et al., 2010). Accordingly, SPT16 silencing increased promoter-proximal GFP expression from a silent BES
up to 25-fold, yet de-repression did not extend to the VSG genes of silent
BESs. However, the de-repression effect was strongly correlated with an
arrest in the G2/early M cell cycle phase, raising the possibility that
SPT16 does not generally facilitate BES repression in the bloodstream
trypanosome. Moreover, SPT16 depletion strongly reduced VSG expression from the active BES, suggesting a separate BES-related function of
SPT16 in facilitating processive RNAPI transcription. Overall, the speciﬁc
function of FACT in the multifunctional RNAPI system remains unclear.
While SPT16 has been co-puriﬁed with RNAPII of the related organism
Leishmania major (Martinez-Calvillo et al., 2007), its association with
T. brucei RNAPI remains to be shown.
The epigenetic factors discussed so far, including RAP1 and DOT1B
(see Section 2, Telomeric silencing, above), function in BES silencing.
The only such factor found to be important for efﬁcient transcription
of the active BES is the high mobility group protein TDP1, which belongs
to a family of architectural chromatin proteins (Narayanan and
Rudenko, 2013). Interestingly, TDP1 exhibited an inverse occupancy
pattern to the core histone H3 at RNAPI-transcribed loci and was up to
ﬁvefold more abundant at the active BES promoter relative to a silent
BES promoter. Accordingly, TDP1 depletion decreased the abundance
of pre-rRNA and VSG mRNA from the active BES. In addition, TDP1, a nuclear protein, exhibited predominant localization to the nucleolus and
the ESB, and its DNA association was found throughout the active BES
and RRNA gene units. Thus, it appears that TDP1 facilitates high rates
of processive RNAPI transcription required for trypanosome survival
(Narayanan and Rudenko, 2013).
6. A model of BES regulation
It is difﬁcult to integrate the data from BES de-repression studies because, for most factors, speciﬁc functions in BES silencing have not been
determined yet. Nevertheless, recent data strongly indicated that BES
regulation occurs at both ends of expression sites. RAP1 and DOT1B depletion studies have clearly shown that BESs are silenced by a telomeredirected mechanism. Moreover, the demonstration that BES silencing
spreads from the telomere towards the promoter (Batram et al., 2014)
strongly supports a telomere-directed BES silencing mechanism. However, it is unlikely that this is the only mechanism regulating monoallelic BES expression. If this was the case one would expect full activation of promoter-proximal transcription once telomeric silencing retreats beyond the promoter region, which should result in a leveling
of the transcription rate between active and silent BESs (given the extremely high expression level of the active BES, it is unlikely that a trypanosome can support full activation of all ﬁfteen BESs). However, in
all cases reported, de-repression of silent BESs is, at best, moderate
with the promoter-proximal expression level remaining manifold
below that of the active BES. Furthermore, RAP1 silencing did not
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strongly affect promoter-proximal transcription of de-repressed BESs
and had only a minor inﬂuence on the high expression level of the active
BES (Yang et al., 2009). Similarly, DOT1B silencing did not affect expression of the active BES at all (Figueiredo et al., 2008). These results
strongly argue for the presence of a separate mechanism involved in
BES regulation.
Transcription attenuation has been proposed to be that mechanism
and, as discussed, there is clear evidence that it does occur on silent
BESs (Kassem et al., 2014; Vanhamme et al., 2000). Moreover, some
data suggested that transcription attenuation is caused by inefﬁcient
transcript processing (Vanhamme et al., 2000) rather than by repressive
chromatin. However, recent data do not support this scenario. The ﬁnding that RAP1 silencing caused gradual BES de-repression with the
greatest effect on telomere-proximal genes, strongly indicated that
transcription elongation on silent BESs is “antagonized” by telomeredirected spreading of repressive chromatin (Yang et al., 2009). Furthermore, upon removal of the apparent transcription elongation barrier,
e.g. pronounced telomeric silencing, by RAP1 (Yang et al., 2009) or
DOT1B (Figueiredo et al., 2008) depletion, promoter-proximal expression remained magnitudes below that of the active site, making it unlikely that transcription attenuation accounts for the strong difference
in promoter-proximal transcription observed between active and silent
BESs. Hence, transcription attenuation appears to be a consequence of
epigenetic silencing rather than a regulatory mechanism, and seems to
be in place to prevent the low level of transcription that does initiate
at silent BESs from reaching the distally located VSG gene.
Based on the RAP1 silencing results on BES de-repression, Yang et al.
(2009) suggested that there has to be a mechanism functioning on the
BES promoter that could explain the striking difference in promoterproximal expression levels between the active and de-repressed/silent
BESs. The strongest support for this idea stems from the demonstration
that CITFA, which is absolutely required for RNAPI transcription, is predominantly associated with the active BES promoter, versus a silent site,
strongly indicating that there is a mechanism in place that allows CITFA
to preferentially interact with the active BES. In addition, the fact that
depletion of several epigenetic factors increased promoter-proximal
transcription with no or very little effect on the downstream VSG gene
further supports the notion of a promoter-dependent regulatory
mechanism.
Taking these data into account, we propose a model in which BESs
are regulated by two opposing forces, namely telomere-directed epigenetic silencing acting on silent BESs and activated transcription initiation at the active BES (Fig. 2). In this model, the active BES promoter
has unrestricted access to CITFA and RNAPI, allowing it to achieve the
high transcription rate necessary for productive VSG expression. In addition, processive RNAPI transcription at the active BES is ensured by the
presence of TDP1. At the same time, telomeric silencing at the active
BES is impaired or pushed back so far that RNAPI transcription can
extend productively past the VSG gene. In contrast, in this model, silent
BES promoters are unable to recruit CITFA and RNAPI in sufﬁcient
amounts to allow for high transcription rates. In addition, a telomeredirected repressive epigenetic gradient spreading from the telomere
into the BES causes transcription attenuation to prevent the low level
of transcription, initiating at inactive BESs, from reaching the VSG gene.
How are BES promoters differentially regulated? An obvious barrier
that could prevent CITFA from interacting with silent BES promoters
and from recruiting RNAPI is a repressive chromatin structure at the
promoter. The epigenetic factors whose depletion led to promoterproximal BES de-repression, e.g. DAC3, histone H1 and NLP, may be
important to build up a repressive chromatin structure at the promoter.
If this is correct, depletion of these factors should lead to higher CITFA
and RNAPI occupancies at de-repressed promoters. An alternative idea
for the low promoter activity at “silent BESs” has been put forward in
studies of CITFA. CITFA was found to be concentrated in both the
nucleolus and the ESB (Nguyen et al., 2014), and it retained this localization even when its promoter-binding capability was impaired by
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Fig. 2. Model of BES regulation in T. brucei. In the model of BES regulation, two opposing forces antagonize each other. The active BES is characterized by high transcription initiation rates
and the lack of telomere-dependent epigenetic silencing, allowing unrestricted transcription elongation past the terminal VSG gene (green arrow). High processive transcription rates are
facilitated by CITFA and TDP1. In silent BESs, low level RNAPI transcription initiation is opposed by BES-speciﬁc telomeric silencing that spreads towards the BES promoter causing transcription attenuation. This silencing depends on a nucleosomal structure, DOT1B and RAP1. RAP1 was shown to bind to telomeric repeats but the association of DOT1B with BESs remains
to be determined (dotted line). Epigenetic factors may work together to build up a repressive chromatin structure at the promoter of silent BESs, preventing efﬁcient binding of CITFA to its
cognate DNA sequence elements. Alternatively, CITFA sequestration may limit the availability of the initiation factor for inactive BESs (not shown).

depletion of the essential subunit CITFA1 (Park et al., 2014). It was
therefore suggested that sequestration of CITFA into the nucleolus and
the ESB could restrict maximal RNAPI transcription to these compartments. This idea is in line with a previous study in which BFs were
forced to co-express two BESs simultaneously by antibiotic selection.
The two marked BESs were consistently detected in close spatial proximity (Chaves et al., 1999), as if they were competing for an essential expression factor. Furthermore, it may explain why de-repressed BES
promoters remain much less active than the promoter from the active
BES.
Finally, this model of two opposing forces is supported by the monitoring of the shut-down/reactivation of the active BES upon ectopic expression of VSG mRNA (Batram et al., 2014). In these experiments the
active BES was gradually inactivated from the telomere towards the
promoter, most likely by an active, telomere-directed process of repressive chromatin spreading, whereas the reactivation of the same BES occurred in the reverse direction, possibly by removal of nucleosomes by
the transcription machinery. An important question emanating from
this study is how does the ectopically expressed VSG mRNA cross-talk
to the active BES? Although this question is beyond the scope of this article, it is tempting to speculate that the VSG mRNA sequestered an important factor for RNAPI transcription, allowing repressive chromatin to
spread onto, and silence, the active BES.
7. Conclusion
Mono-allelic VSG expression in T. brucei differs from other allelic exclusion systems, such as var gene expression in Plasmodium falciparum
(Guizetti and Scherf, 2013; Kirkman and Deitsch, 2012) or olfactory receptor expression in mammals (Magklara and Lomvardas, 2013) by the
fact that the active VSG gene must be transcribed at an extremely high
rate to enable rapidly proliferating trypanosomes to completely cover
themselves with VSG. The careful measurement of RNA abundances
and half lives indicated that the active VSG gene is transcribed at a 50fold higher rate than a β tubulin gene (Ehlers et al., 1987). At the
same time, T. brucei must ensure that VSG genes on other BESs are not
expressed. The parasite achieves this balancing act apparently by
restricting full RNAPI transcription initiation to the active BES and by

shielding VSG genes on silent BESs by a telomere-dependent silencing
mechanism that causes attenuation of RNAPI transcription.
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